{"PMC7306558": [], "566583c1683c66519e8ba0aa3e492e79bdc946f5": [["Background:COVID-19 is a serious illness that currently has no known treatment or vaccine and is spreading in an immune naive population.", [["COVID-19", "SPECIES", 11, 19], ["a serious illness", "PROBLEM", 23, 40], ["vaccine", "TREATMENT", 82, 89], ["immune naive", "OBSERVATION", 113, 125]]], ["Deaths are rising steeply, and health systems are under strain.", [["rising", "OBSERVATION_MODIFIER", 11, 17], ["steeply", "OBSERVATION_MODIFIER", 18, 25]]], ["1 Since the first reported case of COVID-19 in Wuhan, China, at the end of 2019, COVID-19 has rapidly spread throughout China and has also involved many other countries despite global effort s to prevent its spread.", [["COVID-19", "CHEMICAL", 81, 89], ["COVID", "TEST", 35, 40], ["COVID", "TEST", 81, 86], ["global effort s", "PROBLEM", 177, 192]]], ["2 On March 2, 2020, the first case of COVID-19 was diagnosed in Jordan to a patient who came from Italy.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83]]], ["113 of them were admitted to King Abdullah University Hospital (KAUH) which is the only hospital that deals with COVID-19 patients in the north of Jordan.Background:Health care workers are essential workers defined as paid and unpaid persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials.", [["patients", "ORGANISM", 122, 130], ["persons", "ORGANISM", 234, 241], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 122, 130], ["persons", "SPECIES", 234, 241], ["patients", "SPECIES", 332, 340], ["infectious materials", "PROBLEM", 344, 364], ["infectious", "OBSERVATION", 344, 354]]], ["3 They are at increased risk of contracting communicable diseases, including dropletspread respiratory viruses, because of their high level of exposure at work.", [["communicable diseases", "DISEASE", 44, 65], ["respiratory viruses", "DISEASE", 91, 110], ["contracting communicable diseases", "PROBLEM", 32, 65], ["dropletspread respiratory viruses", "PROBLEM", 77, 110], ["contracting", "OBSERVATION_MODIFIER", 32, 43], ["communicable diseases", "OBSERVATION", 44, 65], ["respiratory viruses", "OBSERVATION", 91, 110]]], ["4 The idea of implementing a screening regimen to determine the prevalence of COVID-19 among our HCWs using real-time reverse--transcriptase RT-PCR on nasopharyngeal samples was to assess the subclinical transmission of the disease among HCWs, evaluate our protective measures and to help in making decisions regarding staffing and protection of HCWs in the hospital during the COVID-19 pandemic.", [["nasopharyngeal samples", "ANATOMY", 151, 173], ["COVID-19", "CHEMICAL", 78, 86], ["nasopharyngeal samples", "CANCER", 151, 173], ["a screening regimen", "TREATMENT", 27, 46], ["COVID", "TREATMENT", 78, 83], ["transcriptase RT-PCR", "TEST", 127, 147], ["nasopharyngeal samples", "TEST", 151, 173], ["our protective measures", "TREATMENT", 253, 276], ["the COVID", "TEST", 374, 383], ["pandemic", "PROBLEM", 387, 395]]], ["To the best of our knowledge, very few studies have been conducted about the prevalence of COVID-19 among asymptomatic HCWs during coronavirus pandemic.Methods:This study was approved by IRB of Jordan University of Science and Technology.", [["COVID-19", "CHEMICAL", 91, 99], ["coronavirus pandemic", "DISEASE", 131, 151], ["coronavirus", "ORGANISM", 131, 142], ["COVID", "TEST", 91, 96], ["coronavirus pandemic", "PROBLEM", 131, 151], ["This study", "TEST", 160, 170]]], ["It was a retrospective single center study.", [["a retrospective single center study", "TEST", 7, 42]]], ["Inclusion criterion were all asymptomatic HCWs including physicians, nurses and other personnel (housekeepers, porters and administrative staff) who were assigned to deal with COVID-19 patients at KAUH between March 18, 2020 to April 29, 2020.Methods:The doctor/patient ratio was 1/20 while nurse/patient ratio was 1/5-10.", [["patients", "ORGANISM", 185, 193], ["doctor", "ORGANISM", 255, 261], ["patient", "ORGANISM", 262, 269], ["patient", "ORGANISM", 297, 304], ["patients", "SPECIES", 185, 193], ["patient", "SPECIES", 262, 269], ["patient", "SPECIES", 297, 304]]], ["A total number of 370Methods:HCWs were voluntarily screened for COVID-19 by nasopharyngeal swabs between 22 to 29 April 2020.", [["nasopharyngeal swabs", "ANATOMY", 76, 96], ["HCWs", "ORGANISM", 29, 33], ["COVID", "TEST", 64, 69], ["nasopharyngeal swabs", "TEST", 76, 96]]], ["Sample collection was taken by our trained team and the swabs were tested for COVID-19 RNA using real-time reverse--transcriptase rRT-PCR.", [["swabs", "ANATOMY", 56, 61], ["COVID-19 RNA", "RNA", 78, 90], ["reverse--transcriptase", "PROTEIN", 107, 129], ["Sample collection", "TEST", 0, 17], ["the swabs", "TEST", 52, 61], ["COVID", "TEST", 78, 83], ["transcriptase rRT", "TREATMENT", 116, 133]]], ["Data on age, sex and occupational categories were also analyzed.Methods:HCWs who had any symptoms suggestive of COVID-19 have been excluded from this study.Methods:HCW with comorbidities (diabetes, hypertension, respiratory diseases and other chronic medial illness) and pregnant ladies were not included because they were already excluded from work during this period.", [["respiratory", "ANATOMY", 212, 223], ["diabetes", "DISEASE", 188, 196], ["hypertension", "DISEASE", 198, 210], ["respiratory diseases", "DISEASE", 212, 232], ["chronic medial illness", "DISEASE", 243, 265], ["HCWs", "ORGANISM", 72, 76], ["any symptoms", "PROBLEM", 85, 97], ["COVID", "TEST", 112, 117], ["this study", "TEST", 145, 155], ["diabetes", "PROBLEM", 188, 196], ["hypertension", "PROBLEM", 198, 210], ["respiratory diseases", "PROBLEM", 212, 232], ["other chronic medial illness", "PROBLEM", 237, 265], ["pregnant ladies", "PROBLEM", 271, 286], ["hypertension", "OBSERVATION", 198, 210], ["respiratory diseases", "OBSERVATION", 212, 232], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["medial", "OBSERVATION_MODIFIER", 251, 257], ["illness", "OBSERVATION", 258, 265]]], ["This study was conducted according to STROCSS 2019 guideline.", [["This study", "TEST", 0, 10]]], ["5Results:Total numbers of HCWs were 3000 which were reduced to about 50% (1500) during this pandemic.", [["HCWs", "TEST", 26, 30]]], ["A total number of 385 HCWs were involved in direct contact with COVID-patients.Results:Only of 370 HCWs were screened while 15 were unable to do the test.", [["HCWs", "ORGANISM", 22, 26], ["patients", "ORGANISM", 70, 78], ["HCWs", "ORGANISM", 99, 103], ["patients", "SPECIES", 70, 78], ["the test", "TEST", 145, 153]]], ["The asymptomatic HCWs screened for Covid-19 include the following occupational categories: 61.62% nurses (228 of 370), 31.35% physicians (116 of 370) and 7.02% other personnel including; housekeepers, porters and administrative staff (26 of 370).", [["Covid", "TEST", 35, 40]]], ["This study showed that all asymptomatic HCWs were tested negative (Table 1) .", [["HCWs", "ORGANISM", 40, 44], ["This study", "TEST", 0, 10], ["all asymptomatic HCWs", "TEST", 23, 44]]], ["Therefore, unexpectedly, the prevalence of positive-COVID-19 among asymptomatic HCWs who take care of patients infected with the novel coronavirus was 0%.Discussion:Since December 2019, the world has been in the grip of the severe acute respiratory syndromecoronavirus 2 and the disease it causes, coronavirus disease 2019 (COVID-19).", [["coronavirus", "DISEASE", 135, 146], ["acute respiratory syndromecoronavirus", "DISEASE", 231, 268], ["coronavirus disease", "DISEASE", 298, 317], ["HCWs", "ORGANISM", 80, 84], ["patients", "ORGANISM", 102, 110], ["coronavirus", "ORGANISM", 135, 146], ["patients", "SPECIES", 102, 110], ["the novel coronavirus", "PROBLEM", 125, 146], ["the severe acute respiratory syndromecoronavirus 2", "PROBLEM", 220, 270], ["the disease", "PROBLEM", 275, 286], ["coronavirus disease", "PROBLEM", 298, 317], ["COVID", "TEST", 324, 329], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["respiratory syndromecoronavirus", "OBSERVATION", 237, 268], ["disease", "OBSERVATION", 279, 286], ["coronavirus disease", "OBSERVATION", 298, 317]]], ["6 Since then, the spread of COVID-19 has increased exponentially, with the World Health Organization (WHO) declaring a pandemic on 11 March.", [["COVID-19", "CHEMICAL", 28, 36], ["COVID", "TEST", 28, 33], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["exponentially", "OBSERVATION_MODIFIER", 51, 64]]], ["7 They are at high risk of morbidity and mortality due to health care-associated infections.", [["infections", "DISEASE", 81, 91], ["morbidity", "PROBLEM", 27, 36], ["associated infections", "PROBLEM", 70, 91], ["morbidity", "OBSERVATION", 27, 36], ["infections", "OBSERVATION", 81, 91]]], ["8 It has been estimated that 10% or more of all those infected with COVID-19 in some European countries are HCWs.", [["COVID", "TEST", 68, 73], ["10%", "OBSERVATION_MODIFIER", 29, 32], ["infected", "OBSERVATION", 54, 62]]], ["4 In Italy, HCWs experienced high rates of infection and death.", [["infection", "DISEASE", 43, 52], ["death", "DISEASE", 57, 62], ["HCWs", "ORGANISM", 12, 16], ["infection", "PROBLEM", 43, 52], ["death", "PROBLEM", 57, 62], ["infection", "OBSERVATION", 43, 52]]], ["9 Little is known about the effectiveness of personal protective equipment (PPE) for HCWs who take care of patients infected with COVID-19.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["personal protective equipment", "TREATMENT", 45, 74], ["COVID", "TEST", 130, 135]]], ["10 On the other hand, other studies showed that the prevalence of COVID-19 amongst HCWs will depend upon a range of factors, including the availability of PPE, the healthcare setting and access to testing.Discussion:How well the country handles the Covid-19 crisis depends largely on how effectively health workforce is used.", [["other studies", "TEST", 22, 35], ["COVID", "TEST", 66, 71], ["PPE", "TREATMENT", 155, 158], ["testing", "TEST", 197, 204]]], ["4 Therefore, our local infection control committee started before the beginning of this pandemic in Jordan to educate HCWs about caring for COVID-19 patients regarding hand hygiene, donning and doffing PPE.", [["hand", "ANATOMY", 168, 172], ["infection", "DISEASE", 23, 32], ["patients", "ORGANISM", 149, 157], ["hand", "ORGANISM_SUBDIVISION", 168, 172], ["patients", "SPECIES", 149, 157], ["our local infection control", "TREATMENT", 13, 40], ["hand hygiene", "TREATMENT", 168, 180], ["infection", "OBSERVATION", 23, 32]]], ["Types of PPE used in KAUH were: gloves, N95 masks with tight seal around mouth and nose, face and eye protection including face shields and goggles, clothing which includes gowns, aprons, head covering, and shoe covers.", [["mouth", "ANATOMY", 73, 78], ["nose", "ANATOMY", 83, 87], ["eye", "ANATOMY", 98, 101], ["head", "ANATOMY", 188, 192], ["mouth", "ORGANISM_SUBDIVISION", 73, 78], ["nose", "ORGANISM_SUBDIVISION", 83, 87], ["eye", "ORGAN", 98, 101], ["head", "ORGANISM_SUBDIVISION", 188, 192], ["PPE", "TREATMENT", 9, 12], ["gloves", "TREATMENT", 32, 38], ["N95 masks", "TREATMENT", 40, 49], ["tight seal", "TREATMENT", 55, 65], ["face and eye protection", "TREATMENT", 89, 112], ["face shields", "TREATMENT", 123, 135], ["goggles", "TREATMENT", 140, 147], ["clothing", "TREATMENT", 149, 157], ["gowns", "TREATMENT", 173, 178], ["tight seal", "OBSERVATION", 55, 65], ["mouth", "ANATOMY", 73, 78], ["nose", "ANATOMY", 83, 87], ["face", "ANATOMY", 89, 93], ["eye", "ANATOMY", 98, 101], ["head", "ANATOMY", 188, 192]]], ["In order to minimize the risk to the HCWs, only necessary procedures were allowed.", [["necessary procedures", "TREATMENT", 48, 68]]], ["Aerosol generation procedures were limited to negative pressure rooms, they were undertaken by most expert doctors or nurses available and only necessary HCWs were present in the room.", [["HCWs", "ORGANISM", 154, 158], ["Aerosol generation procedures", "TREATMENT", 0, 29]]], ["HCWs with comorbidities (DM, HTN, respiratory diseases and other chronic medial illness) and pregnant ladies were exempted from work during this period.Discussion:We also adopted a policy which allows every HCW to take two weeks of home self-isolation after finishing working shift (We divided the 385 HCWs into 14 groups each group contains about 27 personnel who work 24 hours.", [["respiratory", "ANATOMY", 34, 45], ["DM", "DISEASE", 25, 27], ["HTN", "DISEASE", 29, 32], ["respiratory diseases", "DISEASE", 34, 54], ["chronic medial illness", "DISEASE", 65, 87], ["comorbidities", "PROBLEM", 10, 23], ["DM", "PROBLEM", 25, 27], ["HTN", "PROBLEM", 29, 32], ["respiratory diseases", "PROBLEM", 34, 54], ["other chronic medial illness", "PROBLEM", 59, 87], ["pregnant ladies", "PROBLEM", 93, 108], ["home self-isolation", "TREATMENT", 232, 251], ["respiratory diseases", "OBSERVATION", 34, 54], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["medial", "OBSERVATION_MODIFIER", 73, 79], ["illness", "OBSERVATION", 80, 87]]], ["This would provide about 2 weeks of home isolation for each HCW).", [["home isolation", "TREATMENT", 36, 50]]], ["Moreover, we separated wards that could be contaminated with the virus from other low risk facilities and we minimized the time of contact between HCWs and infected patients by limiting unnecessary procedures, decreasing the communication times between infected patients and HCWs provided that the patient care is not affected and by trying as much as possible to do many tasks in the same round as taking vital signs, giving medications, distributing meals and doing beddings.Discussion:Early in the pandemic crisis in Jordan (first 5 weeks) there were shortage of PCR-kit due to supply chain problems, the priority was to test only suspected patients and symptomatic HCWs.Discussion:Taking into account that not all cases are symptomatic and some people may be infectious before they develop symptoms, many HCWs were worried about their risk of exposing family members to the virus.", [["patients", "ORGANISM", 165, 173], ["patients", "ORGANISM", 262, 270], ["patient", "ORGANISM", 298, 305], ["patients", "ORGANISM", 644, 652], ["people", "ORGANISM", 749, 755], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 262, 270], ["patient", "SPECIES", 298, 305], ["patients", "SPECIES", 644, 652], ["people", "SPECIES", 749, 755], ["the virus", "PROBLEM", 61, 70], ["unnecessary procedures", "TREATMENT", 186, 208], ["vital signs", "TEST", 406, 417], ["medications", "TREATMENT", 426, 437], ["PCR", "TEST", 566, 569], ["supply chain problems", "PROBLEM", 581, 602], ["symptomatic", "PROBLEM", 728, 739], ["infectious", "PROBLEM", 763, 773], ["symptoms", "PROBLEM", 794, 802]]], ["4 As a result, there was a need for HCWs screening protocol that provides data base about the prevalence of COVID-19 infection among our staff.", [["COVID-19", "CHEMICAL", 108, 116], ["infection", "DISEASE", 117, 126], ["COVID-19", "SPECIES", 108, 116], ["HCWs screening protocol", "TEST", 36, 59], ["COVID", "TEST", 108, 113]]], ["Therefore, a screening regimen has been proposed for all HCWs who work in direct contact with COVID-19 patients including physicians, nurses and other personnel.Discussion:Given the high prevalence of mild clinical presentations that may go undetected 5 and after the availability of PCR-kit, we decided to changed our strategy to be sure that our HCWs are free of infection by both the PCR test and home-isolation period.", [["infection", "DISEASE", 365, 374], ["patients", "ORGANISM", 103, 111], ["HCWs", "ORGANISM", 348, 352], ["patients", "SPECIES", 103, 111], ["a screening regimen", "TREATMENT", 11, 30], ["mild clinical presentations", "PROBLEM", 201, 228], ["PCR", "TEST", 284, 287], ["infection", "PROBLEM", 365, 374], ["the PCR test", "TEST", 383, 395], ["mild", "OBSERVATION_MODIFIER", 201, 205], ["infection", "OBSERVATION", 365, 374]]], ["So, we started to screen all asymptomatic HCWs with any history of contact with COVID-19 patients.Discussion:We think that the advantage of having an objective regimen by lab test will help in decreasing the stress and worries of the HCWs about their risk of having the virus 4 , to reduce the risk of transmitting COVID-19 from HCWs to their colleagues or to other non-COVID-19 patients and to be able to formulate policies regarding workflow, especially in the absence of standard best practices.", [["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 379, 387], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 379, 387], ["an objective regimen", "TREATMENT", 147, 167], ["lab test", "TEST", 171, 179], ["the virus", "PROBLEM", 266, 275]]], ["Moreover, this may help health care providers in other institutions to develop policies regarding HCWs during similar pandemics.Discussion:As mentioned above, some studies showed that about 10% of all those infected with COVID-19 in some European countries are HCWs.", [["some studies", "TEST", 159, 171], ["COVID", "TEST", 221, 226], ["infected", "OBSERVATION", 207, 215]]], ["4 However, in this study, we found that the prevalence of positive-COVID-19 among asymptomatic HCWs who take care of patients infected with the novel coronavirus was 0%.", [["coronavirus", "DISEASE", 150, 161], ["HCWs", "ORGANISM", 95, 99], ["patients", "ORGANISM", 117, 125], ["coronavirus", "ORGANISM", 150, 161], ["patients", "SPECIES", 117, 125], ["this study", "TEST", 14, 24], ["the novel coronavirus", "PROBLEM", 140, 161]]], ["Although this result could be in part due to our policies and protective measures, it was unexpected and against our assumption as HCWs are high risk group.Discussion:Potential explanations for this difference in the result are; firstly, the majority of admitted patients to our hospital were asymptomatic 88% and detected by epidemiological investigation teams as patients are most infectious when they are symptomatic.", [["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 365, 373], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 365, 373], ["protective measures", "TREATMENT", 62, 81], ["symptomatic", "PROBLEM", 408, 419]]], ["Secondly, rRT-PCR test has risk of eliciting false-negative results especially in asymptomatic cases due torelatively lowviral loads.", [["rRT", "DNA", 10, 13], ["rRT", "TEST", 10, 13], ["PCR test", "TEST", 14, 22], ["lowviral loads", "PROBLEM", 118, 132]]], ["Additionally, we used nasopharyngeal swab sampling.", [["nasopharyngeal swab", "ANATOMY", 22, 41], ["nasopharyngeal swab sampling", "TEST", 22, 50], ["nasopharyngeal", "ANATOMY", 22, 36]]], ["However, the optimum sample types during infections caused by COVID-19 remain to be fully determined and require expertise.", [["sample", "ANATOMY", 21, 27], ["infections", "DISEASE", 41, 51], ["the optimum sample types during infections", "PROBLEM", 9, 51], ["COVID", "TEST", 62, 67]]], ["12 The findings of this study have to be seen in light of some limitations.", [["this study", "TEST", 19, 29]]], ["The first is the limited number of COVID-19 patients admitted to our hospital.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["The second limitation concerns the timing of screening which was 4 weeks after the admission of the first COVID-19 patient, during this period, HCWs may have been infected with the virus at some point and recovered by the time of screening.", [["patient", "ORGANISM", 115, 122], ["HCWs", "ORGANISM", 144, 148], ["patient", "SPECIES", 115, 122], ["screening", "TEST", 45, 54], ["the virus", "PROBLEM", 177, 186], ["screening", "TEST", 230, 239]]], ["Additionally, this is an empiric way of screening due to lack of previous research studies that address this subject.Discussion:It is worth mentioning that among the 385 HCWs assigned to deal with COVID-19 patients only two nurses were infected.", [["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["screening", "TEST", 40, 49], ["previous research studies", "TEST", 65, 90], ["COVID", "TEST", 197, 202], ["infected", "OBSERVATION", 236, 244]]], ["First case was male aged 27 years who was diagnosed after he developed symptoms at the beginning of his fist shift, most probably that he had infected outside the hospital.", [["symptoms", "PROBLEM", 71, 79], ["most probably", "UNCERTAINTY", 116, 129]]], ["He was excluded from the study because he was symptomatic and the inclusion criterion was only asymptomatic HCWs.", [["the study", "TEST", 21, 30], ["symptomatic", "PROBLEM", 46, 57]]], ["The second case was 28-year-old asymptomatic female, she diagnosed by rRT-PCR due to history of contact with her infected colleague and she was excluded from the study as the source of infection was outside the hospital.", [["infection", "DISEASE", 185, 194], ["female", "ORGANISM", 45, 51], ["her infected colleague", "PROBLEM", 109, 131], ["the study", "TEST", 158, 167], ["infection", "PROBLEM", 185, 194], ["infection", "OBSERVATION", 185, 194]]], ["Importantly, this is a rapidly moving topic of research.", [["rapidly", "OBSERVATION_MODIFIER", 23, 30]]], ["Therefore, our result must be cautiously interpreted and should not give us a false sense of security regarding the prevalence of positive COVID-19 among HCWs.", [["HCWs", "ORGANISM", 154, 158], ["positive COVID", "TREATMENT", 130, 144]]], ["Our perspective is to improve surveillance of HCWs and to identify the best approach to protect HCWs in order to assure source control to insure a safe working environment.Conclusion:Unexpectedly, the prevalence of positive COVID-19 among asymptomatic HCWs who take care of patients infected with the novel coronavirus was 0%.", [["coronavirus", "DISEASE", 307, 318], ["HCWs", "ORGANISM", 252, 256], ["patients", "ORGANISM", 274, 282], ["coronavirus", "ORGANISM", 307, 318], ["patients", "SPECIES", 274, 282], ["positive COVID", "PROBLEM", 215, 229], ["the novel coronavirus", "PROBLEM", 297, 318]]], ["Further studies are needed in order to find effective strategy of screening HCWs to insure a safe working environment.Conclusion:Provenance and peer review Not commissioned, externally peer reviewed. \u2022 The prevalence of positive COVID-19 among asymptomatic HCWs was 0%.Conclusion:\u2022 The result should not give us a false sense of securityConclusion:\u2022 Improvement of surveillance and protection of HCWs is important", [["Further studies", "TEST", 0, 15], ["screening HCWs", "TREATMENT", 66, 80], ["positive COVID", "PROBLEM", 220, 234], ["surveillance", "TEST", 365, 377]]]], "97843aca6a5f52f51d621a05257a35d214fa92a7": [["potentially life-threatening venous and arterial thrombotic events.", [["venous", "ANATOMY", 29, 35], ["arterial", "ANATOMY", 40, 48], ["thrombotic", "DISEASE", 49, 59], ["venous", "MULTI-TISSUE_STRUCTURE", 29, 35], ["arterial", "MULTI-TISSUE_STRUCTURE", 40, 48], ["threatening venous and arterial thrombotic events", "PROBLEM", 17, 66], ["venous", "ANATOMY", 29, 35], ["arterial", "ANATOMY", 40, 48], ["thrombotic", "OBSERVATION", 49, 59]]], ["The first data from single-center retrospective studies suggest that thrombotic events are a key aspect of COVID-19-associated morbidity and mortality.", [["thrombotic", "DISEASE", 69, 79], ["retrospective studies", "TEST", 34, 55], ["thrombotic events", "PROBLEM", 69, 86], ["COVID", "TEST", 107, 112], ["thrombotic", "OBSERVATION", 69, 79], ["morbidity", "OBSERVATION", 127, 136]]], ["We have planned and will be launching the COvid REgistry on THROMBOSIS (CORE-THROMBOSIS), a large online registry of previously or currently hospitalized patients with COVID-19.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["THROMBOSIS (CORE-THROMBOSIS", "TREATMENT", 60, 87], ["COVID", "TEST", 168, 173], ["THROMBOSIS", "OBSERVATION", 60, 70], ["THROMBOSIS", "OBSERVATION", 77, 87], ["large", "OBSERVATION_MODIFIER", 92, 97]]], ["The study aims to (i) determine the rate of acute thrombotic events in consecutive hospitalized patients with coronavirus (COVID-19); (ii) investigate the current use and trends in thromboprophylaxis regimens; and (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with COVID-19.K E Y W O R D SCOVID-19, registry, SARS-CoV-2, thrombosis, venous thromboembolism Taken together, the first publications summarized above suggest that thrombotic events are a key aspect of COVID-19associated morbidity and mortality.", [["cardiovascular", "ANATOMY", 275, 289], ["venous", "ANATOMY", 382, 388], ["thrombotic", "DISEASE", 50, 60], ["coronavirus", "DISEASE", 110, 121], ["cardiovascular events", "DISEASE", 275, 296], ["K", "CHEMICAL", 323, 324], ["thrombosis", "DISEASE", 370, 380], ["venous thromboembolism", "DISEASE", 382, 404], ["thrombotic", "DISEASE", 474, 484], ["patients", "ORGANISM", 96, 104], ["cardiovascular", "ANATOMICAL_SYSTEM", 275, 289], ["patients", "ORGANISM", 300, 308], ["venous", "MULTI-TISSUE_STRUCTURE", 382, 388], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 300, 308], ["The study", "TEST", 0, 9], ["acute thrombotic events", "PROBLEM", 44, 67], ["coronavirus", "PROBLEM", 110, 121], ["COVID", "TEST", 123, 128], ["thromboprophylaxis regimens", "TREATMENT", 181, 208], ["imaging tests", "TEST", 240, 253], ["cardiovascular events", "PROBLEM", 275, 296], ["COVID", "TEST", 314, 319], ["SCOVID", "TEST", 337, 343], ["SARS", "PROBLEM", 358, 362], ["thrombosis", "PROBLEM", 370, 380], ["venous thromboembolism", "PROBLEM", 382, 404], ["thrombotic events", "PROBLEM", 474, 491], ["19associated morbidity", "PROBLEM", 518, 540], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["thrombotic", "OBSERVATION", 50, 60], ["thrombosis", "OBSERVATION", 370, 380], ["venous", "ANATOMY", 382, 388], ["thromboembolism", "OBSERVATION", 389, 404], ["thrombotic", "OBSERVATION", 474, 484]]], ["16 It is therefore now imperative to move beyond individual and small-group observations to systematic large-scale data collection at a multinational level.", [["small", "OBSERVATION_MODIFIER", 64, 69]]], ["Randomized controlled trials, or even single-arm prospective management studies for diagnosing and managing thrombosis and thromboembolism in the hospital setting, are at least theoretically the best way to generate high-level evidence, but they appear unfeasible at the present stage for several reasons.", [["thrombosis", "DISEASE", 108, 118], ["thromboembolism", "DISEASE", 123, 138], ["single-arm prospective management", "TREATMENT", 38, 71], ["diagnosing", "TEST", 84, 94], ["managing thrombosis", "PROBLEM", 99, 118], ["thromboembolism", "PROBLEM", 123, 138], ["thrombosis", "OBSERVATION", 108, 118], ["thromboembolism", "OBSERVATION", 123, 138]]], ["First, performing serial diagnostic tests, such as computed tomography coronary angiography, as part of study protocols may pose insurmountable logistical challenges to emergency and radiology departments of hospitals overwhelmed by admissions during the outbreak.K E Y W O R D SSecond, the large majority of patients with COVID-19 are, and will increasingly be, expected to enter treatment trials targeted at the viral disease itself, and competition for patients will be counterproductive for all those involved in these efforts.", [["coronary", "ANATOMY", 71, 79], ["K", "CHEMICAL", 264, 265], ["coronary", "MULTI-TISSUE_STRUCTURE", 71, 79], ["patients", "ORGANISM", 309, 317], ["patients", "ORGANISM", 456, 464], ["patients", "SPECIES", 309, 317], ["patients", "SPECIES", 456, 464], ["serial diagnostic tests", "TEST", 18, 41], ["computed tomography coronary angiography", "TEST", 51, 91], ["study protocols", "TEST", 104, 119], ["treatment trials", "TREATMENT", 381, 397], ["the viral disease itself", "PROBLEM", 410, 434], ["coronary", "ANATOMY", 71, 79], ["large", "OBSERVATION_MODIFIER", 291, 296], ["majority", "OBSERVATION_MODIFIER", 297, 305], ["viral disease", "OBSERVATION", 414, 427]]], ["Finally, a purely prospective trial will essentially miss the very large number of pa- (ii) investigate the current use and trends in thromboprophylaxis regimens; and (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with COVID-19.", [["cardiovascular", "ANATOMY", 228, 242], ["cardiovascular events", "DISEASE", 228, 249], ["COVID-19", "CHEMICAL", 267, 275], ["cardiovascular", "ANATOMICAL_SYSTEM", 228, 242], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["thromboprophylaxis regimens", "TREATMENT", 134, 161], ["imaging tests", "TEST", 193, 206], ["cardiovascular events", "PROBLEM", 228, 249], ["COVID", "TEST", 267, 272], ["cardiovascular", "ANATOMY", 228, 242]]], ["The electronic case report form of the study will include strictly anonymized data, permitting rapid, nonbureaucratic approval by local ethics committees and online data entry.", [["the study", "TEST", 35, 44]]], ["Past \"closed\" as well as current and future cases will be included, and participating investigators will commit themselves to do their best to not miss any case of confirmed arterial or venous thrombosis related to COVID-19 in their institution.", [["arterial", "ANATOMY", 174, 182], ["venous", "ANATOMY", 186, 192], ["arterial or venous thrombosis", "DISEASE", 174, 203], ["arterial", "MULTI-TISSUE_STRUCTURE", 174, 182], ["venous", "MULTI-TISSUE_STRUCTURE", 186, 192], ["arterial or venous thrombosis", "PROBLEM", 174, 203], ["COVID", "TEST", 215, 220], ["arterial", "ANATOMY", 174, 182], ["venous", "ANATOMY", 186, 192], ["thrombosis", "OBSERVATION", 193, 203]]], ["Being purely observational and having a user-friendly, fast-to-complete data entry form, CORE-THROMBOSIS will not devour the time of clinical researchers or study teams, and it will not interfere with any parallel therapeutic trials or even other registries.", [["CORE-THROMBOSIS", "PROBLEM", 89, 104], ["THROMBOSIS", "OBSERVATION", 94, 104]]], ["We believe that by including a large number of both prevalent and incident cases within a short time period, CORE-THROMBOSIS will provide observational but nevertheless representative data on the magnitude of the problem, and it will enable us to formulate robust hypotheses to be tested in future prophylaxis and management trials.K E Y W O R D SWe ask interested investigators to join this effort and actively participate in CORE-THROMBOSIS by contacting us at s.barco@unimainz.de.SB reports personal fees from Biocompatibles Group UK and BayerHealthCare, nonfinancial support from Bayer HealthCare and Daiichi Sankyo, outside the submitted work.", [["K", "CHEMICAL", 332, 333], ["K", "CHEMICAL", 332, 333], ["K", "SPECIES", 332, 333], ["CORE-THROMBOSIS", "PROBLEM", 109, 124], ["prophylaxis", "TREATMENT", 298, 309], ["management trials", "TREATMENT", 314, 331], ["large", "OBSERVATION_MODIFIER", 31, 36], ["THROMBOSIS", "OBSERVATION", 114, 124], ["THROMBOSIS", "OBSERVATION", 432, 442]]], ["SVK reports grants and nonfinancial support from Bayer AG, grants and personal fees from Boehringer Ingelheim, personal fees from Bayer AG, grants and personal fees from Actelion, grants and personal fees from Daiichi-Sankyo, grants and personal fees from Biocompatibles Group UK, personal fees from Pfizer-Bristol-Myers Squibb, and grants and personal fees from MSD, outside the submitted work.Stefano Barcohttps://orcid.org/0000-0002-2618-347XTWITTERStefano Barco", [["Barco", "CHEMICAL", 460, 465], ["Barco", "SPECIES", 460, 465], ["Barco", "TREATMENT", 460, 465]]]], "da7b751f51bc858502ced031be77641c6a6f2fbd": [["Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified for the first time in Wuhan, China (4) .", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 49, 96], ["SARS-CoV-2", "ORGANISM", 98, 108], ["Coronavirus disease-2019 (COVID-19", "SPECIES", 0, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["SARS-CoV-2", "SPECIES", 98, 108], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 49, 94], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82]]], ["It originally presented as a cluster of pneumonia-like cases.", [["pneumonia", "DISEASE", 40, 49], ["pneumonia", "PROBLEM", 40, 49], ["cluster", "OBSERVATION_MODIFIER", 29, 36], ["pneumonia", "OBSERVATION", 40, 49]]], ["In a few months, COVID-19 spread across multiple nations and led to a pandemic of global health concern (5).", [["COVID", "TREATMENT", 17, 22]]], ["As of June 20, 2020, COVID-19 has affected 185 countries with 8.7 million cases and 461,000 deaths (6) .", [["deaths", "DISEASE", 92, 98], ["COVID", "TEST", 21, 26]]], ["While respiratory symptoms dominate the presentation, GI manifestations such as nausea, vomiting, abdominal pain, diarrhea, loss of appetite, dysgeusia, and abnormal liver chemistries are increasingly being reported, especially in hospitalized COVID-19 patients.", [["respiratory", "ANATOMY", 6, 17], ["GI", "ANATOMY", 54, 56], ["abdominal", "ANATOMY", 98, 107], ["liver", "ANATOMY", 166, 171], ["respiratory symptoms", "DISEASE", 6, 26], ["nausea", "DISEASE", 80, 86], ["vomiting", "DISEASE", 88, 96], ["abdominal pain", "DISEASE", 98, 112], ["diarrhea", "DISEASE", 114, 122], ["loss of appetite", "DISEASE", 124, 140], ["dysgeusia", "DISEASE", 142, 151], ["abnormal liver chemistries", "DISEASE", 157, 183], ["abdominal", "ORGANISM_SUBDIVISION", 98, 107], ["liver", "ORGAN", 166, 171], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["respiratory symptoms", "PROBLEM", 6, 26], ["GI manifestations", "PROBLEM", 54, 71], ["nausea", "PROBLEM", 80, 86], ["vomiting", "PROBLEM", 88, 96], ["abdominal pain", "PROBLEM", 98, 112], ["diarrhea", "PROBLEM", 114, 122], ["loss of appetite", "PROBLEM", 124, 140], ["dysgeusia", "PROBLEM", 142, 151], ["abnormal liver chemistries", "PROBLEM", 157, 183], ["abdominal", "ANATOMY", 98, 107], ["diarrhea", "OBSERVATION", 114, 122], ["liver", "ANATOMY", 166, 171]]], ["(4, (7) (8) (9) (10) (11) (12) .", [["4, (7) (8) (9) (10) (11)", "SIMPLE_CHEMICAL", 1, 25]]], ["In addition, there have been reports of GI bleeding, colitis, acute pancreatitis, and exacerbation of prior GI diseases (inflammatory bowel disease) (12) (13) (14) (15) .", [["GI", "ANATOMY", 40, 42], ["GI", "ANATOMY", 108, 110], ["bowel", "ANATOMY", 134, 139], ["GI bleeding", "DISEASE", 40, 51], ["colitis", "DISEASE", 53, 60], ["pancreatitis", "DISEASE", 68, 80], ["GI diseases", "DISEASE", 108, 119], ["inflammatory bowel disease", "DISEASE", 121, 147], ["GI", "ORGANISM_SUBDIVISION", 40, 42], ["bowel", "ORGAN", 134, 139], ["GI bleeding", "PROBLEM", 40, 51], ["colitis", "PROBLEM", 53, 60], ["acute pancreatitis", "PROBLEM", 62, 80], ["prior GI diseases", "PROBLEM", 102, 119], ["inflammatory bowel disease", "PROBLEM", 121, 147], ["GI", "ANATOMY", 40, 42], ["bleeding", "OBSERVATION", 43, 51], ["colitis", "OBSERVATION", 53, 60], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["pancreatitis", "OBSERVATION", 68, 80], ["exacerbation", "OBSERVATION_MODIFIER", 86, 98], ["GI", "ANATOMY", 108, 110], ["diseases", "OBSERVATION", 111, 119], ["inflammatory", "OBSERVATION_MODIFIER", 121, 133], ["bowel", "ANATOMY", 134, 139], ["disease", "OBSERVATION", 140, 147]]], ["What follows are key GI findings:A. DiarrheaDiarrhea is the most common GI manifestations in COVID-19 patients.", [["GI", "ANATOMY", 72, 74], ["DiarrheaDiarrhea", "DISEASE", 36, 52], ["GI", "ORGANISM_SUBDIVISION", 72, 74], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110]]], ["Although multiple studies have reported diarrhea in COVID-19, a strict definition is missing (16, 17) .", [["diarrhea", "DISEASE", 40, 48], ["multiple studies", "TEST", 9, 25], ["diarrhea", "PROBLEM", 40, 48], ["COVID", "TEST", 52, 57], ["diarrhea", "OBSERVATION", 40, 48]]], ["Only a few studies have noted the severity and type of diarrhea.", [["diarrhea", "DISEASE", 55, 63], ["a few studies", "TEST", 5, 18], ["the severity", "PROBLEM", 30, 42], ["diarrhea", "PROBLEM", 55, 63], ["diarrhea", "OBSERVATION", 55, 63]]], ["Studies included loose or watery stools ranging from 2 to 10 bowel movements per day.", [["bowel", "ANATOMY", 61, 66], ["watery stools", "DISEASE", 26, 39], ["bowel", "ORGAN", 61, 66], ["Studies", "TEST", 0, 7], ["loose or watery stools", "PROBLEM", 17, 39], ["loose", "OBSERVATION_MODIFIER", 17, 22], ["bowel", "ANATOMY", 61, 66]]], ["In addition, some of the symptoms are not present at hospital admission, making it difficult to ascertain if the diarrhea is from the direct effect of SARS-CoV-2 or indirect effects (such as antiviral medications, antibiotics, altered gut flora).", [["gut flora", "ANATOMY", 235, 244], ["diarrhea", "DISEASE", 113, 121], ["SARS", "DISEASE", 151, 155], ["gut flora", "ORGANISM_SUBDIVISION", 235, 244], ["the symptoms", "PROBLEM", 21, 33], ["the diarrhea", "PROBLEM", 109, 121], ["SARS", "PROBLEM", 151, 155], ["indirect effects", "PROBLEM", 165, 181], ["antiviral medications", "TREATMENT", 191, 212], ["antibiotics", "TREATMENT", 214, 225], ["altered gut flora", "PROBLEM", 227, 244]]], ["Ideally, if diarrhea is attributed to SARS-CoV-2 infection by its direct cytopathic effect, symptoms should be present at the hospital admission, and the stool should be positive for nucleic acid.A. DiarrheaPrevalence: Studies have shown that the prevalence of diarrhea could range from 2% to 50% of the cases (17) .", [["diarrhea", "DISEASE", 12, 20], ["SARS", "DISEASE", 38, 42], ["infection", "DISEASE", 49, 58], ["nucleic acid", "CHEMICAL", 183, 195], ["diarrhea", "DISEASE", 261, 269], ["SARS-CoV-2", "ORGANISM", 38, 48], ["stool", "ORGANISM_SUBSTANCE", 154, 159], ["nucleic acid", "SIMPLE_CHEMICAL", 183, 195], ["SARS-CoV-2", "SPECIES", 38, 48], ["diarrhea", "PROBLEM", 12, 20], ["SARS", "PROBLEM", 38, 42], ["CoV-2 infection", "PROBLEM", 43, 58], ["its direct cytopathic effect", "PROBLEM", 62, 90], ["symptoms", "PROBLEM", 92, 100], ["the stool", "TEST", 150, 159], ["nucleic acid", "PROBLEM", 183, 195], ["diarrhea", "PROBLEM", 261, 269], ["diarrhea", "OBSERVATION", 261, 269]]], ["However, the overall pooled prevalence of diarrhea in COVID-19 based on multiple studies is 5-10% (17, 18 (20) .", [["diarrhea", "DISEASE", 42, 50], ["diarrhea", "PROBLEM", 42, 50], ["COVID", "TEST", 54, 59], ["multiple studies", "TEST", 72, 88], ["diarrhea", "OBSERVATION", 42, 50]]], ["Though the prevalence varied among these studies, few aspects need consideration before evaluating the prevalence of diarrhea.", [["diarrhea", "DISEASE", 117, 125], ["these studies", "TEST", 35, 48], ["diarrhea", "PROBLEM", 117, 125], ["diarrhea", "OBSERVATION", 117, 125]]], ["As noted above, a strict definition of diarrhea is not prevalent in most studies.", [["diarrhea", "DISEASE", 39, 47], ["diarrhea", "PROBLEM", 39, 47], ["diarrhea", "OBSERVATION", 39, 47]]], ["Furthermore, the recognition of symptoms increased as the disease spread across the nations, prevalence varied by the country, and if patients were treated either outpatient or on an inpatient basis.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["symptoms", "PROBLEM", 32, 40], ["the disease spread", "PROBLEM", 54, 72]]], ["For example, the studies from China report an overall lower prevalence of diarrhea of 5.8% (95% CI, 5.3%-6.4%) compared to non-Chinese studies with a prevalence of 18.3% (95% CI, 16.6%-20.1%) (18) .", [["diarrhea", "DISEASE", 74, 82], ["the studies", "TEST", 13, 24], ["diarrhea", "PROBLEM", 74, 82], ["CI", "TEST", 96, 98], ["non-Chinese studies", "TEST", 123, 142], ["a prevalence", "TEST", 148, 160], ["CI", "TEST", 175, 177]]], ["It is unclear if this is due to a lack of recognition of symptoms during early in the pandemic or due to epidemiological differences.A. DiarrheaSimilarly, the pooled prevalence of diarrhea among outpatient COVID-19 patients was 4% (95% CI, 3.1%-5.1%), which was lower as compared to the individuals who were admitted in the hospital 10.4 % (95% CI, 9.4 %-10.7%) (18) .", [["diarrhea", "DISEASE", 180, 188], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["symptoms", "PROBLEM", 57, 65], ["diarrhea", "PROBLEM", 180, 188], ["outpatient COVID", "TEST", 195, 211], ["CI", "TEST", 236, 238], ["CI", "TEST", 345, 347]]], ["This is expected because the number of patients presenting on an outpatient basis was quite low during the pandemic, especially if symptoms were not severe.A. DiarrheaPathogenesis: Understanding the mechanisms of diarrhea in COVID-19 patients is crucial to develop strategies to mitigate the spread of the disease.", [["diarrhea", "DISEASE", 213, 221], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 234, 242], ["symptoms", "PROBLEM", 131, 139], ["diarrhea", "PROBLEM", 213, 221], ["the disease", "PROBLEM", 302, 313], ["DiarrheaPathogenesis", "OBSERVATION", 159, 179], ["disease", "OBSERVATION", 306, 313]]], ["It is well recognized that the functional receptor for SARS-CoV-2 entry is angiotensin-converting enzyme-2 (ACE-2) (21) .", [["SARS", "DISEASE", 55, 59], ["angiotensin", "CHEMICAL", 75, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 75, 106], ["ACE-2", "GENE_OR_GENE_PRODUCT", 108, 113], ["angiotensin-converting enzyme-2", "PROTEIN", 75, 106], ["SARS", "TEST", 55, 59], ["CoV", "TEST", 60, 63], ["angiotensin", "TREATMENT", 75, 86], ["ACE", "TEST", 108, 111]]], ["The abundance of ACE-2 in the epithelium of the GI tract makes it vulnerable to the SARS-CoV-2 entry.", [["epithelium", "ANATOMY", 30, 40], ["GI tract", "ANATOMY", 48, 56], ["SARS", "DISEASE", 84, 88], ["ACE-2", "GENE_OR_GENE_PRODUCT", 17, 22], ["epithelium", "TISSUE", 30, 40], ["GI tract", "ORGANISM_SUBDIVISION", 48, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["ACE-2", "PROTEIN", 17, 22], ["ACE", "TEST", 17, 20], ["the SARS", "TEST", 80, 88], ["abundance", "OBSERVATION_MODIFIER", 4, 13], ["epithelium", "ANATOMY_MODIFIER", 30, 40], ["GI tract", "ANATOMY", 48, 56], ["SARS", "OBSERVATION", 84, 88]]], ["Studies have shown increased ACE-2 expression in the mucosa of the tongue, esophagus, gastric mucosa, ileum, and rectum (22, 23) .", [["mucosa", "ANATOMY", 53, 59], ["tongue", "ANATOMY", 67, 73], ["esophagus", "ANATOMY", 75, 84], ["gastric mucosa", "ANATOMY", 86, 100], ["ileum", "ANATOMY", 102, 107], ["rectum", "ANATOMY", 113, 119], ["ACE-2", "GENE_OR_GENE_PRODUCT", 29, 34], ["mucosa", "MULTI-TISSUE_STRUCTURE", 53, 59], ["tongue", "ORGAN", 67, 73], ["esophagus", "ORGAN", 75, 84], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 86, 100], ["ileum", "MULTI-TISSUE_STRUCTURE", 102, 107], ["rectum", "ORGAN", 113, 119], ["ACE", "PROTEIN", 29, 32], ["Studies", "TEST", 0, 7], ["increased ACE-2 expression in the mucosa of the tongue, esophagus, gastric mucosa, ileum, and rectum", "PROBLEM", 19, 119], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["ACE-2 expression", "OBSERVATION", 29, 45], ["mucosa", "ANATOMY", 53, 59], ["tongue", "ANATOMY", 67, 73], ["esophagus", "ANATOMY", 75, 84], ["gastric mucosa", "ANATOMY", 86, 100], ["ileum", "ANATOMY", 102, 107], ["rectum", "ANATOMY", 113, 119]]], ["Though gastric acid can significantly reduce the life of the virus, SARS-CoV-2 can still potentially make its way to the duodenum and distal small bowel, making them a target for viral cytopathic effect (24) .", [["gastric", "ANATOMY", 7, 14], ["duodenum", "ANATOMY", 121, 129], ["distal small bowel", "ANATOMY", 134, 152], ["SARS", "DISEASE", 68, 72], ["gastric acid", "CHEMICAL", 7, 19], ["gastric acid", "SIMPLE_CHEMICAL", 7, 19], ["SARS-CoV-2", "ORGANISM", 68, 78], ["duodenum", "ORGAN", 121, 129], ["small", "ORGAN", 141, 146], ["bowel", "ORGAN", 147, 152], ["SARS-CoV", "SPECIES", 68, 76], ["gastric acid", "PROBLEM", 7, 19], ["the virus", "PROBLEM", 57, 66], ["viral cytopathic effect", "PROBLEM", 179, 202], ["gastric", "ANATOMY", 7, 14], ["acid", "OBSERVATION", 15, 19], ["duodenum", "ANATOMY", 121, 129], ["distal", "ANATOMY_MODIFIER", 134, 140], ["small bowel", "ANATOMY", 141, 152]]], ["Once the virus enters the epithelium, replication and synthesis occur at a rapid rate resulting in cytopathic changes evidenced by intracellular staining of viral nucleocapsid protein.", [["epithelium", "ANATOMY", 26, 36], ["intracellular", "ANATOMY", 131, 144], ["epithelium", "TISSUE", 26, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 144], ["viral nucleocapsid protein", "PROTEIN", 157, 183], ["the virus", "PROBLEM", 5, 14], ["synthesis", "TREATMENT", 54, 63], ["a rapid rate", "TEST", 73, 85], ["cytopathic changes", "PROBLEM", 99, 117], ["intracellular staining of viral nucleocapsid protein", "PROBLEM", 131, 183], ["virus", "OBSERVATION", 9, 14], ["epithelium", "ANATOMY_MODIFIER", 26, 36], ["cytopathic", "OBSERVATION", 99, 109], ["intracellular staining", "OBSERVATION", 131, 153], ["viral nucleocapsid protein", "OBSERVATION", 157, 183]]], ["It remains to be studied if the presence of SARS-CoV-2 in the stools of these patients is the cause of diarrhea or if the virus is just a bystander.", [["SARS", "DISEASE", 44, 48], ["diarrhea", "DISEASE", 103, 111], ["SARS-CoV-2", "ORGANISM", 44, 54], ["stools", "ORGANISM_SUBDIVISION", 62, 68], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["diarrhea", "PROBLEM", 103, 111], ["the virus", "PROBLEM", 118, 127], ["diarrhea", "OBSERVATION", 103, 111]]], ["This explains the need for stool RNA testing in patients with diarrhea not only to assess for infectivity but also to assess the potential cytopathic effects.A. DiarrheaIn addition to the above mechanisms, gut flora has been shown to be altered in the patient's severe disease state with the use of antimicrobials, and enteral nutrition (25) .", [["gut flora", "ANATOMY", 206, 215], ["diarrhea", "DISEASE", 62, 70], ["patients", "ORGANISM", 48, 56], ["gut", "ORGANISM_SUBDIVISION", 206, 209], ["patient", "ORGANISM", 252, 259], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 252, 259], ["stool RNA testing", "TEST", 27, 44], ["diarrhea", "PROBLEM", 62, 70], ["infectivity", "PROBLEM", 94, 105], ["the potential cytopathic effects", "PROBLEM", 125, 157], ["the above mechanisms", "TREATMENT", 184, 204], ["gut flora", "PROBLEM", 206, 215], ["the patient's severe disease state", "PROBLEM", 248, 282], ["antimicrobials", "TREATMENT", 299, 313], ["enteral nutrition", "TREATMENT", 319, 336], ["cytopathic", "OBSERVATION", 139, 149], ["flora", "OBSERVATION", 210, 215], ["altered", "OBSERVATION_MODIFIER", 237, 244], ["severe", "OBSERVATION_MODIFIER", 262, 268], ["disease", "OBSERVATION", 269, 276]]], ["Hyperinflammation noted in COVID-19 patients (cytokine storm syndrome) can release a number of cytokines such as interleukins (IL-2, 7), granulocyte monocyte colony-stimulating factor (GM-CSF) and tumor necrosis factors (\u03a4\u039dF\u03b1) which not only alter the gut motility but also affects the GI flora, increasing the risk for diarrhea (26) .", [["gut", "ANATOMY", 252, 255], ["GI flora", "ANATOMY", 286, 294], ["Hyperinflammation", "DISEASE", 0, 17], ["tumor necrosis", "DISEASE", 197, 211], ["diarrhea", "DISEASE", 320, 328], ["patients", "ORGANISM", 36, 44], ["interleukins", "GENE_OR_GENE_PRODUCT", 113, 125], ["IL-2", "GENE_OR_GENE_PRODUCT", 127, 131], ["7", "GENE_OR_GENE_PRODUCT", 133, 134], ["granulocyte monocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 137, 183], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 185, 191], ["tumor necrosis factors", "GENE_OR_GENE_PRODUCT", 197, 219], ["\u03a4\u039dF\u03b1", "GENE_OR_GENE_PRODUCT", 221, 225], ["gut", "ORGANISM_SUBDIVISION", 252, 255], ["GI flora", "PATHOLOGICAL_FORMATION", 286, 294], ["cytokine", "PROTEIN", 46, 54], ["cytokines", "PROTEIN", 95, 104], ["interleukins", "PROTEIN", 113, 125], ["IL-2, 7", "PROTEIN", 127, 134], ["granulocyte monocyte colony-stimulating factor", "PROTEIN", 137, 183], ["GM", "PROTEIN", 185, 187], ["CSF", "PROTEIN", 188, 191], ["tumor necrosis factors", "PROTEIN", 197, 219], ["\u03a4\u039dF\u03b1", "PROTEIN", 221, 225], ["patients", "SPECIES", 36, 44], ["Hyperinflammation", "PROBLEM", 0, 17], ["COVID", "TEST", 27, 32], ["cytokine storm syndrome", "PROBLEM", 46, 69], ["cytokines", "PROBLEM", 95, 104], ["interleukins (IL", "TEST", 113, 129], ["granulocyte monocyte colony", "TEST", 137, 164], ["stimulating factor", "PROBLEM", 165, 183], ["GM-CSF", "TEST", 185, 191], ["tumor necrosis factors", "PROBLEM", 197, 219], ["the GI flora", "PROBLEM", 282, 294], ["diarrhea", "PROBLEM", 320, 328], ["granulocyte monocyte", "ANATOMY", 137, 157], ["tumor", "OBSERVATION_MODIFIER", 197, 202], ["necrosis", "OBSERVATION", 203, 211], ["GI", "ANATOMY", 286, 288], ["flora", "OBSERVATION", 289, 294]]], ["Multiple antiviral and antibiotics are used in the management of COVID-19 patients, which can directly induce diarrhea as a part adverse effects of these medications (27) .", [["diarrhea", "DISEASE", 110, 118], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Multiple antiviral", "TREATMENT", 0, 18], ["antibiotics", "TREATMENT", 23, 34], ["COVID", "TEST", 65, 70], ["diarrhea", "PROBLEM", 110, 118], ["these medications", "TREATMENT", 148, 165], ["antiviral", "OBSERVATION", 9, 18]]], ["Fecal calprotectin is elevated in COVID-19 patients who have diarrhea lasting for more than 48 hours (14) .", [["Fecal", "ANATOMY", 0, 5], ["diarrhea", "DISEASE", 61, 69], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["calprotectin", "GENE_OR_GENE_PRODUCT", 6, 18], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Fecal calprotectin", "TEST", 0, 18], ["diarrhea", "PROBLEM", 61, 69], ["calprotectin", "OBSERVATION", 6, 18], ["elevated", "OBSERVATION_MODIFIER", 22, 30], ["diarrhea", "OBSERVATION", 61, 69]]], ["Furthermore, ACE-2 activity is overexpressed in inflamed gut tissue, especially in inflammatory bowel disease (IBD) (28) .", [["gut tissue", "ANATOMY", 57, 67], ["bowel", "ANATOMY", 96, 101], ["inflammatory bowel disease", "DISEASE", 83, 109], ["IBD", "DISEASE", 111, 114], ["ACE-2", "GENE_OR_GENE_PRODUCT", 13, 18], ["gut tissue", "TISSUE", 57, 67], ["bowel", "ORGAN", 96, 101], ["ACE", "PROTEIN", 13, 16], ["ACE-2 activity", "TREATMENT", 13, 27], ["inflamed gut tissue", "PROBLEM", 48, 67], ["inflammatory bowel disease", "PROBLEM", 83, 109], ["inflamed", "OBSERVATION", 48, 56], ["gut tissue", "ANATOMY", 57, 67], ["inflammatory", "OBSERVATION_MODIFIER", 83, 95], ["bowel", "ANATOMY", 96, 101], ["disease", "OBSERVATION", 102, 109]]], ["This signifies the role of gut inflammation in these patients.", [["gut", "ANATOMY", 27, 30], ["inflammation", "DISEASE", 31, 43], ["gut", "ORGANISM_SUBDIVISION", 27, 30], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["gut inflammation", "PROBLEM", 27, 43], ["gut", "ANATOMY", 27, 30], ["inflammation", "OBSERVATION", 31, 43]]], ["It is unclear if an isolated mechanism or a combination of factors plays a role in diarrhea in COVID-19 patients (29) .A. DiarrheaNevertheless, identification of these pathways might be used for potential therapeutic drug targets for treatment for the symptoms in the future.A. DiarrheaStool Testing: As SARS-CoV-2 gains entry through the mucous membranes and can affect the GI epithelium, it is expected that stools can be positive for viral RNA particles.", [["mucous membranes", "ANATOMY", 339, 355], ["GI epithelium", "ANATOMY", 375, 388], ["stools", "ANATOMY", 410, 416], ["diarrhea", "DISEASE", 83, 91], ["patients", "ORGANISM", 104, 112], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 339, 355], ["GI epithelium", "TISSUE", 375, 388], ["stools", "ORGANISM_SUBSTANCE", 410, 416], ["viral RNA particles", "RNA", 437, 456], ["patients", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 304, 312], ["an isolated mechanism", "PROBLEM", 17, 38], ["diarrhea", "PROBLEM", 83, 91], ["therapeutic drug targets", "TREATMENT", 205, 229], ["treatment", "TREATMENT", 234, 243], ["the symptoms", "PROBLEM", 248, 260], ["stools", "PROBLEM", 410, 416], ["viral RNA particles", "PROBLEM", 437, 456], ["unclear if", "UNCERTAINTY", 6, 16], ["mucous membranes", "ANATOMY", 339, 355], ["GI epithelium", "ANATOMY", 375, 388]]], ["A systematic review of 12 studies showed a pooled prevalence of 48.1% (95% CI, 38.3%-57.9%) for stool RNA positivity (30) .A. DiarrheaFew aspects need consideration to identify the importance of stool positivity and fecal shedding.", [["stool", "ANATOMY", 195, 200], ["fecal", "ANATOMY", 216, 221], ["stool", "ORGANISM_SUBSTANCE", 195, 200], ["fecal", "ORGANISM_SUBSTANCE", 216, 221], ["A systematic review", "TEST", 0, 19], ["12 studies", "TEST", 23, 33], ["a pooled prevalence", "TEST", 41, 60], ["CI", "TEST", 75, 77], ["stool RNA positivity", "TEST", 96, 116], ["stool positivity", "PROBLEM", 195, 211], ["fecal shedding", "PROBLEM", 216, 230]]], ["In patients with SARS-CoV-2 infection, viral replication occurs in different organ systems, including the GI tract.", [["organ systems", "ANATOMY", 77, 90], ["GI tract", "ANATOMY", 106, 114], ["SARS-CoV-2 infection", "DISEASE", 17, 37], ["patients", "ORGANISM", 3, 11], ["SARS-CoV-2", "ORGANISM", 17, 27], ["organ", "ORGAN", 77, 82], ["GI tract", "ORGANISM_SUBDIVISION", 106, 114], ["patients", "SPECIES", 3, 11], ["SARS-CoV-2", "SPECIES", 17, 27], ["SARS", "PROBLEM", 17, 21], ["CoV", "PROBLEM", 22, 25], ["2 infection", "PROBLEM", 26, 37], ["viral replication", "PROBLEM", 39, 56], ["the GI tract", "PROBLEM", 102, 114], ["SARS", "OBSERVATION", 17, 21], ["infection", "OBSERVATION", 28, 37], ["viral replication", "OBSERVATION", 39, 56], ["GI tract", "ANATOMY", 106, 114]]], ["A study conducted in Hong Kong among 59 patients with COVID-19, nine patients (15.3%) had positive stool viral RNA (30) .", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 69, 77], ["A study", "TEST", 0, 7], ["COVID", "TEST", 54, 59], ["positive stool viral RNA", "PROBLEM", 90, 114], ["viral RNA", "OBSERVATION_MODIFIER", 105, 114]]], ["In the same study, patients without diarrhea were also tested positive for the stool viral RNA, but a lower rate.", [["diarrhea", "DISEASE", 36, 44], ["patients", "ORGANISM", 19, 27], ["stool viral RNA", "RNA", 79, 94], ["patients", "SPECIES", 19, 27], ["the same study", "TEST", 3, 17], ["diarrhea", "PROBLEM", 36, 44], ["the stool viral RNA", "PROBLEM", 75, 94], ["viral RNA", "OBSERVATION", 85, 94]]], ["The median fecal viral RNA load was higher in individuals with diarrhea compared to without diarrhea (5.1 log 10 copies/ml vs. 3.9 log 10 copies/ml; p=0.06) (30) .A. DiarrheaA study by Wolfel et al. noted that stool specimens could be positive for 11 days in individuals presenting with diarrhea as an initial symptom (31) .", [["stool specimens", "ANATOMY", 210, 225], ["diarrhea", "DISEASE", 63, 71], ["diarrhea", "DISEASE", 92, 100], ["diarrhea", "DISEASE", 287, 295], ["stool specimens", "ORGANISM_SUBSTANCE", 210, 225], ["The median fecal viral RNA load", "TEST", 0, 31], ["diarrhea", "PROBLEM", 63, 71], ["diarrhea", "PROBLEM", 92, 100], ["p", "TEST", 149, 150], ["DiarrheaA study", "TEST", 166, 181], ["stool specimens", "TEST", 210, 225], ["diarrhea", "PROBLEM", 287, 295], ["median fecal", "ANATOMY", 4, 16], ["viral RNA load", "OBSERVATION", 17, 31], ["diarrhea", "OBSERVATION", 63, 71], ["stool", "OBSERVATION", 210, 215]]], ["In addition, the use of steroids and immunosuppressive medications could prolong the stool viral RNA shedding (32, 33 (34) .", [["steroids", "CHEMICAL", 24, 32], ["steroids", "CHEMICAL", 24, 32], ["steroids", "SIMPLE_CHEMICAL", 24, 32], ["steroids", "TREATMENT", 24, 32], ["immunosuppressive medications", "TREATMENT", 37, 66], ["the stool viral RNA shedding", "PROBLEM", 81, 109]]], ["Additionally, the median fecal viral load to establish infectivity from infected patients to non-infected individuals is essential (30) .A. DiarrheaRegardless of diarrhea, identification of stool positivity is vital in all patients as they can potentially spread the virus to a non-infected individual.", [["stool", "ANATOMY", 190, 195], ["infectivity from infected", "DISEASE", 55, 80], ["diarrhea", "DISEASE", 162, 170], ["fecal", "ORGANISM_SUBSTANCE", 25, 30], ["patients", "ORGANISM", 81, 89], ["stool", "ORGANISM_SUBSTANCE", 190, 195], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 223, 231], ["the median fecal viral load", "PROBLEM", 14, 41], ["infectivity", "PROBLEM", 55, 66], ["diarrhea", "PROBLEM", 162, 170], ["stool positivity", "PROBLEM", 190, 206], ["the virus", "PROBLEM", 263, 272], ["viral load", "OBSERVATION", 31, 41], ["diarrhea", "OBSERVATION", 162, 170], ["stool", "OBSERVATION", 190, 195]]], ["Previous outbreaks of SARS in 2003, the sewage system was a significant source of infection (35, 36) .", [["SARS", "DISEASE", 22, 26], ["infection", "DISEASE", 82, 91], ["SARS", "PROBLEM", 22, 26], ["infection", "PROBLEM", 82, 91], ["SARS", "OBSERVATION_MODIFIER", 22, 26], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["infection", "OBSERVATION", 82, 91]]], ["Similarly, testing of waste-water treatment plants showed positivity for SARS-CoV-2 as well (37) .", [["SARS", "DISEASE", 73, 77], ["SARS-CoV", "SPECIES", 73, 81], ["water treatment plants", "TREATMENT", 28, 50], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81]]], ["These studies uncovered the potential of the fecaloral route of transmission of SARS-CoV-2.A. DiarrheaEarly identification of GI manifestations is not only crucial in the management but also of public health importance (36, 38) .", [["GI", "ANATOMY", 126, 128], ["SARS", "DISEASE", 80, 84], ["SARS-CoV-2.A", "ORGANISM", 80, 92], ["GI", "PATHOLOGICAL_FORMATION", 126, 128], ["SARS-CoV-2.A", "SPECIES", 80, 92], ["These studies", "TEST", 0, 13], ["CoV", "TEST", 85, 88], ["GI manifestations", "PROBLEM", 126, 143], ["GI", "ANATOMY", 126, 128], ["manifestations", "OBSERVATION", 129, 143]]], ["The presence of SARS-CoV-2 in stool, especially in patients with diarrhea, makes it a potential route of transmission.", [["stool", "ANATOMY", 30, 35], ["SARS", "DISEASE", 16, 20], ["diarrhea", "DISEASE", 65, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 16, 26], ["stool", "ORGANISM", 30, 35], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["stool", "PROBLEM", 30, 35], ["diarrhea", "PROBLEM", 65, 73], ["SARS", "OBSERVATION", 16, 20], ["stool", "OBSERVATION", 30, 35], ["diarrhea", "OBSERVATION", 65, 73]]], ["This can put the endoscopists and the ancillary staff at the risk of acquiring the infection via direct contact GI secretions (3) .", [["infection", "DISEASE", 83, 92], ["the infection", "PROBLEM", 79, 92], ["infection", "OBSERVATION", 83, 92]]], ["Moreover, the generation of aerosols because of suctioning during endoscopies carry a further risk of transmission to the hospital staff members (3, 39, 40) .", [["aerosols", "TREATMENT", 28, 36], ["suctioning", "TREATMENT", 48, 58], ["endoscopies", "TREATMENT", 66, 77]]], ["Patients with only GI symptoms involved in professions such as food handling, restaurant staff carry the risk of super-spreaders of the disease (41).B. Nausea or vomitingPatients with COVID-19 can develop nausea and vomiting during the initial presentation of the disease.", [["Nausea", "DISEASE", 152, 158], ["vomiting", "DISEASE", 162, 170], ["COVID-19", "CHEMICAL", 184, 192], ["nausea", "DISEASE", 205, 211], ["vomiting", "DISEASE", 216, 224], ["Patients", "ORGANISM", 0, 8], ["Patients", "ORGANISM", 170, 178], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 170, 178], ["GI symptoms", "PROBLEM", 19, 30], ["the disease", "PROBLEM", 132, 143], ["Nausea", "PROBLEM", 152, 158], ["vomiting", "PROBLEM", 162, 170], ["COVID", "TEST", 184, 189], ["nausea", "PROBLEM", 205, 211], ["vomiting", "PROBLEM", 216, 224], ["the disease", "PROBLEM", 260, 271], ["disease", "OBSERVATION", 136, 143], ["Nausea", "OBSERVATION", 152, 158], ["nausea", "OBSERVATION", 205, 211], ["disease", "OBSERVATION", 264, 271]]], ["While this could imply a viral prodrome, the persistence of symptoms could herald potential GI involvement.", [["GI", "ANATOMY", 92, 94], ["viral prodrome", "DISEASE", 25, 39], ["GI", "PATHOLOGICAL_FORMATION", 92, 94], ["a viral prodrome", "PROBLEM", 23, 39], ["symptoms", "PROBLEM", 60, 68], ["viral", "OBSERVATION", 25, 30]]], ["A pooled analysis of 5955 patients with COVID-19 showed a prevalence of nausea or vomiting in 7.8% (95% CI, 7.1%-8.5%) of the patients (18) .", [["nausea", "DISEASE", 72, 78], ["vomiting", "DISEASE", 82, 90], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 126, 134], ["A pooled analysis", "TEST", 0, 17], ["COVID", "TEST", 40, 45], ["nausea", "PROBLEM", 72, 78], ["vomiting", "PROBLEM", 82, 90], ["CI", "TEST", 104, 106]]], ["Similar to diarrhea, the prevalence of nausea or vomiting in Chinese studies was low (5.2%; 95% CI 4.4%-5.9%), probably due to decreased awareness of GI manifestations early in the pandemic (18) .B. Nausea or vomitingThe mechanism of nausea or vomiting in COVID-19 is unclear.", [["GI", "ANATOMY", 150, 152], ["diarrhea", "DISEASE", 11, 19], ["nausea", "DISEASE", 39, 45], ["vomiting", "DISEASE", 49, 57], ["pandemic", "DISEASE", 181, 189], ["Nausea", "DISEASE", 199, 205], ["vomiting", "DISEASE", 209, 217], ["nausea", "DISEASE", 234, 240], ["vomiting", "DISEASE", 244, 252], ["COVID-19", "CHEMICAL", 256, 264], ["GI", "ORGANISM_SUBDIVISION", 150, 152], ["diarrhea", "PROBLEM", 11, 19], ["nausea", "PROBLEM", 39, 45], ["vomiting", "PROBLEM", 49, 57], ["Chinese studies", "TEST", 61, 76], ["CI", "TEST", 96, 98], ["GI manifestations", "PROBLEM", 150, 167], ["Nausea", "PROBLEM", 199, 205], ["vomiting", "PROBLEM", 209, 217], ["nausea", "PROBLEM", 234, 240], ["vomiting", "PROBLEM", 244, 252], ["COVID", "TEST", 256, 261], ["diarrhea", "OBSERVATION", 11, 19], ["GI", "ANATOMY", 150, 152], ["nausea", "OBSERVATION", 234, 240]]], ["It is suspected that the interaction between the gut and central nervous system may play a potential role in the pathophysiology of these symptoms.", [["gut", "ANATOMY", 49, 52], ["central nervous system", "ANATOMY", 57, 79], ["gut", "ORGANISM_SUBDIVISION", 49, 52], ["central nervous system", "ANATOMICAL_SYSTEM", 57, 79], ["the interaction between the gut and central nervous system", "PROBLEM", 21, 79], ["these symptoms", "PROBLEM", 132, 146], ["gut", "ANATOMY", 49, 52], ["central", "ANATOMY_MODIFIER", 57, 64], ["nervous", "ANATOMY", 65, 72]]], ["The release of pro-inflammatory cytokines in COVID-19 can alter the gut-brain axis involvement of vagal nerve or through vascular/ lymphatic system (25) .", [["gut", "ANATOMY", 68, 71], ["brain", "ANATOMY", 72, 77], ["vagal nerve", "ANATOMY", 98, 109], ["vascular", "ANATOMY", 121, 129], ["lymphatic system", "ANATOMY", 131, 147], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["gut", "ORGANISM_SUBDIVISION", 68, 71], ["brain", "ORGAN", 72, 77], ["vagal nerve", "MULTI-TISSUE_STRUCTURE", 98, 109], ["vascular", "MULTI-TISSUE_STRUCTURE", 121, 129], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 131, 147], ["pro-inflammatory cytokines", "PROTEIN", 15, 41], ["pro-inflammatory cytokines", "TEST", 15, 41], ["COVID", "TEST", 45, 50], ["vagal nerve", "PROBLEM", 98, 109], ["gut", "ANATOMY", 68, 71], ["brain axis", "ANATOMY", 72, 82], ["vagal nerve", "ANATOMY", 98, 109], ["vascular", "ANATOMY", 121, 129], ["lymphatic system", "ANATOMY", 131, 147]]], ["Lateral hypothalamic nuclei are closely involved pathogenesis of nausea and vomiting (42) .", [["Lateral hypothalamic nuclei", "ANATOMY", 0, 27], ["nausea", "DISEASE", 65, 71], ["vomiting", "DISEASE", 76, 84], ["Lateral hypothalamic nuclei", "PROBLEM", 0, 27], ["nausea", "PROBLEM", 65, 71], ["vomiting", "PROBLEM", 76, 84], ["hypothalamic nuclei", "ANATOMY", 8, 27], ["nausea", "OBSERVATION", 65, 71]]], ["Neurological manifestations in COVID-19 patients can range up to 36.4%, and symptoms increase with age and underlying comorbidities (43) .", [["Neurological", "ANATOMY", 0, 12], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Neurological manifestations", "PROBLEM", 0, 27], ["COVID", "TEST", 31, 36], ["symptoms", "PROBLEM", 76, 84], ["underlying comorbidities", "PROBLEM", 107, 131]]], ["If the involvement of the hypothalamus directly or indirectly plays a role in these GI symptoms remains to be studied.", [["hypothalamus", "ANATOMY", 26, 38], ["GI", "ANATOMY", 84, 86], ["hypothalamus", "ORGAN", 26, 38], ["GI", "ANATOMICAL_SYSTEM", 84, 86], ["these GI symptoms", "PROBLEM", 78, 95], ["hypothalamus", "ANATOMY", 26, 38]]], ["Furthermore, viral replication in the GI tract can interfere with neurohormonal signaling, which can induce nausea and vomiting (44) .", [["GI tract", "ANATOMY", 38, 46], ["nausea", "DISEASE", 108, 114], ["vomiting", "DISEASE", 119, 127], ["GI tract", "ORGANISM_SUBDIVISION", 38, 46], ["viral replication in the GI tract", "PROBLEM", 13, 46], ["neurohormonal signaling", "PROBLEM", 66, 89], ["nausea", "PROBLEM", 108, 114], ["vomiting", "PROBLEM", 119, 127], ["viral replication", "OBSERVATION", 13, 30], ["GI tract", "ANATOMY", 38, 46]]], ["Further studies are needed to elucidate the precise mechanism of these symptoms.C. Loss of appetiteLoss of appetite is a common GI manifestation in COVID-19.", [["GI", "ANATOMY", 128, 130], ["C", "GENE_OR_GENE_PRODUCT", 80, 81], ["GI", "CANCER", 128, 130], ["Further studies", "TEST", 0, 15], ["these symptoms", "PROBLEM", 65, 79], ["Loss of appetiteLoss of appetite", "PROBLEM", 83, 115], ["COVID", "TEST", 148, 153]]], ["However, due to its non-specific nature, it is typically combined with other GI symptoms for its relevance.", [["other GI symptoms", "PROBLEM", 71, 88]]], ["Individual studies have reported a prevalence of 12.2% to 50.2% in patients with COVID-19 (45) (46) (47) .", [["COVID-19", "CHEMICAL", 81, 89], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Individual studies", "TEST", 0, 18], ["a prevalence", "TEST", 33, 45], ["COVID", "TEST", 81, 86]]], ["Among 18 studies, the pooled prevalence of loss of appetite was 26.8% (95% CI, 16.2%-40.8%).", [["loss of appetite", "DISEASE", 43, 59], ["loss of appetite", "PROBLEM", 43, 59], ["CI", "TEST", 75, 77]]], ["Though this is higher than the prevalence of diarrhea, it is unclear if they are isolated without other GI symptoms (abdominal pain, nausea/vomiting, or diarrhea).", [["GI", "ANATOMY", 104, 106], ["abdominal", "ANATOMY", 117, 126], ["diarrhea", "DISEASE", 45, 53], ["abdominal pain", "DISEASE", 117, 131], ["nausea/vomiting", "DISEASE", 133, 148], ["diarrhea", "DISEASE", 153, 161], ["GI", "ORGANISM_SUBDIVISION", 104, 106], ["abdominal", "ORGANISM_SUBDIVISION", 117, 126], ["diarrhea", "PROBLEM", 45, 53], ["other GI symptoms", "PROBLEM", 98, 115], ["abdominal pain", "PROBLEM", 117, 131], ["nausea", "PROBLEM", 133, 139], ["vomiting", "PROBLEM", 140, 148], ["diarrhea", "PROBLEM", 153, 161], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["diarrhea", "OBSERVATION", 45, 53], ["abdominal", "ANATOMY", 117, 126]]], ["Mechanism of anorexia is probably related to nausea and vomiting, but assessing the literature to evaluate the precise pathophysiology is not available.D. Abdominal painPatients with COVID-19 reports abdominal pain on an infrequent basis.", [["abdominal", "ANATOMY", 200, 209], ["anorexia", "DISEASE", 13, 21], ["nausea", "DISEASE", 45, 51], ["vomiting", "DISEASE", 56, 64], ["abdominal pain", "DISEASE", 200, 214], ["abdominal", "ORGANISM_SUBDIVISION", 200, 209], ["anorexia", "PROBLEM", 13, 21], ["nausea", "PROBLEM", 45, 51], ["vomiting", "PROBLEM", 56, 64], ["COVID", "TEST", 183, 188], ["abdominal pain", "PROBLEM", 200, 214], ["anorexia", "OBSERVATION", 13, 21], ["probably related to", "UNCERTAINTY", 25, 44], ["nausea", "OBSERVATION", 45, 51], ["Abdominal", "ANATOMY", 155, 164], ["abdominal", "ANATOMY", 200, 209], ["pain", "OBSERVATION", 210, 214]]], ["The prevalence of abdominal pain is lower compared to diarrhea, nausea, or vomiting, or anorexia.", [["abdominal", "ANATOMY", 18, 27], ["abdominal pain", "DISEASE", 18, 32], ["diarrhea", "DISEASE", 54, 62], ["nausea", "DISEASE", 64, 70], ["vomiting", "DISEASE", 75, 83], ["anorexia", "DISEASE", 88, 96], ["abdominal", "ORGANISM_SUBDIVISION", 18, 27], ["abdominal pain", "PROBLEM", 18, 32], ["diarrhea", "PROBLEM", 54, 62], ["nausea", "PROBLEM", 64, 70], ["vomiting", "PROBLEM", 75, 83], ["anorexia", "PROBLEM", 88, 96], ["abdominal", "ANATOMY", 18, 27], ["pain", "OBSERVATION", 28, 32], ["anorexia", "OBSERVATION", 88, 96]]], ["Similar to other GI symptoms, the prevalence of this symptom is lower in Chinese studies 2.7% (95% CI, 2.0%-3.4%), whereas the non-Chinese studies report a prevalence of 5.3% (95% CI, 4.2%-6.6%) (18) .", [["other GI symptoms", "PROBLEM", 11, 28], ["this symptom", "PROBLEM", 48, 60], ["Chinese studies", "TEST", 73, 88], ["CI", "TEST", 99, 101], ["the non-Chinese studies", "TEST", 123, 146], ["CI", "TEST", 180, 182], ["lower", "OBSERVATION_MODIFIER", 64, 69]]], ["Few aspects of abdominal pain need consideration.", [["abdominal", "ANATOMY", 15, 24], ["abdominal pain", "DISEASE", 15, 29], ["abdominal", "ORGANISM_SUBDIVISION", 15, 24], ["abdominal pain", "PROBLEM", 15, 29], ["abdominal", "ANATOMY", 15, 24], ["pain", "OBSERVATION", 25, 29]]], ["Symptoms can range from generalized abdominal pain or epigastric pain or just non-specific abdominal discomfort.", [["abdominal", "ANATOMY", 36, 45], ["epigastric", "ANATOMY", 54, 64], ["abdominal", "ANATOMY", 91, 100], ["abdominal pain", "DISEASE", 36, 50], ["epigastric pain", "DISEASE", 54, 69], ["abdominal discomfort", "DISEASE", 91, 111], ["abdominal", "ORGANISM_SUBDIVISION", 36, 45], ["epigastric", "ORGANISM_SUBDIVISION", 54, 64], ["abdominal", "ORGANISM_SUBDIVISION", 91, 100], ["Symptoms", "PROBLEM", 0, 8], ["generalized abdominal pain", "PROBLEM", 24, 50], ["epigastric pain", "PROBLEM", 54, 69], ["non-specific abdominal discomfort", "PROBLEM", 78, 111], ["abdominal", "ANATOMY", 36, 45], ["pain", "OBSERVATION", 46, 50], ["epigastric", "ANATOMY", 54, 64], ["abdominal", "ANATOMY", 91, 100], ["discomfort", "OBSERVATION", 101, 111]]], ["Furthermore, COVID-19 induced pancreatitis has been reported with symptoms of abdominal pain (12, 50, 51) .", [["abdominal", "ANATOMY", 78, 87], ["COVID-19", "CHEMICAL", 13, 21], ["pancreatitis", "DISEASE", 30, 42], ["abdominal pain", "DISEASE", 78, 92], ["COVID-19", "CHEMICAL", 13, 21], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["abdominal", "ORGANISM_SUBDIVISION", 78, 87], ["COVID", "TEST", 13, 18], ["pancreatitis", "PROBLEM", 30, 42], ["symptoms", "PROBLEM", 66, 74], ["abdominal pain", "PROBLEM", 78, 92], ["pancreatitis", "OBSERVATION", 30, 42], ["abdominal", "ANATOMY", 78, 87], ["pain", "OBSERVATION", 88, 92]]], ["Though elevated levels of lipase are noted in COVID- 19 , it remains unclear if they indicate a low-level of ongoing pancreatic injury or non-pancreatic causes such as gastritis or enteritis (52).", [["pancreatic", "ANATOMY", 117, 127], ["non-pancreatic", "ANATOMY", 138, 152], ["pancreatic injury", "DISEASE", 117, 134], ["gastritis", "DISEASE", 168, 177], ["enteritis", "DISEASE", 181, 190], ["lipase", "GENE_OR_GENE_PRODUCT", 26, 32], ["pancreatic", "ORGAN", 117, 127], ["lipase", "PROTEIN", 26, 32], ["elevated levels of lipase", "PROBLEM", 7, 32], ["COVID", "TEST", 46, 51], ["ongoing pancreatic injury", "PROBLEM", 109, 134], ["non-pancreatic causes", "PROBLEM", 138, 159], ["gastritis", "PROBLEM", 168, 177], ["enteritis", "PROBLEM", 181, 190], ["elevated", "OBSERVATION_MODIFIER", 7, 15], ["levels", "OBSERVATION_MODIFIER", 16, 22], ["lipase", "ANATOMY", 26, 32], ["pancreatic", "ANATOMY", 117, 127], ["injury", "OBSERVATION", 128, 134], ["gastritis", "OBSERVATION", 168, 177], ["enteritis", "OBSERVATION", 181, 190]]], ["The duration of these symptoms in the studies was missing.Although abdominal discomfort (from cramps) is frequently noted in viral infection, it is unclear if itcorrelates with the severity of GI involvement.", [["abdominal", "ANATOMY", 67, 76], ["GI", "ANATOMY", 193, 195], ["abdominal discomfort", "DISEASE", 67, 87], ["cramps", "DISEASE", 94, 100], ["viral infection", "DISEASE", 125, 140], ["abdominal", "ORGANISM_SUBDIVISION", 67, 76], ["GI", "ORGANISM_SUBDIVISION", 193, 195], ["these symptoms", "PROBLEM", 16, 30], ["the studies", "TEST", 34, 45], ["abdominal discomfort", "PROBLEM", 67, 87], ["cramps", "PROBLEM", 94, 100], ["viral infection", "PROBLEM", 125, 140], ["GI involvement", "PROBLEM", 193, 207], ["abdominal", "ANATOMY", 67, 76], ["discomfort", "OBSERVATION", 77, 87], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infection", "OBSERVATION", 131, 140], ["GI", "ANATOMY", 193, 195], ["involvement", "OBSERVATION", 196, 207]]], ["If abdominal pain corresponds to the viral cytopathic effect and involvement of the enteric nervous system is yet to be studied.E. Other GI symptomsAlthough GI symptoms such as diarrhea, anorexia, nausea or vomiting, and abdominal pain are commonly reported, few cases of gastrointestinal bleeding, colitis, and secondary bacterial infections were reported (53).", [["abdominal", "ANATOMY", 3, 12], ["enteric nervous system", "ANATOMY", 84, 106], ["GI", "ANATOMY", 157, 159], ["abdominal", "ANATOMY", 221, 230], ["gastrointestinal", "ANATOMY", 272, 288], ["abdominal pain", "DISEASE", 3, 17], ["GI symptoms", "DISEASE", 157, 168], ["diarrhea", "DISEASE", 177, 185], ["anorexia", "DISEASE", 187, 195], ["nausea", "DISEASE", 197, 203], ["vomiting", "DISEASE", 207, 215], ["abdominal pain", "DISEASE", 221, 235], ["gastrointestinal bleeding", "DISEASE", 272, 297], ["colitis", "DISEASE", 299, 306], ["bacterial infections", "DISEASE", 322, 342], ["abdominal", "ORGANISM_SUBDIVISION", 3, 12], ["enteric nervous system", "ANATOMICAL_SYSTEM", 84, 106], ["abdominal", "ORGANISM_SUBDIVISION", 221, 230], ["gastrointestinal", "ORGANISM_SUBDIVISION", 272, 288], ["abdominal pain", "PROBLEM", 3, 17], ["the viral cytopathic effect", "PROBLEM", 33, 60], ["the enteric nervous system", "PROBLEM", 80, 106], ["Other GI symptoms", "PROBLEM", 131, 148], ["GI symptoms", "PROBLEM", 157, 168], ["diarrhea", "PROBLEM", 177, 185], ["anorexia", "PROBLEM", 187, 195], ["nausea", "PROBLEM", 197, 203], ["vomiting", "PROBLEM", 207, 215], ["abdominal pain", "PROBLEM", 221, 235], ["gastrointestinal bleeding", "PROBLEM", 272, 297], ["colitis", "PROBLEM", 299, 306], ["secondary bacterial infections", "PROBLEM", 312, 342], ["abdominal", "ANATOMY", 3, 12], ["pain", "OBSERVATION", 13, 17], ["viral", "OBSERVATION_MODIFIER", 37, 42], ["cytopathic effect", "OBSERVATION", 43, 60], ["enteric nervous", "ANATOMY", 84, 99], ["GI", "ANATOMY", 137, 139], ["symptoms", "OBSERVATION", 140, 148], ["anorexia", "OBSERVATION", 187, 195], ["abdominal", "ANATOMY", 221, 230], ["pain", "OBSERVATION", 231, 235], ["gastrointestinal", "ANATOMY", 272, 288], ["bleeding", "OBSERVATION", 289, 297], ["colitis", "OBSERVATION", 299, 306], ["secondary", "OBSERVATION_MODIFIER", 312, 321], ["bacterial", "OBSERVATION_MODIFIER", 322, 331], ["infections", "OBSERVATION", 332, 342]]], ["Lin et al. reported episodes of GI bleeding in severe COVID-19 patients with gastroduodenal ulceration (23) .", [["GI", "ANATOMY", 32, 34], ["gastroduodenal", "ANATOMY", 77, 91], ["GI bleeding", "DISEASE", 32, 43], ["COVID", "DISEASE", 54, 59], ["gastroduodenal ulceration", "DISEASE", 77, 102], ["GI", "ORGANISM_SUBDIVISION", 32, 34], ["patients", "ORGANISM", 63, 71], ["gastroduodenal ulceration", "PATHOLOGICAL_FORMATION", 77, 102], ["patients", "SPECIES", 63, 71], ["GI bleeding", "PROBLEM", 32, 43], ["severe COVID", "PROBLEM", 47, 59], ["gastroduodenal ulceration", "PROBLEM", 77, 102], ["et al", "OBSERVATION", 4, 9], ["GI", "ANATOMY", 32, 34], ["bleeding", "OBSERVATION", 35, 43], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["gastroduodenal", "ANATOMY", 77, 91], ["ulceration", "OBSERVATION", 92, 102]]], ["Multiple round herpetic erosions were noted with positive SARS-CoV-2 in the esophageal samples.", [["esophageal samples", "ANATOMY", 76, 94], ["herpetic erosions", "DISEASE", 15, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["esophageal samples", "CANCER", 76, 94], ["Multiple round herpetic erosions", "PROBLEM", 0, 32], ["positive SARS", "PROBLEM", 49, 62], ["CoV", "TEST", 63, 66], ["round", "OBSERVATION_MODIFIER", 9, 14], ["herpetic", "OBSERVATION_MODIFIER", 15, 23], ["erosions", "OBSERVATION", 24, 32], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["SARS", "OBSERVATION", 58, 62], ["esophageal", "ANATOMY", 76, 86]]], ["It remains unclear if it is directly related to viral cytopathic effect or due to other causes (53, 54) .", [["viral cytopathic effect", "PROBLEM", 48, 71], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["cytopathic", "OBSERVATION", 54, 64]]], ["Furthermore, clostridium difficile infections have been reported in COVID-19 patients, probably due to altered gut flora and the use of multiple antimicrobial agents (15, 55) .", [["gut flora", "ANATOMY", 111, 120], ["clostridium difficile infections", "DISEASE", 13, 45], ["clostridium difficile", "ORGANISM", 13, 34], ["patients", "ORGANISM", 77, 85], ["gut", "ORGANISM_SUBDIVISION", 111, 114], ["clostridium difficile", "SPECIES", 13, 34], ["patients", "SPECIES", 77, 85], ["clostridium difficile", "SPECIES", 13, 34], ["clostridium difficile infections", "PROBLEM", 13, 45], ["altered gut flora", "PROBLEM", 103, 120], ["multiple antimicrobial agents", "TREATMENT", 136, 165], ["clostridium difficile", "OBSERVATION", 13, 34], ["probably due to", "UNCERTAINTY", 87, 102], ["gut", "ANATOMY", 111, 114], ["flora", "OBSERVATION", 115, 120]]], ["Though patients with COVID-19 have altered flora and increased cytokine release, studies showed that IBD patients are not at risk of COVID-19 and related mortality (56) .Ageusia/DysgeusiaAltered taste (ageusia/ dysgeusia) has been reported as high as 49.8% (95% CI: 8.2% -91.5%) (8) .", [["IBD", "DISEASE", 101, 104], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 105, 113], ["DysgeusiaAltered taste", "ORGANISM", 178, 200], ["cytokine", "PROTEIN", 63, 71], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 105, 113], ["COVID", "TEST", 21, 26], ["altered flora", "PROBLEM", 35, 48], ["increased cytokine release", "PROBLEM", 53, 79], ["studies", "TEST", 81, 88], ["IBD", "PROBLEM", 101, 104], ["COVID", "TEST", 133, 138], ["Ageusia", "TEST", 170, 177], ["DysgeusiaAltered taste", "PROBLEM", 178, 200], ["ageusia/ dysgeusia", "PROBLEM", 202, 220], ["CI", "TEST", 262, 264], ["flora", "OBSERVATION", 43, 48], ["IBD", "OBSERVATION", 101, 104], ["high", "OBSERVATION_MODIFIER", 243, 247]]], ["It is unclear if taste changes can precede the development of anorexia, nausea, or diarrheal symptoms.F. Hepatic manifestations of COVID-19The most common hepatic manifestations include asymptomatic elevation of liver chemistries.F. Hepatic manifestations of COVID-19However, worsening of underlying liver disease presenting with significant elevation of liver chemistries have also been documented (57) (58) (59) .", [["Hepatic", "ANATOMY", 105, 112], ["hepatic", "ANATOMY", 155, 162], ["liver", "ANATOMY", 212, 217], ["Hepatic", "ANATOMY", 233, 240], ["liver", "ANATOMY", 300, 305], ["liver", "ANATOMY", 355, 360], ["anorexia", "DISEASE", 62, 70], ["nausea", "DISEASE", 72, 78], ["diarrheal symptoms", "DISEASE", 83, 101], ["elevation of liver chemistries", "DISEASE", 199, 229], ["liver disease", "DISEASE", 300, 313], ["elevation of liver chemistries", "DISEASE", 342, 372], ["hepatic", "ORGAN", 155, 162], ["liver", "ORGAN", 212, 217], ["liver", "ORGAN", 300, 305], ["liver", "ORGAN", 355, 360], ["taste changes", "PROBLEM", 17, 30], ["anorexia", "PROBLEM", 62, 70], ["nausea", "PROBLEM", 72, 78], ["diarrheal symptoms", "PROBLEM", 83, 101], ["COVID", "TEST", 131, 136], ["asymptomatic elevation of liver chemistries", "PROBLEM", 186, 229], ["COVID", "TEST", 259, 264], ["underlying liver disease", "PROBLEM", 289, 313], ["significant elevation of liver chemistries", "PROBLEM", 330, 372], ["anorexia", "OBSERVATION", 62, 70], ["Hepatic", "ANATOMY", 105, 112], ["manifestations", "OBSERVATION", 113, 127], ["hepatic", "ANATOMY", 155, 162], ["manifestations", "OBSERVATION", 163, 177], ["asymptomatic", "OBSERVATION_MODIFIER", 186, 198], ["elevation", "OBSERVATION", 199, 208], ["liver", "ANATOMY", 212, 217], ["Hepatic", "ANATOMY", 233, 240], ["manifestations", "OBSERVATION", 241, 255], ["worsening", "OBSERVATION_MODIFIER", 276, 285], ["liver", "ANATOMY", 300, 305], ["disease", "OBSERVATION", 306, 313], ["significant", "OBSERVATION_MODIFIER", 330, 341], ["elevation", "OBSERVATION", 342, 351], ["liver", "ANATOMY", 355, 360]]], ["Abnormal liver chemistries can be present in 14%-53% of COVID-19 patients (60) .", [["liver", "ANATOMY", 9, 14], ["Abnormal liver chemistries", "DISEASE", 0, 26], ["liver", "ORGAN", 9, 14], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["Abnormal liver chemistries", "PROBLEM", 0, 26], ["COVID", "TEST", 56, 61], ["liver", "ANATOMY", 9, 14], ["chemistries", "OBSERVATION", 15, 26]]], ["The pattern of derangement in liver chemistries is predominately hepatocellular (7, 59, 61, 62) .", [["liver", "ANATOMY", 30, 35], ["hepatocellular", "ANATOMY", 65, 79], ["liver", "ORGAN", 30, 35], ["hepatocellular", "CANCER", 65, 79], ["derangement in liver chemistries", "PROBLEM", 15, 47], ["pattern", "OBSERVATION_MODIFIER", 4, 11], ["derangement", "OBSERVATION", 15, 26], ["liver", "ANATOMY", 30, 35], ["predominately", "OBSERVATION_MODIFIER", 51, 64], ["hepatocellular", "OBSERVATION", 65, 79]]], ["A systemic review showed a pooled prevalence of elevated aspartate Post-liver-transplant recipients are a specialized subset of populations who are at higher risk of COVID-19 infection due to their use of immune suppression (4, 63) .", [["liver", "ANATOMY", 72, 77], ["aspartate", "CHEMICAL", 57, 66], ["infection", "DISEASE", 175, 184], ["aspartate", "CHEMICAL", 57, 66], ["aspartate", "SIMPLE_CHEMICAL", 57, 66], ["liver", "ORGAN", 72, 77], ["recipients", "ORGANISM", 89, 99], ["COVID-19", "ORGANISM", 166, 174], ["COVID-19", "SPECIES", 166, 174], ["A systemic review", "TEST", 0, 17], ["elevated aspartate", "PROBLEM", 48, 66], ["transplant recipients", "TREATMENT", 78, 99], ["COVID-19 infection", "PROBLEM", 166, 184], ["immune suppression", "TREATMENT", 205, 223], ["elevated", "OBSERVATION", 48, 56], ["liver", "ANATOMY", 72, 77], ["transplant", "OBSERVATION", 78, 88], ["infection", "OBSERVATION", 175, 184]]], ["Immune-mediated organ damage is noted in COVID-19 patients, and suppression of the immune system might be protective in these individuals.", [["organ", "ANATOMY", 16, 21], ["immune system", "ANATOMY", 83, 96], ["organ damage", "DISEASE", 16, 28], ["organ", "ORGAN", 16, 21], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["mediated organ damage", "PROBLEM", 7, 28], ["COVID", "TEST", 41, 46], ["suppression of the immune system", "PROBLEM", 64, 96], ["organ", "ANATOMY", 16, 21], ["damage", "OBSERVATION", 22, 28]]], ["In addition, the use of immunosuppression can mitigate the effects of the cytokine storm seen in COVID-19 patients.F. Hepatic manifestations of COVID-19The precise mechanism of liver involvement in COVID-19 patients is unclear.", [["Hepatic", "ANATOMY", 118, 125], ["liver", "ANATOMY", 177, 182], ["COVID-19", "CHEMICAL", 144, 152], ["COVID-19", "CHEMICAL", 144, 152], ["patients", "ORGANISM", 106, 114], ["liver", "ORGAN", 177, 182], ["patients", "ORGANISM", 207, 215], ["cytokine", "PROTEIN", 74, 82], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 207, 215], ["immunosuppression", "TREATMENT", 24, 41], ["the cytokine storm", "TREATMENT", 70, 88], ["COVID", "TEST", 144, 149], ["Hepatic", "ANATOMY", 118, 125], ["liver", "ANATOMY", 177, 182], ["involvement", "OBSERVATION", 183, 194]]], ["ACE-2, the functional receptor of SARS-CoV-2, is expressed in higher amounts in the biliary epithelium (20 times compared to hepatocytes).", [["biliary epithelium", "ANATOMY", 84, 102], ["hepatocytes", "ANATOMY", 125, 136], ["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["biliary epithelium", "TISSUE", 84, 102], ["hepatocytes", "CELL", 125, 136], ["ACE", "PROTEIN", 0, 3], ["hepatocytes", "CELL_TYPE", 125, 136], ["ACE", "TEST", 0, 3], ["SARS", "OBSERVATION", 34, 38], ["higher", "OBSERVATION_MODIFIER", 62, 68], ["amounts", "OBSERVATION_MODIFIER", 69, 76], ["biliary epithelium", "ANATOMY", 84, 102], ["hepatocytes", "ANATOMY", 125, 136]]], ["As SARS-CoV-2 enters the mucous membranes, it can access the biliary system via the portal vein.", [["mucous membranes", "ANATOMY", 25, 41], ["biliary system", "ANATOMY", 61, 75], ["portal vein", "ANATOMY", 84, 95], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 3, 13], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 25, 41], ["biliary system", "MULTI-TISSUE_STRUCTURE", 61, 75], ["portal vein", "MULTI-TISSUE_STRUCTURE", 84, 95], ["mucous membranes", "ANATOMY", 25, 41], ["biliary system", "ANATOMY", 61, 75], ["portal vein", "ANATOMY", 84, 95]]], ["SARS-CoV-2 can cause direct immune damage to hepatocytes (cytopathic effect).", [["hepatocytes", "ANATOMY", 45, 56], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["hepatocytes", "CELL", 45, 56], ["hepatocytes", "CELL_TYPE", 45, 56], ["direct immune damage to hepatocytes", "PROBLEM", 21, 56], ["hepatocytes", "ANATOMY", 45, 56]]], ["Direct viral cytopathy with microvesicular steatosis, mild lobular, or portal involvement has been reported (61, 64) .", [["microvesicular", "ANATOMY", 28, 42], ["lobular", "ANATOMY", 59, 66], ["portal", "ANATOMY", 71, 77], ["steatosis", "DISEASE", 43, 52], ["microvesicular steatosis", "PATHOLOGICAL_FORMATION", 28, 52], ["lobular", "CANCER", 59, 66], ["Direct viral cytopathy", "PROBLEM", 0, 22], ["microvesicular steatosis", "PROBLEM", 28, 52], ["mild lobular", "PROBLEM", 54, 66], ["portal involvement", "PROBLEM", 71, 89], ["viral cytopathy", "OBSERVATION", 7, 22], ["microvesicular", "OBSERVATION_MODIFIER", 28, 42], ["steatosis", "OBSERVATION", 43, 52], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["lobular", "OBSERVATION", 59, 66], ["portal", "ANATOMY", 71, 77]]], ["Cytokine storm noted in COVID-19 patients can lead to excess inflammatory burden and potential immune-mediated damage.F. Hepatic manifestations of COVID-19Immunosuppressive medications such as calcineurin inhibitors reduce the Interleukin-2 and mycophenolic acid inhibits IL-17, which interferes with T-cell function.", [["Hepatic", "ANATOMY", 121, 128], ["T-cell", "ANATOMY", 301, 307], ["mycophenolic acid", "CHEMICAL", 245, 262], ["mycophenolic acid", "CHEMICAL", 245, 262], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 33, 41], ["COVID-19Immunosuppressive", "SIMPLE_CHEMICAL", 147, 172], ["calcineurin", "GENE_OR_GENE_PRODUCT", 193, 204], ["Interleukin-2", "GENE_OR_GENE_PRODUCT", 227, 240], ["mycophenolic acid", "SIMPLE_CHEMICAL", 245, 262], ["IL-17", "GENE_OR_GENE_PRODUCT", 272, 277], ["T-cell", "CELL", 301, 307], ["Cytokine", "PROTEIN", 0, 8], ["calcineurin", "PROTEIN", 193, 204], ["IL-17", "PROTEIN", 272, 277], ["patients", "SPECIES", 33, 41], ["Cytokine storm", "PROBLEM", 0, 14], ["COVID", "TEST", 24, 29], ["excess inflammatory burden", "PROBLEM", 54, 80], ["mediated damage", "PROBLEM", 102, 117], ["COVID-19Immunosuppressive medications", "TREATMENT", 147, 184], ["calcineurin inhibitors", "TREATMENT", 193, 215], ["the Interleukin", "TREATMENT", 223, 238], ["mycophenolic acid inhibits IL", "TREATMENT", 245, 274], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73], ["damage", "OBSERVATION", 111, 117], ["Hepatic", "ANATOMY", 121, 128]]], ["Furthermore, passive congestion due to increased use of positive pressure ventilation, drug-induced liver injury from medications (antiviral and antibiotics) commonly used during the course of illness are real possibilities (60, 65) .Severe Acute Respiratory Syndrome (SARS)The first case of severe acute respiratory syndrome (SARS) was reported in China on November 16, 2002 , and it spread to more than 30 countries.", [["liver", "ANATOMY", 100, 105], ["congestion", "DISEASE", 21, 31], ["liver injury", "DISEASE", 100, 112], ["illness", "DISEASE", 193, 200], ["Acute Respiratory Syndrome", "DISEASE", 241, 267], ["SARS", "DISEASE", 269, 273], ["acute respiratory syndrome", "DISEASE", 299, 325], ["SARS", "DISEASE", 327, 331], ["liver", "ORGAN", 100, 105], ["passive congestion", "PROBLEM", 13, 31], ["positive pressure ventilation", "TREATMENT", 56, 85], ["drug", "TREATMENT", 87, 91], ["liver injury", "PROBLEM", 100, 112], ["medications", "TREATMENT", 118, 129], ["antiviral and antibiotics", "TREATMENT", 131, 156], ["illness", "PROBLEM", 193, 200], ["Severe Acute Respiratory Syndrome", "PROBLEM", 234, 267], ["severe acute respiratory syndrome", "PROBLEM", 292, 325], ["SARS", "PROBLEM", 327, 331], ["passive", "OBSERVATION_MODIFIER", 13, 20], ["congestion", "OBSERVATION", 21, 31], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["positive pressure ventilation", "OBSERVATION", 56, 85], ["liver", "ANATOMY", 100, 105], ["injury", "OBSERVATION", 106, 112], ["Acute", "OBSERVATION_MODIFIER", 241, 246], ["Respiratory Syndrome", "OBSERVATION", 247, 267], ["severe", "OBSERVATION_MODIFIER", 292, 298], ["acute", "OBSERVATION_MODIFIER", 299, 304], ["respiratory syndrome", "OBSERVATION", 305, 325]]], ["Overall, 8098 cases were reported with 774 deaths caused by SARS-CoV-1 (66, 67) .", [["deaths", "DISEASE", 43, 49], ["SARS", "DISEASE", 60, 64], ["SARS-CoV-1", "SPECIES", 60, 70], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68]]], ["In July 2003, WHO declared the end of the SARS epidemic.", [["SARS", "DISEASE", 42, 46], ["the SARS epidemic", "PROBLEM", 38, 55]]], ["As the name suggests, it is primarily a disease of the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 55, 78], ["lower", "ORGANISM_SUBDIVISION", 55, 60], ["respiratory tract", "ORGANISM_SUBDIVISION", 61, 78], ["a disease of the lower respiratory tract", "PROBLEM", 38, 78], ["disease", "OBSERVATION", 40, 47], ["lower", "ANATOMY_MODIFIER", 55, 60], ["respiratory tract", "ANATOMY", 61, 78]]], ["However, enteric involvement is also common in SARS.Severe Acute Respiratory Syndrome (SARS)Diarrhea was the most common GI symptoms observed in patients with SARS (68, 69) .", [["GI", "ANATOMY", 121, 123], ["SARS", "DISEASE", 47, 51], ["Acute Respiratory Syndrome", "DISEASE", 59, 85], ["SARS", "DISEASE", 87, 91], ["Diarrhea", "DISEASE", 92, 100], ["SARS", "DISEASE", 159, 163], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["Severe Acute Respiratory Syndrome", "PROBLEM", 52, 85], ["SARS)", "PROBLEM", 87, 92], ["Diarrhea", "PROBLEM", 92, 100], ["GI symptoms", "PROBLEM", 121, 132], ["SARS", "PROBLEM", 159, 163], ["enteric", "OBSERVATION_MODIFIER", 9, 16], ["involvement", "OBSERVATION", 17, 28], ["Acute", "OBSERVATION_MODIFIER", 59, 64], ["Respiratory Syndrome", "OBSERVATION", 65, 85]]], ["In a retrospective study by Leung et al., 20% of patients had watery diarrhea at the time of presentation, and 38% of the patients developed diarrhea overall during the course of the illness (70) .", [["diarrhea", "DISEASE", 69, 77], ["diarrhea", "DISEASE", 141, 149], ["illness", "DISEASE", 183, 190], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 122, 130], ["a retrospective study", "TEST", 3, 24], ["watery diarrhea", "PROBLEM", 62, 77], ["diarrhea", "PROBLEM", 141, 149], ["diarrhea", "OBSERVATION", 141, 149]]], ["Some patients presented with fever and diarrhea, without the presence of respiratory symptoms.", [["respiratory", "ANATOMY", 73, 84], ["fever", "DISEASE", 29, 34], ["diarrhea", "DISEASE", 39, 47], ["respiratory symptoms", "DISEASE", 73, 93], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["fever", "PROBLEM", 29, 34], ["diarrhea", "PROBLEM", 39, 47], ["respiratory symptoms", "PROBLEM", 73, 93], ["fever", "OBSERVATION", 29, 34], ["diarrhea", "OBSERVATION", 39, 47], ["respiratory", "ANATOMY", 73, 84], ["symptoms", "OBSERVATION", 85, 93]]], ["Diarrhea lasted for an average of 3.7 days and resolved spontaneously in the majority of cases.", [["Diarrhea", "DISEASE", 0, 8], ["Diarrhea", "PROBLEM", 0, 8]]], ["However, SARS-CoV-1 RNA was detected in the stool for up to ten weeks after the onset of symptoms (71) .Severe Acute Respiratory Syndrome (SARS)Diarrhea was also reported in other SARS outbreaks.", [["stool", "ANATOMY", 44, 49], ["Acute Respiratory Syndrome", "DISEASE", 111, 137], ["SARS", "DISEASE", 139, 143], ["Diarrhea", "DISEASE", 144, 152], ["SARS", "DISEASE", 180, 184], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 9, 19], ["stool", "ORGANISM_SUBSTANCE", 44, 49], ["SARS-CoV-1 RNA", "RNA", 9, 23], ["SARS-CoV-1", "SPECIES", 9, 19], ["SARS", "PROBLEM", 9, 13], ["CoV", "TEST", 14, 17], ["symptoms", "PROBLEM", 89, 97], ["Severe Acute Respiratory Syndrome", "PROBLEM", 104, 137], ["SARS)", "PROBLEM", 139, 144], ["Diarrhea", "PROBLEM", 144, 152], ["stool", "ANATOMY", 44, 49], ["Acute", "OBSERVATION_MODIFIER", 111, 116], ["Respiratory Syndrome", "OBSERVATION", 117, 137]]], ["In a study from Toronto, the prevalence of diarrhea was 23.6%, whereas another study from Hong Kong reported diarrhea in 70% of their patients (72, 73) .", [["diarrhea", "DISEASE", 43, 51], ["diarrhea", "DISEASE", 109, 117], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["a study", "TEST", 3, 10], ["diarrhea", "PROBLEM", 43, 51], ["another study", "TEST", 71, 84], ["diarrhea", "PROBLEM", 109, 117]]], ["The higher prevalence of diarrhea was attributed to the different modes of transmission.", [["diarrhea", "DISEASE", 25, 33], ["diarrhea", "PROBLEM", 25, 33], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["diarrhea", "OBSERVATION", 25, 33]]], ["The mode of transmission from the Hong Kong study was linked to a faulty sewage system resulting in fecal-oral transmission, whereas in other studies, droplet transmission is the main mode of transmission.Severe Acute Respiratory Syndrome (SARS)Reactive hepatitis has also been reported in SARS.", [["oral", "ANATOMY", 106, 110], ["fecal-oral transmission", "DISEASE", 100, 123], ["Acute Respiratory Syndrome", "DISEASE", 212, 238], ["SARS", "DISEASE", 240, 244], ["Reactive hepatitis", "DISEASE", 245, 263], ["SARS", "DISEASE", 290, 294], ["fecal", "ORGANISM_SUBDIVISION", 100, 105], ["oral", "ORGANISM_SUBDIVISION", 106, 110], ["the Hong Kong study", "TEST", 30, 49], ["a faulty sewage system", "PROBLEM", 64, 86], ["other studies", "TEST", 136, 149], ["Severe Acute Respiratory Syndrome", "PROBLEM", 205, 238], ["Reactive hepatitis", "PROBLEM", 245, 263], ["fecal", "ANATOMY", 100, 105], ["main", "OBSERVATION_MODIFIER", 179, 183], ["Acute", "OBSERVATION_MODIFIER", 212, 217], ["Respiratory Syndrome", "OBSERVATION", 218, 238], ["Reactive", "OBSERVATION_MODIFIER", 245, 253], ["hepatitis", "OBSERVATION", 254, 263]]], ["In a study of 294 SARS patients, 24% had elevated ALT on admission, and 69% developed ALT elevation during the course of hospitalization (74) .", [["SARS", "DISEASE", 18, 22], ["patients", "ORGANISM", 23, 31], ["ALT", "SIMPLE_CHEMICAL", 50, 53], ["ALT", "SIMPLE_CHEMICAL", 86, 89], ["patients", "SPECIES", 23, 31], ["a study", "TEST", 3, 10], ["SARS patients", "TEST", 18, 31], ["elevated ALT", "PROBLEM", 41, 53], ["ALT elevation", "PROBLEM", 86, 99]]], ["In patients with elevated ALT, further worsening of the liver chemistries was noted with systemic corticosteroid and ribavirin treatment (69) .", [["liver", "ANATOMY", 56, 61], ["ribavirin", "CHEMICAL", 117, 126], ["ribavirin", "CHEMICAL", 117, 126], ["patients", "ORGANISM", 3, 11], ["ALT", "SIMPLE_CHEMICAL", 26, 29], ["liver", "ORGAN", 56, 61], ["ribavirin", "SIMPLE_CHEMICAL", 117, 126], ["patients", "SPECIES", 3, 11], ["elevated ALT", "PROBLEM", 17, 29], ["further worsening of the liver chemistries", "PROBLEM", 31, 73], ["systemic corticosteroid", "TREATMENT", 89, 112], ["ribavirin treatment", "TREATMENT", 117, 136], ["worsening", "OBSERVATION_MODIFIER", 39, 48], ["liver", "ANATOMY", 56, 61]]], ["Spontaneous improvement in ALT was noticed in correlation with the overall clinical improvement.", [["ALT", "SIMPLE_CHEMICAL", 27, 30], ["ALT", "PROTEIN", 27, 30], ["ALT", "TEST", 27, 30], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["The cytokine release from inflammatory cells was postulated to be the most likely cause of the ALT elevation, although a precise etiology was not determined the probable culprit (74) .", [["inflammatory cells", "ANATOMY", 26, 44], ["inflammatory cells", "CELL", 26, 44], ["ALT", "SIMPLE_CHEMICAL", 95, 98], ["cytokine", "PROTEIN", 4, 12], ["inflammatory cells", "CELL_TYPE", 26, 44], ["The cytokine release", "TREATMENT", 0, 20], ["inflammatory cells", "PROBLEM", 26, 44], ["the ALT elevation", "PROBLEM", 91, 108], ["inflammatory cells", "OBSERVATION", 26, 44], ["postulated to be the most likely", "UNCERTAINTY", 49, 81], ["ALT", "ANATOMY", 95, 98], ["elevation", "OBSERVATION", 99, 108]]], ["Other laboratory abnormalities that were associated with abnormal transaminases include elevated creatinine, elevated creatinine kinase, and thrombocytopenia (75).Middle Eastern Respiratory Syndrome (MERS)MERS-CoV was first reported in Saudi Arabia on September 20, 2012 (76) .", [["creatinine", "CHEMICAL", 97, 107], ["creatinine", "CHEMICAL", 118, 128], ["thrombocytopenia", "DISEASE", 141, 157], ["Respiratory Syndrome", "DISEASE", 178, 198], ["creatinine", "CHEMICAL", 97, 107], ["creatinine", "CHEMICAL", 118, 128], ["creatinine", "SIMPLE_CHEMICAL", 97, 107], ["creatinine", "GENE_OR_GENE_PRODUCT", 118, 128], ["Middle Eastern Respiratory", "ORGANISM", 163, 189], ["MERS-CoV", "ORGANISM", 205, 213], ["creatinine kinase", "PROTEIN", 118, 135], ["Middle Eastern Respiratory Syndrome (MERS)MERS-CoV", "SPECIES", 163, 213], ["Other laboratory abnormalities", "PROBLEM", 0, 30], ["abnormal transaminases", "PROBLEM", 57, 79], ["elevated creatinine", "PROBLEM", 88, 107], ["elevated creatinine kinase", "PROBLEM", 109, 135], ["thrombocytopenia", "PROBLEM", 141, 157], ["Middle Eastern Respiratory Syndrome", "PROBLEM", 163, 198], ["thrombocytopenia", "OBSERVATION", 141, 157], ["Respiratory Syndrome", "OBSERVATION", 178, 198]]], ["MERS became an epidemic with 2521 laboratory-confirmed cases and 919 deaths (case fatality rate 36%) (77) .", [["deaths", "DISEASE", 69, 75], ["case fatality rate", "TEST", 77, 95]]], ["MERS-CoV cases are predominately reported from the Arabian Peninsula, with around 84% from Saudi Arabia (77) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["Arabian", "ANATOMY_MODIFIER", 51, 58], ["Peninsula", "ANATOMY_MODIFIER", 59, 68]]], ["Dromedary camels (Camelus dromedarius) are major reservoir/intermediate hosts for MERS-CoV.", [["Dromedary camels", "ORGANISM", 0, 16], ["Camelus dromedarius", "ORGANISM", 18, 37], ["MERS-CoV", "ORGANISM", 82, 90], ["Camelus dromedarius", "SPECIES", 18, 37], ["Camelus dromedarius", "SPECIES", 18, 37], ["MERS-CoV", "SPECIES", 82, 90], ["Dromedary camels (Camelus dromedarius)", "TREATMENT", 0, 38]]], ["Although there are cases of human-to-human transition, especially in health care settings due to close contact while delivering unprotected care to a patient, the virus does not pass easily from the human-to-human (79) .", [["human", "ORGANISM", 28, 33], ["human", "ORGANISM", 37, 42], ["patient", "ORGANISM", 150, 157], ["human", "ORGANISM", 199, 204], ["human", "ORGANISM", 208, 213], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 37, 42], ["patient", "SPECIES", 150, 157], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 208, 213], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 208, 213], ["the virus", "PROBLEM", 159, 168]]], ["In an epidemiological study of 47 patients with MERS from Saudi Arabia, 26% had diarrhea, 21% had vomiting, and 17% had abdominal pain (80) .", [["abdominal", "ANATOMY", 120, 129], ["MERS from Saudi Arabia", "DISEASE", 48, 70], ["diarrhea", "DISEASE", 80, 88], ["vomiting", "DISEASE", 98, 106], ["abdominal pain", "DISEASE", 120, 134], ["patients", "ORGANISM", 34, 42], ["abdominal", "ORGANISM_SUBDIVISION", 120, 129], ["patients", "SPECIES", 34, 42], ["an epidemiological study", "TEST", 3, 27], ["diarrhea", "PROBLEM", 80, 88], ["vomiting", "PROBLEM", 98, 106], ["abdominal pain", "PROBLEM", 120, 134], ["abdominal", "ANATOMY", 120, 129]]], ["Hepatic abnormalities are not common with AST elevations in only 15% of patients and ALT elevations in about 11% of the patients (81) .", [["Hepatic", "ANATOMY", 0, 7], ["Hepatic abnormalities", "DISEASE", 0, 21], ["Hepatic", "ORGAN", 0, 7], ["AST", "SIMPLE_CHEMICAL", 42, 45], ["patients", "ORGANISM", 72, 80], ["ALT", "SIMPLE_CHEMICAL", 85, 88], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 120, 128], ["Hepatic abnormalities", "PROBLEM", 0, 21], ["AST elevations", "PROBLEM", 42, 56], ["ALT elevations", "PROBLEM", 85, 99], ["abnormalities", "OBSERVATION", 8, 21], ["not common", "UNCERTAINTY", 26, 36]]], ["Similar to SARS, other laboratory abnormalities in MERS include leukopenia, thrombocytopenia, elevated lactate dehydrogenase levels, and elevations in creatinine (78, 82, 83) .GAPS IN KNOWLEDGEGI and hepatic manifestations are increasingly being recognized due to an increase in the number of cases.", [["hepatic", "ANATOMY", 200, 207], ["SARS", "DISEASE", 11, 15], ["MERS", "DISEASE", 51, 55], ["leukopenia", "DISEASE", 64, 74], ["thrombocytopenia", "DISEASE", 76, 92], ["lactate", "CHEMICAL", 103, 110], ["creatinine", "CHEMICAL", 151, 161], ["hepatic manifestations", "DISEASE", 200, 222], ["lactate", "CHEMICAL", 103, 110], ["creatinine", "CHEMICAL", 151, 161], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 103, 124], ["creatinine", "SIMPLE_CHEMICAL", 151, 161], ["hepatic", "ORGAN", 200, 207], ["lactate dehydrogenase", "PROTEIN", 103, 124], ["SARS", "PROBLEM", 11, 15], ["other laboratory abnormalities in MERS", "PROBLEM", 17, 55], ["leukopenia", "PROBLEM", 64, 74], ["thrombocytopenia", "PROBLEM", 76, 92], ["elevated lactate dehydrogenase levels", "PROBLEM", 94, 131], ["elevations", "PROBLEM", 137, 147], ["creatinine", "TEST", 151, 161], ["hepatic manifestations", "PROBLEM", 200, 222], ["SARS", "OBSERVATION", 11, 15], ["leukopenia", "OBSERVATION", 64, 74], ["thrombocytopenia", "OBSERVATION", 76, 92], ["elevated", "OBSERVATION_MODIFIER", 94, 102], ["lactate dehydrogenase", "OBSERVATION", 103, 124], ["elevations", "OBSERVATION_MODIFIER", 137, 147], ["hepatic", "ANATOMY", 200, 207], ["manifestations", "OBSERVATION", 208, 222], ["increase", "OBSERVATION_MODIFIER", 267, 275]]], ["Although anorexia, nausea, vomiting, and diarrhea are being noted as common manifestations, risk of heterogeneity among pooled estimates, geographical location, the publication of bias is inherently present.", [["anorexia", "DISEASE", 9, 17], ["nausea", "DISEASE", 19, 25], ["vomiting", "DISEASE", 27, 35], ["diarrhea", "DISEASE", 41, 49], ["anorexia", "PROBLEM", 9, 17], ["nausea", "PROBLEM", 19, 25], ["vomiting", "PROBLEM", 27, 35], ["diarrhea", "PROBLEM", 41, 49], ["common manifestations", "PROBLEM", 69, 90], ["heterogeneity", "PROBLEM", 100, 113], ["anorexia", "OBSERVATION", 9, 17], ["nausea", "OBSERVATION", 19, 25], ["diarrhea", "OBSERVATION", 41, 49], ["bias", "OBSERVATION", 180, 184]]], ["Potential confounder such as the use of antiviral, antibiotics, enteral feeding can cause nausea, vomiting, anorexia, and diarrhea by themselves and change the prevalence of these symptoms in affected patients.", [["nausea", "DISEASE", 90, 96], ["vomiting", "DISEASE", 98, 106], ["anorexia", "DISEASE", 108, 116], ["diarrhea", "DISEASE", 122, 130], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["antiviral", "TREATMENT", 40, 49], ["antibiotics", "TREATMENT", 51, 62], ["enteral feeding", "TREATMENT", 64, 79], ["nausea", "PROBLEM", 90, 96], ["vomiting", "PROBLEM", 98, 106], ["anorexia", "PROBLEM", 108, 116], ["diarrhea", "PROBLEM", 122, 130], ["these symptoms", "PROBLEM", 174, 188]]], ["The use of sound methodology with evaluating the cause of these symptoms, along with these confounders, can provide the precise prevalence of the GI and hepatic manifestations.", [["GI", "ANATOMY", 146, 148], ["hepatic", "ANATOMY", 153, 160], ["GI", "CANCER", 146, 148], ["hepatic", "ORGAN", 153, 160], ["sound methodology", "TREATMENT", 11, 28], ["these symptoms", "PROBLEM", 58, 72], ["the GI and hepatic manifestations", "PROBLEM", 142, 175], ["GI", "ANATOMY", 146, 148], ["hepatic", "ANATOMY", 153, 160], ["manifestations", "OBSERVATION", 161, 175]]], ["CONCLUSION COVID-19 is the latest of the coronavirus outbreaks in Humans, and it has already caused a devastating impact in the world.", [["coronavirus outbreaks", "DISEASE", 41, 62], ["coronavirus", "ORGANISM", 41, 52], ["COVID", "TEST", 11, 16], ["coronavirus", "OBSERVATION", 41, 52], ["devastating", "OBSERVATION_MODIFIER", 102, 113], ["impact", "OBSERVATION", 114, 120]]], ["It is predominately a respiratory disease with pneumonia, severe acute respiratory distress syndrome, and multiorgan failure.", [["respiratory", "ANATOMY", 22, 33], ["respiratory", "ANATOMY", 71, 82], ["multiorgan", "ANATOMY", 106, 116], ["respiratory disease", "DISEASE", 22, 41], ["pneumonia", "DISEASE", 47, 56], ["acute respiratory distress syndrome", "DISEASE", 65, 100], ["multiorgan failure", "DISEASE", 106, 124], ["a respiratory disease", "PROBLEM", 20, 41], ["pneumonia", "PROBLEM", 47, 56], ["severe acute respiratory distress syndrome", "PROBLEM", 58, 100], ["multiorgan failure", "PROBLEM", 106, 124], ["predominately", "OBSERVATION_MODIFIER", 6, 19], ["respiratory disease", "OBSERVATION", 22, 41], ["pneumonia", "OBSERVATION", 47, 56], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory distress syndrome", "OBSERVATION", 71, 100], ["multiorgan failure", "OBSERVATION", 106, 124]]], ["However, non-pulmonary symptoms are increasingly being recognized.", [["non-pulmonary", "ANATOMY", 9, 22], ["non-pulmonary symptoms", "PROBLEM", 9, 31], ["non-pulmonary", "ANATOMY", 9, 22], ["symptoms", "OBSERVATION", 23, 31]]], ["Anorexia, nausea, vomiting, diarrhea, and abdominal pain are the common GI symptoms noted in these patients.", [["abdominal", "ANATOMY", 42, 51], ["GI", "ANATOMY", 72, 74], ["Anorexia", "DISEASE", 0, 8], ["nausea", "DISEASE", 10, 16], ["vomiting", "DISEASE", 18, 26], ["diarrhea", "DISEASE", 28, 36], ["abdominal pain", "DISEASE", 42, 56], ["abdominal", "ORGANISM_SUBDIVISION", 42, 51], ["GI", "ORGANISM_SUBDIVISION", 72, 74], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Anorexia", "PROBLEM", 0, 8], ["nausea", "PROBLEM", 10, 16], ["vomiting", "PROBLEM", 18, 26], ["diarrhea", "PROBLEM", 28, 36], ["abdominal pain", "PROBLEM", 42, 56], ["the common GI symptoms", "PROBLEM", 61, 83], ["nausea", "OBSERVATION", 10, 16], ["abdominal", "ANATOMY", 42, 51], ["pain", "OBSERVATION", 52, 56]]], ["Patients with diarrhea can precede the development of respiratory symptoms, and in a small proportion of cases, it can be the only presenting symptom.GAPS IN KNOWLEDGEDiarrhea can contribute to fecal-oral transmission and could of public health importance in developing mitigation strategies.", [["respiratory", "ANATOMY", 54, 65], ["oral", "ANATOMY", 200, 204], ["diarrhea", "DISEASE", 14, 22], ["respiratory symptoms", "DISEASE", 54, 74], ["KNOWLEDGEDiarrhea", "CHEMICAL", 158, 175], ["fecal-oral transmission", "DISEASE", 194, 217], ["Patients", "ORGANISM", 0, 8], ["fecal", "ORGANISM_SUBDIVISION", 194, 199], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["Patients", "SPECIES", 0, 8], ["diarrhea", "PROBLEM", 14, 22], ["respiratory symptoms", "PROBLEM", 54, 74], ["presenting symptom", "PROBLEM", 131, 149], ["fecal-oral transmission", "PROBLEM", 194, 217], ["mitigation strategies", "TREATMENT", 270, 291], ["diarrhea", "OBSERVATION", 14, 22], ["respiratory", "ANATOMY", 54, 65], ["symptoms", "OBSERVATION", 66, 74]]], ["Abnormal liver chemistries are noted in 10-15% of cases in COVID-unfolds, it is expected that mechanism of GI and hepatic manifestations can further improve in the future.", [["liver", "ANATOMY", 9, 14], ["GI", "ANATOMY", 107, 109], ["hepatic", "ANATOMY", 114, 121], ["Abnormal liver chemistries", "DISEASE", 0, 26], ["GI and hepatic manifestations", "DISEASE", 107, 136], ["liver", "ORGAN", 9, 14], ["GI", "PATHOLOGICAL_FORMATION", 107, 109], ["hepatic", "ORGAN", 114, 121], ["Abnormal liver chemistries", "PROBLEM", 0, 26], ["GI and hepatic manifestations", "PROBLEM", 107, 136], ["liver", "ANATOMY", 9, 14], ["chemistries", "OBSERVATION", 15, 26], ["hepatic", "ANATOMY", 114, 121]]]], "PMC7383093": [["Participants ::: MethodThe online study was completed by 384 participants (54 men, 328 women, 1 non-binary gender, 1 unspecified; Mage = 50.92 years, SDage = 15.09 years, age range = 23\u201389 years).", [["men", "ORGANISM", 78, 81], ["women", "ORGANISM", 87, 92], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 61, 73], ["men", "SPECIES", 78, 81], ["women", "SPECIES", 87, 92], ["The online study", "TEST", 23, 39]]], ["Participants were required to be adults (18+), to be Australian residents/citizens and live alone.", [["Participants", "SPECIES", 0, 12]]], ["Most participants reported having a university education (31.5% undergraduate and 37.5% postgraduate).", [["participants", "SPECIES", 5, 17]]], ["Of the total sample, 30.20% indicated they lived with a dog (n = 116), 32.81% indicated they lived with a cat (n = 126), and 3.65% (n = 14) indicated they lived with another animal.", [["dog", "ORGANISM", 56, 59], ["dog", "SPECIES", 56, 59], ["the total sample", "TEST", 3, 19]]], ["For the purposes of the study, pet owners were asked to choose the pet they were closest to or spent the most time with and were classified as either \u2018dog owners\u2019 or \u2018cat owners\u2019 (refer to Table 1); however it is possible that owners could have more than one pet.", [["dog", "SPECIES", 151, 154], ["cat", "SPECIES", 167, 170], ["the study", "TEST", 20, 29]]], ["As shown in Table 1, almost 66% of the participants were self-isolated or quarantined during the time of the study.", [["participants", "ORGANISM", 39, 51], ["participants", "SPECIES", 39, 51], ["the study", "TEST", 105, 114]]], ["Only a small proportion knew someone diagnosed with COVID-19, with no participants diagnosed themselves.Measures ::: MethodParticipants initially responded to a series of questions regarding their COVID-19 experience.", [["participants", "SPECIES", 70, 82], ["COVID", "TEST", 52, 57], ["small", "OBSERVATION_MODIFIER", 7, 12]]], ["An opportunity was also provided to pet owners to respond to two open-ended questions about how being a pet owner impacted their experience of COVID-19 and how they perceived the COVID-19 experience affected their pet.Measures ::: MethodThe Pet Interactions subscale of the Cat/Dog Owner Relationship Scale (C/DORS; Howell et al., 2017) was used to measure pet interaction frequency on a 5-point Likert-type scale at least once a day, every few days, once a week, once a month and never.", [["Method", "TREATMENT", 231, 237]]], ["Only dog questions were administered to dog owners and cat questions to cat owners.", [["dog", "ORGANISM", 5, 8], ["dog", "ORGANISM", 40, 43], ["cat", "ORGANISM", 55, 58], ["cat", "ORGANISM", 72, 75]]], ["However, two of the dog-related questions were removed because they asked about activities not possible during COVID-19 lockdown (\u2018How often do you take your pet in the car?\u2019 and \u2018How often do you take your pet to visit people?\u2019), leaving a total of seven questions for dog owners and six for cat owners.", [["dog", "ORGANISM", 20, 23], ["dog", "ORGANISM", 270, 273], ["cat", "ORGANISM", 293, 296], ["people", "SPECIES", 220, 226]]], ["The word \u2018pet\u2019 was also changed to \u2018dog\u2019 or \u2018cat\u2019 as appropriate, and participants were instructed to reflect on the period of the lockdown when responding to the questions.", [["dog", "SPECIES", 36, 39], ["participants", "SPECIES", 70, 82]]], ["In this study, the measure demonstrated acceptable reliability for the cat scale (\u03b1 = .75); however, the modified dog scale did not reach an acceptable level (\u03b1 = .65).", [["cat", "ORGANISM", 71, 74], ["dog", "ORGANISM", 114, 117], ["this study", "TEST", 3, 13], ["the cat scale", "TEST", 67, 80], ["the modified dog scale", "TEST", 101, 123]]], ["Cronbach\u2019s alpha is slightly lower than that previously reported for both dogs (\u03b1 = .67, Dwyer et al., 2006; \u03b1 = .72, Oliva et al., 2016) and cats (\u03b1 = .82, Howell et al., 2017); however, removal of items did not substantially improve the reliability of the scale; therefore, the scale items were retained as administered.Measures ::: MethodThe Freiburg Mindfulness Inventory (FMI; Walach et al., 2006) is a 14-item questionnaire rated on a 4-point Likert-type scale rarely, occasionally, fairly often and almost always.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 0, 16], ["Cronbach\u2019s alpha", "TEST", 0, 16], ["slightly lower", "PROBLEM", 20, 34], ["\u03b1", "TEST", 109, 110], ["Oliva et al.", "TEST", 118, 130], ["cats", "TEST", 142, 146], ["removal", "TREATMENT", 188, 195], ["slightly", "OBSERVATION_MODIFIER", 20, 28], ["lower", "OBSERVATION_MODIFIER", 29, 34]]], ["The FMI can be used as a total score where high scores indicate high mindfulness.", [["FMI", "PROTEIN", 4, 7], ["a total score", "TEST", 23, 36], ["high mindfulness", "PROBLEM", 64, 80], ["high mindfulness", "OBSERVATION", 64, 80]]], ["In this study, a time frame of \u2018the last two weeks\u2019 was chosen to capture participants\u2019 state of mind mid-lockdown.", [["participants", "SPECIES", 74, 86], ["this study", "TEST", 3, 13]]], ["The measure demonstrated good reliability in this study (\u03b1 = .87), consistent with previous research on this scale (see, for example, Walach et al., 2006).Measures ::: MethodParticipants were also asked to indicate their previous mindfulness and meditation experience on a 5-point Likert-type scale: I\u2019ve never had any mindfulness or meditation training experience, I\u2019ve tried mindfulness or meditation before but only briefly (<10 times), I have experimented with mindfulness or meditation training several times (i.e., 10 times or more) but never picked up a consistent practice, I have had (either now or in the past) a frequent (once a week or more) mindfulness or meditation practice but for less than six consecutive months and I have had (either now or in the past) a frequent (once a week or more) mindfulness or meditation practice for more than 6 months.", [["this study", "TEST", 45, 55], ["this scale", "TREATMENT", 104, 114], ["meditation training", "TREATMENT", 334, 353], ["meditation training", "TREATMENT", 480, 499], ["meditation practice", "TREATMENT", 669, 688], ["meditation practice", "TREATMENT", 821, 840], ["good", "OBSERVATION_MODIFIER", 25, 29], ["reliability", "OBSERVATION_MODIFIER", 30, 41], ["consistent with", "UNCERTAINTY", 67, 82]]], ["This scale was created specifically for this study.Measures ::: MethodThe 3-item University of California, Los Angeles (UCLA) Loneliness Scale (Hughes et al., 2004) is a short version of the longer questionnaire developed by Russell et al. (1980) specifically designed for use in large surveys.", [["This scale", "TREATMENT", 0, 10], ["this study", "TEST", 40, 50], ["Method", "TEST", 64, 70]]], ["Participants were asked to consider how often they felt they lacked companionship, were left out or felt isolated during the COVID-19 lockdown period.", [["Participants", "SPECIES", 0, 12]]], ["In this study, the measure demonstrated good reliability (\u03b1 = .87), which is higher than previous research using this scale (\u03b1 = .72; Hughes et al., 2004).Measures ::: MethodParticipants were also asked to indicate how often they had \u2018felt lonely during COVID-19 lockdown\u2019 as a single-item (i.e., direct) measure of loneliness, as recommended by the Office for National Statistics (2018) and by Antonacopoulos (2017) for measuring loneliness in a pet owner sample.", [["loneliness", "DISEASE", 431, 441], ["this study", "TEST", 3, 13], ["this scale", "TEST", 113, 123], ["good", "OBSERVATION_MODIFIER", 40, 44], ["reliability", "OBSERVATION_MODIFIER", 45, 56], ["higher", "OBSERVATION_MODIFIER", 77, 83]]], ["This single item correlated highly with the UCLA Loneliness scale (r = .82 and p < .001), demonstrating good convergent validity between the two measures.Measures ::: MethodThe Depression, Anxiety and Stress Scale 21-item Version (DASS-21; Lovibond & Lovibond, 1995) is a 21-item questionnaire rated on a 4-point Likert-type scale never, sometimes, often and always.", [["Depression", "DISEASE", 177, 187], ["Anxiety", "DISEASE", 189, 196], ["MethodThe Depression", "PROBLEM", 167, 187], ["Anxiety", "PROBLEM", 189, 196], ["Stress Scale", "TEST", 201, 213], ["Depression", "OBSERVATION", 177, 187]]], ["It was chosen as a widely accepted and psychometrically sound measure of mood which emphasises mood state over clinical diagnosis.", [["mood", "PROBLEM", 73, 77]]], ["As expected from previous research (e.g., Crawford & Henry, 2003), the measure demonstrated excellent overall reliability in this study (\u03b1 = .93 Total Scale; \u03b1 = .90 Depression, .80 Anxiety, .87 Stress).Data analysis ::: Design and Procedure ::: MethodData were exported from Qualtrics to Statistical Package for Social Sciences (SPSS).", [["Depression", "DISEASE", 166, 176], ["Anxiety", "DISEASE", 182, 189], ["this study", "TEST", 125, 135], ["Total Scale", "TEST", 145, 156], ["\u03b1", "TEST", 158, 159], ["Depression", "PROBLEM", 166, 176], ["Anxiety", "PROBLEM", 182, 189], ["Data analysis", "TEST", 203, 216], ["excellent", "OBSERVATION_MODIFIER", 92, 101]]], ["Missing data were managed using listwise deletion.", [["listwise deletion", "DNA", 32, 49], ["listwise deletion", "PROBLEM", 32, 49]]], ["Bootstrapping was applied to all analyses.", [["Bootstrapping", "TREATMENT", 0, 13]]], ["Initial comparisons were made between mindfulness levels of participants for those who do not own a pet and those who nominated their primary pet as a dog and those who nominated their primary pet as a cat, adjusting for previous mindfulness experiences.", [["dog", "ORGANISM", 151, 154], ["cat", "ORGANISM", 202, 205], ["participants", "SPECIES", 60, 72], ["previous mindfulness experiences", "TREATMENT", 221, 253]]], ["Two hierarchical multiple regressions (HMRs) were used to determine the relative value of pet ownership, mindfulness, mood, age and gender in the prediction of loneliness, one using the 3-item UCLA and one using the direct measure.", [["loneliness", "DISEASE", 160, 170], ["mood", "PROBLEM", 118, 122], ["hierarchical", "OBSERVATION_MODIFIER", 4, 16], ["multiple", "OBSERVATION_MODIFIER", 17, 25], ["regressions", "OBSERVATION", 26, 37]]], ["Regression analysis using PROCESS macro for mediation was used to explore the role of mindfulness in the relationship between more frequent pet interactions and decreased loneliness (using the 1-item measure), separately for dog owners and cat owners.", [["decreased loneliness", "DISEASE", 161, 181], ["dog", "ORGANISM", 225, 228], ["cat", "ORGANISM", 240, 243], ["Regression analysis", "TEST", 0, 19], ["decreased loneliness", "PROBLEM", 161, 181]]], ["The experience of COVID-19 and pet ownership, as described in the two open-ended questions, was analysed using thematic content analysis to identify key themes.Quantitative analyses ::: ResultsPrior to analyses, the models were assessed for violations of the assumptions underlying analysis of variance (ANOVA) and multivariate regression.", [["COVID", "TEST", 18, 23], ["thematic content analysis", "TEST", 111, 136], ["the models", "TEST", 212, 222], ["multivariate regression", "PROBLEM", 315, 338]]], ["No problematic issues were noted for any of the models being tested; therefore, analyses proceeded with the original data.Quantitative analyses ::: ResultsDescriptive analysis of the key variables is presented in Table 2.", [["problematic issues", "PROBLEM", 3, 21], ["the original data", "TEST", 104, 121], ["problematic", "OBSERVATION_MODIFIER", 3, 14], ["issues", "OBSERVATION", 15, 21]]], ["Scores on the DASS-21 were doubled to allow for normative comparison; mean scores indicated that in the week prior to survey, the sample experienced relatively low levels of emotional distress, as evidenced by a mean score in the normal range for anxiety (0\u20136), normal range for stress (0\u201310) and mild range for depression (10\u201312).", [["emotional distress", "DISEASE", 174, 192], ["anxiety", "DISEASE", 247, 254], ["depression", "DISEASE", 312, 322], ["DASS-21", "DNA", 14, 21], ["the DASS", "TEST", 10, 18], ["mean scores", "TEST", 70, 81], ["emotional distress", "PROBLEM", 174, 192], ["a mean score", "TEST", 210, 222], ["anxiety", "PROBLEM", 247, 254], ["stress", "PROBLEM", 279, 285], ["depression", "PROBLEM", 312, 322], ["normal range", "OBSERVATION_MODIFIER", 230, 242], ["mild", "OBSERVATION_MODIFIER", 297, 301]]], ["It is important to note, however, that the DASS scores should be regarded as providing an individual\u2019s score on an underlying dimension; therefore, these cut-offs are provided purely for comparative purposes (Crawford & Henry, 2003).", [["the DASS scores", "TEST", 39, 54]]], ["Most participants had engaged in previous mindfulness or meditation; 25.6% (n = 82) had tried it briefly, 26.9% (n = 103) had experimented but not established a consistent practice, 6.3% (n = 24) had a frequent practice currently or in the past of less than 6 months\u2019 duration and 19.8% (n = 76) had a frequent practice currently or in the past of more than 6 months\u2019 duration.", [["participants", "SPECIES", 5, 17], ["meditation", "TEST", 57, 67]]], ["In addition, 38.5% (n = 148) reported that they had engaged in a mindfulness practice during the lockdown, with approximately equal frequencies across non-owners, dog owners, and cat owners.Quantitative analyses ::: ResultsThere were significant correlations between depression, anxiety, stress, loneliness and mindfulness scores, as shown in Table 3.Quantitative analyses ::: ResultsA one-way analysis of covariance (ANCOVA) was used to compare mindfulness levels between those who owned a pet (dog owner n = 111 and cat owner n = 101) and those who did not own a pet (n = 167).", [["depression", "DISEASE", 267, 277], ["anxiety", "DISEASE", 279, 286], ["dog", "ORGANISM", 163, 166], ["cat", "ORGANISM", 179, 182], ["depression", "PROBLEM", 267, 277], ["anxiety", "PROBLEM", 279, 286], ["stress, loneliness and mindfulness scores", "PROBLEM", 288, 329], ["mindfulness levels", "TEST", 446, 464], ["a pet", "TEST", 489, 494], ["a pet", "TEST", 563, 568]]], ["A covariate was included to partial out the effects of previous mindfulness training/experience from the analysis.", [["previous mindfulness training", "TREATMENT", 55, 84], ["the analysis", "TEST", 101, 113]]], ["The ANCOVA indicated that, after accounting for the effects of previous mindfulness training/experience, there was a statistically significant effect of pet ownership on mindfulness, F(2, 375) = 3.27, p = .039, \u03b7p2=.017.", [["previous mindfulness training", "TREATMENT", 63, 92], ["p", "TEST", 201, 202], ["\u03b7p2", "TEST", 211, 214], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["effect", "OBSERVATION_MODIFIER", 143, 149]]], ["Simple contrasts revealed that there was a significant difference between cat owners and non-owners (p = .015), but not between dog owners and non-owners (p = .097).Quantitative analyses ::: ResultsTo ascertain the relative importance of pet ownership, mindfulness, mood, age and gender in the prediction of loneliness using the 3-item UCLA, a hierarchical multiple regression analysis (MRA) was conducted.", [["loneliness", "DISEASE", 308, 318], ["cat", "ORGANISM", 74, 77], ["dog", "ORGANISM", 128, 131], ["a significant difference between cat owners", "PROBLEM", 41, 84], ["MRA", "TEST", 387, 390], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["difference", "OBSERVATION", 55, 65]]], ["Variables were entered in accordance with their established connection to loneliness in the previous literature.", [["loneliness", "DISEASE", 74, 84]]], ["Hence, dog/cat ownership and mindfulness were entered in the first block, mood (depression, anxiety, stress) in the second block, and age and gender in the third block.", [["depression", "DISEASE", 80, 90], ["anxiety", "DISEASE", 92, 99], ["dog", "ORGANISM", 7, 10], ["cat", "ORGANISM", 11, 14], ["dog", "SPECIES", 7, 10], ["dog/cat ownership", "TREATMENT", 7, 24], ["mood (depression", "PROBLEM", 74, 90], ["anxiety", "PROBLEM", 92, 99], ["stress", "PROBLEM", 101, 107]]], ["At Step 1, dog ownership, cat ownership and mindfulness accounted for a significant 10% of the variance in loneliness, R2 = .10, F(3, 368) = 13.87, p < .001.", [["loneliness", "DISEASE", 107, 117], ["dog", "ORGANISM", 11, 14], ["cat", "ORGANISM", 26, 29], ["loneliness", "TEST", 107, 117], ["R2", "TEST", 119, 121]]], ["At Step 2, depression, anxiety and stress added to the regression equation accounted for an additional 19% of the variance in loneliness, \u0394R2 = .19, \u0394F(3, 365) = 31.68, p < .001.", [["depression", "DISEASE", 11, 21], ["anxiety", "DISEASE", 23, 30], ["loneliness", "DISEASE", 126, 136], ["depression", "PROBLEM", 11, 21], ["anxiety", "PROBLEM", 23, 30], ["stress", "PROBLEM", 35, 41], ["the regression equation", "PROBLEM", 51, 74], ["loneliness", "TEST", 126, 136], ["\u0394R2", "TEST", 138, 141], ["\u0394F", "TEST", 149, 151], ["p", "TEST", 169, 170]]], ["At Step 3, age and gender accounted for a non-significant amount of the variance in loneliness, \u0394R2 = .00, \u0394F(2, 363) = .70, p = .497.", [["loneliness", "DISEASE", 84, 94], ["the variance in loneliness", "PROBLEM", 68, 94], ["\u0394R2", "TEST", 96, 99], ["\u0394F", "TEST", 107, 109], ["p", "TEST", 125, 126]]], ["A statistical post hoc power analysis using G Power software 3.1 confirmed that the non-significant findings in Model 3 were not due to inadequate power (1 \u2013 \u03b2 > .99).", [["hoc power analysis", "TEST", 19, 37], ["G Power software", "TEST", 44, 60]]], ["In combination, the five predictor variables in Model 2 explained 29.0% of the variance in loneliness (R2 = .29, Adj. R2 = .28).Quantitative analyses ::: ResultsUnstandardised (B) and standardised (\u03b2) coefficients, and squared semi-partial correlations (sr2) for each predictor in Models 1 and 2 of the hierarchical MRA are reported in Table 4.", [["loneliness", "DISEASE", 91, 101], ["R2", "TEST", 103, 105], ["R2", "TEST", 118, 120], ["the hierarchical MRA", "TEST", 299, 319]]], ["As can be seen, there were three significant predictors of loneliness in Model 2: depression (sr2 = .07), stress (sr2 = .01) and dog ownership (sr2 = .01).Quantitative analyses ::: ResultsIn line with recommendations by Antonacopoulos (2017) for measuring loneliness in a pet owner sample, the same hierarchical MRA was re-run using the single-item loneliness score as the outcome variable.", [["loneliness", "DISEASE", 59, 69], ["depression", "DISEASE", 82, 92], ["loneliness", "DISEASE", 256, 266], ["depression", "PROBLEM", 82, 92], ["sr2", "TEST", 94, 97], ["stress", "TEST", 106, 112], ["sr2", "TEST", 114, 117], ["dog ownership", "TEST", 129, 142]]], ["At Step 1, dog ownership, cat ownership and mindfulness accounted for a significant 15% of the variance in loneliness, R2 = .15, F(3, 366) = 22.28, p < .001.", [["loneliness", "DISEASE", 107, 117], ["dog", "ORGANISM", 11, 14], ["cat", "ORGANISM", 26, 29], ["loneliness", "TEST", 107, 117], ["R2", "TEST", 119, 121]]], ["At Step 2, depression, anxiety and stress added to the regression equation accounted for an additional 14% of the variance in loneliness, \u0394R2 = .14, \u0394F(3, 363) = 23.19, p < .001.", [["depression", "DISEASE", 11, 21], ["anxiety", "DISEASE", 23, 30], ["loneliness", "DISEASE", 126, 136], ["depression", "PROBLEM", 11, 21], ["anxiety", "PROBLEM", 23, 30], ["stress", "PROBLEM", 35, 41], ["the regression equation", "PROBLEM", 51, 74], ["the variance in loneliness", "PROBLEM", 110, 136], ["\u0394R2", "TEST", 138, 141], ["\u0394F", "TEST", 149, 151], ["p", "TEST", 169, 170]]], ["At Step 3, age and gender accounted for a non-significant amount of the variance in loneliness, \u0394R2 = .01, \u0394F(2, 361) = 1.45, p = .235.", [["loneliness", "DISEASE", 84, 94], ["the variance in loneliness", "PROBLEM", 68, 94], ["\u0394R2", "TEST", 96, 99], ["\u0394F", "TEST", 107, 109], ["p", "TEST", 126, 127]]], ["A statistical post hoc power analysis using G Power software 3.1 confirmed that the non-significant findings in Model 3 were not due to inadequate power (1 \u2013 \u03b2 > .99).", [["hoc power analysis", "TEST", 19, 37], ["G Power software", "TEST", 44, 60]]], ["In combination, the five predictor variables in Model 2 explained 29.0% of the variance in loneliness (R2 = .29, Adj. R2 = .28).Quantitative analyses ::: ResultsUnstandardised (B) and standardised (\u03b2) coefficients, and squared semi-partial correlations (sr2) for each predictor in Models 1 and 2 of the hierarchical MRA are reported in Table 5.", [["loneliness", "DISEASE", 91, 101], ["R2", "TEST", 103, 105], ["R2", "TEST", 118, 120], ["the hierarchical MRA", "TEST", 299, 319]]], ["As can be seen, there were three significant predictors of loneliness in Model 2: depression (sr2 = .07), stress (sr2 = .01) and dog ownership (sr2 = .01).Quantitative analyses ::: ResultsTo test the hypotheses that pet interaction is predictive of lower levels of loneliness, and that this relationship may also be indirect in nature via mindfulness, two mediation models were conducted (Model 1: dog owners and Model 2: cat owners) using the single-item loneliness measure.", [["loneliness", "DISEASE", 59, 69], ["depression", "DISEASE", 82, 92], ["dog", "ORGANISM", 398, 401], ["cat", "ORGANISM", 422, 425], ["depression", "PROBLEM", 82, 92], ["sr2", "TEST", 94, 97], ["stress", "TEST", 106, 112], ["sr2", "TEST", 114, 117], ["dog ownership", "TEST", 129, 142], ["lower levels of loneliness", "PROBLEM", 249, 275]]], ["Bootstrapping and heteroscedasticity-consistent approach to estimating standard errors (HC3) were applied as part of the model testing procedure.", [["Bootstrapping", "TEST", 0, 13], ["heteroscedasticity", "TEST", 18, 36], ["estimating standard errors (HC3)", "TREATMENT", 60, 92], ["the model testing procedure", "TREATMENT", 117, 144]]], ["Previous mindfulness experience/training was included as a covariate mediator.Quantitative analyses ::: ResultsThe first mediation model (n = 111) indicated that dog interaction and mindfulness accounted for 15% significant unique variance in loneliness, R2 = .19, F(3, 107) = 11.91, p < .001.", [["dog", "ORGANISM", 162, 165], ["15% significant unique variance in loneliness", "PROBLEM", 208, 253], ["R2", "TEST", 255, 257]]], ["The hypothesis predicting that the direct effect of dog interaction predicted unique variance in loneliness, holding the levels of mindfulness consistent, was not supported by the model, c\u2032 = .06, lower level of confidence interval (LLCI)/upper level of confidence interval (ULCI) = 0, p = .74.", [["loneliness", "DISEASE", 97, 107], ["dog", "ORGANISM", 52, 55], ["dog interaction", "PROBLEM", 52, 67], ["c\u2032", "TEST", 187, 189], ["LLCI", "TEST", 233, 237], ["ULCI", "TEST", 275, 279], ["p", "TEST", 286, 287], ["upper", "ANATOMY_MODIFIER", 239, 244]]], ["The hypothesis predicting that mindfulness would mediate the relationship between dog interaction and loneliness was also not supported by the model, ab = \u2013.02, LLCI/ULCI = 0, p > .05.", [["dog", "ORGANISM", 82, 85], ["ab", "TEST", 150, 152], ["LLCI", "TEST", 161, 165], ["ULCI", "TEST", 166, 170]]], ["Examination of the pathways indicated that there was a significant inverse relationship between mindfulness and loneliness (B = \u2013.16, p < .001), however no other model pathways were significant.Quantitative analyses ::: ResultsThe second mediation model (n = 101) indicated that cat interaction and mindfulness accounted for 10% significant unique variance in loneliness, R2 = .10, F(3, 97) = 3.18, p = .033.", [["loneliness", "DISEASE", 112, 122], ["cat", "ORGANISM", 279, 282], ["Examination of the pathways", "TEST", 0, 27], ["significant unique variance in loneliness", "PROBLEM", 329, 370], ["R2", "TEST", 372, 374], ["p", "TEST", 399, 400], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["inverse", "OBSERVATION", 67, 74]]], ["The hypothesis predicting that the direct effect of cat interaction predicted unique variance in loneliness, holding the levels of mindfulness consistent, was not supported by the model, c\u2032 = \u2013.06, LLCI/ULCI = 0, p = .81.", [["loneliness", "DISEASE", 97, 107], ["cat", "ORGANISM", 52, 55], ["c\u2032", "TEST", 187, 189], ["LLCI", "TEST", 198, 202], ["ULCI", "TEST", 203, 207], ["p", "TEST", 213, 214]]], ["The hypothesis predicting that the indirect effect of cat interaction via mindfulness would account for significant unique variance in loneliness was also not supported by the model, ab = .03, LLCI/ULCI = 0, p > .05, indicating no mediation.", [["cat", "ORGANISM", 54, 57], ["significant unique variance in loneliness", "PROBLEM", 104, 145], ["ab", "TEST", 183, 185], ["LLCI", "TEST", 193, 197], ["ULCI", "TEST", 198, 202], ["p", "TEST", 208, 209], ["no", "UNCERTAINTY", 228, 230]]], ["Examination of the pathways indicated that the only significant pathway was a significant inverse relationship between mindfulness and loneliness (B = \u2013.11, p < .05).Qualitative analyses ::: ResultsTo better capture the personal experiences of pets and owners, owners were asked how being a pet owner affected their experience of COVID-19 and how COVID-19 affected their pet.", [["loneliness", "DISEASE", 135, 145], ["Examination of the pathways", "TEST", 0, 27], ["COVID", "TEST", 330, 335]]], ["Once achieved, a single rater (J.L.O.) completed the coding and then K.L.J. reviewed it and any discrepancies were resolved through discussion.", [["any discrepancies", "PROBLEM", 92, 109]]], ["Themes endorsed by 5% of either the cat or dog owner populations are presented in Tables 6 and 7.Qualitative analyses ::: ResultsThe most commonly endorsed way that being a pet owner affected the experience of the COVID-19 lockdown in Australia was, for example, made the isolation easier, reduced loneliness and/or increased companionship.", [["loneliness", "DISEASE", 298, 308], ["cat", "ORGANISM", 36, 39], ["dog", "ORGANISM", 43, 46], ["dog", "SPECIES", 43, 46]]], ["While this was consistent across dog and cat owners, dog owners placed more importance on the physical connection aspect of this theme, for example, \u2018I have someone to cuddle having dogs\u2019, while both dog and cat owners expressed the importance of having someone to talk to: \u2018She gives me a reason to talk out loud\u2019.", [["dog", "ORGANISM", 33, 36], ["cat", "ORGANISM", 41, 44], ["dog", "ORGANISM", 53, 56], ["dogs", "ORGANISM", 182, 186], ["dog", "ORGANISM", 200, 203], ["cat", "ORGANISM", 208, 211], ["dog", "SPECIES", 53, 56], ["dogs", "SPECIES", 182, 186]]], ["Similarly, how the pet improved the mental state/well-being of the owner also appeared to differ between dog and cat owners, with cat owners endorsing the \u2018mood improvement\u2019 aspect over the \u2018greater sense of purpose, motivation and routine\u2019 aspect, at a ratio of approximately 3:1, and dog owners endorsing both aspects approximately equally.", [["dog", "ORGANISM", 105, 108], ["cat", "ORGANISM", 113, 116], ["cat", "ORGANISM", 130, 133], ["dog", "ORGANISM", 286, 289]]], ["All other themes showed similar patterns of endorsement across dog and cat owners, except for source of worry, which was more common in cat owners, and themes which were unique to dog owners.Qualitative analyses ::: ResultsIn addition to the themes presented in the table, 13 dog owners and 8 cat owners provided unique responses.", [["dog", "ORGANISM", 63, 66], ["cat", "ORGANISM", 71, 74], ["cat", "ORGANISM", 136, 139], ["dog", "ORGANISM", 180, 183], ["dog", "ORGANISM", 276, 279], ["cat", "ORGANISM", 293, 296]]], ["Two dog owners and one cat owner provided responses that did not address the question, and one dog owner and one cat owner did not provide any response and were therefore not included in the sample size calculation for this question.Qualitative analyses ::: ResultsThe most commonly endorsed way that a pet was affected by the experience of the COVID-19 lockdown in Australia was that they received more companionship or attention, and this was consistent across both cat and dog owners.", [["COVID-19 lockdown", "CHEMICAL", 345, 362], ["dog", "ORGANISM", 4, 7], ["cat", "ORGANISM", 23, 26], ["dog", "ORGANISM", 95, 98], ["cat", "ORGANISM", 113, 116], ["cat", "ORGANISM", 468, 471], ["dog", "ORGANISM", 476, 479], ["cat", "SPECIES", 23, 26], ["dog", "SPECIES", 95, 98], ["dog", "SPECIES", 476, 479]]], ["However, the second most commonly endorsed theme differed between dog and cat owners, with dogs experiencing little to no difference and cats demonstrating a change in emotion or behaviour.", [["dog", "ORGANISM", 66, 69], ["cat", "ORGANISM", 74, 77], ["dogs", "ORGANISM", 91, 95], ["dogs", "SPECIES", 91, 95], ["a change in emotion or behaviour", "PROBLEM", 156, 188]]], ["In dogs, changes were most commonly an increase in happiness and being more settled and relaxed, or they had become more clingy/needy.", [["dogs", "ORGANISM", 3, 7], ["dogs", "SPECIES", 3, 7], ["dogs", "OBSERVATION", 3, 7], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["Conversely, cats showed a greater range of emotional or behaviour changes, with some appearing happier and more relaxed, while others were described as \u2018put-out\u2019 or disturbed by their owner being home more.", [["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16], ["greater", "OBSERVATION_MODIFIER", 26, 33]]], ["More exercise was unique to dog owners, and the impact on regular activity was more common among dog owners than cat owners.", [["dog", "ORGANISM", 28, 31], ["dog", "ORGANISM", 97, 100], ["cat", "ORGANISM", 113, 116]]], ["Concern for pet post-isolation was similar across both dog and cat owners.Qualitative analyses ::: ResultsIn addition to the themes presented in the table, 11 dog owners and 9 cat owners provided unique responses.", [["dog", "ORGANISM", 55, 58], ["cat", "ORGANISM", 63, 66], ["dog", "ORGANISM", 159, 162], ["cat", "ORGANISM", 176, 179], ["dog", "SPECIES", 55, 58], ["cat", "SPECIES", 63, 66], ["dog", "SPECIES", 55, 58], ["pet post-isolation", "PROBLEM", 12, 30]]], ["Two dog owners provided responses that did not address the question and three cat owners expressed that they had obtained their cat prior to or during the lockdown and were therefore unable to provide a comparison and were therefore not included in the sample size calculation for this question.DiscussionThe aim of this study was to capture the experience of the COVID-19 lockdown in an Australian population living alone, with and without a dog or a cat.", [["dog", "ORGANISM", 4, 7], ["cat", "ORGANISM", 78, 81], ["cat", "ORGANISM", 128, 131], ["dog", "ORGANISM", 443, 446], ["cat", "ORGANISM", 452, 455], ["COVID-19 lockdown", "DNA", 364, 381], ["dog", "SPECIES", 443, 446], ["this study", "TEST", 316, 326]]], ["While there was a difference in mindfulness scores between cat owners and non-owners, it was the non-owners who demonstrated significantly higher levels, and no differences were observed between non-owners and dog owners.", [["cat", "ORGANISM", 59, 62], ["dog", "ORGANISM", 210, 213], ["dog", "SPECIES", 210, 213], ["a difference in mindfulness scores", "PROBLEM", 16, 50]]], ["The hypothesis that mindfulness would mediate the relationship between more frequent pet interactions and loneliness was also not supported.DiscussionThe finding that pet ownership offers no benefits in terms of mindfulness is in contrast to findings supporting an association between mindfulness and pet ownership (Garcia, 2020), and mindfulness and connectedness to nature (Schutte & Malouff, 2018).", [["loneliness", "DISEASE", 106, 116]]], ["Perhaps interacting with animals in a human, technology-heavy environment has blocked our ability to have a sense of connection to nature through them.", [["human", "ORGANISM", 38, 43], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43]]], ["The findings that cat owners are less mindful than non-owners might be explained by the fact that more cats than dogs were shown to be a source of worry for their owners (Table 6) and were less predictable in terms of their reaction to their owners being home more, with many cats being \u2018put out\u2019 or disturbed by this (Table 7).", [["cat", "ORGANISM", 18, 21], ["cats", "ORGANISM", 103, 107], ["dogs", "ORGANISM", 113, 117], ["cats", "ORGANISM", 276, 280], ["cats", "SPECIES", 103, 107], ["dogs", "SPECIES", 113, 117]]], ["Alternatively, it is possible that cat owners are just inherently less mindful.", [["cat", "ORGANISM", 35, 38], ["is possible", "UNCERTAINTY", 18, 29]]], ["Similar differences have been observed with other traits (e.g. \u2018cat people\u2019 have been shown to score significantly higher on neuroticism than \u2018dog people\u2019; Gosling et al., 2010).", [["cat", "ORGANISM", 64, 67], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["dog", "SPECIES", 143, 146], ["people", "SPECIES", 147, 153]]], ["This is further supported by the differences in how cats and dogs were reported to improve the mental state/well-being of their owners (Table 6), with more cat owners endorsing the mood enhancement aspect of this theme, as compared to the \u2018greater sense of purpose, motivation and routine\u2019 aspect.DiscussionWhile dog interactions were not found to reduce loneliness scores, dog ownership was found to significantly protect against loneliness (using both the 1-item and 3-item measures), while negative mood states, specifically depression (and stress using the 3-item measure), predicted it.", [["loneliness", "DISEASE", 431, 441], ["depression", "DISEASE", 528, 538], ["cats", "ORGANISM", 52, 56], ["dogs", "ORGANISM", 61, 65], ["cat", "ORGANISM", 156, 159], ["dog", "ORGANISM", 313, 316], ["dog", "ORGANISM", 374, 377], ["cats", "SPECIES", 52, 56], ["dogs", "SPECIES", 61, 65], ["depression", "PROBLEM", 528, 538]]], ["The loneliness buffering effect of dog ownership is in line with the previous literature (Antonacopoulos, 2017; Hajek & K\u00f6nig, 2019); however, unlike the study by Antonacopoulos, this study was able to demonstrate this using both the 3-item UCLA Loneliness Scale and the single-item measure, albeit more strongly with the single-item measure.", [["dog", "ORGANISM", 35, 38], ["the study", "TEST", 150, 159], ["this study", "TEST", 179, 189], ["dog ownership", "OBSERVATION", 35, 48]]], ["This difference might be explained by the fact that the three items of the 3-item UCLA Loneliness Scales differed across the two studies.", [["the two studies", "TEST", 121, 136], ["might be explained", "UNCERTAINTY", 16, 34]]], ["However, other differences were observed when using the different measures, for example, when predicting scores on the 3-item measure with only dog ownership, cat ownership and mindfulness scores in the model (Model 1, Table 4), mindfulness was a significant predictor of loneliness; however, in Model 2, with the addition of depression and stress scores, it no longer was.", [["loneliness", "DISEASE", 272, 282], ["depression", "DISEASE", 326, 336], ["dog", "ORGANISM", 144, 147], ["mindfulness scores", "TEST", 177, 195], ["depression", "PROBLEM", 326, 336], ["stress scores", "PROBLEM", 341, 354], ["loneliness", "OBSERVATION", 272, 282], ["depression", "OBSERVATION", 326, 336], ["no longer", "UNCERTAINTY", 359, 368]]], ["This suggests that although the loneliness measures demonstrated high convergent validity, they may not be tapping into the exact same construct and highlights the importance of considering whether traditional loneliness scales are appropriate for evaluating the loneliness reducing power of pets.DiscussionThe association between increased mindfulness and decreased loneliness is consistent with emerging literature (Clear et al., 2020; Jin et al., 2020), and the association between loneliness and mood is consistent with findings reported by Lim (2018).", [["loneliness", "DISEASE", 367, 377], ["loneliness", "DISEASE", 485, 495], ["traditional loneliness scales", "PROBLEM", 198, 227], ["increased mindfulness", "PROBLEM", 331, 352], ["decreased loneliness", "PROBLEM", 357, 377], ["may not be", "UNCERTAINTY", 96, 106], ["decreased", "OBSERVATION_MODIFIER", 357, 366], ["loneliness", "OBSERVATION", 367, 377], ["consistent with", "UNCERTAINTY", 381, 396], ["consistent with", "UNCERTAINTY", 508, 523]]], ["This might reflect that the impact of a lockdown on loneliness affects people of all ages equally, rather than these feelings being associated with any one particular stage of life.DiscussionIt is interesting that while dog interactions were not found to reduce loneliness scores, simply owning a dog did appear to buffer the effects of loneliness in some way.", [["loneliness", "DISEASE", 52, 62], ["loneliness", "DISEASE", 337, 347], ["people", "ORGANISM", 71, 77], ["dog", "ORGANISM", 220, 223], ["dog", "ORGANISM", 297, 300], ["people", "SPECIES", 71, 77]]], ["Qualitative insights offered in this study suggest that this is by the pet acting as a companion through the lockdown experience.", [["this study", "TEST", 32, 42]]], ["For dog owners more so than cat owners, an important aspect of this was the existence of a physical connection, that is, being able to touch and feel another living creature in the house.", [["dog", "ORGANISM", 4, 7], ["cat", "ORGANISM", 28, 31]]], ["Both dog and cat owners expressed the importance of the pet as an excuse to talk out loud, which has been shown to improve concentration and performance on cognitive tasks (Kirkham et al., 2012; Lupyan & Swingley, 2012) and may also play an important role in well-being during solitude.DiscussionWhile owning a cat was not found to predict lower loneliness scores, it is interesting that the most commonly endorsed theme for cat owners was that their pet makes isolation easier/reduces loneliness/increases companionship, similar to what dog owners expressed.", [["dog", "ORGANISM", 5, 8], ["cat", "ORGANISM", 13, 16], ["cat", "ORGANISM", 311, 314], ["cat", "ORGANISM", 425, 428], ["dog", "ORGANISM", 538, 541], ["dog", "SPECIES", 5, 8], ["cat", "SPECIES", 13, 16], ["lower loneliness scores", "PROBLEM", 340, 363]]], ["This might suggest a lack of sensitivity in the loneliness scale in adequately measuring this construct as it relates to pet owners.", [["sensitivity in the loneliness scale", "PROBLEM", 29, 64]]], ["However, dog owners also endorsed two themes that were unique to them: that their dogs encouraged them to take them for a walk and offered them an opportunity to socialise with other people.", [["dog", "ORGANISM", 9, 12], ["dogs", "ORGANISM", 82, 86], ["people", "ORGANISM", 183, 189], ["dog", "SPECIES", 9, 12], ["dogs", "SPECIES", 82, 86], ["people", "SPECIES", 183, 189]]], ["Walking has been shown to positively impact mood and well-being (Hallam et al., 2018) and offers opportunity for connection with others, as has been previously reported (Campbell et al., 2016); therefore, this may explain why these differences in the prediction of loneliness scores were observed in dog versus cat owners.", [["dog", "ORGANISM", 300, 303], ["cat", "ORGANISM", 311, 314], ["dog", "SPECIES", 300, 303], ["loneliness scores", "PROBLEM", 265, 282]]], ["Hence, it would be interesting for future studies to investigate this in countries where going out for walks during the lockdown was prohibited.DiscussionFinally, this study sought to understand how the COVID-19 lockdown impacted pets themselves.", [["COVID-19", "DNA", 203, 211], ["future studies", "TEST", 35, 49], ["this study", "TEST", 163, 173]]], ["The most commonly perceived way both dogs and cats were affected was that they received more companionship or attention.", [["dogs", "ORGANISM", 37, 41], ["cats", "ORGANISM", 46, 50], ["dogs", "SPECIES", 37, 41], ["cats", "SPECIES", 46, 50]]], ["However, this was closely followed by little to no difference for dogs and a change in emotion or behaviour in cats.", [["dogs", "ORGANISM", 66, 70], ["cats", "ORGANISM", 111, 115], ["dogs", "SPECIES", 66, 70], ["cats", "SPECIES", 111, 115], ["dogs", "PROBLEM", 66, 70], ["a change in emotion or behaviour in cats", "PROBLEM", 75, 115]]], ["While dogs generally became happier/more relaxed or more clingy/needy, cats experienced a greater variety of changes, including being \u2018put-out\u2019, happier, more needy, demanding, affectionate or playful.", [["dogs", "ORGANISM", 6, 10], ["cats", "ORGANISM", 71, 75], ["dogs", "SPECIES", 6, 10]]], ["In light of these changes, it is not surprising that common across both dog and cat owners was concern for their pet post-isolation, when owners will start to return to their normal routines.", [["dog", "ORGANISM", 72, 75], ["cat", "ORGANISM", 80, 83]]], ["Future studies should investigate not only the impact of the COVID-19 lockdown but also the ripple effects of such an event when things return to \u2018normal\u2019.DiscussionThe strength of this study is that data were collected during the period of the government-enforced lockdown in Australia during the COVID-19 pandemic, allowing the construct of social isolation to be largely controlled for in a sample of people living alone.", [["people", "ORGANISM", 404, 410], ["people", "SPECIES", 404, 410], ["Future studies", "TEST", 0, 14], ["the COVID", "TREATMENT", 57, 66], ["this study", "TEST", 181, 191], ["the COVID", "TEST", 294, 303], ["social isolation", "TREATMENT", 343, 359], ["normal", "OBSERVATION", 147, 153]]], ["However, the study was limited by the fact that approximately one-quarter of our sample were deemed \u2018essential workers\u2019 and were therefore still potentially able to interact with others in a face-to-face manner in their workplace.", [["the study", "TEST", 9, 18]]], ["The social media recruitment strategy used in this study has been demonstrated to be effective for collecting rapid survey data in a short period time during health crises such as COVID-19 (Ali et al., 2020); however, it is also commonly biased by a higher number of female responders, as was observed in our sample.", [["The social media recruitment strategy", "TREATMENT", 0, 37], ["this study", "TEST", 46, 56], ["collecting rapid survey data", "TEST", 99, 127]]], ["Further, the proposed mediation models would benefit from replication using a larger sample as it is unclear whether the non-significant mediation is genuine or a statistical artefact due to suppression effects and inadequate power.", [["a larger sample", "TREATMENT", 76, 91], ["a statistical artefact", "PROBLEM", 161, 183], ["suppression effects", "PROBLEM", 191, 210]]], ["Finally, this study was limited by the fact that the dog interactions scale did not reach an acceptable level of reliability.", [["dog", "ORGANISM", 53, 56], ["this study", "TEST", 9, 19], ["the dog interactions scale", "PROBLEM", 49, 75]]], ["This may suggest that the items comprising this scale are not accurately capturing owner\u2013dog interactions during a period of lockdown and/or the factor structure of this scale may need to be re-evaluated.DiscussionIn conclusion, this study provided evidence that dog ownership and high levels of mindfulness protect against loneliness during a lockdown, while negative mood states make one more susceptible to it.", [["loneliness", "DISEASE", 324, 334], ["dog", "ORGANISM", 263, 266], ["this scale", "TREATMENT", 43, 53], ["lockdown", "TREATMENT", 125, 133], ["this scale", "TREATMENT", 165, 175], ["this study", "TEST", 229, 239], ["dog ownership", "PROBLEM", 263, 276], ["may suggest", "UNCERTAINTY", 5, 16]]], ["While dog ownership does not appear to influence mindfulness levels, its buffering effect against loneliness might be via opportunities to keep a routine involving leaving the house to walk and potentially interact with other dog owners, which are opportunities not associated with being a cat owner.", [["loneliness", "DISEASE", 98, 108], ["dog", "ORGANISM", 6, 9], ["dog", "ORGANISM", 226, 229], ["cat", "ORGANISM", 290, 293], ["mindfulness levels", "TEST", 49, 67], ["loneliness", "PROBLEM", 98, 108]]], ["Despite cat ownership not being a significant predictor of loneliness scores, qualitative insights suggest that both dog and cat owners perceived their experience of the lockdown to have been made easier by having a pet to share it with.", [["cat", "ORGANISM", 8, 11], ["dog", "ORGANISM", 117, 120], ["cat", "ORGANISM", 125, 128]]], ["However, our findings suggest that the increased demand for pets observed by Australian animal shelters prior to the COVID-19 lockdown (Roy, 2020) may offer no additional benefit than going outside for a walk or striking up a conversation with neighbours.", [["the increased demand", "PROBLEM", 35, 55], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["Results do suggest, however, that dogs might be wonderful catalysts for these activities.", [["dogs", "ORGANISM", 34, 38], ["dogs", "SPECIES", 34, 38]]], ["This study adds to the current literature on the experience on loneliness during a lockdown, as well as the impact of pet ownership for Australians living alone.", [["loneliness", "DISEASE", 63, 73], ["This study", "TEST", 0, 10]]]], "9a17bdcd3c3e268ce2a27a487b2c4be1ac40118b": [["INTRODUCTION 60Since early December 2019, a pandemic infectious disease due to a novel coronavirus, called 61 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading all over the world.", [["infectious disease", "DISEASE", 53, 71], ["coronavirus", "DISEASE", 87, 98], ["acute respiratory syndrome coronavirus", "DISEASE", 117, 155], ["coronavirus", "ORGANISM", 87, 98], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 110, 157], ["SARS-CoV-2", "ORGANISM", 159, 169], ["coronavirus", "SPECIES", 87, 98], ["syndrome coronavirus", "SPECIES", 135, 155], ["severe acute respiratory syndrome coronavirus", "SPECIES", 110, 155], ["SARS-CoV-2", "SPECIES", 159, 169], ["a pandemic infectious disease", "PROBLEM", 42, 71], ["a novel coronavirus", "PROBLEM", 79, 98], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 110, 155], ["infectious", "OBSERVATION", 53, 63], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["respiratory syndrome", "OBSERVATION", 123, 143]]], ["62INTRODUCTION 60To date, no specific therapeutic agent has proven its clinical efficacy against this outbreak.", [["this outbreak", "PROBLEM", 97, 110]]], ["63INTRODUCTION 60However, due to the urgent need for a treatment, several antiviral drugs are being repurposed and 64 used off-label to treat Covid-19, including lopinavir/ritonavir (LPV/r) (1).", [["Covid-19", "CHEMICAL", 142, 150], ["lopinavir/ritonavir", "CHEMICAL", 162, 181], ["LPV", "CHEMICAL", 183, 186], ["lopinavir", "CHEMICAL", 162, 171], ["ritonavir", "CHEMICAL", 172, 181], ["LPV", "CHEMICAL", 183, 186], ["Covid-19", "SIMPLE_CHEMICAL", 142, 150], ["lopinavir", "SIMPLE_CHEMICAL", 162, 171], ["ritonavir", "SIMPLE_CHEMICAL", 172, 181], ["a treatment", "TREATMENT", 53, 64], ["several antiviral drugs", "TREATMENT", 66, 89], ["Covid", "TEST", 142, 147], ["lopinavir", "TREATMENT", 162, 171], ["ritonavir (LPV/r)", "TREATMENT", 172, 189]]], ["The latter is a human 65 immunodeficiency virus (HIV) protease inhibitor approved since years.", [["human 65 immunodeficiency virus (HIV)", "DISEASE", 16, 53], ["human", "ORGANISM", 16, 21], ["65 immunodeficiency virus", "ORGANISM", 22, 47], ["HIV", "ORGANISM", 49, 52], ["human", "SPECIES", 16, 21], ["65 immunodeficiency virus", "SPECIES", 22, 47], ["human 65 immunodeficiency virus", "SPECIES", 16, 47], ["HIV", "SPECIES", 49, 52], ["a human 65 immunodeficiency virus (HIV) protease inhibitor", "TREATMENT", 14, 72]]], ["LPV is prescribed in 66 patients with HIV in association with another protease inhibitor, ritonavir (RTV), used as a potent 67 P450 3A4 cytochrome (CYP) inhibitor in order to dramatically increase LPV plasma exposure.", [["plasma", "ANATOMY", 201, 207], ["LPV", "CHEMICAL", 0, 3], ["ritonavir", "CHEMICAL", 90, 99], ["RTV", "CHEMICAL", 101, 104], ["LPV", "CHEMICAL", 197, 200], ["ritonavir", "CHEMICAL", 90, 99], ["RTV", "CHEMICAL", 101, 104], ["patients", "ORGANISM", 24, 32], ["HIV", "ORGANISM", 38, 41], ["ritonavir", "SIMPLE_CHEMICAL", 90, 99], ["RTV", "SIMPLE_CHEMICAL", 101, 104], ["P450 3A4 cytochrome", "GENE_OR_GENE_PRODUCT", 127, 146], ["CYP", "GENE_OR_GENE_PRODUCT", 148, 151], ["LPV", "ORGANISM", 197, 200], ["plasma", "ORGANISM_SUBSTANCE", 201, 207], ["CYP", "PROTEIN", 148, 151], ["patients", "SPECIES", 24, 32], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["LPV", "TREATMENT", 0, 3], ["HIV", "PROBLEM", 38, 41], ["another protease inhibitor", "TREATMENT", 62, 88], ["ritonavir (RTV)", "TREATMENT", 90, 105], ["a potent 67 P450 3A4 cytochrome (CYP) inhibitor", "TREATMENT", 115, 162], ["LPV plasma exposure", "TREATMENT", 197, 216]]], ["68 LPV/r has been proposed in previous coronavirus outbreaks in 2003 and 2012 due to SARS-69INTRODUCTION 60CoV-1 and to Middle East respiratory syndrome coronavirus (MERS-CoV), respectively (2, 3).", [["coronavirus outbreaks", "DISEASE", 39, 60], ["SARS", "DISEASE", 85, 89], ["Middle East respiratory syndrome coronavirus", "DISEASE", 120, 164], ["coronavirus", "ORGANISM", 39, 50], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 120, 164], ["MERS-CoV", "ORGANISM", 166, 174], ["SARS-69INTRODUCTION 60CoV-1", "SPECIES", 85, 112], ["Middle East respiratory syndrome coronavirus", "SPECIES", 120, 164], ["MERS-CoV", "SPECIES", 166, 174], ["SARS", "TEST", 85, 89], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 120, 164], ["Middle", "ANATOMY_MODIFIER", 120, 126], ["respiratory syndrome", "ANATOMY", 132, 152]]], ["70INTRODUCTION 60In vitro activity and data from rodent models showed LPV has an antiviral activity against 71 MERS-CoV(4, 5).", [["LPV", "CHEMICAL", 70, 73], ["LPV", "ORGANISM", 70, 73], ["MERS-CoV", "ORGANISM", 111, 119], ["MERS-CoV", "SPECIES", 111, 119], ["data from rodent models", "TEST", 39, 62], ["LPV", "TREATMENT", 70, 73], ["an antiviral activity", "TREATMENT", 78, 99], ["antiviral activity", "OBSERVATION", 81, 99]]], ["It has also proven its potency to inhibit SARS-CoV-2 replication in vitro (6).", [["CoV-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["SARS-CoV", "SPECIES", 42, 50], ["CoV", "TEST", 47, 50], ["potency", "OBSERVATION_MODIFIER", 23, 30]]], ["72INTRODUCTION 60Furthermore, in an open-label study comparing the addition of LPV/r to ribavirin in patients with 73 SARS-CoV, the authors showed a reduced risk of acute respiratory distress syndrome (ARDS) or 74 death by comparison with a historical control group treated by ribavirin alone (2).", [["respiratory", "ANATOMY", 171, 182], ["LPV", "CHEMICAL", 79, 82], ["ribavirin", "CHEMICAL", 88, 97], ["SARS", "DISEASE", 118, 122], ["acute respiratory distress syndrome", "DISEASE", 165, 200], ["ARDS", "DISEASE", 202, 206], ["death", "DISEASE", 214, 219], ["ribavirin", "CHEMICAL", 277, 286], ["ribavirin", "CHEMICAL", 88, 97], ["ribavirin", "CHEMICAL", 277, 286], ["LPV", "ORGANISM", 79, 82], ["ribavirin", "SIMPLE_CHEMICAL", 88, 97], ["patients", "ORGANISM", 101, 109], ["-CoV", "ORGANISM", 122, 126], ["ribavirin", "SIMPLE_CHEMICAL", 277, 286], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 118, 126], ["label study", "TEST", 41, 52], ["LPV", "TREATMENT", 79, 82], ["ribavirin", "TREATMENT", 88, 97], ["acute respiratory distress syndrome", "PROBLEM", 165, 200], ["ARDS", "PROBLEM", 202, 206], ["a historical control group", "TREATMENT", 239, 265], ["ribavirin", "TREATMENT", 277, 286], ["ribavirin", "OBSERVATION", 88, 97], ["acute", "OBSERVATION_MODIFIER", 165, 170], ["respiratory distress syndrome", "OBSERVATION", 171, 200]]], ["Viral load was 75 also reduced in the LPV/r treated patients.", [["Viral", "ORGANISM", 0, 5], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Viral load", "TEST", 0, 10], ["reduced", "OBSERVATION_MODIFIER", 23, 30]]], ["76INTRODUCTION 60Based on these results, this drug has been considered to be potentially useful in patients with 77 6 first symptoms.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["6 first symptoms", "PROBLEM", 116, 132]]], ["Furthermore, no therapeutic drug monitoring was performed for LPV/r to assess 83 an ideal drug exposure.", [["therapeutic drug monitoring", "TEST", 16, 43], ["LPV", "TEST", 62, 65]]], ["Nevertheless, due to the absence of specific treatment for Covid-19, 84 LPV/r is still a therapeutic option used for patients with moderate to severe Covid-19 pneumonia.", [["pneumonia", "DISEASE", 159, 168], ["LPV", "ORGANISM", 72, 75], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["specific treatment", "TREATMENT", 36, 54], ["Covid", "TEST", 59, 64], ["LPV", "TEST", 72, 75], ["a therapeutic option", "TREATMENT", 87, 107], ["moderate to severe Covid-19 pneumonia", "PROBLEM", 131, 168], ["moderate", "OBSERVATION_MODIFIER", 131, 139], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["pneumonia", "OBSERVATION", 159, 168]]], ["85INTRODUCTION 60To date, more than 40 clinical trials assessing the efficacy of LPV/r against Covid-19 are ongoing 86 around the world (8).", [["LPV", "CHEMICAL", 81, 84], ["LPV", "TEST", 81, 84], ["Covid", "TEST", 95, 100]]], ["87INTRODUCTION 60In order to assess LPV/r plasma concentration and its safety in Covid-19 patients, we conducted a 88 retrospective cohort study as part of routine care in adult patients hospitalized for a Covid-19 89 infection and requiring oxygen.", [["plasma", "ANATOMY", 42, 48], ["infection", "DISEASE", 218, 227], ["oxygen", "CHEMICAL", 242, 248], ["oxygen", "CHEMICAL", 242, 248], ["LPV", "ORGANISM", 36, 39], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 178, 186], ["oxygen", "SIMPLE_CHEMICAL", 242, 248], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 178, 186], ["Covid-19 89", "SPECIES", 206, 217], ["LPV/r plasma concentration", "TREATMENT", 36, 62], ["routine care", "TREATMENT", 156, 168], ["a Covid", "TEST", 204, 211], ["infection", "PROBLEM", 218, 227], ["oxygen", "TREATMENT", 242, 248], ["infection", "OBSERVATION", 218, 227]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) patients did not receive any antibiotic at admission or before being hospitalized.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["any antibiotic", "TREATMENT", 228, 242], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["LPV/r was 103 started within the first 48 hours after hospitalization and median time to starting LPV/r after 104 symptom onset was 8 days (IQR, 7-10 days).", [["LPV", "TEST", 0, 3]]], ["No patient had drug-drug interaction involving 105 RTV and 13 (42%) patients did not received concomitant therapy.", [["RTV", "CHEMICAL", 51, 54], ["RTV", "CHEMICAL", 51, 54], ["patient", "ORGANISM", 3, 10], ["patients", "ORGANISM", 68, 76], ["patient", "SPECIES", 3, 10], ["patients", "SPECIES", 68, 76], ["concomitant therapy", "TREATMENT", 94, 113]]], ["LPV/r treatment duration was 106 7 (IDR, 3-8) days.", [["LPV/r treatment duration", "TREATMENT", 0, 24], ["IDR", "TEST", 36, 39]]], ["At the end of the LPV/r course, five patients had recovered, eight patients 107 were transferred to intensive care unit or died, 17 were still hospitalized with oxygen 108 dependency.", [["oxygen", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 161, 167], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 67, 75], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 67, 75], ["the LPV/r course", "TREATMENT", 14, 30], ["oxygen 108 dependency", "PROBLEM", 161, 182]]], ["Clinical outcome is unknown for one patient that has been transferred to another 109 hospital during treatment.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["treatment", "TREATMENT", 101, 110]]], ["In all patients, considering either trough or peak for LPV and RTV, plasma 117 concentrations were above the average concentrations observed during HIV treatment (4,000 118 ng/mL and 9,000 ng/mL for trough and peak concentrations, respectively) ( Figure 1A ).", [["plasma", "ANATOMY", 68, 74], ["RTV", "CHEMICAL", 63, 66], ["RTV", "CHEMICAL", 63, 66], ["patients", "ORGANISM", 7, 15], ["RTV", "SIMPLE_CHEMICAL", 63, 66], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["patients", "SPECIES", 7, 15], ["HIV", "SPECIES", 148, 151], ["trough", "TEST", 36, 42], ["LPV", "TEST", 55, 58], ["RTV", "TEST", 63, 66], ["plasma 117 concentrations", "TEST", 68, 93], ["HIV treatment", "TREATMENT", 148, 161], ["trough", "TEST", 199, 205], ["peak concentrations", "TEST", 210, 229]]], ["All 119 except two patients had plasma concentration over the upper limit of the concentration ranges 120 observed in HIV.", [["plasma", "ANATOMY", 32, 38], ["patients", "ORGANISM", 19, 27], ["plasma", "ORGANISM_SUBSTANCE", 32, 38], ["patients", "SPECIES", 19, 27], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 118, 121], ["plasma concentration", "TREATMENT", 32, 52], ["HIV", "PROBLEM", 118, 121], ["upper limit", "OBSERVATION_MODIFIER", 62, 73]]], ["With regards with these plasma concentration ranges, LPV concentrations in 121INTRODUCTION 60Covid-19 patients were increased of about 4.6-fold (IQR 2.9-6.4) ( Figure 1B) .", [["plasma", "ANATOMY", 24, 30], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["these plasma concentration ranges", "TEST", 18, 51], ["LPV concentrations", "TEST", 53, 71], ["IQR", "TEST", 145, 148]]], ["Extent of LPV 122 plasma concentration increase was not associated with CRP or IL-6 levels (data not shown).", [["plasma", "ANATOMY", 18, 24], ["LPV 122", "CHEMICAL", 10, 17], ["LPV 122", "CHEMICAL", 10, 17], ["LPV 122", "GENE_OR_GENE_PRODUCT", 10, 17], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["CRP", "GENE_OR_GENE_PRODUCT", 72, 75], ["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["CRP", "PROTEIN", 72, 75], ["IL", "PROTEIN", 79, 81], ["LPV 122 plasma concentration", "TEST", 10, 38], ["CRP", "TEST", 72, 75], ["IL", "TEST", 79, 81]]], ["123 124 Safety 125 LPV/r was discontinued before the end of scheduled course for 14 (45%) patients (Table 2) .", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["Safety", "TEST", 8, 14], ["LPV", "TEST", 19, 22]]], ["126INTRODUCTION 60Reasons for early ending LPV/r therapy were the occurrence of adverse drug reaction, therapeutic 127 limitation or patient deceased and poor efficacy in seven (22%), four (13%) and three (10%) 128 patients, respectively.", [["adverse drug reaction", "DISEASE", 80, 101], ["patient", "ORGANISM", 133, 140], ["patients", "ORGANISM", 215, 223], ["patient", "SPECIES", 133, 140], ["patients", "SPECIES", 215, 223], ["early ending LPV/r therapy", "TREATMENT", 30, 56], ["adverse drug reaction", "PROBLEM", 80, 101]]], ["Suspected adverse drug reaction were assessed as possibly related to LPV/r 129 therapy.", [["adverse drug reaction", "DISEASE", 10, 31], ["LPV/r 129", "CHEMICAL", 69, 78], ["adverse drug reaction", "PROBLEM", 10, 31], ["LPV/r 129 therapy", "TREATMENT", 69, 86], ["adverse", "OBSERVATION_MODIFIER", 10, 17], ["drug reaction", "OBSERVATION", 18, 31]]], ["They consisted in four cases of liver injuries (three cases moderate cytolytic hepatitis 130 between three and six times above the upper limit of normal range and one case of isolated 131 hyperbilirubinemia), two cases of gastrointestinal disorders (nausea/vomiting and diarrhea) and 132 one case of psychiatric disorders (agitation/anxiety).", [["liver", "ANATOMY", 32, 37], ["gastrointestinal", "ANATOMY", 222, 238], ["liver injuries", "DISEASE", 32, 46], ["hepatitis", "DISEASE", 79, 88], ["hyperbilirubinemia", "DISEASE", 188, 206], ["gastrointestinal disorders", "DISEASE", 222, 248], ["nausea/vomiting", "DISEASE", 250, 265], ["diarrhea", "DISEASE", 270, 278], ["psychiatric disorders", "DISEASE", 300, 321], ["agitation", "DISEASE", 323, 332], ["anxiety", "DISEASE", 333, 340], ["liver", "ORGAN", 32, 37], ["gastrointestinal", "ORGAN", 222, 238], ["liver injuries", "PROBLEM", 32, 46], ["moderate cytolytic hepatitis", "PROBLEM", 60, 88], ["isolated 131 hyperbilirubinemia", "PROBLEM", 175, 206], ["gastrointestinal disorders", "PROBLEM", 222, 248], ["nausea", "PROBLEM", 250, 256], ["vomiting", "PROBLEM", 257, 265], ["diarrhea", "PROBLEM", 270, 278], ["psychiatric disorders", "PROBLEM", 300, 321], ["agitation", "PROBLEM", 323, 332], ["anxiety", "PROBLEM", 333, 340], ["liver", "ANATOMY", 32, 37], ["injuries", "OBSERVATION", 38, 46], ["upper limit", "OBSERVATION_MODIFIER", 131, 142], ["hyperbilirubinemia", "OBSERVATION", 188, 206], ["gastrointestinal", "ANATOMY", 222, 238]]], ["These adverse effects were mild and all 133 patients recovered after drug withdrawn.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["These adverse effects", "PROBLEM", 0, 21], ["mild", "OBSERVATION_MODIFIER", 27, 31]]], ["In patients with cytolytic hepatitis, LPV plasma 134 concentrations were 6.1-fold above average plasma concentrations in HIV patients.", [["plasma", "ANATOMY", 42, 48], ["plasma", "ANATOMY", 96, 102], ["cytolytic hepatitis", "DISEASE", 17, 36], ["patients", "ORGANISM", 3, 11], ["LPV", "ORGANISM", 38, 41], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 3, 11], ["HIV", "SPECIES", 121, 124], ["patients", "SPECIES", 125, 133], ["HIV", "SPECIES", 121, 124], ["cytolytic hepatitis", "PROBLEM", 17, 36], ["LPV plasma", "TEST", 38, 48], ["concentrations", "TEST", 53, 67], ["HIV patients", "TREATMENT", 121, 133], ["cytolytic hepatitis", "OBSERVATION", 17, 36]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)INTRODUCTION 60The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105650 doi: medRxiv preprint plasma exposure with regards to the therapeutic levels in HIV.", [["plasma", "ANATOMY", 358, 364], ["CC", "CHEMICAL", 0, 2], ["plasma", "ORGANISM_SUBSTANCE", 358, 364], ["HIV", "ORGANISM", 416, 419], ["HIV", "SPECIES", 416, 419], ["HIV", "SPECIES", 416, 419], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 217, 237], ["medRxiv preprint plasma exposure", "TREATMENT", 341, 373], ["HIV", "PROBLEM", 416, 419], ["med", "ANATOMY", 105, 108]]], ["Although LPV/r regimen was 140 400/100 mg bid as in HIV treatment, LPV plasma concentrations were in median about 4.6-fold 141 higher, and up to 8-fold higher in some patients.", [["plasma", "ANATOMY", 71, 77], ["LPV/r regimen", "CHEMICAL", 9, 22], ["LPV", "ORGANISM", 9, 12], ["HIV", "ORGANISM", 52, 55], ["LPV", "ORGANISM", 67, 70], ["plasma", "ORGANISM_SUBSTANCE", 71, 77], ["patients", "ORGANISM", 167, 175], ["HIV", "SPECIES", 52, 55], ["patients", "SPECIES", 167, 175], ["HIV", "SPECIES", 52, 55], ["LPV/r regimen", "TREATMENT", 9, 22], ["HIV treatment", "TREATMENT", 52, 65], ["LPV plasma concentrations", "TEST", 67, 92]]], ["All patients of this retrospective cohort had a 142 LPV plasma concentration over the average concentrations observed in HIV patients.", [["plasma", "ANATOMY", 56, 62], ["patients", "ORGANISM", 4, 12], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 4, 12], ["HIV", "SPECIES", 121, 124], ["patients", "SPECIES", 125, 133], ["HIV", "SPECIES", 121, 124], ["a 142 LPV plasma concentration", "TREATMENT", 46, 76]]], ["As LPV is 143 extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the 144 CYP3A isozyme, LPV/r therapy was not started in the event of drug-drug interaction.", [["hepatic", "ANATOMY", 45, 52], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 53, 68], ["CYP3A", "GENE_OR_GENE_PRODUCT", 107, 112], ["hepatic cytochrome P450", "PROTEIN", 45, 68], ["144 CYP3A isozyme", "PROTEIN", 103, 120], ["LPV", "TEST", 3, 6], ["CYP3A isozyme", "TREATMENT", 107, 120], ["LPV/r therapy", "TREATMENT", 122, 135], ["hepatic", "ANATOMY", 45, 52]]], ["None was 145 detected during therapy and no patient had liver cirrhosis, which could have impaired LPV/r 146 clearance.", [["liver cirrhosis", "ANATOMY", 56, 71], ["liver cirrhosis", "DISEASE", 56, 71], ["patient", "ORGANISM", 44, 51], ["liver", "ORGAN", 56, 61], ["patient", "SPECIES", 44, 51], ["liver cirrhosis", "PROBLEM", 56, 71], ["liver", "ANATOMY", 56, 61], ["cirrhosis", "OBSERVATION", 62, 71]]], ["Only two patients had a medical history of hepatitis, including one patient with an 147 active hepatitis B without hepatic insufficiency.", [["hepatic", "ANATOMY", 115, 122], ["hepatitis", "DISEASE", 43, 52], ["hepatitis B", "DISEASE", 95, 106], ["hepatic insufficiency", "DISEASE", 115, 136], ["patients", "ORGANISM", 9, 17], ["patient", "ORGANISM", 68, 75], ["hepatic", "ORGAN", 115, 122], ["patients", "SPECIES", 9, 17], ["patient", "SPECIES", 68, 75], ["hepatitis", "PROBLEM", 43, 52], ["an 147 active hepatitis B", "PROBLEM", 81, 106], ["hepatic insufficiency", "PROBLEM", 115, 136], ["hepatitis", "OBSERVATION", 43, 52], ["active", "OBSERVATION_MODIFIER", 88, 94], ["hepatitis", "OBSERVATION", 95, 104], ["without", "UNCERTAINTY", 107, 114], ["hepatic", "ANATOMY", 115, 122], ["insufficiency", "OBSERVATION", 123, 136]]], ["148INTRODUCTION 60Some clinical evidence show that patients with moderate to severe Covid-19 have a major 149 inflammation.", [["inflammation", "DISEASE", 110, 122], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["moderate to severe Covid", "PROBLEM", 65, 89], ["a major 149 inflammation", "PROBLEM", 98, 122], ["moderate", "OBSERVATION_MODIFIER", 65, 73], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["inflammation", "OBSERVATION", 110, 122]]], ["Elevated levels of blood IL-6 are commonly seen in severe Covid-19 illness and 150 could led to a cytokine storm syndrome (9).", [["blood", "ANATOMY", 19, 24], ["illness", "DISEASE", 67, 74], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["blood IL-6", "PROTEIN", 19, 29], ["cytokine", "PROTEIN", 98, 106], ["Elevated levels", "PROBLEM", 0, 15], ["blood IL", "TEST", 19, 27], ["a cytokine storm syndrome", "PROBLEM", 96, 121], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["cytokine storm", "OBSERVATION", 98, 112]]], ["Previous studies in macaques inoculated with SARS-151INTRODUCTION 60CoV found that defects in T-cell and B-cell function and the excess production of type 2 152 cytokines could lead to a deficiency in control of viral replication and prolonged proinflammatory 153 responses (10).", [["T-cell", "ANATOMY", 94, 100], ["B-cell", "ANATOMY", 105, 111], ["macaques", "ORGANISM", 20, 28], ["T-cell", "CELL", 94, 100], ["B-cell", "CELL", 105, 111], ["SARS-151INTRODUCTION 60CoV", "DNA", 45, 71], ["type 2 152 cytokines", "PROTEIN", 150, 170], ["macaques", "SPECIES", 20, 28], ["Previous studies", "TEST", 0, 16], ["SARS-151INTRODUCTION", "TEST", 45, 65], ["defects in T-cell", "PROBLEM", 83, 100], ["type 2 152 cytokines", "PROBLEM", 150, 170], ["a deficiency", "PROBLEM", 185, 197], ["viral replication", "TREATMENT", 212, 229], ["defects", "OBSERVATION", 83, 90], ["cell function", "OBSERVATION", 107, 120], ["viral replication", "OBSERVATION", 212, 229]]], ["In Covid-19 patients, a persistent blood virus load and an exacerbated 154 inflammatory response has been shown to be partially driven by the transcriptional factor NF\u03baB 155 (11) .", [["blood", "ANATOMY", 35, 40], ["patients", "ORGANISM", 12, 20], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["NF\u03baB 155", "GENE_OR_GENE_PRODUCT", 165, 173], ["transcriptional factor", "PROTEIN", 142, 164], ["NF\u03baB 155", "PROTEIN", 165, 173], ["patients", "SPECIES", 12, 20], ["a persistent blood virus load", "PROBLEM", 22, 51], ["an exacerbated 154 inflammatory response", "PROBLEM", 56, 96], ["virus load", "OBSERVATION", 41, 51], ["inflammatory response", "OBSERVATION", 75, 96]]], ["These results are in line with our cohort where patients had very high CRP and IL-6 levels 156 at starting therapy.", [["patients", "ORGANISM", 48, 56], ["CRP", "GENE_OR_GENE_PRODUCT", 71, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["CRP", "PROTEIN", 71, 74], ["IL", "PROTEIN", 79, 81], ["patients", "SPECIES", 48, 56], ["very high CRP", "PROBLEM", 61, 74], ["IL", "TEST", 79, 81]]], ["Besides, it is long-standing known that inflammatory responses and infections 157 decrease drug metabolism capacity in human and experimental animals (12).", [["infections", "DISEASE", 67, 77], ["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 119, 124], ["inflammatory responses", "PROBLEM", 40, 62], ["infections", "PROBLEM", 67, 77], ["drug metabolism capacity", "PROBLEM", 91, 115], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52]]], ["In cultured human 158 hepatocytes, direct treatments with tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), 159 interleukin-6 (IL-6), interferon-\u03b3 (IFN-\u03b3) and transforming growth factor-\u03b2 (TGF-\u03b2) can reduce 160 the expression of CYP1A2, CYP2C8 and CYP3A4 (13, 14).", [["hepatocytes", "ANATOMY", 22, 33], ["tumor necrosis", "DISEASE", 58, 72], ["human", "ORGANISM", 12, 17], ["hepatocytes", "CELL", 22, 33], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 58, 81], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 91, 105], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 107, 112], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 119, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 134, 138], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 141, 153], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 155, 160], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 166, 194], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 196, 201], ["CYP1A2", "GENE_OR_GENE_PRODUCT", 236, 242], ["CYP2C8", "GENE_OR_GENE_PRODUCT", 244, 250], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 255, 261], ["cultured human 158 hepatocytes", "CELL_LINE", 3, 33], ["tumor necrosis factor-\u03b1 (TNF-\u03b1", "PROTEIN", 58, 88], ["interleukin-1\u03b2 (IL-1\u03b2", "PROTEIN", 91, 112], ["159 interleukin-6 (IL-6", "PROTEIN", 115, 138], ["interferon-\u03b3", "PROTEIN", 141, 153], ["IFN", "PROTEIN", 155, 158], ["\u03b3", "PROTEIN", 159, 160], ["transforming growth factor-\u03b2", "PROTEIN", 166, 194], ["TGF-\u03b2", "PROTEIN", 196, 201], ["CYP1A2", "PROTEIN", 236, 242], ["CYP2C8", "PROTEIN", 244, 250], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["hepatocytes", "TEST", 22, 33], ["direct treatments", "TREATMENT", 35, 52], ["tumor necrosis factor", "TEST", 58, 79], ["TNF", "TEST", 83, 86], ["interleukin", "TEST", 91, 102], ["IL", "TEST", 107, 109], ["interleukin", "TEST", 119, 130], ["IL", "TEST", 134, 136], ["interferon", "TEST", 141, 151], ["IFN", "TEST", 155, 158], ["transforming growth factor", "TEST", 166, 192], ["TGF", "TEST", 196, 199], ["CYP1A2", "TEST", 236, 242], ["CYP2C8", "TEST", 244, 250], ["CYP3A4", "TEST", 255, 261], ["necrosis", "OBSERVATION", 64, 72]]], ["In animals and humans, several 161 .", [["humans", "ORGANISM", 15, 21], ["humans", "SPECIES", 15, 21], ["humans", "SPECIES", 15, 21]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105650 doi: medRxiv preprint studies or reports have shown the role of inflammation in reducing drug metabolism and CYP450 162 inhibition (15, 16).", [["CC", "CHEMICAL", 0, 2], ["inflammation", "DISEASE", 384, 396], ["CYP450 162", "GENE_OR_GENE_PRODUCT", 429, 439], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint studies", "TEST", 325, 349], ["inflammation", "PROBLEM", 384, 396], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["inflammation", "OBSERVATION", 384, 396]]], ["CYP3A4 expression is transcriptionally regulated by pregnane X receptor 163 (PXR), which is a ligand-dependent transcription factor (17).", [["CYP3A4", "GENE_OR_GENE_PRODUCT", 0, 6], ["pregnane X receptor 163", "GENE_OR_GENE_PRODUCT", 52, 75], ["PXR", "GENE_OR_GENE_PRODUCT", 77, 80], ["CYP3A4", "PROTEIN", 0, 6], ["pregnane X receptor 163", "PROTEIN", 52, 75], ["PXR", "PROTEIN", 77, 80], ["transcription factor", "PROTEIN", 111, 131], ["pregnane X receptor", "TEST", 52, 71]]], ["NF-\u03baB activation by tumor necrosis 164 factor-\u03b1, in a setting of inflammatory response, has been shown to suppress PXR activation and 165 PXR-mediated gene expression (17, 18) .", [["tumor", "DISEASE", 20, 25], ["necrosis", "DISEASE", 26, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor necrosis 164 factor-\u03b1", "GENE_OR_GENE_PRODUCT", 20, 47], ["PXR", "GENE_OR_GENE_PRODUCT", 115, 118], ["PXR", "GENE_OR_GENE_PRODUCT", 138, 141], ["NF-\u03baB", "PROTEIN", 0, 5], ["tumor necrosis 164 factor-\u03b1", "PROTEIN", 20, 47], ["PXR", "PROTEIN", 115, 118], ["PXR", "PROTEIN", 138, 141], ["tumor necrosis", "PROBLEM", 20, 34], ["factor", "TEST", 39, 45], ["inflammatory response", "PROBLEM", 65, 86], ["PXR activation", "TEST", 115, 129], ["PXR", "TEST", 138, 141], ["tumor", "OBSERVATION_MODIFIER", 20, 25], ["necrosis", "OBSERVATION_MODIFIER", 26, 34], ["inflammatory", "OBSERVATION", 65, 77]]], ["This results in a reduced CYP450 expression and a 166 decreased drug metabolism, especially CYP450-mediated metabolism.", [["CYP450", "GENE_OR_GENE_PRODUCT", 26, 32], ["CYP450", "GENE_OR_GENE_PRODUCT", 92, 98], ["CYP450", "PROTEIN", 26, 32], ["CYP450", "PROTEIN", 92, 98], ["a reduced CYP450 expression", "PROBLEM", 16, 43], ["a 166 decreased drug metabolism", "PROBLEM", 48, 79], ["CYP450", "TEST", 92, 98]]], ["Other genes regulated by 167 PXR, including ABCB1, coding for P-glycoprotein transporter, could also have their expression 168 decreased, contributing to decrease non-renal drug clearance, such as LPV/r.", [["non-renal", "ANATOMY", 163, 172], ["PXR", "GENE_OR_GENE_PRODUCT", 29, 32], ["ABCB1", "GENE_OR_GENE_PRODUCT", 44, 49], ["167 PXR", "PROTEIN", 25, 32], ["ABCB1", "PROTEIN", 44, 49], ["P-glycoprotein transporter", "PROTEIN", 62, 88], ["P-glycoprotein transporter", "TREATMENT", 62, 88], ["decrease non-renal drug clearance", "PROBLEM", 154, 187], ["drug clearance", "OBSERVATION", 173, 187]]], ["Owing to its low 169 oral bioavailability and extensive metabolism by CYP3A4 isoenzyme, LPV needs to be co-170 administered with low doses of RTV, a potent CYP3A inhibitor, to achieve drug concentrations 171 high enough to inhibit viral replication (19).", [["oral", "ANATOMY", 21, 25], ["RTV", "CHEMICAL", 142, 145], ["RTV", "CHEMICAL", 142, 145], ["oral", "ORGANISM_SUBDIVISION", 21, 25], ["CYP3A4 isoenzyme", "GENE_OR_GENE_PRODUCT", 70, 86], ["RTV", "SIMPLE_CHEMICAL", 142, 145], ["CYP3A", "GENE_OR_GENE_PRODUCT", 156, 161], ["CYP3A4 isoenzyme", "PROTEIN", 70, 86], ["CYP3A4 isoenzyme", "TEST", 70, 86], ["LPV", "TEST", 88, 91], ["RTV", "TREATMENT", 142, 145], ["a potent CYP3A inhibitor", "TREATMENT", 147, 171], ["drug concentrations", "TEST", 184, 203], ["viral replication", "TREATMENT", 231, 248]]], ["An added reduced expression of CYP3A4 could 172 dramatically increase LPV plasma concentrations in Covid-19 patients.", [["plasma", "ANATOMY", 74, 80], ["LPV", "CHEMICAL", 70, 73], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 31, 37], ["LPV", "ORGANISM_SUBSTANCE", 70, 73], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["patients", "ORGANISM", 108, 116], ["CYP3A4", "PROTEIN", 31, 37], ["patients", "SPECIES", 108, 116], ["CYP3A4", "TEST", 31, 37], ["plasma concentrations", "TEST", 74, 95], ["Covid", "TEST", 99, 104], ["reduced", "OBSERVATION_MODIFIER", 9, 16]]], ["173(which was not certified by peer review)Interestingly, nevertheless very high plasma concentrations in all assayed patients, LPV/r was 174 overall well tolerated.", [["plasma", "ANATOMY", 81, 87], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["very high plasma concentrations", "PROBLEM", 71, 102], ["LPV", "TEST", 128, 131]]], ["The main adverse effects were moderate hepatobiliary disorders that have 175 been attributed to LPV/r therapy.", [["hepatobiliary", "ANATOMY", 39, 52], ["hepatobiliary disorders", "DISEASE", 39, 62], ["moderate hepatobiliary disorders", "PROBLEM", 30, 62], ["LPV/r therapy", "TREATMENT", 96, 109], ["main", "OBSERVATION_MODIFIER", 4, 8], ["adverse effects", "OBSERVATION", 9, 24], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["hepatobiliary", "ANATOMY", 39, 52], ["r therapy", "OBSERVATION", 100, 109]]], ["In HIV, moderate-to-severe elevations in serum 176 aminotransferase levels (>5 times the upper limit of normal) are found in 3% to 10% of patients, 177 although rates may be higher in patients with HIV-HCV coinfection (20).", [["serum", "ANATOMY", 41, 46], ["HIV-HCV coinfection", "DISEASE", 198, 217], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["176 aminotransferase", "GENE_OR_GENE_PRODUCT", 47, 67], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 184, 192], ["HIV-HCV", "ORGANISM", 198, 205], ["HIV", "SPECIES", 3, 6], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 184, 192], ["HIV-HCV", "SPECIES", 198, 205], ["HIV", "SPECIES", 3, 6], ["HIV-HCV", "SPECIES", 198, 205], ["HIV", "PROBLEM", 3, 6], ["moderate-to-severe elevations", "PROBLEM", 8, 37], ["serum 176 aminotransferase levels", "TEST", 41, 74], ["rates", "TEST", 161, 166], ["HIV", "PROBLEM", 198, 201], ["HCV coinfection", "PROBLEM", 202, 217], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["-to-severe", "OBSERVATION_MODIFIER", 16, 26], ["elevations", "OBSERVATION_MODIFIER", 27, 37], ["upper limit", "OBSERVATION_MODIFIER", 89, 100], ["normal", "OBSERVATION", 104, 110], ["may be", "UNCERTAINTY", 167, 173], ["higher", "OBSERVATION_MODIFIER", 174, 180], ["HCV", "OBSERVATION", 202, 205]]], ["These elevations are 178 usually asymptomatic and self-limited and can resolve even with continuation of the medication.", [["These elevations", "PROBLEM", 0, 16], ["the medication", "TREATMENT", 105, 119], ["elevations", "OBSERVATION_MODIFIER", 6, 16]]], ["179(which was not certified by peer review)Drug causality could be hardly assessable as about 20% of the patients with Covid-19 have been 180 reported to have increased transaminases (9).", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["Drug causality", "PROBLEM", 43, 57], ["Covid", "TEST", 119, 124], ["increased transaminases", "PROBLEM", 159, 182], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["transaminases", "OBSERVATION", 169, 182]]], ["However, in our cohort, transaminases quickly 181 decreased after stopping lopinavir, making drug causality probable.", [["lopinavir", "CHEMICAL", 75, 84], ["lopinavir", "CHEMICAL", 75, 84], ["transaminases", "SIMPLE_CHEMICAL", 24, 37], ["lopinavir", "SIMPLE_CHEMICAL", 75, 84], ["transaminases", "TEST", 24, 37], ["lopinavir", "TREATMENT", 75, 84], ["drug causality", "TEST", 93, 107]]], ["Overall, adverse effects 182 reported in this Covid-19 cohort are in line with LPV/r safety profile (21).", [["this Covid", "TEST", 41, 51]]], ["Adverse effects led to 183 stop LPV/r treatment in seven (22%) patients, which could appear elevated, even though, due to 184 .", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Adverse effects", "PROBLEM", 0, 15], ["LPV/r treatment", "TREATMENT", 32, 47], ["elevated", "OBSERVATION", 92, 100]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105650 doi: medRxiv preprint considering whether a dose is appropriate for SARS-CoV-2, it is critical to consider free drug 210 concentrations.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 483, 487], ["SARS-CoV", "SPECIES", 483, 491], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 296, 316], ["medRxiv", "TREATMENT", 420, 427], ["SARS", "PROBLEM", 483, 487], ["CoV", "TEST", 488, 491], ["med", "ANATOMY", 105, 108], ["med", "ANATOMY", 200, 203]]], ["For standard HIV-1, Cmin after 75 ng/mL that is substantially below EC 50 211 reported for coronaviruses (27).", [["Cmin", "CHEMICAL", 20, 24], ["HIV-1", "ORGANISM", 13, 18], ["Cmin", "GENE_OR_GENE_PRODUCT", 20, 24], ["EC", "CELL", 68, 70], ["HIV-1", "SPECIES", 13, 18], ["HIV-1", "SPECIES", 13, 18], ["coronaviruses", "PROBLEM", 91, 104]]], ["Therefore, targeting SARS-CoV-2 antiviral activity in patients is 212(which was not certified by peer review)challenging.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "ORGANISM", 21, 31], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["SARS", "OBSERVATION", 21, 25]]], ["It appears that LPV/r dosage should not be reduced on the basis of therapeutic drug 213 monitoring in the absence of adverse drug reaction.", [["adverse drug reaction", "DISEASE", 117, 138], ["LPV", "ORGANISM", 16, 19], ["LPV/r dosage", "TREATMENT", 16, 28], ["therapeutic drug", "TREATMENT", 67, 83], ["adverse drug reaction", "PROBLEM", 117, 138], ["adverse", "OBSERVATION_MODIFIER", 117, 124], ["drug reaction", "OBSERVATION", 125, 138]]], ["214(which was not certified by peer review)Our study has several limitations.", [["Our study", "TEST", 43, 52]]], ["First, due to the retrospective design using data from routine 215 care, plasma assays were drawn at different times that prevent from an accurate pharmacokinetic 216 estimation.", [["plasma", "ANATOMY", 73, 79], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["plasma assays", "TEST", 73, 86]]], ["Second, according to different practices in wards, Covid-19 severity at baseline was 217 heterogeneous between patients.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Covid", "TEST", 51, 56], ["heterogeneous", "OBSERVATION_MODIFIER", 89, 102]]], ["However, most importantly, in all except three due to drawing 218 issue, LPV plasma concentrations regardless assays timing were unexpectedly high comparing 219 HIV experience.", [["plasma", "ANATOMY", 77, 83], ["LPV", "ORGANISM", 73, 76], ["plasma", "ORGANISM_SUBSTANCE", 77, 83], ["HIV", "SPECIES", 161, 164], ["LPV plasma concentrations", "TREATMENT", 73, 98]]], ["Finally, unbound concentrations, which are the active ones, were not estimated.", [["unbound concentrations", "PROBLEM", 9, 31], ["active", "OBSERVATION_MODIFIER", 47, 53]]], ["220221In conclusion, in our single center Covid-19 experience, we found that LPV/r treated patients had 222 unexpected very high plasma concentrations, well above those observed in HIV patients.", [["plasma", "ANATOMY", 129, 135], ["LPV", "ORGANISM", 77, 80], ["patients", "ORGANISM", 91, 99], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 91, 99], ["HIV", "SPECIES", 181, 184], ["patients", "SPECIES", 185, 193], ["HIV", "SPECIES", 181, 184], ["LPV", "TEST", 77, 80], ["very high plasma concentrations", "PROBLEM", 119, 150]]], ["223221However, LPV dosage should not be reduced in the absence of adverse effect, owing that to high 224 plasma concentration may be required for an in vivo antiviral activity as suggested by previous 225 studies.", [["plasma", "ANATOMY", 105, 111], ["223221However", "CHEMICAL", 0, 13], ["LPV", "CHEMICAL", 15, 18], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["LPV dosage", "TREATMENT", 15, 25]]], ["We observed that about one over four to five patients stopped LPV/r therapy in relation 226 with moderate adverse drug reactions attributed to LPV therapy.", [["LPV", "CHEMICAL", 62, 65], ["adverse drug reactions", "DISEASE", 106, 128], ["LPV", "CHEMICAL", 143, 146], ["LPV", "CHEMICAL", 143, 146], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["LPV/r therapy", "TREATMENT", 62, 75], ["moderate adverse drug reactions", "PROBLEM", 97, 128], ["LPV therapy", "TREATMENT", 143, 154], ["LPV therapy", "OBSERVATION", 143, 154]]], ["Cautious is needed in this 227 context of drug repurposing, which can be associated with a new drug safety profile.", [["drug repurposing", "TREATMENT", 42, 58]]], ["These early 228 data need to be confirmed with prospective studies.", [["prospective studies", "TEST", 47, 66]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The calibration range was from 160 (limit of quantification, LOQ) to 40,000 ng/mL for LPV and 268 10 (LOQ) to 2,500 ng/mL for ritonavir.", [["ritonavir", "CHEMICAL", 126, 135], ["ritonavir", "CHEMICAL", 126, 135], ["ritonavir", "SIMPLE_CHEMICAL", 126, 135], ["The calibration range", "TEST", 0, 21], ["LPV", "TEST", 86, 89], ["ritonavir", "TREATMENT", 126, 135]]], ["The inter-and intra-assay bias and CV were inferior to 269 15% for LPV and ritonavir.", [["LPV", "CHEMICAL", 67, 70], ["ritonavir", "CHEMICAL", 75, 84], ["LPV", "CHEMICAL", 67, 70], ["ritonavir", "CHEMICAL", 75, 84], ["ritonavir", "SIMPLE_CHEMICAL", 75, 84], ["The inter-and intra-assay bias", "TEST", 0, 30], ["CV", "TEST", 35, 37], ["LPV", "TREATMENT", 67, 70], ["ritonavir", "TREATMENT", 75, 84]]], ["No significant matrix effect on quantification of LPV and ritonavir 270 was found in this method.", [["matrix", "ANATOMY", 15, 21], ["LPV", "CHEMICAL", 50, 53], ["ritonavir 270", "CHEMICAL", 58, 71], ["ritonavir 270", "CHEMICAL", 58, 71], ["matrix", "CELLULAR_COMPONENT", 15, 21], ["LPV", "SIMPLE_CHEMICAL", 50, 53], ["ritonavir", "SIMPLE_CHEMICAL", 58, 67], ["significant matrix effect", "PROBLEM", 3, 28], ["LPV", "TREATMENT", 50, 53], ["ritonavir", "TREATMENT", 58, 67], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["matrix effect", "OBSERVATION", 15, 28]]], ["LPV plasma concentrations were considered as peak level (Cmax) and 271 as through level (Cmin) for assays drawn between one hour to five hours, and from eight hours 272 after tablet intake, respectively.", [["plasma", "ANATOMY", 4, 10], ["LPV", "ORGANISM", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["LPV plasma concentrations", "TEST", 0, 25], ["peak level", "TEST", 45, 55], ["Cmax", "TEST", 57, 61], ["assays", "TEST", 99, 105]]], ["In HIV treatment, observed Cmin and Cmax ranges are 1,000-273 8,000 ng/mL (target > 4,000 ng/mL for non-na\u00efve patients) and 7,000-11,000 ng/mL, respectively 274 (31, 32).", [["Cmax", "CHEMICAL", 36, 40], ["HIV", "ORGANISM", 3, 6], ["Cmax", "SIMPLE_CHEMICAL", 36, 40], ["patients", "ORGANISM", 110, 118], ["HIV", "SPECIES", 3, 6], ["patients", "SPECIES", 110, 118], ["HIV", "SPECIES", 3, 6], ["HIV treatment", "TREATMENT", 3, 16], ["Cmin and Cmax ranges", "TEST", 27, 47], ["HIV treatment", "OBSERVATION", 3, 16]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105650 doi: medRxiv preprint LPV/r treatment safety 277 LPV/r treatment safety was assessed in a routine care setting.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint LPV", "TREATMENT", 325, 345], ["r treatment safety", "TREATMENT", 346, 364], ["LPV/r treatment safety", "TREATMENT", 369, 391], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Cases of suspected adverse drug 278 reaction were spontaneously notified to the Pharmacovigilance regional center.", [["adverse drug 278 reaction", "DISEASE", 19, 44], ["adverse drug 278 reaction", "PROBLEM", 19, 44]]], ["After case-by-279 case review assessment and review by a senior pharmacologist, cases were reported to the French .", [["assessment", "TEST", 30, 40]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.18.20105650 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint", "TREATMENT", 325, 341], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 22, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Lopinavir/ritonavir therapy characteristics Time from symptom onset to starting lopinavir/ritonavirdays 8 (7-10) Type of specific anti-COVID-19 drug associated with lopinavir/ritonavir -None -Cephalosporin or penicillin* -Cephalosporin* and macrolide* -Macrolide* -Corticosteroids -Corticosteroids and antibiotics -Sarilumab (anti-IL-6) 13 (42%) 6 (19%) 3 (10%) 3 (10%) 2 (6%) 2 (6%) 2 (6%) Duration of lopinavir/ritonavir therapydays 7 (3-8) Lopinavir plasma concentration-ng/mL -at trough -at peak 20,153 (IQR, 16,633-26,505) 22,550 (IQR 12,720-33,612) Lopinavir plasma concentrationfold increase** 4.6 (IQR 2.9-6.4) Reasons for therapy termination -Scheduled end of treatment -Adverse drug reaction -Therapeutic limitation or deceased -Poor efficacy 17 (52%) 7 (22%) 4 (13%) 3 (10%) Types of adverse drug reaction -Cytolytic hepatitis -Isolated hyperbilirubinemia -Nausea and vomiting -Diarrhea -Agitation/anxiety", [["plasma", "ANATOMY", 453, 459], ["plasma", "ANATOMY", 565, 571], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["lopinavir/ritonavirdays", "CHEMICAL", 80, 103], ["anti-COVID-19", "CHEMICAL", 130, 143], ["lopinavir/ritonavir -None -Cephalosporin", "CHEMICAL", 165, 205], ["penicillin* -Cephalosporin", "CHEMICAL", 209, 235], ["macrolide", "CHEMICAL", 241, 250], ["Macrolide", "CHEMICAL", 253, 262], ["Sarilumab", "CHEMICAL", 315, 324], ["lopinavir", "CHEMICAL", 403, 412], ["ritonavir", "CHEMICAL", 413, 422], ["Lopinavir", "CHEMICAL", 443, 452], ["Lopinavir", "CHEMICAL", 555, 564], ["Adverse drug reaction", "DISEASE", 680, 701], ["adverse drug reaction", "DISEASE", 795, 816], ["hepatitis", "DISEASE", 828, 837], ["hyperbilirubinemia", "DISEASE", 848, 866], ["Nausea", "DISEASE", 868, 874], ["vomiting", "DISEASE", 879, 887], ["Diarrhea", "DISEASE", 889, 897], ["Agitation", "DISEASE", 899, 908], ["anxiety", "DISEASE", 909, 916], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 10, 19], ["lopinavir", "CHEMICAL", 80, 89], ["ritonavirdays", "CHEMICAL", 90, 103], ["lopinavir", "CHEMICAL", 165, 174], ["ritonavir", "CHEMICAL", 175, 184], ["Cephalosporin", "CHEMICAL", 192, 205], ["penicillin* -Cephalosporin", "CHEMICAL", 209, 235], ["macrolide", "CHEMICAL", 241, 250], ["Sarilumab", "CHEMICAL", 315, 324], ["lopinavir", "CHEMICAL", 403, 412], ["ritonavir", "CHEMICAL", 413, 422], ["Lopinavir", "CHEMICAL", 443, 452], ["Lopinavir", "CHEMICAL", 555, 564], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 10, 19], ["lopinavir", "SIMPLE_CHEMICAL", 80, 89], ["anti-COVID-19", "SIMPLE_CHEMICAL", 130, 143], ["lopinavir", "SIMPLE_CHEMICAL", 165, 174], ["ritonavir -None -Cephalosporin", "SIMPLE_CHEMICAL", 175, 205], ["penicillin* -Cephalosporin*", "SIMPLE_CHEMICAL", 209, 236], ["macrolide*", "SIMPLE_CHEMICAL", 241, 251], ["Macrolide* -Corticosteroids -Corticosteroids", "SIMPLE_CHEMICAL", 253, 297], ["antibiotics -Sarilumab", "SIMPLE_CHEMICAL", 302, 324], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 326, 335], ["lopinavir", "SIMPLE_CHEMICAL", 403, 412], ["ritonavir", "SIMPLE_CHEMICAL", 413, 422], ["Lopinavir", "ORGANISM", 443, 452], ["plasma", "ORGANISM_SUBSTANCE", 453, 459], ["plasma", "ORGANISM_SUBSTANCE", 565, 571], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir therapy", "TREATMENT", 10, 27], ["lopinavir/ritonavirdays", "TREATMENT", 80, 103], ["specific anti-COVID", "TREATMENT", 121, 140], ["lopinavir", "TREATMENT", 165, 174], ["ritonavir", "TREATMENT", 175, 184], ["Cephalosporin", "TREATMENT", 192, 205], ["penicillin*", "TREATMENT", 209, 220], ["Cephalosporin", "TREATMENT", 222, 235], ["macrolide", "TREATMENT", 241, 250], ["Macrolide", "TREATMENT", 253, 262], ["Corticosteroids", "TREATMENT", 265, 280], ["Corticosteroids", "TREATMENT", 282, 297], ["antibiotics", "TREATMENT", 302, 313], ["Sarilumab (anti-IL", "TREATMENT", 315, 333], ["lopinavir", "TREATMENT", 403, 412], ["ritonavir therapydays", "TREATMENT", 413, 434], ["Lopinavir plasma concentration", "TEST", 443, 473], ["Lopinavir plasma concentrationfold", "TEST", 555, 589], ["therapy termination", "TREATMENT", 631, 650], ["treatment", "TREATMENT", 669, 678], ["Adverse drug reaction", "PROBLEM", 680, 701], ["adverse drug reaction", "PROBLEM", 795, 816], ["Cytolytic hepatitis", "PROBLEM", 818, 837], ["Isolated hyperbilirubinemia", "PROBLEM", 839, 866], ["Nausea", "PROBLEM", 868, 874], ["vomiting", "PROBLEM", 879, 887], ["Diarrhea", "PROBLEM", 889, 897], ["Agitation", "PROBLEM", 899, 908], ["anxiety", "PROBLEM", 909, 916], ["hyperbilirubinemia", "OBSERVATION", 848, 866]]]], "a6eccd525dfe60a6bf90781e86165398595b279c": [["INTRODUCTIONPoultry infections with the novel reassortant and highly pathologic avian influenza (HPAI) A (H5N6) viruses that have acquired the neuraminidase gene from H6N6 viruses of ducks in southern China have been reported in China, Laos and Vietnam since 2013.", [["infections", "DISEASE", 20, 30], ["avian influenza", "DISEASE", 80, 95], ["HPAI", "DISEASE", 97, 101], ["avian influenza (HPAI) A (H5N6) viruses", "ORGANISM", 80, 119], ["H6N6 viruses", "ORGANISM", 167, 179], ["ducks", "ORGANISM", 183, 188], ["neuraminidase gene", "DNA", 143, 161], ["avian influenza", "SPECIES", 80, 95], ["HPAI", "SPECIES", 97, 101], ["ducks", "SPECIES", 183, 188], ["HPAI", "SPECIES", 97, 101], ["H5N6", "SPECIES", 106, 110], ["INTRODUCTIONPoultry infections", "PROBLEM", 0, 30], ["the novel reassortant", "PROBLEM", 36, 57], ["highly pathologic avian influenza (HPAI) A (H5N6) viruses", "PROBLEM", 62, 119], ["the neuraminidase gene", "TREATMENT", 139, 161], ["infections", "OBSERVATION", 20, 30]]], ["[1] [2] [3] [4] [5] [6] The H5N6 viruses were also detected in swan geese and mammals, including cats and swine, in 2014.", [["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 23], ["H5N6", "ORGANISM", 28, 32], ["cats", "ORGANISM", 97, 101], ["cats", "SPECIES", 97, 101], ["swine", "SPECIES", 106, 111], ["swan geese", "SPECIES", 63, 73], ["swine", "SPECIES", 106, 111], ["The H5N6 viruses", "PROBLEM", 24, 40]]], ["7, 8 The H5N6 viruses isolated from poultry and swine were found to be highly pathogenic in chickens and mildly virulent in BALB/c mice.", [["H5N6 viruses", "ORGANISM", 9, 21], ["poultry", "ORGANISM", 36, 43], ["swine", "ORGANISM", 48, 53], ["chickens", "ORGANISM", 92, 100], ["BALB/c mice", "ORGANISM", 124, 135], ["poultry", "SPECIES", 36, 43], ["swine", "SPECIES", 48, 53], ["chickens", "SPECIES", 92, 100], ["mice", "SPECIES", 131, 135], ["poultry", "SPECIES", 36, 43], ["swine", "SPECIES", 48, 53], ["chickens", "SPECIES", 92, 100], ["mice", "SPECIES", 131, 135], ["The H5N6 viruses", "PROBLEM", 5, 21], ["mildly virulent in BALB", "PROBLEM", 105, 128], ["mildly", "OBSERVATION_MODIFIER", 105, 111], ["virulent", "OBSERVATION_MODIFIER", 112, 120]]], ["5, 7 Since the first H5N6 human case was identified in April 2014, 9 nine human infections have been reported in China.", [["human infections", "DISEASE", 74, 90], ["human", "ORGANISM", 26, 31], ["human", "ORGANISM", 74, 79], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 74, 79], ["infections", "OBSERVATION", 80, 90]]], ["[9] [10] [11] [12] Most of the patients had poultry exposure histories prior to illness onset and developed severe respiratory disease.", [["respiratory", "ANATOMY", 115, 126], ["illness", "DISEASE", 80, 87], ["respiratory disease", "DISEASE", 115, 134], ["[9] [10] [11] [12]", "SIMPLE_CHEMICAL", 0, 18], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["severe respiratory disease", "PROBLEM", 108, 134], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["respiratory disease", "OBSERVATION", 115, 134]]], ["10 Exposure to live poultry markets (LPMs) increases the risk of human avian influenza virus infection, 4, [13] [14] [15] and LPM closures effectively control poultry-to-human transmission.", [["influenza virus infection", "DISEASE", 77, 102], ["4, [13] [14] [15]", "CHEMICAL", 104, 121], ["human", "ORGANISM", 65, 70], ["avian influenza virus", "ORGANISM", 71, 92], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 65, 70], ["avian influenza virus", "SPECIES", 71, 92], ["human", "SPECIES", 170, 175], ["human avian influenza virus", "SPECIES", 65, 92], ["human", "SPECIES", 170, 175], ["human avian influenza virus infection", "PROBLEM", 65, 102], ["LPM closures", "TREATMENT", 126, 138]]], ["16 However, the current strategy for LPM closures is primarily based on retrospective investigations that followed the detection or reporting of human infections.", [["infections", "DISEASE", 151, 161], ["LPM", "MULTI-TISSUE_STRUCTURE", 37, 40], ["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["LPM closures", "TREATMENT", 37, 49], ["retrospective investigations", "TEST", 72, 100], ["the detection", "TEST", 115, 128], ["human infections", "PROBLEM", 145, 161], ["infections", "OBSERVATION", 151, 161]]], ["To investigate the role of LPMs in the poultry-to-human transmission of avian influenza viruses, a sustained LPM surveillance program was established in Shenzhen.", [["avian influenza viruses", "DISEASE", 72, 95], ["LPMs", "GENE_OR_GENE_PRODUCT", 27, 31], ["human", "ORGANISM", 50, 55], ["avian influenza viruses", "ORGANISM", 72, 95], ["human", "SPECIES", 50, 55], ["avian influenza viruses", "SPECIES", 72, 95], ["human", "SPECIES", 50, 55], ["avian influenza viruses", "PROBLEM", 72, 95], ["a sustained LPM surveillance program", "TREATMENT", 97, 133], ["influenza viruses", "OBSERVATION", 78, 95]]], ["Two human cases were detected shortly after the identification of H5N6 viruses in LPMs in Shenzhen in December 2015 and January 2016, and the potential linkage between human infection and the viruses in the LPMs was analyzed.", [["LPMs", "ANATOMY", 207, 211], ["human infection", "DISEASE", 168, 183], ["human", "ORGANISM", 4, 9], ["H5N6 viruses", "ORGANISM", 66, 78], ["LPMs", "PATHOLOGICAL_FORMATION", 82, 86], ["human", "ORGANISM", 168, 173], ["LPMs", "CANCER", 207, 211], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 4, 9], ["H5N6", "SPECIES", 66, 70], ["human", "SPECIES", 168, 173], ["H5N6 viruses", "PROBLEM", 66, 78], ["human infection", "PROBLEM", 168, 183], ["the viruses in the LPMs", "PROBLEM", 188, 211], ["infection", "OBSERVATION", 174, 183], ["viruses", "OBSERVATION", 192, 199]]], ["Our study verified that sustained LPM surveillance could be an effective system for providing early warning about human infections with the avian influenza virus.Surveillance of avian influenza viruses in LPMsThere are ten districts in Shenzhen.", [["infections", "DISEASE", 120, 130], ["avian influenza virus", "DISEASE", 140, 161], ["avian influenza viruses", "DISEASE", 178, 201], ["LPMs", "DISEASE", 205, 209], ["human", "ORGANISM", 114, 119], ["avian influenza virus", "ORGANISM", 140, 161], ["avian influenza viruses", "ORGANISM", 178, 201], ["LPMs", "CELL", 205, 209], ["human", "SPECIES", 114, 119], ["avian influenza virus", "SPECIES", 140, 161], ["avian influenza", "SPECIES", 178, 193], ["human", "SPECIES", 114, 119], ["Our study", "TEST", 0, 9], ["sustained LPM surveillance", "TEST", 24, 50], ["human infections", "PROBLEM", 114, 130], ["the avian influenza virus", "PROBLEM", 136, 161], ["avian influenza viruses", "PROBLEM", 178, 201], ["influenza viruses", "OBSERVATION", 184, 201], ["ten", "OBSERVATION_MODIFIER", 219, 222], ["districts", "OBSERVATION", 223, 232]]], ["The activity of avian influenza virus is associated with the environmental temperature.", [["influenza virus", "DISEASE", 22, 37], ["avian influenza virus", "ORGANISM", 16, 37], ["avian influenza virus", "SPECIES", 16, 37], ["avian influenza virus", "SPECIES", 16, 37], ["avian influenza virus", "PROBLEM", 16, 37], ["the environmental temperature", "PROBLEM", 57, 86], ["influenza virus", "OBSERVATION", 22, 37]]], ["For example, lower-temperature conditions are associated with an increased risk of the survival of avian influenza viruses that have been implicated in human infections in LPMs.", [["LPMs", "ANATOMY", 172, 176], ["influenza viruses", "DISEASE", 105, 122], ["infections", "DISEASE", 158, 168], ["LPMs", "DISEASE", 172, 176], ["avian influenza viruses", "ORGANISM", 99, 122], ["human", "ORGANISM", 152, 157], ["LPMs", "PATHOLOGICAL_FORMATION", 172, 176], ["avian influenza viruses", "SPECIES", 99, 122], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["lower-temperature conditions", "PROBLEM", 13, 41], ["avian influenza viruses", "PROBLEM", 99, 122], ["human infections in LPMs", "PROBLEM", 152, 176], ["lower", "OBSERVATION_MODIFIER", 13, 18], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["influenza viruses", "OBSERVATION", 105, 122], ["human", "OBSERVATION_MODIFIER", 152, 157], ["infections", "OBSERVATION", 158, 168]]], ["17 Therefore, we first conducted baseline surveillance of avian influenza viruses in LPMs in the Nanshan (NS) and Longgang (LG) districts of Shenzhen city in each month from June to November of 2015.", [["avian influenza viruses", "DISEASE", 58, 81], ["avian influenza viruses", "ORGANISM", 58, 81], ["avian influenza", "SPECIES", 58, 73], ["avian influenza viruses", "PROBLEM", 58, 81], ["influenza viruses", "OBSERVATION", 64, 81]]], ["From December 2015 to January 2016, we extended the monthly surveillance to all ten districts in Shenzhen by including the other eight districts of Longhuaxin, Futian, Guangming, Luohu, Pingshan, Dapeng, Bao'an and Yantian.", [["Longhuaxin", "TREATMENT", 148, 158], ["Futian", "TREATMENT", 160, 166]]], ["There were no restrictions on the numbers or locations of the LPMs surveilled in each district.", [["no", "UNCERTAINTY", 11, 13], ["restrictions", "OBSERVATION", 14, 26]]], ["During each monthly sampling of each district, 10-20 environmental samples were collected from the same or different LPMs during this study period.", [["samples", "ANATOMY", 67, 74], ["this study", "TEST", 129, 139]]], ["The environmental samples included poultry feces, drinking water, sewage and swabs from poultry cages, feathers and poultry processing tools.", [["samples", "ANATOMY", 18, 25], ["feces", "ANATOMY", 43, 48], ["feces", "ORGANISM_SUBDIVISION", 43, 48], ["feathers", "ORGANISM_SUBDIVISION", 103, 111], ["swabs from poultry cages", "TREATMENT", 77, 101]]], ["The samples were maintained in viral transport medium and transferred immediately at low temperature to the local Centers for Disease Control and Prevention.Surveillance of avian influenza viruses in LPMsInvestigation, reporting and data collection from the patients A standardized surveillance and reporting form was used to collect the following epidemiological and clinical data: demographic characteristics; underlying medical conditions; recent exposure to poultry, swine or other animals; recent visits to LPMs; clinical signs and symptoms; antiviral treatments; clinical complications; and outcomes.", [["samples", "ANATOMY", 4, 11], ["avian influenza viruses", "DISEASE", 173, 196], ["LPMs", "DISEASE", 512, 516], ["avian influenza viruses", "ORGANISM", 173, 196], ["patients", "ORGANISM", 258, 266], ["avian influenza viruses", "SPECIES", 173, 196], ["patients", "SPECIES", 258, 266], ["swine", "SPECIES", 471, 476], ["swine", "SPECIES", 471, 476], ["The samples", "TEST", 0, 11], ["viral transport medium", "TREATMENT", 31, 53], ["Disease Control", "TREATMENT", 126, 141], ["avian influenza viruses", "PROBLEM", 173, 196], ["A standardized surveillance", "TEST", 267, 294], ["underlying medical conditions", "PROBLEM", 412, 441], ["clinical signs and symptoms", "PROBLEM", 518, 545], ["antiviral treatments", "TREATMENT", 547, 567], ["clinical complications", "PROBLEM", 569, 591], ["influenza viruses", "OBSERVATION", 179, 196]]], ["As a public health response to the outbreak, the requirement for the written informed consent of the patients was waived according to the Chinese law.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109]]], ["Active surveillance was performed by collecting environmental samples in the epidemiologically implicated LPMs of the patients.Surveillance of avian influenza viruses in LPMsRNA extraction and real-time reverse transcriptase-PCR Viral RNA was extracted from all collected samples using a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.", [["samples", "ANATOMY", 62, 69], ["samples", "ANATOMY", 272, 279], ["avian influenza viruses", "DISEASE", 143, 166], ["LPMs", "CANCER", 106, 110], ["patients", "ORGANISM", 118, 126], ["avian influenza viruses", "ORGANISM", 143, 166], ["reverse transcriptase", "PROTEIN", 203, 224], ["Viral RNA", "RNA", 229, 238], ["patients", "SPECIES", 118, 126], ["avian influenza viruses", "SPECIES", 143, 166], ["avian influenza viruses", "PROBLEM", 143, 166], ["LPMsRNA extraction", "TREATMENT", 170, 188], ["Viral RNA", "PROBLEM", 229, 238], ["a QIAamp", "TREATMENT", 286, 294], ["influenza viruses", "OBSERVATION", 149, 166]]], ["Specific real-time reverse transcriptase-PCR (RT-PCR) assay for FluA was initially used to screen all of the collected samples.", [["samples", "ANATOMY", 119, 126], ["FluA", "SIMPLE_CHEMICAL", 64, 68], ["reverse transcriptase", "PROTEIN", 19, 40], ["FluA", "PROTEIN", 64, 68], ["PCR", "TEST", 41, 44], ["RT-PCR", "TEST", 46, 52], ["FluA", "TEST", 64, 68], ["the collected samples", "TEST", 105, 126]]], ["Real-time RT-PCR assays for human seasonal influenza viruses (H1, H3 or B) were applied to the respiratory samples from the patients, and assays for the avian influenza H5, H7, H9, H10, N1, N6, N8 and N9 subtypes were performed for all samples to verify the viral subtypes.Virus isolation and genome sequencingThe samples that were detected as H5N6-positive were then subjected to virus isolation.", [["respiratory samples", "ANATOMY", 95, 114], ["samples", "ANATOMY", 236, 243], ["samples", "ANATOMY", 314, 321], ["influenza viruses", "DISEASE", 43, 60], ["human", "ORGANISM", 28, 33], ["seasonal influenza viruses", "ORGANISM", 34, 60], ["H3", "GENE_OR_GENE_PRODUCT", 66, 68], ["B", "CELL", 72, 73], ["patients", "ORGANISM", 124, 132], ["avian influenza H5", "ORGANISM", 153, 171], ["H7, H9, H10", "ORGANISM", 173, 184], ["N1", "CELL", 186, 188], ["N6", "CELL", 190, 192], ["N8", "CELL", 194, 196], ["N9 subtypes", "CELL", 201, 212], ["avian influenza H5, H7, H9, H10, N1, N6, N8 and N9 subtypes", "CELL_LINE", 153, 212], ["human", "SPECIES", 28, 33], ["seasonal influenza viruses", "SPECIES", 34, 60], ["patients", "SPECIES", 124, 132], ["avian influenza H5", "SPECIES", 153, 171], ["human", "SPECIES", 28, 33], ["H1", "SPECIES", 62, 64], ["H5N6", "SPECIES", 344, 348], ["time RT-PCR assays", "TEST", 5, 23], ["human seasonal influenza viruses", "PROBLEM", 28, 60], ["H1", "PROBLEM", 62, 64], ["assays", "TEST", 138, 144], ["the avian influenza H5", "TEST", 149, 171], ["N1", "TEST", 186, 188], ["N6", "TEST", 190, 192], ["N8", "TEST", 194, 196], ["N9 subtypes", "TEST", 201, 212], ["all samples", "TEST", 232, 243], ["the viral subtypes", "PROBLEM", 254, 272], ["Virus isolation", "TREATMENT", 273, 288], ["genome sequencing", "TEST", 293, 310], ["The samples", "TEST", 310, 321], ["H5N6", "TEST", 344, 348], ["virus isolation", "TREATMENT", 381, 396], ["respiratory", "ANATOMY", 95, 106], ["viral subtypes", "OBSERVATION", 258, 272]]], ["The specimens were maintained in a viral transport medium and were inoculated and grown in nine-to ten-day-old specific pathogen-free (SPF) embryonated chicken eggs for 48-72 h at 37\u00b0C. The full genomes of the virus isolates were amplified with a Qiagen OneStep RT-PCR Kit for sequencing (Qiagen, Germany).", [["specimens", "ANATOMY", 4, 13], ["eggs", "ANATOMY", 160, 164], ["specimens", "CELL", 4, 13], ["chicken", "ORGANISM", 152, 159], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 160, 164], ["chicken", "SPECIES", 152, 159], ["SPF", "SPECIES", 135, 138], ["chicken", "SPECIES", 152, 159], ["a viral transport medium", "TREATMENT", 33, 57], ["embryonated chicken eggs", "TREATMENT", 140, 164], ["the virus isolates", "PROBLEM", 206, 224], ["a Qiagen OneStep RT", "TREATMENT", 245, 264]]], ["18 The PCR products were purified from an agarose gel with a QIAquick Gel Extraction Kit (Qiagen, Germany).", [["agarose", "SIMPLE_CHEMICAL", 42, 49], ["The PCR products", "TREATMENT", 3, 19], ["an agarose gel", "TREATMENT", 39, 53], ["a QIAquick Gel Extraction", "TREATMENT", 59, 84]]], ["Deep sequencing was performed at the Beijing Genomics Instituteten (BGI) using the Illumina HiSeq 2000 (Shenzhen, Beijing, China) platform.", [["Deep sequencing", "TEST", 0, 15], ["the Illumina HiSeq", "TREATMENT", 79, 97]]], ["Sequences from the two human H5N6 viruses, that is, A/Shenzhen/1/2015 (SZ15) and A/Shenzhen/ 1/2016 (SZ16), were obtained from original respiratory samples from patients 1 and 2, respectively.", [["respiratory samples", "ANATOMY", 136, 155], ["human", "ORGANISM", 23, 28], ["H5N6 viruses", "ORGANISM", 29, 41], ["SZ16", "CELL", 101, 105], ["patients", "ORGANISM", 161, 169], ["human", "SPECIES", 23, 28], ["patients", "SPECIES", 161, 169], ["human H5N6 viruses", "SPECIES", 23, 41], ["A/Shenzhen/1/2015", "SPECIES", 52, 69], ["A/Shenzhen/ 1/2016", "SPECIES", 81, 99], ["Sequences", "TEST", 0, 9], ["original respiratory samples", "TEST", 127, 155]]], ["Sequences of three environmental isolates, that is, A/Environment/Shenzhen/1/2015 (H5N6, E1) (Env1), A/Environment/Shenzhen/2/2015 (H5N6, E1) (Env2) and A/Environment/ Shenzhen/3/2015 (H5N6, E1) (Env3), were obtained from passage viruses.", [["E1", "GENE_OR_GENE_PRODUCT", 191, 193], ["Env3", "GENE_OR_GENE_PRODUCT", 196, 200], ["Shenzhen/1/2015", "SPECIES", 66, 81], ["A/Environment/Shenzhen/2/2015", "SPECIES", 101, 130], ["A/Environment/ Shenzhen/3/2015", "SPECIES", 153, 183]]], ["The accession numbers of the viral sequences obtained in this study are provided in Supplementary Table S1 .Genetic analysisThe identity of each viral gene was determined using MegAlign7.1.", [["viral sequences", "DNA", 29, 44], ["viral gene", "DNA", 145, 155], ["MegAlign7", "PROTEIN", 177, 186], ["the viral sequences", "TEST", 25, 44], ["this study", "TEST", 57, 67], ["Genetic analysis", "TEST", 108, 124], ["viral gene", "OBSERVATION", 145, 155]]], ["The data sets were obtained from the Global Initiative on Sharing All Influenza Data (GISAID) EpiFlu Database (Supplementary Table S2 ).", [["The data sets", "TEST", 0, 13]]], ["Maximum likelihood phylogenetic trees of the nucleotide sequences of each of the genes of the selected influenza viruses were constructed with RAxML version 8.", [["nucleotide", "CHEMICAL", 45, 55], ["the nucleotide sequences", "TEST", 41, 65], ["the selected influenza viruses", "PROBLEM", 90, 120], ["RAxML version", "TREATMENT", 143, 156], ["phylogenetic trees", "OBSERVATION", 19, 37], ["influenza viruses", "OBSERVATION", 103, 120]]], ["19 The bootstrap method with up to 1000 repetitions was used to test the phylogenies.RESULTSIncreased H5N6 virus-positive rates of the LPMs associated with human H5N6 infection From June 2015 to January 2016, routine surveillance of avian influenza viruses in the LPMs was conducted in the LG and NS districts of Shenzhen.", [["LPMs", "DISEASE", 135, 139], ["H5N6 infection", "DISEASE", 162, 176], ["avian influenza viruses", "DISEASE", 233, 256], ["H5N6 virus", "ORGANISM", 102, 112], ["LPMs", "PATHOLOGICAL_FORMATION", 135, 139], ["human", "ORGANISM", 156, 161], ["avian influenza viruses", "ORGANISM", 233, 256], ["human", "SPECIES", 156, 161], ["avian influenza viruses", "SPECIES", 233, 256], ["human", "SPECIES", 156, 161], ["The bootstrap method", "TREATMENT", 3, 23], ["H5N6 virus", "PROBLEM", 102, 112], ["human H5N6 infection", "PROBLEM", 156, 176], ["routine surveillance", "TEST", 209, 229], ["avian influenza viruses", "PROBLEM", 233, 256], ["influenza viruses", "OBSERVATION", 239, 256], ["LG", "ANATOMY", 290, 292]]], ["Intensive LPM surveillance was conducted by collecting environmental samples from all 10 districts from December 2015 to January 2016.", [["Intensive LPM surveillance", "TEST", 0, 26]]], ["Before December, a total of 120 environmental samples were collected in selected LPMs in LG and NS districts.", [["samples", "ANATOMY", 46, 53], ["samples", "CANCER", 46, 53], ["LG", "ANATOMY", 89, 91]]], ["Positive samples were only detected in LG district.", [["samples", "ANATOMY", 9, 16], ["Positive samples", "TEST", 0, 16]]], ["There were 34 out of 60 samples positive for FluA, but the avian influenza virus subtypes H5N6, H7N9 and H10N8 were not detected, with the exception of the H9N2 virus, which exhibited a positive rate of 25% (95% confidence interval (CI) 20%-30%; Supplementary Table S3 ).", [["samples", "ANATOMY", 24, 31], ["influenza virus", "DISEASE", 65, 80], ["samples", "CANCER", 24, 31], ["FluA", "GENE_OR_GENE_PRODUCT", 45, 49], ["avian", "ORGANISM", 59, 64], ["influenza virus subtypes H5N6", "ORGANISM", 65, 94], ["H10N8", "ORGANISM", 105, 110], ["H9N2 virus", "ORGANISM", 156, 166], ["FluA", "PROTEIN", 45, 49], ["avian influenza virus", "SPECIES", 59, 80], ["H9N2 virus", "SPECIES", 156, 166], ["H7N9", "SPECIES", 96, 100], ["H10N8", "SPECIES", 105, 110], ["H9N2 virus", "SPECIES", 156, 166], ["FluA", "PROBLEM", 45, 49], ["the avian influenza virus subtypes H5N6", "PROBLEM", 55, 94], ["H7N9", "PROBLEM", 96, 100], ["the H9N2 virus", "PROBLEM", 152, 166], ["CI", "TEST", 233, 235], ["H9N2 virus", "OBSERVATION", 156, 166]]], ["The virus was continually detected in all 10 districts beginning in December 2015 (December: 34.5%, 95% CI: 21%-48%, January: 53, 95% CI: 33%-73%) but the subtype H7N9 and H10N8 viruses were still not detected in any of the LPMs in our study area.", [["H10N8 viruses", "ORGANISM", 172, 185], ["LPMs", "PATHOLOGICAL_FORMATION", 224, 228], ["The virus", "PROBLEM", 0, 9], ["CI", "TEST", 104, 106], ["CI", "TEST", 134, 136], ["the subtype H7N9", "TEST", 151, 167], ["H10N8 viruses", "PROBLEM", 172, 185], ["virus", "OBSERVATION", 4, 9], ["subtype", "OBSERVATION_MODIFIER", 155, 162], ["H7N9", "OBSERVATION", 163, 167]]], ["Notably, considerable increases in the H5N6 RT-PCR-positive rate (December: 29%, 95% CI: 14%-44%, January: 19%, 95% CI: 3%-35%) were observed beginning in December 2015 in all 10 districts (Supplementary Table S3 were detected between late December and early January in Shenzhen, Guangdong Province, during the period of the increased H5N6 viruspositive rates in the LPMs (Figure 1 ).", [["H5N6", "SPECIES", 39, 43], ["the H5N6 RT", "TEST", 35, 46], ["PCR", "TEST", 47, 50], ["CI", "TEST", 85, 87], ["CI", "TEST", 116, 118], ["the increased H5N6 viruspositive rates", "TREATMENT", 321, 359], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["increases", "OBSERVATION_MODIFIER", 22, 31]]], ["We proposed that sustained surveillance in LPMs may show some evidence that the risk of human infection might increase along with the increased activity of H5N6 virus in LPMs.", [["infection", "DISEASE", 94, 103], ["human", "ORGANISM", 88, 93], ["H5N6 virus", "ORGANISM", 156, 166], ["LPMs", "PATHOLOGICAL_FORMATION", 170, 174], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["H5N6 virus", "SPECIES", 156, 166], ["surveillance in LPMs", "TEST", 27, 47], ["human infection", "PROBLEM", 88, 103], ["the increased activity of H5N6 virus in LPMs", "PROBLEM", 130, 174], ["human", "OBSERVATION_MODIFIER", 88, 93], ["infection", "OBSERVATION", 94, 103], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["activity", "OBSERVATION_MODIFIER", 144, 152]]], ["The incidence of two new cases infected with H5N6 virus might be avoidable assuming that some interventions such as LPMs closures were implemented when the virus were widely detected via our surveillance.RESULTSEpidemiological investigation of the patients confirmed that LPM exposure was potentially the cause of the human infections Patient 1 was a 26-year-old female without underlying diseases.", [["infections", "DISEASE", 324, 334], ["H5N6 virus", "ORGANISM", 45, 55], ["patients", "ORGANISM", 248, 256], ["human", "ORGANISM", 318, 323], ["female", "ORGANISM", 363, 369], ["patients", "SPECIES", 248, 256], ["human", "SPECIES", 318, 323], ["Patient", "SPECIES", 335, 342], ["H5N6 virus", "SPECIES", 45, 55], ["human", "SPECIES", 318, 323], ["H5N6 virus", "TREATMENT", 45, 55], ["some interventions", "TREATMENT", 89, 107], ["LPMs closures", "TREATMENT", 116, 129], ["the virus", "PROBLEM", 152, 161], ["our surveillance", "TEST", 187, 203], ["RESULTSEpidemiological investigation", "TEST", 204, 240], ["LPM exposure", "PROBLEM", 272, 284], ["the human infections", "PROBLEM", 314, 334], ["underlying diseases", "PROBLEM", 378, 397], ["two", "OBSERVATION_MODIFIER", 17, 20], ["new", "OBSERVATION_MODIFIER", 21, 24], ["infected", "OBSERVATION", 31, 39], ["infections", "OBSERVATION", 324, 334], ["without", "UNCERTAINTY", 370, 377], ["diseases", "OBSERVATION", 389, 397]]], ["She developed fever and cough on 24 December 2015 and deteriorated with a high fever (40.2\u00b0C) on 26 December.", [["fever", "DISEASE", 14, 19], ["cough", "DISEASE", 24, 29], ["fever", "DISEASE", 79, 84], ["fever", "PROBLEM", 14, 19], ["cough", "PROBLEM", 24, 29], ["a high fever", "PROBLEM", 72, 84], ["fever", "OBSERVATION", 14, 19], ["cough", "OBSERVATION", 24, 29]]], ["The patient was hospitalized on 27 December and treated with mechanical ventilation.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["mechanical ventilation", "TREATMENT", 61, 83], ["mechanical ventilation", "OBSERVATION", 61, 83]]], ["Tamiflu was immediately administered to the patient.", [["Tamiflu", "CHEMICAL", 0, 7], ["Tamiflu", "CHEMICAL", 0, 7], ["Tamiflu", "SIMPLE_CHEMICAL", 0, 7], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["Tamiflu", "TREATMENT", 0, 7]]], ["The patient eventually died from severe pneumonia, respiratory failure and septic shock on the 30 December 2015.", [["respiratory", "ANATOMY", 51, 62], ["pneumonia", "DISEASE", 40, 49], ["respiratory failure", "DISEASE", 51, 70], ["septic shock", "DISEASE", 75, 87], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["severe pneumonia", "PROBLEM", 33, 49], ["respiratory failure", "PROBLEM", 51, 70], ["septic shock", "PROBLEM", 75, 87], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["pneumonia", "OBSERVATION", 40, 49], ["respiratory failure", "OBSERVATION", 51, 70], ["septic shock", "OBSERVATION", 75, 87]]], ["Respiratory samples were collected on 28 December and found to be HPAI H5N6-positive.", [["Respiratory samples", "ANATOMY", 0, 19], ["Respiratory samples", "CANCER", 0, 19], ["HPAI", "ORGANISM", 66, 70], ["HPAI H5N6", "SPECIES", 66, 75], ["Respiratory samples", "TEST", 0, 19], ["HPAI H5N6", "TEST", 66, 75], ["HPAI", "OBSERVATION", 66, 70], ["positive", "OBSERVATION", 76, 84]]], ["Patient 2 was a 25-year-old healthy man who runs a small restaurant in Shenzhen.", [["man", "ORGANISM", 36, 39], ["Patient", "SPECIES", 0, 7], ["man", "SPECIES", 36, 39]]], ["On 1 January 2016, the patient developed a high fever (39.5 1C), cough and dyspnea.", [["fever", "DISEASE", 48, 53], ["cough", "DISEASE", 65, 70], ["dyspnea", "DISEASE", 75, 82], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["a high fever", "PROBLEM", 41, 53], ["cough", "PROBLEM", 65, 70], ["dyspnea", "PROBLEM", 75, 82], ["dyspnea", "OBSERVATION", 75, 82]]], ["On 6 January, the patient was hospitalized and diagnosed with severe pneumonia, Type 1 respiratory failure, acute respiratory distress syndrome, left pleural effusion and an electrolyte disorder.", [["respiratory", "ANATOMY", 87, 98], ["respiratory", "ANATOMY", 114, 125], ["left pleural", "ANATOMY", 145, 157], ["pneumonia", "DISEASE", 69, 78], ["Type 1 respiratory failure", "DISEASE", 80, 106], ["acute respiratory distress syndrome", "DISEASE", 108, 143], ["left pleural effusion", "DISEASE", 145, 166], ["electrolyte disorder", "DISEASE", 174, 194], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["severe pneumonia", "PROBLEM", 62, 78], ["Type 1 respiratory failure", "PROBLEM", 80, 106], ["acute respiratory distress syndrome", "PROBLEM", 108, 143], ["left pleural effusion", "PROBLEM", 145, 166], ["an electrolyte disorder", "PROBLEM", 171, 194], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["pneumonia", "OBSERVATION", 69, 78], ["respiratory failure", "OBSERVATION", 87, 106], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory distress", "OBSERVATION", 114, 134], ["syndrome", "OBSERVATION", 135, 143], ["left", "ANATOMY_MODIFIER", 145, 149], ["pleural", "ANATOMY", 150, 157], ["effusion", "OBSERVATION", 158, 166], ["electrolyte disorder", "OBSERVATION", 174, 194]]], ["He was immediately administered antiviral treatment with Tamiflu (150 mg bid).", [["Tamiflu", "CHEMICAL", 57, 64], ["Tamiflu", "CHEMICAL", 57, 64], ["He", "ORGANISM", 0, 2], ["Tamiflu", "SIMPLE_CHEMICAL", 57, 64], ["antiviral treatment", "TREATMENT", 32, 51], ["Tamiflu", "TREATMENT", 57, 64]]], ["Respiratory samples were collected on the 6th of January and found to be HPAI H5N6positive.", [["Respiratory samples", "ANATOMY", 0, 19], ["Respiratory samples", "CANCER", 0, 19], ["Respiratory samples", "TEST", 0, 19], ["HPAI", "PROBLEM", 73, 77], ["HPAI", "OBSERVATION", 73, 77]]], ["Combined antiviral therapy with Tamiflu (150 mg bid), zanamivir (10 mg each time, bid) and peramivir (300 mg qd) was then administered on 7 January.", [["Tamiflu", "CHEMICAL", 32, 39], ["zanamivir", "CHEMICAL", 54, 63], ["peramivir", "CHEMICAL", 91, 100], ["Tamiflu", "CHEMICAL", 32, 39], ["zanamivir", "CHEMICAL", 54, 63], ["peramivir", "CHEMICAL", 91, 100], ["Tamiflu", "SIMPLE_CHEMICAL", 32, 39], ["zanamivir", "SIMPLE_CHEMICAL", 54, 63], ["peramivir", "SIMPLE_CHEMICAL", 91, 100], ["Combined antiviral therapy", "TREATMENT", 0, 26], ["Tamiflu", "TREATMENT", 32, 39], ["zanamivir", "TREATMENT", 54, 63], ["peramivir", "TREATMENT", 91, 100], ["antiviral therapy", "OBSERVATION", 9, 26]]], ["The patient eventually recovered from his severe condition.RESULTSEpidemiological investigations of the infection sources of both human H5N6 infections were conducted when the patients were confirmed as H5N6-positive.", [["infection", "DISEASE", 104, 113], ["H5N6 infections", "DISEASE", 136, 151], ["patient", "ORGANISM", 4, 11], ["human", "ORGANISM", 130, 135], ["H5N6", "ORGANISM", 136, 140], ["patients", "ORGANISM", 176, 184], ["patient", "SPECIES", 4, 11], ["human", "SPECIES", 130, 135], ["patients", "SPECIES", 176, 184], ["human", "SPECIES", 130, 135], ["H5N6", "SPECIES", 136, 140], ["H5N6", "SPECIES", 203, 207], ["his severe condition", "PROBLEM", 38, 58], ["RESULTSEpidemiological investigations", "TEST", 59, 96], ["the infection", "PROBLEM", 100, 113], ["both human H5N6 infections", "PROBLEM", 125, 151], ["H5N6", "TEST", 203, 207], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["infection", "OBSERVATION", 104, 113]]], ["Patient 1 bought a duck from a neighboring LPM approximately four days prior to the onset of her illness.", [["duck", "ORGANISM", 19, 23], ["LPM", "CANCER", 43, 46], ["Patient", "SPECIES", 0, 7], ["her illness", "PROBLEM", 93, 104], ["illness", "OBSERVATION", 97, 104]]], ["Patient 2 reported a history of visiting an LPM prior to the onset of his illness.", [["Patient", "SPECIES", 0, 7], ["his illness", "PROBLEM", 70, 81]]], ["Environmental samples and swabs of poultry feathers collected from the epidemiologically identified LPMs tested positive for the H5N6 virus (Supplementary Table S4 ).", [["samples", "ANATOMY", 14, 21], ["swabs", "ANATOMY", 26, 31], ["feathers", "ANATOMY", 43, 51], ["LPMs", "ANATOMY", 100, 104], ["poultry", "ORGANISM", 35, 42], ["feathers", "ORGANISM_SUBDIVISION", 43, 51], ["LPMs", "CANCER", 100, 104], ["H5N6 virus", "ORGANISM", 129, 139], ["H5N6 virus", "SPECIES", 129, 139], ["Environmental samples", "TEST", 0, 21], ["swabs of poultry feathers", "TEST", 26, 51], ["LPMs", "TEST", 100, 104], ["the H5N6 virus", "PROBLEM", 125, 139]]], ["The hemagglutinin (HA) and neuraminidase genes of all five H5N6 viruses identified in Shenzhen were located in the same lineage of A/Guangzhou/39715/2014 (GZ39715, H5N6; Figure 3 ).", [["hemagglutinin", "GENE_OR_GENE_PRODUCT", 4, 17], ["HA", "GENE_OR_GENE_PRODUCT", 19, 21], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 27, 40], ["H5N6 viruses", "ORGANISM", 59, 71], ["hemagglutinin (HA) and neuraminidase genes", "DNA", 4, 46], ["A/Guangzhou/39715/2014", "SPECIES", 131, 153], ["The hemagglutinin (HA)", "TREATMENT", 0, 22], ["neuraminidase genes", "TREATMENT", 27, 46], ["all five H5N6 viruses", "TREATMENT", 50, 71]]], ["However, all six internal genes of SZ15 and SZ16 clustered with the H9N2 or H7N9 viruses that were circulating in poultry, whereas the internal genes of GZ39715 belonged to H5N1 (Figure 4 and Supplementary Figure S1 ).", [["GZ39715", "CHEMICAL", 153, 160], ["H5N1", "DISEASE", 173, 177], ["SZ15", "GENE_OR_GENE_PRODUCT", 35, 39], ["SZ16", "GENE_OR_GENE_PRODUCT", 44, 48], ["H9N2", "ORGANISM", 68, 72], ["H7N9 viruses", "ORGANISM", 76, 88], ["GZ39715", "ORGANISM", 153, 160], ["SZ15", "DNA", 35, 39], ["SZ16", "DNA", 44, 48], ["internal genes", "DNA", 135, 149], ["H9N2", "SPECIES", 68, 72], ["H7N9 viruses", "SPECIES", 76, 88], ["SZ15", "TEST", 35, 39], ["SZ16", "TREATMENT", 44, 48], ["the H9N2", "PROBLEM", 64, 72], ["H7N9 viruses", "PROBLEM", 76, 88]]], ["The polymerase acidic protein (PA), polymerase basic protein 1 (PB1), nucleoprotein (NP), matrix protein (MP) and non-structural protein (NS) genes of Env3 were located in the H5 linage, which was similar to GZ39715 (Supplementary Figure S1 ).", [["GZ39715", "CHEMICAL", 208, 215], ["polymerase acidic protein (PA), polymerase basic protein 1", "GENE_OR_GENE_PRODUCT", 4, 62], ["PB1", "GENE_OR_GENE_PRODUCT", 64, 67], ["nucleoprotein (NP), matrix protein", "GENE_OR_GENE_PRODUCT", 70, 104], ["MP", "GENE_OR_GENE_PRODUCT", 106, 108], ["non-structural protein (NS)", "GENE_OR_GENE_PRODUCT", 114, 141], ["Env3", "GENE_OR_GENE_PRODUCT", 151, 155], ["polymerase acidic protein", "PROTEIN", 4, 29], ["PA", "PROTEIN", 31, 33], ["polymerase basic protein 1", "PROTEIN", 36, 62], ["PB1", "PROTEIN", 64, 67], ["nucleoprotein", "PROTEIN", 70, 83], ["NP", "PROTEIN", 85, 87], ["matrix protein", "PROTEIN", 90, 104], ["MP", "PROTEIN", 106, 108], ["non-structural protein (NS) genes", "DNA", 114, 147], ["Env3", "DNA", 151, 155], ["The polymerase acidic protein", "TEST", 0, 29], ["polymerase basic protein", "TEST", 36, 60], ["PB1", "TEST", 64, 67], ["nucleoprotein (NP)", "TEST", 70, 88], ["matrix protein", "TEST", 90, 104], ["non-structural protein (NS) genes of Env3", "PROBLEM", 114, 155]]], ["The PB2 gene was located in a different sub-lineage with the H5N6, H6N6 and H6N2 viruses from birds ( Figure 4 ).", [["PB2", "GENE_OR_GENE_PRODUCT", 4, 7], ["H6N2 viruses", "ORGANISM", 76, 88], ["PB2 gene", "DNA", 4, 12], ["H6N6", "SPECIES", 67, 71], ["The PB2 gene", "TREATMENT", 0, 12], ["the H5N6", "TREATMENT", 57, 65], ["H6N6", "TREATMENT", 67, 71], ["H6N2 viruses", "PROBLEM", 76, 88]]], ["These results demonstrated the genetic diversity of the HPAI H5N6 viruses circulating in the LPMs.", [["LPMs", "ANATOMY", 93, 97], ["HPAI H5N6 viruses", "ORGANISM", 56, 73], ["LPMs", "PATHOLOGICAL_FORMATION", 93, 97], ["HPAI", "SPECIES", 56, 60], ["HPAI H5N6 viruses", "SPECIES", 56, 73]]], ["The high sequence identities of the viruses from the patients and the LPMs further confirmed the linkage between the human infections and LPM exposure.", [["infections", "DISEASE", 123, 133], ["patients", "ORGANISM", 53, 61], ["human", "ORGANISM", 117, 122], ["patients", "SPECIES", 53, 61], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["the viruses", "PROBLEM", 32, 43], ["the LPMs", "TEST", 66, 74], ["the human infections", "PROBLEM", 113, 133], ["LPM exposure", "TREATMENT", 138, 150], ["viruses", "OBSERVATION", 36, 43], ["human", "OBSERVATION_MODIFIER", 117, 122], ["infections", "OBSERVATION", 123, 133], ["LPM exposure", "OBSERVATION", 138, 150]]], ["Multiple basic amino acids were present at the cleavage site between HA1 and HA2, which indicated that these viruses were highly pathogenic in chickens (Table 1) .", [["amino acids", "CHEMICAL", 15, 26], ["amino acids", "CHEMICAL", 15, 26], ["amino acids", "AMINO_ACID", 15, 26], ["chickens", "ORGANISM", 143, 151], ["cleavage site", "PROTEIN", 47, 60], ["HA1", "PROTEIN", 69, 72], ["HA2", "PROTEIN", 77, 80], ["chickens", "SPECIES", 143, 151], ["chickens", "SPECIES", 143, 151], ["Multiple basic amino acids", "TREATMENT", 0, 26], ["HA2", "PROBLEM", 77, 80], ["these viruses", "PROBLEM", 103, 116], ["amino acids", "OBSERVATION", 15, 26], ["viruses", "OBSERVATION", 109, 116]]], ["Mutations (S123P, I151T and T156A; H5 numbering) in HA related to an enhanced human-like receptor binding ability were detected in the human and environmental viruses ( Table 1 ).", [["human", "ORGANISM", 78, 83], ["human", "ORGANISM", 135, 140], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 135, 140], ["Mutations", "TEST", 0, 9], ["HA", "PROBLEM", 52, 54], ["an enhanced human-like receptor binding ability", "PROBLEM", 66, 113]]], ["The I368V mutation at PB1, which has been reported to be associated with increased transmissibility in ferrets, was detected in the present study.RESULTSThe amino acid lengths of PB1-F2 in the human and two of the environmental H5N6 isolates were longer than those of previously reported human H5N6 viruses, which indicated the pathogenicity of these viruses in mice.", [["amino acid", "CHEMICAL", 157, 167], ["PB1-F2", "CHEMICAL", 179, 185], ["amino acid", "CHEMICAL", 157, 167], ["I368V", "GENE_OR_GENE_PRODUCT", 4, 9], ["ferrets", "ORGANISM", 103, 110], ["amino acid", "AMINO_ACID", 157, 167], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 179, 185], ["human", "ORGANISM", 193, 198], ["human", "ORGANISM", 288, 293], ["H5N6 viruses", "ORGANISM", 294, 306], ["mice", "ORGANISM", 362, 366], ["PB1", "DNA", 22, 25], ["PB1", "PROTEIN", 179, 182], ["ferrets", "SPECIES", 103, 110], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 288, 293], ["mice", "SPECIES", 362, 366], ["ferrets", "SPECIES", 103, 110], ["human", "SPECIES", 193, 198], ["human H5N6 viruses", "SPECIES", 288, 306], ["mice", "SPECIES", 362, 366], ["increased transmissibility in ferrets", "PROBLEM", 73, 110], ["the present study", "TEST", 128, 145], ["RESULTSThe amino acid lengths", "TEST", 146, 175], ["PB1", "TEST", 179, 182], ["human H5N6 viruses", "PROBLEM", 288, 306], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["transmissibility", "OBSERVATION", 83, 99], ["ferrets", "OBSERVATION_MODIFIER", 103, 110], ["viruses", "OBSERVATION", 351, 358]]], ["The C-terminal truncations of NS1 partially or completely removed its C-terminal tail, which contains features that might be involved in the biological activities of NS1.", [["C", "CHEMICAL", 70, 71], ["NS1", "GENE_OR_GENE_PRODUCT", 30, 33], ["NS1", "GENE_OR_GENE_PRODUCT", 166, 169], ["C-terminal truncations", "PROTEIN", 4, 26], ["NS1", "PROTEIN", 30, 33], ["C-terminal tail", "PROTEIN", 70, 85], ["NS1", "PROTEIN", 166, 169], ["The C-terminal truncations of NS1", "PROBLEM", 0, 33], ["NS1", "PROBLEM", 166, 169], ["-terminal", "OBSERVATION_MODIFIER", 5, 14], ["truncations", "OBSERVATION", 15, 26], ["NS1", "OBSERVATION", 30, 33], ["terminal", "ANATOMY_MODIFIER", 72, 80], ["tail", "ANATOMY", 81, 85]]], ["These features include the PDZbinding motif, which is composed of NS1's four C-terminal residues and generally consists of the motif 227ESEV230 in the NS1 of avian influenza viruses.", [["influenza viruses", "DISEASE", 164, 181], ["C", "CHEMICAL", 77, 78], ["NS1", "GENE_OR_GENE_PRODUCT", 66, 69], ["NS1", "GENE_OR_GENE_PRODUCT", 151, 154], ["avian influenza viruses", "ORGANISM", 158, 181], ["PDZbinding motif", "DNA", 27, 43], ["NS1", "PROTEIN", 66, 69], ["C-terminal residues", "PROTEIN", 77, 96], ["227ESEV230", "PROTEIN", 133, 143], ["NS1", "PROTEIN", 151, 154], ["avian influenza", "SPECIES", 158, 173], ["the PDZbinding motif", "TREATMENT", 23, 43], ["NS1's four C-terminal residues", "PROBLEM", 66, 96], ["avian influenza viruses", "PROBLEM", 158, 181], ["influenza viruses", "OBSERVATION", 164, 181]]], ["20 The avian C-terminal ESEV motif of NS1 increases virulence in mice, 21 but truncations were detected in all of the isolates in this study.", [["ESEV", "GENE_OR_GENE_PRODUCT", 24, 28], ["NS1", "GENE_OR_GENE_PRODUCT", 38, 41], ["mice", "ORGANISM", 65, 69], ["avian C-terminal ESEV motif", "PROTEIN", 7, 34], ["NS1", "PROTEIN", 38, 41], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["The avian C-terminal ESEV motif", "TREATMENT", 3, 34], ["NS1", "PROBLEM", 38, 41], ["truncations", "PROBLEM", 78, 89], ["this study", "TEST", 130, 140], ["NS1", "OBSERVATION", 38, 41], ["increases", "OBSERVATION_MODIFIER", 42, 51], ["virulence", "OBSERVATION_MODIFIER", 52, 61]]], ["All isolates were resistant to adamantane derivatives but were susceptible to neuraminidase inhibitors.", [["adamantane", "CHEMICAL", 31, 41], ["adamantane", "CHEMICAL", 31, 41], ["adamantane derivatives", "SIMPLE_CHEMICAL", 31, 53], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 78, 102], ["All isolates", "TREATMENT", 0, 12], ["adamantane derivatives", "TREATMENT", 31, 53], ["neuraminidase inhibitors", "TREATMENT", 78, 102]]], ["However, the PB2 E627K mutation that is associated with an increased adaptation and virulence in mammals was detected only in SZ16.DISCUSSIONLPM exposure is known to be an important source of the poultry-tohuman transmission of avian influenza viruses, including the H5N1, H7N9 and H10N8 viruses.", [["avian influenza viruses", "DISEASE", 228, 251], ["E627K", "GENE_OR_GENE_PRODUCT", 17, 22], ["avian influenza viruses", "ORGANISM", 228, 251], ["H10N8 viruses", "ORGANISM", 282, 295], ["PB2 E627K mutation", "DNA", 13, 31], ["avian influenza viruses", "SPECIES", 228, 251], ["H5N1", "SPECIES", 267, 271], ["H7N9", "SPECIES", 273, 277], ["the PB2 E627K mutation", "PROBLEM", 9, 31], ["an increased adaptation", "PROBLEM", 56, 79], ["avian influenza viruses", "PROBLEM", 228, 251], ["the H5N1", "PROBLEM", 263, 271], ["H7N9", "PROBLEM", 273, 277], ["H10N8 viruses", "TREATMENT", 282, 295], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["adaptation", "OBSERVATION", 69, 79], ["influenza viruses", "OBSERVATION", 234, 251]]], ["14, [22] [23] [24] To monitor the viral activities in LPMs in Shenzhen, a routine LPM surveillance system was established in 2013.", [["LPMs", "PATHOLOGICAL_FORMATION", 54, 58], ["a routine LPM surveillance system", "TEST", 72, 105]]], ["In our study, no H5N6 virus was detected in the LPMs in Shenzhen prior to December 2015.", [["H5N6 virus", "ORGANISM", 17, 27], ["H5N6 virus", "SPECIES", 17, 27], ["our study", "TEST", 3, 12], ["H5N6 virus", "PROBLEM", 17, 27], ["no", "UNCERTAINTY", 14, 16], ["virus", "OBSERVATION", 22, 27]]], ["However, markedly increased H5N6 virus frequencies in the LPMs were detected in all of the sampling sites distributed across the entire city beginning in December 2015.", [["H5N6 virus", "ORGANISM", 28, 38], ["LPMs", "CANCER", 58, 62], ["H5N6 virus", "SPECIES", 28, 38], ["markedly increased H5N6 virus frequencies in the LPMs", "PROBLEM", 9, 62], ["markedly", "OBSERVATION_MODIFIER", 9, 17], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["H5N6 virus frequencies", "OBSERVATION", 28, 50]]], ["Two human cases of H5N6 virus infection were detected coincident with the increase in viral activity, and the epidemiological and genetic investigation results confirmed that the human infections were associated with LPM exposure.", [["H5N6 virus infection", "DISEASE", 19, 39], ["infections", "DISEASE", 185, 195], ["human", "ORGANISM", 4, 9], ["H5N6 virus", "ORGANISM", 19, 29], ["human", "ORGANISM", 179, 184], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 4, 9], ["H5N6 virus", "SPECIES", 19, 29], ["human", "SPECIES", 179, 184], ["H5N6 virus infection", "PROBLEM", 19, 39], ["viral activity", "PROBLEM", 86, 100], ["genetic investigation", "TEST", 130, 151], ["the human infections", "PROBLEM", 175, 195], ["LPM exposure", "PROBLEM", 217, 229], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["viral activity", "OBSERVATION", 86, 100], ["infections", "OBSERVATION", 185, 195]]], ["These results suggest that sustained surveillance of LPMs could serve as an effective early warning that could provide the opportunity to conduct interventions before the emergence of human infections with zoonotic avian influenza viruses.", [["infections", "DISEASE", 190, 200], ["zoonotic avian influenza viruses", "DISEASE", 206, 238], ["human", "ORGANISM", 184, 189], ["avian influenza viruses", "ORGANISM", 215, 238], ["human", "SPECIES", 184, 189], ["avian influenza", "SPECIES", 215, 230], ["human", "SPECIES", 184, 189], ["sustained surveillance of LPMs", "PROBLEM", 27, 57], ["interventions", "TREATMENT", 146, 159], ["human infections", "PROBLEM", 184, 200], ["zoonotic avian influenza viruses", "PROBLEM", 206, 238]]], ["LPMs act as sites for the mixing of avian influenza viruses and play important roles in viral reassortment and human infection.", [["influenza viruses", "DISEASE", 42, 59], ["infection", "DISEASE", 117, 126], ["LPMs", "GENE_OR_GENE_PRODUCT", 0, 4], ["avian influenza viruses", "ORGANISM", 36, 59], ["human", "ORGANISM", 111, 116], ["LPMs", "PROTEIN", 0, 4], ["avian influenza", "SPECIES", 36, 51], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["avian influenza viruses", "PROBLEM", 36, 59], ["viral reassortment", "TREATMENT", 88, 106], ["human infection", "PROBLEM", 111, 126], ["viral reassortment", "OBSERVATION", 88, 106], ["infection", "OBSERVATION", 117, 126]]], ["[25] [26] [27] [28] [29] [30] In the present study, the H9N2 virus provided internal genes for H5N6 viruses that were also found in the in H7N9 and H10N8 viruses.", [["[25] [26] [27] [28] [29] [30", "SIMPLE_CHEMICAL", 0, 28], ["H9N2 virus", "ORGANISM", 56, 66], ["H5N6 viruses", "ORGANISM", 95, 107], ["H10N8 viruses", "ORGANISM", 148, 161], ["H9N2 virus", "SPECIES", 56, 66], ["H5N6", "SPECIES", 95, 99], ["H7N9", "SPECIES", 139, 143], ["the present study", "TEST", 33, 50], ["the H9N2 virus", "PROBLEM", 52, 66], ["H5N6 viruses", "PROBLEM", 95, 107], ["H7N9", "PROBLEM", 139, 143], ["H10N8 viruses", "PROBLEM", 148, 161]]], ["These findings suggest that the H9N2 virus might be the key contributor to the genesis of novel virus genotypes in poultry.", [["H9N2 virus", "ORGANISM", 32, 42], ["H9N2 virus", "SPECIES", 32, 42], ["poultry", "SPECIES", 115, 122], ["the H9N2 virus", "PROBLEM", 28, 42], ["novel virus genotypes", "PROBLEM", 90, 111], ["H9N2 virus", "OBSERVATION", 32, 42]]], ["31 One possible reason could be the wide circulation of the H9N2 virus in LPMs, which is supported by the results of our surveillance that revealed increases in the H9N2 virus-positive rates that ranged from 25% (95% CI: 20%-30%) to 53% (95% CI: 33%-73%) from June 2015 to January 2016 (Supplementary Table S3 ).", [["H9N2 virus", "ORGANISM", 60, 70], ["LPMs", "PATHOLOGICAL_FORMATION", 74, 78], ["H9N2 virus", "ORGANISM", 165, 175], ["H9N2 virus", "SPECIES", 60, 70], ["H9N2 virus", "SPECIES", 60, 70], ["H9N2 virus", "SPECIES", 165, 175], ["the H9N2 virus", "PROBLEM", 56, 70], ["our surveillance", "TEST", 117, 133], ["the H9N2 virus", "PROBLEM", 161, 175], ["CI", "TEST", 217, 219], ["CI", "TEST", 242, 244], ["possible reason could be", "UNCERTAINTY", 7, 31], ["H9N2 virus", "OBSERVATION", 60, 70], ["increases", "OBSERVATION_MODIFIER", 148, 157], ["H9N2 virus", "OBSERVATION", 165, 175]]], ["Another reason that H9N2 viruses might contribute to novel genotypes is the high genetic compatibility of H9N2 viruses observed in previous studies that have indicated that the internal genes of H9N2 viruses increase replication and transmissibility in animals.", [["H9N2 viruses", "DISEASE", 20, 32], ["H9N2 viruses", "DISEASE", 106, 118], ["H9N2 viruses", "ORGANISM", 20, 32], ["H9N2 viruses", "ORGANISM", 106, 118], ["H9N2 viruses", "ORGANISM", 195, 207], ["H9N2", "SPECIES", 20, 24], ["H9N2 viruses", "SPECIES", 106, 118], ["H9N2 viruses", "SPECIES", 195, 207], ["H9N2 viruses", "PROBLEM", 20, 32], ["novel genotypes", "PROBLEM", 53, 68], ["H9N2 viruses", "PROBLEM", 106, 118], ["previous studies", "TEST", 131, 147], ["H9N2 viruses", "PROBLEM", 195, 207], ["H9N2 viruses", "OBSERVATION", 106, 118]]], ["32, 33 Moreover, some mammalian adaptation mutations have also been detected in the internal genes of H9N2.", [["H9N2", "DISEASE", 102, 106], ["H9N2", "ORGANISM", 102, 106], ["internal genes", "DNA", 84, 98], ["some mammalian adaptation mutations", "PROBLEM", 17, 52], ["adaptation mutations", "OBSERVATION", 32, 52], ["internal genes", "ANATOMY", 84, 98]]], ["In addition, mutations (S123P, I151T, and T156A) associated with enhanced human receptor binding ability were found in HA of the H5N6 viruses in this study.", [["human", "ORGANISM", 74, 79], ["H5N6 viruses", "ORGANISM", 129, 141], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["mutations", "TEST", 13, 22], ["enhanced human receptor binding ability", "PROBLEM", 65, 104], ["HA", "PROBLEM", 119, 121], ["the H5N6 viruses", "PROBLEM", 125, 141], ["this study", "TEST", 145, 155]]], ["Thus, the H5N6 viruses presented here might be associated with a greater risk of human infection.DISCUSSIONSimilar to human infections with the H5N1 and H7N9 viruses, people infected with the highly pathogenic avian influenza A (H5N6) virus develop severe symptoms, including pneumonia and acute respiratory distress syndrome, and thus the H5N6 virus poses a threat to humans.", [["respiratory", "ANATOMY", 296, 307], ["infection", "DISEASE", 87, 96], ["human infections", "DISEASE", 118, 134], ["avian influenza A (H5N6) virus", "DISEASE", 210, 240], ["pneumonia", "DISEASE", 276, 285], ["acute respiratory distress syndrome", "DISEASE", 290, 325], ["H5N6 viruses", "ORGANISM", 10, 22], ["human", "ORGANISM", 81, 86], ["human", "ORGANISM", 118, 123], ["H7N9 viruses", "ORGANISM", 153, 165], ["people", "ORGANISM", 167, 173], ["avian influenza A (H5N6) virus", "ORGANISM", 210, 240], ["H5N6 virus", "ORGANISM", 340, 350], ["humans", "ORGANISM", 369, 375], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 118, 123], ["people", "SPECIES", 167, 173], ["avian influenza A (H5N6) virus", "SPECIES", 210, 240], ["humans", "SPECIES", 369, 375], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 118, 123], ["H7N9 viruses", "SPECIES", 153, 165], ["avian influenza A (H5N6) virus", "SPECIES", 210, 240], ["H5N6 virus", "SPECIES", 340, 350], ["humans", "SPECIES", 369, 375], ["the H5N6 viruses", "PROBLEM", 6, 22], ["human infection", "PROBLEM", 81, 96], ["human infections", "PROBLEM", 118, 134], ["the H5N1 and H7N9 viruses", "PROBLEM", 140, 165], ["the highly pathogenic avian influenza A (H5N6) virus", "PROBLEM", 188, 240], ["severe symptoms", "PROBLEM", 249, 264], ["pneumonia", "PROBLEM", 276, 285], ["acute respiratory distress syndrome", "PROBLEM", 290, 325], ["the H5N6 virus", "TREATMENT", 336, 350], ["human", "OBSERVATION_MODIFIER", 81, 86], ["infection", "OBSERVATION", 87, 96], ["infections", "OBSERVATION", 124, 134], ["pneumonia", "OBSERVATION", 276, 285], ["acute", "OBSERVATION_MODIFIER", 290, 295], ["respiratory distress syndrome", "OBSERVATION", 296, 325]]], ["9,12 LPM closures have been effective in the control of human risks of H7N9 and H5N1 virus infections.", [["H5N1 virus infections", "DISEASE", 80, 101], ["human", "ORGANISM", 56, 61], ["H7N9", "ORGANISM", 71, 75], ["H5N1 virus", "ORGANISM", 80, 90], ["human", "SPECIES", 56, 61], ["H5N1 virus", "SPECIES", 80, 90], ["human", "SPECIES", 56, 61], ["H7N9", "SPECIES", 71, 75], ["H5N1 virus", "SPECIES", 80, 90], ["LPM closures", "TREATMENT", 5, 17], ["H7N9", "PROBLEM", 71, 75], ["H5N1 virus infections", "PROBLEM", 80, 101], ["effective", "OBSERVATION_MODIFIER", 28, 37]]], ["16, 34, 35 The risk of human infection might be reduced if related interventions, such as LPM closures, are immediately implemented when increases in the frequencies of viruses are widely identified in LPMs.", [["infection", "DISEASE", 29, 38], ["human", "ORGANISM", 23, 28], ["LPMs", "PATHOLOGICAL_FORMATION", 202, 206], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["human infection", "PROBLEM", 23, 38], ["LPM closures", "TREATMENT", 90, 102], ["viruses", "PROBLEM", 169, 176], ["infection", "OBSERVATION", 29, 38], ["viruses", "OBSERVATION", 169, 176]]], ["On the basis of our findings, we propose that the decision for LPM closures in Shenzhen city might need to be executed before December.", [["LPM closures", "TREATMENT", 63, 75]]], ["Moreover, the supervision and information distribution by local public health facilities should be strengthened to prevent the unofficial trading of live poultry during LPM closure periods, which is often neglected in routine LPM management measures.", [["LPM closure periods", "TREATMENT", 169, 188], ["routine LPM management measures", "TREATMENT", 218, 249]]]], "PMC7152159": [["Hepatitis A ::: VirusesHepatitis A virus (HAV) is an RNA virus in the Picornaviridae family.", [["Hepatitis", "DISEASE", 0, 9], ["HAV", "DISEASE", 42, 45], ["VirusesHepatitis A virus", "ORGANISM", 16, 40], ["HAV", "ORGANISM", 42, 45], ["VirusesHepatitis A virus", "SPECIES", 16, 40], ["VirusesHepatitis A virus", "SPECIES", 16, 40], ["HAV", "SPECIES", 42, 45], ["VirusesHepatitis", "PROBLEM", 16, 32], ["A virus (HAV", "PROBLEM", 33, 45], ["an RNA virus", "PROBLEM", 50, 62], ["virus", "OBSERVATION", 35, 40]]], ["Although the incidence of HAV infection has fallen dramatically since the introduction of vaccines, it still causes approximately 60,000 infections per year and occasionally causes dramatic outbreaks with fulminant hepatitis and death.1 Fecal-oral transmission is facilitated by extensive viral shedding in feces during the 3- to 6-week incubation period, which reaches a maximum just before the onset of hepatocellular injury.1 An increasing incidence has been noted among urban homosexual men.", [["oral", "ANATOMY", 243, 247], ["feces", "ANATOMY", 307, 312], ["hepatocellular", "ANATOMY", 405, 419], ["HAV infection", "DISEASE", 26, 39], ["infections", "DISEASE", 137, 147], ["hepatitis", "DISEASE", 215, 224], ["death", "DISEASE", 229, 234], ["hepatocellular injury", "DISEASE", 405, 426], ["HAV", "ORGANISM", 26, 29], ["oral", "ORGANISM_SUBDIVISION", 243, 247], ["feces", "ORGANISM_SUBSTANCE", 307, 312], ["hepatocellular", "ORGAN", 405, 419], ["men", "ORGANISM", 491, 494], ["men", "SPECIES", 491, 494], ["HAV", "SPECIES", 26, 29], ["HAV infection", "PROBLEM", 26, 39], ["vaccines", "TREATMENT", 90, 98], ["fulminant hepatitis", "PROBLEM", 205, 224], ["death", "PROBLEM", 229, 234], ["extensive viral shedding in feces", "PROBLEM", 279, 312], ["hepatocellular injury", "PROBLEM", 405, 426], ["HAV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39], ["fallen", "OBSERVATION_MODIFIER", 44, 50], ["dramatically", "OBSERVATION_MODIFIER", 51, 63], ["infections", "OBSERVATION", 137, 147], ["dramatic", "OBSERVATION_MODIFIER", 181, 189], ["outbreaks", "OBSERVATION_MODIFIER", 190, 199], ["fulminant", "OBSERVATION_MODIFIER", 205, 214], ["hepatitis", "OBSERVATION", 215, 224], ["Fecal", "ANATOMY", 237, 242], ["extensive", "OBSERVATION_MODIFIER", 279, 288], ["viral", "OBSERVATION_MODIFIER", 289, 294], ["shedding", "OBSERVATION", 295, 303], ["hepatocellular", "ANATOMY", 405, 419], ["injury", "OBSERVATION", 420, 426], ["increasing", "OBSERVATION_MODIFIER", 432, 442]]], ["An effective vaccine has been developed.Hepatitis A ::: VirusesThe signs and symptoms of hepatitis A are related to patient age.", [["Hepatitis", "DISEASE", 40, 49], ["hepatitis A", "DISEASE", 89, 100], ["Viruses", "ORGANISM", 56, 63], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["Viruses", "SPECIES", 56, 63], ["hepatitis A", "SPECIES", 89, 100], ["An effective vaccine", "TREATMENT", 0, 20], ["Viruses", "PROBLEM", 56, 63], ["The signs and symptoms", "PROBLEM", 63, 85], ["hepatitis A", "PROBLEM", 89, 100], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["vaccine", "OBSERVATION", 13, 20], ["signs", "OBSERVATION_MODIFIER", 67, 72], ["hepatitis", "OBSERVATION", 89, 98]]], ["In children younger than 3 years of age, more than 80% of infections are clinically silent, whereas in adolescents and adults, more than 75% of cases are symptomatic.2 Symptoms include fever, malaise, abdominal pain, and jaundice.", [["abdominal", "ANATOMY", 201, 210], ["infections", "DISEASE", 58, 68], ["fever", "DISEASE", 185, 190], ["abdominal pain", "DISEASE", 201, 215], ["jaundice", "DISEASE", 221, 229], ["children", "ORGANISM", 3, 11], ["abdominal", "ORGANISM_SUBDIVISION", 201, 210], ["children", "SPECIES", 3, 11], ["adolescents", "SPECIES", 103, 114], ["infections", "PROBLEM", 58, 68], ["symptomatic", "PROBLEM", 154, 165], ["Symptoms", "PROBLEM", 168, 176], ["fever", "PROBLEM", 185, 190], ["malaise", "PROBLEM", 192, 199], ["abdominal pain", "PROBLEM", 201, 215], ["jaundice", "PROBLEM", 221, 229], ["infections", "OBSERVATION", 58, 68], ["fever", "OBSERVATION", 185, 190], ["malaise", "OBSERVATION", 192, 199], ["abdominal", "ANATOMY", 201, 210], ["pain", "OBSERVATION", 211, 215], ["jaundice", "OBSERVATION", 221, 229]]], ["Marked transaminase elevations are characteristic.", [["transaminase", "SIMPLE_CHEMICAL", 7, 19], ["Marked transaminase elevations", "PROBLEM", 0, 30], ["transaminase elevations", "OBSERVATION", 7, 30]]], ["About 100 cases of HAV-related fulminant liver failure are reported each year, predominantly in adults.2 Chronic infection does not occur.", [["liver", "ANATOMY", 41, 46], ["HAV", "DISEASE", 19, 22], ["fulminant liver failure", "DISEASE", 31, 54], ["Chronic infection", "DISEASE", 105, 122], ["HAV", "ORGANISM", 19, 22], ["liver", "ORGAN", 41, 46], ["HAV", "PROBLEM", 19, 22], ["fulminant liver failure", "PROBLEM", 31, 54], ["Chronic infection", "PROBLEM", 105, 122], ["fulminant", "OBSERVATION_MODIFIER", 31, 40], ["liver", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54], ["Chronic", "OBSERVATION_MODIFIER", 105, 112], ["infection", "OBSERVATION", 113, 122]]], ["However, HAV infection can precipitate autoimmune hepatitis, which can progress to chronic hepatitis with fibrosis or cirrhosis.3., 4., 5., 6.", [["HAV infection", "DISEASE", 9, 22], ["autoimmune hepatitis", "DISEASE", 39, 59], ["hepatitis", "DISEASE", 91, 100], ["fibrosis", "DISEASE", 106, 114], ["cirrhosis", "DISEASE", 118, 127], ["HAV", "ORGANISM", 9, 12], ["HAV", "SPECIES", 9, 12], ["HAV infection", "PROBLEM", 9, 22], ["autoimmune hepatitis", "PROBLEM", 39, 59], ["chronic hepatitis", "PROBLEM", 83, 100], ["fibrosis", "PROBLEM", 106, 114], ["cirrhosis", "PROBLEM", 118, 127], ["infection", "OBSERVATION", 13, 22], ["autoimmune hepatitis", "OBSERVATION", 39, 59], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["hepatitis", "OBSERVATION", 91, 100], ["fibrosis", "OBSERVATION", 106, 114], ["cirrhosis", "OBSERVATION", 118, 127]]]], "PMC4772695": [["Identification of the Conserved Lysine ::: IntroductionThe RdRp is one out of four categories of polymerases and its crystal structure shows a close evolutionary relationship not only to other RdRps but also to that of DNA-dependent DNA-polymerases (DdDps), DNA-dependent RNA-polymerases (DdRps), and RNA-dependent DNA-polymerases (RdDps) also known as reverse transcriptases (RTs).", [["Lysine", "CHEMICAL", 32, 38], ["Lysine", "CHEMICAL", 32, 38], ["RdRps", "GENE_OR_GENE_PRODUCT", 193, 198], ["DNA", "CELLULAR_COMPONENT", 219, 222], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["DdDps", "GENE_OR_GENE_PRODUCT", 250, 255], ["DNA", "CELLULAR_COMPONENT", 258, 261], ["-dependent RNA-polymerases", "GENE_OR_GENE_PRODUCT", 261, 287], ["DdRps", "GENE_OR_GENE_PRODUCT", 289, 294], ["DNA", "CELLULAR_COMPONENT", 315, 318], ["RdDps", "GENE_OR_GENE_PRODUCT", 332, 337], ["RdRp", "PROTEIN", 59, 63], ["polymerases", "PROTEIN", 97, 108], ["RdRps", "PROTEIN", 193, 198], ["DNA-dependent DNA-polymerases", "PROTEIN", 219, 248], ["DdDps", "PROTEIN", 250, 255], ["DNA-dependent RNA-polymerases", "PROTEIN", 258, 287], ["DdRps", "PROTEIN", 289, 294], ["RNA-dependent DNA-polymerases", "PROTEIN", 301, 330], ["RdDps", "PROTEIN", 332, 337], ["reverse transcriptases", "PROTEIN", 353, 375], ["The RdRp", "TREATMENT", 55, 63], ["polymerases", "TREATMENT", 97, 108], ["DNA", "TEST", 219, 222], ["dependent DNA", "PROBLEM", 223, 236], ["polymerases (DdDps", "TEST", 237, 255], ["DNA", "TEST", 258, 261], ["dependent RNA", "PROBLEM", 262, 275], ["RNA-dependent DNA", "PROBLEM", 301, 318], ["Lysine", "OBSERVATION", 32, 38], ["RdRp", "OBSERVATION", 59, 63]]], ["All resemble a cupped right-handed structure consisting of the thumb, fingers, and palm subdomains [16, 17].", [["thumb", "ANATOMY", 63, 68], ["fingers", "ANATOMY", 70, 77], ["thumb", "ORGANISM_SUBDIVISION", 63, 68], ["fingers", "ORGANISM_SUBDIVISION", 70, 77], ["thumb, fingers, and palm subdomains", "PROTEIN", 63, 98], ["right", "ANATOMY_MODIFIER", 22, 27], ["thumb", "ANATOMY", 63, 68], ["fingers", "ANATOMY", 70, 77], ["palm", "ANATOMY_MODIFIER", 83, 87]]], ["The palm is where the active site of the polymerase lies and consists of four conserved structural motifs A\u2013D [16].", [["palm", "ORGANISM_SUBDIVISION", 4, 8], ["palm", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 22, 28]]], ["A fifth and sixth motif, E and F, exists in the RNA-dependent polymerases but not the DNA-dependent polymerases [16].", [["DNA", "CELLULAR_COMPONENT", 86, 89], ["fifth and sixth motif", "DNA", 2, 23], ["E", "DNA", 25, 26], ["RNA-dependent polymerases", "PROTEIN", 48, 73], ["DNA-dependent polymerases", "PROTEIN", 86, 111], ["A fifth and sixth motif, E and F", "PROBLEM", 0, 32], ["dependent polymerases", "PROBLEM", 52, 73], ["the DNA-dependent polymerases", "PROBLEM", 82, 111]]], ["The latter motifs are not in the active site but line this region.", [["not in", "UNCERTAINTY", 22, 28], ["active", "OBSERVATION_MODIFIER", 33, 39], ["site", "OBSERVATION", 40, 44], ["line", "OBSERVATION", 49, 53]]], ["RdRps are error prone but they are as faithful as DNA polymerases that lack proofreading exonucleases [18].", [["RdRps", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["RdRps", "PROTEIN", 0, 5], ["DNA polymerases", "PROTEIN", 50, 65], ["proofreading exonucleases", "PROTEIN", 76, 101]]], ["The absence of a repair mechanism in the PV genome is what leads to an enhanced rate of mutation during viral replication.Identification of the Conserved Lysine ::: IntroductionNucleic acid polymerases use a two-metal-ion mechanism for nucleotidyl transfer [19].", [["Lysine", "CHEMICAL", 154, 160], ["IntroductionNucleic acid", "CHEMICAL", 165, 189], ["nucleotidyl", "CHEMICAL", 236, 247], ["Lysine", "CHEMICAL", 154, 160], ["nucleotidyl", "CHEMICAL", 236, 247], ["IntroductionNucleic acid", "SIMPLE_CHEMICAL", 165, 189], ["nucleotidyl", "SIMPLE_CHEMICAL", 236, 247], ["PV genome", "DNA", 41, 50], ["IntroductionNucleic acid polymerases", "PROTEIN", 165, 201], ["PV", "SPECIES", 41, 43], ["a repair mechanism", "TREATMENT", 15, 33], ["an enhanced rate of mutation", "PROBLEM", 68, 96], ["viral replication", "TREATMENT", 104, 121], ["IntroductionNucleic acid polymerases", "TREATMENT", 165, 201], ["repair", "OBSERVATION", 17, 23], ["PV genome", "OBSERVATION", 41, 50], ["Lysine", "OBSERVATION", 154, 160]]], ["In this mechanism, two magnesium ions are used to organize the reactants.", [["magnesium", "CHEMICAL", 23, 32], ["magnesium", "CHEMICAL", 23, 32], ["magnesium ions", "SIMPLE_CHEMICAL", 23, 37], ["two magnesium ions", "TREATMENT", 19, 37], ["reactants", "OBSERVATION_MODIFIER", 63, 72]]], ["Recently, the chemical mechanism of nucleotidyl transfer has been expanded to include a general acid, which protonates the pyrophosphate leaving group of the NTP substrate and enhance the efficiency of nucleotidyl transfer [20, 21].", [["nucleotidyl", "CHEMICAL", 36, 47], ["pyrophosphate", "CHEMICAL", 123, 136], ["NTP", "CHEMICAL", 158, 161], ["nucleotidyl", "CHEMICAL", 202, 213], ["nucleotidyl", "CHEMICAL", 36, 47], ["pyrophosphate", "CHEMICAL", 123, 136], ["NTP", "CHEMICAL", 158, 161], ["nucleotidyl", "CHEMICAL", 202, 213], ["nucleotidyl", "SIMPLE_CHEMICAL", 36, 47], ["pyrophosphate", "SIMPLE_CHEMICAL", 123, 136], ["NTP", "SIMPLE_CHEMICAL", 158, 161], ["nucleotidyl", "SIMPLE_CHEMICAL", 202, 213], ["a general acid", "TEST", 86, 100], ["the NTP substrate", "TREATMENT", 154, 171], ["nucleotidyl transfer", "TEST", 202, 222]]], ["The general acid of PV RdRp is Lys359, located in motif D, which is conserved throughout all RdRps and RTs.", [["PV RdRp", "ORGANISM", 20, 27], ["Lys359", "GENE_OR_GENE_PRODUCT", 31, 37], ["RdRps", "GENE_OR_GENE_PRODUCT", 93, 98], ["PV RdRp", "PROTEIN", 20, 27], ["motif D", "PROTEIN", 50, 57], ["RdRps", "PROTEIN", 93, 98], ["PV RdRp", "TREATMENT", 20, 27], ["PV RdRp", "OBSERVATION", 20, 27]]], ["Importantly, an orthologous residue at this site is known or predicted in RNA viruses for which rational design of vaccines would greatly benefit.In Vitro and In Vivo Biological Analysis ::: IntroductionIn order to determine what effect biochemical changes have on the multiplication of the virus in cell culture we created a PV genome encoding the arginine mutation in the PV subgenomic replicon (pRLucRA) and viral cDNA (pMoVRA).", [["cell culture", "ANATOMY", 300, 312], ["arginine", "CHEMICAL", 349, 357], ["arginine", "CHEMICAL", 349, 357], ["cell", "CELL", 300, 304], ["arginine", "AMINO_ACID", 349, 357], ["PV subgenomic replicon", "ORGANISM", 374, 396], ["pRLucRA", "GENE_OR_GENE_PRODUCT", 398, 405], ["PV genome", "DNA", 326, 335], ["PV subgenomic replicon", "DNA", 374, 396], ["pRLucRA", "DNA", 398, 405], ["viral cDNA", "DNA", 411, 421], ["pMoVRA", "DNA", 423, 429], ["PV", "SPECIES", 326, 328], ["an orthologous residue at this site", "PROBLEM", 13, 48], ["RNA viruses", "PROBLEM", 74, 85], ["vaccines", "TREATMENT", 115, 123], ["biochemical changes", "PROBLEM", 237, 256], ["the virus", "PROBLEM", 287, 296], ["cell culture", "TEST", 300, 312], ["a PV genome", "PROBLEM", 324, 335], ["the arginine mutation", "PROBLEM", 345, 366], ["the PV subgenomic replicon", "TREATMENT", 370, 396], ["viral cDNA", "PROBLEM", 411, 421], ["orthologous residue", "OBSERVATION", 16, 35], ["PV genome", "OBSERVATION", 326, 335], ["PV", "ANATOMY", 374, 376], ["subgenomic replicon", "OBSERVATION", 377, 396]]], ["Quantification of virus by plaque assay provides insight into fitness of the viral population.", [["plaque", "ANATOMY", 27, 33], ["virus", "PROBLEM", 18, 23], ["plaque assay", "TEST", 27, 39], ["the viral population", "PROBLEM", 73, 93], ["virus", "OBSERVATION", 18, 23], ["plaque", "OBSERVATION", 27, 33], ["viral", "OBSERVATION", 77, 82]]], ["The subgenomic replicon permits indirect evaluation of RNA synthesis by measurement of luciferase activity.", [["luciferase", "GENE_OR_GENE_PRODUCT", 87, 97], ["luciferase", "PROTEIN", 87, 97], ["The subgenomic replicon", "TREATMENT", 0, 23], ["indirect evaluation", "TEST", 32, 51], ["RNA synthesis", "PROBLEM", 55, 68], ["subgenomic replicon", "OBSERVATION", 4, 23]]], ["Analysis of RNA replication in the absence of virus production can provide insight on whether RNA replication is the rate-limiting step for virus production.In Vitro and In Vivo Biological Analysis ::: IntroductionThe characteristics of live-virus multiplication and their plaque phenotype can predict whether the virus will be attenuated in the mouse model.", [["plaque", "ANATOMY", 273, 279], ["live-virus", "ORGANISM", 237, 247], ["mouse", "ORGANISM", 346, 351], ["mouse", "SPECIES", 346, 351], ["mouse", "SPECIES", 346, 351], ["RNA replication", "PROBLEM", 12, 27], ["virus production", "PROBLEM", 46, 62], ["RNA replication", "PROBLEM", 94, 109], ["the rate", "TEST", 113, 121], ["virus production", "PROBLEM", 140, 156], ["live-virus multiplication", "TREATMENT", 237, 262], ["their plaque phenotype", "PROBLEM", 267, 289], ["the virus", "PROBLEM", 310, 319], ["RNA replication", "OBSERVATION", 12, 27], ["virus", "OBSERVATION", 46, 51]]], ["However, viral quantification by plaque forming units (pfu) selects variants based on phenotype and therefore can be an unreliable measure of viruses present due to phenotypic differences between viral strains.", [["plaque", "ANATOMY", 33, 39], ["viral quantification", "TEST", 9, 29], ["viruses", "PROBLEM", 142, 149], ["phenotypic differences between viral strains", "PROBLEM", 165, 209], ["viruses", "OBSERVATION", 142, 149], ["viral strains", "OBSERVATION", 196, 209]]], ["In addition to pfu, quantifying virus based on genomes accounts for total viral particles produced.", [["pfu", "PROBLEM", 15, 18], ["quantifying virus", "PROBLEM", 20, 37], ["total viral particles", "PROBLEM", 68, 89], ["virus", "OBSERVATION", 32, 37], ["viral particles", "OBSERVATION", 74, 89]]], ["This is a more accurate measurement of total viruses in the population and the number of genomes produced by the polymerase.In Vitro and In Vivo Biological Analysis ::: IntroductionWhile these characteristics predict attenuation, actual confirmation is determined using a mouse transgenic for the PV receptor.", [["mouse", "ORGANISM", 272, 277], ["PV receptor", "GENE_OR_GENE_PRODUCT", 297, 308], ["polymerase", "PROTEIN", 113, 123], ["PV receptor", "PROTEIN", 297, 308], ["mouse", "SPECIES", 272, 277], ["mouse", "SPECIES", 272, 277], ["PV", "SPECIES", 297, 299], ["total viruses", "PROBLEM", 39, 52], ["actual confirmation", "TEST", 230, 249], ["a mouse transgenic", "TREATMENT", 270, 288], ["the PV receptor", "TREATMENT", 293, 308], ["total", "OBSERVATION_MODIFIER", 39, 44], ["viruses", "OBSERVATION", 45, 52], ["genomes", "OBSERVATION", 89, 96]]], ["In this system, wild-type (WT) PV is generally lethal.", [["wild-type (WT) PV", "ORGANISM", 16, 33], ["PV", "SPECIES", 31, 33], ["lethal", "OBSERVATION", 47, 53]]], ["At the highest dose, the mutated polymerase (lysine to arginine) failed to cause disease in the mice.", [["lysine", "CHEMICAL", 45, 51], ["arginine", "CHEMICAL", 55, 63], ["lysine", "CHEMICAL", 45, 51], ["arginine", "CHEMICAL", 55, 63], ["lysine", "AMINO_ACID", 45, 51], ["arginine", "AMINO_ACID", 55, 63], ["mice", "ORGANISM", 96, 100], ["mutated polymerase", "PROTEIN", 25, 43], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["the mutated polymerase (lysine to arginine)", "TREATMENT", 21, 64], ["disease in the mice", "PROBLEM", 81, 100]]], ["To determine if the mutant virus replicated, mice surviving the initial infection were challenged with a lethal dose of WT PV.", [["infection", "DISEASE", 72, 81], ["mutant virus", "ORGANISM", 20, 32], ["mice", "ORGANISM", 45, 49], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["PV", "SPECIES", 123, 125], ["the mutant virus", "PROBLEM", 16, 32], ["the initial infection", "PROBLEM", 60, 81], ["a lethal dose of WT PV", "TREATMENT", 103, 125], ["infection", "OBSERVATION", 72, 81]]], ["We can conclude from the mice that survive this challenge, the mutant is replication competent and elicits an immune response sufficient enough to protect against a lethal dose of WT PV [3].In Vitro and In Vivo Biological Analysis ::: IntroductionUsing PV as our model we have developed a rational design for polymerase-based mechanism of attenuation.", [["mice", "ORGANISM", 25, 29], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["PV", "SPECIES", 183, 185], ["polymerase", "TEST", 309, 319], ["attenuation", "PROBLEM", 339, 350], ["attenuation", "OBSERVATION_MODIFIER", 339, 350]]], ["By altering the nature of the general acid lysine residue to an arginine, we have shown that we maintain the ability to tune RdRp speed and fidelity creating a viral RdRp that is slower and more faithful than the WT enzyme.", [["acid lysine", "CHEMICAL", 38, 49], ["arginine", "CHEMICAL", 64, 72], ["lysine", "CHEMICAL", 43, 49], ["arginine", "CHEMICAL", 64, 72], ["arginine", "AMINO_ACID", 64, 72], ["viral RdRp", "PROTEIN", 160, 170], ["WT enzyme", "PROTEIN", 213, 222], ["the general acid lysine residue", "PROBLEM", 26, 57], ["a viral RdRp", "PROBLEM", 158, 170], ["the WT enzyme", "TEST", 209, 222], ["viral RdRp", "OBSERVATION", 160, 170], ["slower", "OBSERVATION_MODIFIER", 179, 185]]], ["This results in an attenuated virus with a restricted viral quasispecies that fails to cause disease, yet elicits a protective immune response.", [["an attenuated virus", "PROBLEM", 16, 35], ["a restricted viral quasispecies", "PROBLEM", 41, 72], ["disease", "PROBLEM", 93, 100], ["attenuated", "OBSERVATION_MODIFIER", 19, 29], ["virus", "OBSERVATION", 30, 35], ["viral quasispecies", "OBSERVATION", 54, 72]]], ["This approach has the ability to be applied to any RNA virus given the conserved nature of the motif D lysine residue.Identification of the Conserved Lysine ::: MaterialsTable 1 is an alignment of residues found in motif D of the RdRp for positive and negative strand RNA virus families.", [["Lysine", "CHEMICAL", 150, 156], ["lysine", "CHEMICAL", 103, 109], ["Lysine", "CHEMICAL", 150, 156], ["RdRp", "GENE_OR_GENE_PRODUCT", 230, 234], ["RdRp", "PROTEIN", 230, 234], ["This approach", "TREATMENT", 0, 13], ["any RNA virus", "PROBLEM", 47, 60], ["the motif D lysine residue", "TREATMENT", 91, 117], ["the RdRp", "TEST", 226, 234], ["lysine residue", "OBSERVATION", 103, 117], ["Lysine", "OBSERVATION", 150, 156]]], ["Numbers indicate the position from the first amino acid of motif D in the RdRp domain.", [["amino acid", "CHEMICAL", 45, 55], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["D", "AMINO_ACID", 65, 66], ["motif D", "PROTEIN", 59, 66], ["RdRp domain", "PROTEIN", 74, 85], ["position", "OBSERVATION_MODIFIER", 21, 29]]], ["The conserved lysine residue is shown in boldfaced type.", [["lysine", "CHEMICAL", 14, 20], ["lysine", "CHEMICAL", 14, 20], ["lysine", "AMINO_ACID", 14, 20], ["The conserved lysine residue", "PROBLEM", 0, 28], ["lysine residue", "OBSERVATION", 14, 28], ["boldfaced type", "OBSERVATION", 41, 55]]], ["Other conserved residues are underlined.", [["Other conserved residues", "PROBLEM", 0, 24], ["residues", "OBSERVATION", 16, 24]]], ["All sequences were obtained from the NCBI Database.", [["All sequences", "TEST", 0, 13]]], ["Sequences were aligned using ClustalW2 and based upon alignments previously published [22].", [["ClustalW2", "DNA", 29, 38], ["ClustalW2", "TEST", 29, 38]]]], "PMC7103987": [["IntroductionRIG-I-like receptors (RLRs) are ubiquitously expressed cytoplasmic pathogen recognition receptors.", [["cytoplasmic", "ANATOMY", 67, 78], ["IntroductionRIG-I-", "CHEMICAL", 0, 18], ["IntroductionRIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 0, 32], ["RLRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["cytoplasmic", "ORGANISM_SUBSTANCE", 67, 78], ["pathogen recognition receptors", "GENE_OR_GENE_PRODUCT", 79, 109], ["IntroductionRIG-I-like receptors", "PROTEIN", 0, 32], ["RLRs", "PROTEIN", 34, 38], ["cytoplasmic pathogen recognition receptors", "PROTEIN", 67, 109]]], ["The RLR family of proteins are DExD/H box RNA helicases, and two of its members, namely retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5), specialize in detecting viral RNAs in infected cells (reviewed in Kato et al., 2011).", [["cells", "ANATOMY", 229, 234], ["RLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["DExD", "GENE_OR_GENE_PRODUCT", 31, 35], ["retinoic acid-inducible gene-I", "GENE_OR_GENE_PRODUCT", 88, 118], ["RIG-I", "GENE_OR_GENE_PRODUCT", 120, 125], ["melanoma differentiation-associated gene 5", "GENE_OR_GENE_PRODUCT", 131, 173], ["MDA5", "GENE_OR_GENE_PRODUCT", 175, 179], ["cells", "CELL", 229, 234], ["RLR family", "PROTEIN", 4, 14], ["DExD", "PROTEIN", 31, 35], ["H box RNA helicases", "PROTEIN", 36, 55], ["retinoic acid-inducible gene-I", "DNA", 88, 118], ["RIG-I", "DNA", 120, 125], ["melanoma differentiation-associated gene 5", "DNA", 131, 173], ["MDA5", "DNA", 175, 179], ["viral RNAs", "RNA", 206, 216], ["infected cells", "CELL_TYPE", 220, 234], ["melanoma differentiation", "PROBLEM", 131, 155], ["viral RNAs in infected cells", "PROBLEM", 206, 234], ["melanoma", "OBSERVATION", 131, 139], ["viral RNAs", "OBSERVATION", 206, 216], ["infected cells", "OBSERVATION", 220, 234]]], ["Upon ligand recognition, RIG-I and MDA5 interact with a mitochondrion-anchored adaptor molecule, MAVS, which activates kinase complexes eventually leading to the transcription of type I interferons (IFN-\u03b1/\u03b2) and other proinflammatory cytokine genes (Kato et al., 2011).IntroductionRIG-I and MDA5 play differential roles in virus recognition.", [["mitochondrion", "ANATOMY", 56, 69], ["RIG-I", "GENE_OR_GENE_PRODUCT", 25, 30], ["MDA5", "GENE_OR_GENE_PRODUCT", 35, 39], ["mitochondrion", "CELLULAR_COMPONENT", 56, 69], ["MAVS", "GENE_OR_GENE_PRODUCT", 97, 101], ["type I interferons", "GENE_OR_GENE_PRODUCT", 179, 197], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 199, 204], ["\u03b2", "GENE_OR_GENE_PRODUCT", 205, 206], ["IntroductionRIG-I", "GENE_OR_GENE_PRODUCT", 269, 286], ["MDA5", "GENE_OR_GENE_PRODUCT", 291, 295], ["RIG-I", "PROTEIN", 25, 30], ["MDA5", "PROTEIN", 35, 39], ["mitochondrion-anchored adaptor molecule", "PROTEIN", 56, 95], ["MAVS", "PROTEIN", 97, 101], ["kinase complexes", "PROTEIN", 119, 135], ["type I interferons", "PROTEIN", 179, 197], ["IFN", "PROTEIN", 199, 202], ["\u03b1", "PROTEIN", 203, 204], ["\u03b2", "PROTEIN", 205, 206], ["proinflammatory cytokine genes", "DNA", 218, 248], ["MDA5", "PROTEIN", 291, 295], ["ligand recognition", "TEST", 5, 23], ["a mitochondrion-anchored adaptor molecule", "TREATMENT", 54, 95], ["MAVS", "PROBLEM", 97, 101], ["activates kinase complexes", "PROBLEM", 109, 135], ["type I interferons", "PROBLEM", 179, 197], ["IFN", "TEST", 199, 202], ["other proinflammatory cytokine genes", "PROBLEM", 212, 248]]], ["RIG-I recognizes most single-stranded (ss) RNA viruses investigated to date, including all minus-strand RNA [(\u2212)RNA] viruses (e.g., influenza virus, Sendai virus, and vesicular stomatitis virus) and some plus-strand RNA [(+)RNA] viruses (e.g., hepatitis C virus and Japanese encephalitis virus) (Kato et al., 2011).", [["vesicular stomatitis", "DISEASE", 167, 187], ["hepatitis C", "DISEASE", 244, 255], ["Japanese encephalitis", "DISEASE", 266, 287], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["influenza virus", "ORGANISM", 132, 147], ["Sendai virus", "ORGANISM", 149, 161], ["vesicular stomatitis virus", "ORGANISM", 167, 193], ["hepatitis C virus", "ORGANISM", 244, 261], ["Japanese encephalitis virus", "ORGANISM", 266, 293], ["RIG-I", "DNA", 0, 5], ["influenza virus", "SPECIES", 132, 147], ["Sendai virus", "SPECIES", 149, 161], ["vesicular stomatitis virus", "SPECIES", 167, 193], ["hepatitis C virus", "SPECIES", 244, 261], ["Japanese encephalitis virus", "SPECIES", 266, 293], ["Sendai virus", "SPECIES", 149, 161], ["vesicular stomatitis virus", "SPECIES", 167, 193], ["hepatitis C virus", "SPECIES", 244, 261], ["Japanese encephalitis virus", "SPECIES", 266, 293], ["RNA viruses", "PROBLEM", 43, 54], ["strand RNA", "TEST", 97, 107], ["RNA] viruses (e.g.", "PROBLEM", 112, 130], ["influenza virus", "PROBLEM", 132, 147], ["Sendai virus", "PROBLEM", 149, 161], ["vesicular stomatitis virus", "PROBLEM", 167, 193], ["strand RNA", "PROBLEM", 209, 219], ["RNA] viruses (e.g.", "PROBLEM", 224, 242], ["hepatitis C virus", "PROBLEM", 244, 261], ["Japanese encephalitis virus", "PROBLEM", 266, 293], ["vesicular stomatitis", "ANATOMY", 167, 187]]], ["MDA5 recognizes some other (+)RNA viruses, namely encephalomyocarditis virus (EMCV) (Gitlin et al., 2006; Kato et al., 2006), Theiler\u2019s murine encephalomyelitis virus (TMEV) (Pichlmair et al., 2009), coxsackievirus B3 (CVB3) (Wang et al., 2010)\u2014all of which are members of the Picornavirus family\u2014and mouse norovirus (McCartney et al., 2008).", [["encephalomyocarditis virus", "DISEASE", 50, 76], ["Theiler\u2019s murine encephalomyelitis", "DISEASE", 126, 160], ["MDA5", "GENE_OR_GENE_PRODUCT", 0, 4], ["encephalomyocarditis virus", "ORGANISM", 50, 76], ["EMCV", "ORGANISM", 78, 82], ["Theiler\u2019s murine encephalomyelitis virus", "ORGANISM", 126, 166], ["TMEV", "ORGANISM", 168, 172], ["coxsackievirus B3", "ORGANISM", 200, 217], ["CVB3", "ORGANISM", 219, 223], ["mouse", "ORGANISM", 301, 306], ["norovirus", "ORGANISM", 307, 316], ["MDA5", "PROTEIN", 0, 4], ["encephalomyocarditis virus", "SPECIES", 50, 76], ["Theiler", "SPECIES", 126, 133], ["murine encephalomyelitis virus", "SPECIES", 136, 166], ["TMEV", "SPECIES", 168, 172], ["coxsackievirus B3", "SPECIES", 200, 217], ["mouse", "SPECIES", 301, 306], ["encephalomyocarditis virus", "SPECIES", 50, 76], ["EMCV", "SPECIES", 78, 82], ["Theiler\u2019s murine encephalomyelitis virus", "SPECIES", 126, 166], ["TMEV", "SPECIES", 168, 172], ["coxsackievirus B3", "SPECIES", 200, 217], ["CVB3", "SPECIES", 219, 223], ["mouse", "SPECIES", 301, 306], ["RNA viruses", "PROBLEM", 30, 41], ["namely encephalomyocarditis virus", "PROBLEM", 43, 76], ["Theiler\u2019s murine encephalomyelitis virus", "PROBLEM", 126, 166]]], ["Other ssRNA viruses, such as dengue virus, West Nile virus, mouse hepatitis virus, and several paramyxoviruses, are recognized by both RIG-I and MDA5 (Kato et al., 2011).", [["dengue virus", "DISEASE", 29, 41], ["mouse hepatitis virus", "DISEASE", 60, 81], ["dengue virus", "ORGANISM", 29, 41], ["West Nile virus", "ORGANISM", 43, 58], ["mouse hepatitis virus", "ORGANISM", 60, 81], ["RIG-I", "GENE_OR_GENE_PRODUCT", 135, 140], ["MDA5", "GENE_OR_GENE_PRODUCT", 145, 149], ["RIG-I", "PROTEIN", 135, 140], ["MDA5", "PROTEIN", 145, 149], ["dengue virus", "SPECIES", 29, 41], ["West Nile virus", "SPECIES", 43, 58], ["mouse", "SPECIES", 60, 65], ["hepatitis virus", "SPECIES", 66, 81], ["dengue virus", "SPECIES", 29, 41], ["West Nile virus", "SPECIES", 43, 58], ["mouse hepatitis virus", "SPECIES", 60, 81], ["Other ssRNA viruses", "PROBLEM", 0, 19], ["dengue virus", "PROBLEM", 29, 41], ["West Nile virus", "PROBLEM", 43, 58], ["mouse hepatitis virus", "PROBLEM", 60, 81], ["several paramyxoviruses", "PROBLEM", 87, 110], ["ssRNA viruses", "OBSERVATION", 6, 19], ["hepatitis virus", "OBSERVATION", 66, 81], ["paramyxoviruses", "OBSERVATION", 95, 110]]], ["Recognition of a double-stranded (ds) RNA virus, reovirus, has also been shown to involve both of these RLRs (Kato et al., 2008).IntroductionThe differential recognition of viruses by RIG-I and MDA5 has been attributed to their distinct preferences for RNA ligands.", [["reovirus", "ORGANISM", 49, 57], ["RLRs", "GENE_OR_GENE_PRODUCT", 104, 108], ["RIG-I", "GENE_OR_GENE_PRODUCT", 184, 189], ["MDA5", "GENE_OR_GENE_PRODUCT", 194, 198], ["RIG-I", "PROTEIN", 184, 189], ["MDA5", "PROTEIN", 194, 198], ["a double-stranded (ds) RNA virus", "PROBLEM", 15, 47], ["reovirus", "PROBLEM", 49, 57], ["viruses", "PROBLEM", 173, 180], ["RNA ligands", "PROBLEM", 253, 264], ["viruses", "OBSERVATION", 173, 180]]], ["RIG-I can be activated by 5\u2032-triphosphate (ppp)-containing RNAs as well as short (<2 kbp) dsRNAs (Kato et al., 2011).", [["5\u2032-triphosphate", "CHEMICAL", 26, 41], ["ppp", "CHEMICAL", 43, 46], ["5\u2032-triphosphate", "CHEMICAL", 26, 41], ["ppp", "CHEMICAL", 43, 46], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["5\u2032-triphosphate", "SIMPLE_CHEMICAL", 26, 41], ["ppp", "SIMPLE_CHEMICAL", 43, 46], ["RIG", "PROTEIN", 0, 3], ["5\u2032-triphosphate (ppp)-containing RNAs", "RNA", 26, 63], ["short (<2 kbp) dsRNAs", "DNA", 75, 96], ["RNAs", "TREATMENT", 59, 63]]], ["The ligand specificity of RIG-I provides an explanation for how it differentiates viral RNAs from cellular RNAs.", [["cellular", "ANATOMY", 98, 106], ["RIG-I", "GENE_OR_GENE_PRODUCT", 26, 31], ["cellular", "CELL", 98, 106], ["RIG-I", "PROTEIN", 26, 31], ["viral RNAs", "RNA", 82, 92], ["cellular RNAs", "RNA", 98, 111], ["viral RNAs from cellular RNAs", "PROBLEM", 82, 111], ["cellular RNAs", "OBSERVATION", 98, 111]]], ["Many RNA viruses carry genomes that contain 5\u2032ppp or produce 5\u2032ppp-containing RNAs during their replication cycle in the cytoplasm of infected cells, whereas cytoplasmic cellular RNAs generally lack 5\u2032ppp.", [["cytoplasm", "ANATOMY", 121, 130], ["cells", "ANATOMY", 143, 148], ["cytoplasmic cellular", "ANATOMY", 158, 178], ["5", "ORGANISM", 44, 45], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 45, 49], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 62, 66], ["cytoplasm", "ORGANISM_SUBSTANCE", 121, 130], ["cells", "CELL", 143, 148], ["cytoplasmic", "ORGANISM_SUBSTANCE", 158, 169], ["cellular", "CELL", 170, 178], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 200, 204], ["5\u2032ppp-containing RNAs", "RNA", 61, 82], ["infected cells", "CELL_TYPE", 134, 148], ["cytoplasmic cellular RNAs", "RNA", 158, 183], ["\u2032ppp", "PROTEIN", 200, 204], ["Many RNA viruses carry genomes", "PROBLEM", 0, 30], ["RNAs", "TREATMENT", 78, 82], ["their replication cycle", "TREATMENT", 90, 113], ["infected cells", "PROBLEM", 134, 148], ["cytoplasmic cellular RNAs", "PROBLEM", 158, 183], ["RNA viruses", "OBSERVATION", 5, 16], ["infected cells", "OBSERVATION", 134, 148], ["cellular RNAs", "OBSERVATION", 170, 183]]], ["The ligands of MDA5 are as yet poorly defined.", [["MDA5", "GENE_OR_GENE_PRODUCT", 15, 19], ["MDA5", "PROTEIN", 15, 19], ["MDA5", "OBSERVATION", 15, 19]]], ["MDA5 is activated by transfection of a long (>2 kbp), synthetic dsRNA analog of artificial sequence, namely polyinosinic:polycytidylic [poly(I:C)].", [["polyinosinic:polycytidylic [poly(I:C)", "CHEMICAL", 108, 145], ["MDA5", "GENE_OR_GENE_PRODUCT", 0, 4], ["polyinosinic:polycytidylic", "SIMPLE_CHEMICAL", 108, 134], ["poly(I:C", "SIMPLE_CHEMICAL", 136, 144], ["MDA5", "PROTEIN", 0, 4], ["a long (>2 kbp)", "TREATMENT", 37, 52], ["synthetic dsRNA analog of artificial sequence", "TREATMENT", 54, 99]]], ["Additionally, transfection-based experiments showed that the L segments of the reovirus genome (\u223c3.9 kbp dsRNAs) induce an IFN-\u03b2 response that is partially dependent on MDA5 (Kato et al., 2006).", [["reovirus", "ORGANISM", 79, 87], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 123, 128], ["MDA5", "GENE_OR_GENE_PRODUCT", 169, 173], ["L segments", "DNA", 61, 71], ["reovirus genome", "DNA", 79, 94], ["IFN", "PROTEIN", 123, 126], ["\u03b2", "PROTEIN", 127, 128], ["MDA5", "PROTEIN", 169, 173], ["the reovirus genome", "PROBLEM", 75, 94], ["kbp dsRNAs", "TREATMENT", 101, 111], ["an IFN-\u03b2 response", "PROBLEM", 120, 137], ["partially dependent", "PROBLEM", 146, 165], ["L", "ANATOMY_MODIFIER", 61, 62], ["segments", "ANATOMY_MODIFIER", 63, 71], ["reovirus genome", "OBSERVATION", 79, 94], ["dependent", "OBSERVATION_MODIFIER", 156, 165]]], ["Based on these findings, it is believed that MDA5 recognizes long dsRNAs, which would be intrinsically \u201cnonself.\u201d", [["MDA5", "GENE_OR_GENE_PRODUCT", 45, 49], ["MDA5", "PROTEIN", 45, 49], ["long dsRNAs", "DNA", 61, 72], ["long dsRNAs", "PROBLEM", 61, 72]]], ["However, little is known about the identities and characteristics of physiological ligands of MDA5 in infected cells.IntroductionMany (+)RNA viruses, including picornaviruses, produce dsRNAs during infection.", [["cells", "ANATOMY", 111, 116], ["infection", "DISEASE", 198, 207], ["MDA5", "GENE_OR_GENE_PRODUCT", 94, 98], ["cells", "CELL", 111, 116], ["MDA5", "PROTEIN", 94, 98], ["infected cells", "CELL_TYPE", 102, 116], ["dsRNAs", "DNA", 184, 190], ["physiological ligands of MDA5 in infected cells", "PROBLEM", 69, 116], ["RNA viruses", "PROBLEM", 137, 148], ["picornaviruses", "PROBLEM", 160, 174], ["dsRNAs during infection", "PROBLEM", 184, 207], ["infected cells", "OBSERVATION", 102, 116], ["dsRNAs", "OBSERVATION", 184, 190], ["infection", "OBSERVATION", 198, 207]]], ["Picornaviridae is a large, highly diverse family of human and animal viruses, including many pathogens of great medical and/or economical significance.", [["Picornaviridae", "CHEMICAL", 0, 14], ["human and animal viruses", "DISEASE", 52, 76], ["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Picornaviridae", "TREATMENT", 0, 14], ["animal viruses", "PROBLEM", 62, 76], ["large", "OBSERVATION_MODIFIER", 20, 25], ["viruses", "OBSERVATION", 69, 76]]], ["The picornavirus genome is a 7.5\u20138.5 kb ssRNA molecule that harbors a single open reading frame flanked by structured 5\u2032 and 3\u2032 nontranslated regions and a poly(A) tail at the 3\u2032 end.", [["picornavirus", "ORGANISM", 4, 16], ["poly(A) tail", "GENE_OR_GENE_PRODUCT", 156, 168], ["picornavirus genome", "DNA", 4, 23], ["7.5\u20138.5 kb ssRNA molecule", "DNA", 29, 54], ["open reading frame", "DNA", 77, 95], ["5\u2032 and 3\u2032 nontranslated regions", "DNA", 118, 149], ["poly(A) tail", "DNA", 156, 168], ["3\u2032 end", "DNA", 176, 182], ["The picornavirus genome", "PROBLEM", 0, 23], ["a 7.5\u20138.5 kb ssRNA molecule", "PROBLEM", 27, 54], ["a poly(A) tail", "TREATMENT", 154, 168], ["picornavirus genome", "OBSERVATION", 4, 23], ["tail", "ANATOMY", 164, 168]]], ["The 5\u2032 terminus contains a small (20\u201324 aa) viral peptide, VPg, linked via an unusual tyrosine-RNA phosphodiester bond.", [["tyrosine", "CHEMICAL", 86, 94], ["phosphodiester", "CHEMICAL", 99, 113], ["tyrosine", "CHEMICAL", 86, 94], ["phosphodiester", "CHEMICAL", 99, 113], ["VPg", "GENE_OR_GENE_PRODUCT", 59, 62], ["tyrosine", "AMINO_ACID", 86, 94], ["5\u2032 terminus", "PROTEIN", 4, 15], ["VPg", "PROTEIN", 59, 62], ["a small (20\u201324 aa) viral peptide", "TREATMENT", 25, 57], ["VPg", "TEST", 59, 62], ["an unusual tyrosine-RNA phosphodiester bond", "TREATMENT", 75, 118], ["small", "OBSERVATION_MODIFIER", 27, 32], ["RNA phosphodiester bond", "OBSERVATION", 95, 118]]], ["Upon virus entry and uncoating, the virion RNA (vRNA) is released into the cytoplasm where it is directly translated.", [["cytoplasm", "ANATOMY", 75, 84], ["vRNA", "GENE_OR_GENE_PRODUCT", 48, 52], ["cytoplasm", "ORGANISM_SUBSTANCE", 75, 84], ["virion RNA", "RNA", 36, 46], ["vRNA", "RNA", 48, 52], ["virus", "OBSERVATION", 5, 10], ["virion RNA", "OBSERVATION", 36, 46]]], ["Viral RNA templates used for protein synthesis no longer contain VPg due to the activity of a yet unknown cellular enzyme (further referred to as unlinkase) (Rozovics et al., 2011).", [["cellular", "ANATOMY", 106, 114], ["cellular", "CELL", 106, 114], ["VPg", "PROTEIN", 65, 68], ["cellular enzyme", "PROTEIN", 106, 121], ["unlinkase", "PROTEIN", 146, 155], ["Viral RNA templates", "TREATMENT", 0, 19], ["protein synthesis", "TREATMENT", 29, 46], ["VPg", "PROBLEM", 65, 68], ["unknown cellular enzyme", "PROBLEM", 98, 121]]], ["The viral polyprotein is proteolytically processed to release the viral proteins that engage in genomic RNA replication.", [["viral proteins", "PROTEIN", 66, 80], ["The viral polyprotein", "TREATMENT", 0, 21], ["the viral proteins", "PROBLEM", 62, 80], ["genomic RNA replication", "TREATMENT", 96, 119], ["viral polyprotein", "OBSERVATION", 4, 21], ["viral proteins", "OBSERVATION", 66, 80], ["RNA replication", "OBSERVATION", 104, 119]]], ["During this complex process, several species of viral RNAs with unique features are generated (Figure 2A).", [["viral RNAs", "RNA", 48, 58], ["this complex process", "PROBLEM", 7, 27], ["several species of viral RNAs", "PROBLEM", 29, 58], ["viral RNAs", "OBSERVATION", 48, 58]]], ["First, the viral genomic ssRNA is transcribed into a complementary (\u2212)RNA by the virally encoded RNA-dependent RNA polymerase using VPg as primer, yielding a 7.5 kbp dsRNA named the replicative form (RF).", [["VPg", "GENE_OR_GENE_PRODUCT", 132, 135], ["viral genomic ssRNA", "RNA", 11, 30], ["complementary (\u2212)RNA", "RNA", 53, 73], ["virally encoded RNA-dependent RNA polymerase", "PROTEIN", 81, 125], ["7.5 kbp dsRNA", "DNA", 158, 171], ["RF", "PROTEIN", 200, 202], ["the viral genomic ssRNA", "PROBLEM", 7, 30], ["a complementary (\u2212)RNA", "PROBLEM", 51, 73], ["the virally encoded RNA", "PROBLEM", 77, 100], ["dependent RNA polymerase", "PROBLEM", 101, 125], ["VPg as primer", "TREATMENT", 132, 145], ["a 7.5 kbp dsRNA", "TREATMENT", 156, 171], ["viral genomic ssRNA", "OBSERVATION", 11, 30]]], ["The (\u2212)RNA is subsequently used as a template for VPg-primed synthesis of large amounts of new (+)RNAs, which are identical to vRNA.", [["vRNA", "CELLULAR_COMPONENT", 127, 131], ["(\u2212)RNA", "RNA", 4, 10], ["new (+)RNAs", "RNA", 91, 102], ["vRNA", "RNA", 127, 131], ["The (\u2212)RNA", "TREATMENT", 0, 10], ["a template", "TREATMENT", 35, 45], ["VPg", "TEST", 50, 53], ["new (+)RNAs", "PROBLEM", 91, 102], ["vRNA", "PROBLEM", 127, 131], ["large", "OBSERVATION_MODIFIER", 74, 79], ["amounts", "OBSERVATION_MODIFIER", 80, 87], ["new", "OBSERVATION_MODIFIER", 91, 94], ["vRNA", "OBSERVATION", 127, 131]]], ["Newly synthesized (+)RNAs either enter a new cycle of translation and RNA replication or are encapsidated to form new virion particles.", [["Newly synthesized (+)RNAs", "PROBLEM", 0, 25], ["a new cycle of translation", "TREATMENT", 39, 65], ["RNA replication", "TREATMENT", 70, 85], ["new virion particles", "PROBLEM", 114, 134], ["new", "OBSERVATION_MODIFIER", 114, 117], ["virion particles", "OBSERVATION", 118, 134]]], ["During the process of (+)RNA synthesis, a partially ds replicative intermediate (RI)\u2014consisting of multiple incomplete (+)RNAs undergoing active transcription along the full-length (\u2212)RNA\u2014is formed.IntroductionIt is generally assumed that viral dsRNAs produced in cells infected with picornaviruses, as well as other (+)RNA viruses, activate MDA5.", [["cells", "ANATOMY", 264, 269], ["cells", "CELL", 264, 269], ["MDA5", "GENE_OR_GENE_PRODUCT", 342, 346], ["multiple incomplete (+)RNAs", "RNA", 99, 126], ["full-length (\u2212)RNA\u2014is", "DNA", 169, 190], ["viral dsRNAs", "DNA", 239, 251], ["MDA5", "PROTEIN", 342, 346], ["RNA synthesis", "PROBLEM", 25, 38], ["a partially ds replicative intermediate (RI)", "PROBLEM", 40, 84], ["multiple incomplete (+)RNAs", "PROBLEM", 99, 126], ["active transcription", "TREATMENT", 138, 158], ["viral dsRNAs", "PROBLEM", 239, 251], ["picornaviruses", "PROBLEM", 284, 298], ["other (+)RNA viruses", "PROBLEM", 311, 331], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["viral dsRNAs", "OBSERVATION", 239, 251], ["picornaviruses", "OBSERVATION", 284, 298], ["RNA viruses", "OBSERVATION", 320, 331]]], ["In this study, we sought to identify physiological ligand(s) of MDA5 by studying the recognition of distinct picornavirus RNA species in transfected cells as well as during infection.", [["cells", "ANATOMY", 149, 154], ["infection", "DISEASE", 173, 182], ["MDA5", "GENE_OR_GENE_PRODUCT", 64, 68], ["cells", "CELL", 149, 154], ["MDA5", "PROTEIN", 64, 68], ["picornavirus RNA species", "RNA", 109, 133], ["transfected cells", "CELL_LINE", 137, 154], ["this study", "TEST", 3, 13], ["MDA5", "PROBLEM", 64, 68], ["distinct picornavirus RNA species in transfected cells", "PROBLEM", 100, 154], ["infection", "PROBLEM", 173, 182], ["distinct", "OBSERVATION_MODIFIER", 100, 108], ["picornavirus RNA species", "OBSERVATION", 109, 133], ["transfected cells", "OBSERVATION", 137, 154], ["infection", "OBSERVATION", 173, 182]]], ["Here, we identify a naturally occurring RNA from infected cells, the picornavirus RF, as a potent and specific activator of MDA5 during infection.MDA5 Recognizes Viruses from Various Picornavirus Genera ::: ResultsThe Picornavirus family contains hundreds of highly diverse members that are subcategorized in 12 genera.", [["cells", "ANATOMY", 58, 63], ["infection", "DISEASE", 136, 145], ["cells", "CELL", 58, 63], ["MDA5", "GENE_OR_GENE_PRODUCT", 124, 128], ["MDA5", "GENE_OR_GENE_PRODUCT", 146, 150], ["infected cells", "CELL_TYPE", 49, 63], ["picornavirus RF", "PROTEIN", 69, 84], ["MDA5", "PROTEIN", 124, 128], ["MDA5", "PROTEIN", 146, 150], ["Picornavirus family", "PROTEIN", 218, 237], ["a naturally occurring RNA", "PROBLEM", 18, 43], ["infected cells", "PROBLEM", 49, 63], ["the picornavirus RF", "PROBLEM", 65, 84], ["infection", "PROBLEM", 136, 145], ["infected cells", "OBSERVATION", 49, 63], ["picornavirus RF", "OBSERVATION", 69, 84], ["infection", "OBSERVATION", 136, 145], ["Picornavirus", "OBSERVATION", 218, 230]]], ["Based on the observation that MDA5 recognizes EMCV and TMEV, both members of the Cardiovirus genus, and CVB3, an Enterovirus (Kato et al., 2011), it is generally assumed that all picornaviruses are recognized by MDA5, but experimental proof for this is lacking.", [["Enterovirus", "DISEASE", 113, 124], ["MDA5", "GENE_OR_GENE_PRODUCT", 30, 34], ["EMCV", "ORGANISM", 46, 50], ["TMEV", "ORGANISM", 55, 59], ["Cardiovirus genus", "ORGANISM", 81, 98], ["CVB3", "ORGANISM", 104, 108], ["picornaviruses", "ORGANISM", 179, 193], ["MDA5", "GENE_OR_GENE_PRODUCT", 212, 216], ["MDA5", "PROTEIN", 30, 34], ["MDA5", "PROTEIN", 212, 216], ["EMCV", "SPECIES", 46, 50], ["TMEV", "SPECIES", 55, 59], ["CVB3", "SPECIES", 104, 108], ["EMCV", "TEST", 46, 50], ["CVB3", "PROBLEM", 104, 108], ["all picornaviruses", "PROBLEM", 175, 193], ["picornaviruses", "OBSERVATION", 179, 193]]], ["Here, we set out to investigate the role of RLRs in the recognition of representative picornaviruses from various genera using wild-type (WT) and RIG-I\u2212/\u2212, MDA5\u2212/\u2212, or MAVS\u2212/\u2212 mouse embryonic fibroblasts (MEFs).", [["MDA5\u2212/\u2212", "ANATOMY", 156, 163], ["embryonic fibroblasts", "ANATOMY", 182, 203], ["MEFs", "ANATOMY", 205, 209], ["RLRs", "GENE_OR_GENE_PRODUCT", 44, 48], ["wild-type (WT)", "ORGANISM", 127, 141], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 146, 152], ["\u2212", "GENE_OR_GENE_PRODUCT", 153, 154], ["MDA5\u2212", "GENE_OR_GENE_PRODUCT", 156, 161], ["mouse", "ORGANISM", 176, 181], ["embryonic fibroblasts", "CELL", 182, 203], ["MEFs", "CELL", 205, 209], ["RLRs", "PROTEIN", 44, 48], ["wild-type (WT) and RIG-I\u2212/\u2212, MDA5\u2212/\u2212, or MAVS\u2212/\u2212 mouse embryonic fibroblasts", "CELL_LINE", 127, 203], ["MEFs", "CELL_LINE", 205, 209], ["mouse", "SPECIES", 176, 181], ["mouse", "SPECIES", 176, 181], ["representative picornaviruses", "PROBLEM", 71, 100], ["WT", "TEST", 138, 140], ["RIG", "TEST", 146, 149], ["MAVS\u2212", "TREATMENT", 168, 173], ["picornaviruses", "OBSERVATION", 86, 100], ["embryonic fibroblasts", "OBSERVATION", 182, 203]]], ["To bypass the requirement for specific entry receptors, we introduced vRNAs into the cytoplasm by transfection rather than infection.", [["cytoplasm", "ANATOMY", 85, 94], ["infection", "DISEASE", 123, 132], ["vRNAs", "GENE_OR_GENE_PRODUCT", 70, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["entry receptors", "PROTEIN", 39, 54], ["vRNAs", "PROTEIN", 70, 75], ["bypass", "TREATMENT", 3, 9], ["specific entry receptors", "TREATMENT", 30, 54], ["infection", "PROBLEM", 123, 132], ["bypass", "OBSERVATION", 3, 9]]], ["Figure 1A shows IFN-\u03b2 responses in WT and knockout MEFs triggered by transfection of vRNA of WT mengovirus (a strain of EMCV) or infection of a mutant mengovirus (mengo-Zn).", [["MEFs", "ANATOMY", 51, 55], ["infection", "DISEASE", 129, 138], ["mengo-Zn", "CHEMICAL", 163, 171], ["Zn", "CHEMICAL", 169, 171], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 16, 21], ["MEFs", "CELL", 51, 55], ["WT mengovirus", "ORGANISM", 93, 106], ["EMCV", "ORGANISM", 120, 124], ["mutant mengovirus", "ORGANISM", 144, 161], ["mengo-Zn", "SIMPLE_CHEMICAL", 163, 171], ["IFN", "PROTEIN", 16, 19], ["\u03b2", "PROTEIN", 20, 21], ["mutant mengovirus", "PROTEIN", 144, 161], ["Zn", "PROTEIN", 169, 171], ["EMCV", "SPECIES", 120, 124], ["Figure 1A", "TEST", 0, 9], ["IFN", "PROBLEM", 16, 19], ["WT", "TEST", 35, 37], ["knockout MEFs", "PROBLEM", 42, 55], ["WT mengovirus", "PROBLEM", 93, 106], ["a strain of EMCV", "PROBLEM", 108, 124], ["infection", "PROBLEM", 129, 138], ["a mutant mengovirus", "PROBLEM", 142, 161]]], ["This virus generates high levels of IFN-\u03b2 because its IFN antagonist has been compromised (Hato et al., 2007).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 36, 41], ["IFN antagonist", "GENE_OR_GENE_PRODUCT", 54, 68], ["IFN", "PROTEIN", 36, 39], ["\u03b2", "PROTEIN", 40, 41], ["IFN", "PROTEIN", 54, 57], ["This virus", "PROBLEM", 0, 10], ["IFN", "TREATMENT", 36, 39], ["its IFN antagonist", "TREATMENT", 50, 68], ["high levels", "OBSERVATION_MODIFIER", 21, 32]]], ["Both methods resulted in a MDA5- and MAVS-dependent, but RIG-I-independent, IFN-\u03b2 induction, demonstrating the suitability of the transfection method to identify the RLR(s) responsible for detecting picornaviruses.MDA5 Recognizes Viruses from Various Picornavirus Genera ::: ResultsUsing this vRNA transfection assay, we studied recognition of members of three human Enterovirus species.", [["MDA5", "GENE_OR_GENE_PRODUCT", 27, 31], ["MAVS", "GENE_OR_GENE_PRODUCT", 37, 41], ["RIG-I-", "GENE_OR_GENE_PRODUCT", 57, 63], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["RLR", "GENE_OR_GENE_PRODUCT", 166, 169], ["MDA5", "GENE_OR_GENE_PRODUCT", 214, 218], ["human", "ORGANISM", 361, 366], ["Enterovirus species", "ORGANISM", 367, 386], ["MDA5", "PROTEIN", 27, 31], ["MAVS", "PROTEIN", 37, 41], ["RIG", "PROTEIN", 57, 60], ["IFN", "PROTEIN", 76, 79], ["MDA5", "PROTEIN", 214, 218], ["human", "SPECIES", 361, 366], ["human", "SPECIES", 361, 366], ["a MDA5", "TEST", 25, 31], ["the transfection method", "TREATMENT", 126, 149], ["picornaviruses", "PROBLEM", 199, 213], ["this vRNA transfection assay", "TEST", 288, 316], ["three human Enterovirus species", "PROBLEM", 355, 386], ["picornaviruses", "OBSERVATION", 199, 213]]], ["In addition, we included Saffold virus (a recently identified human Cardiovirus), human parechovirus (Parechovirus genus), and equine rhinitis A virus (a member of the Aphthovirus genus that also includes foot-and-mouth disease virus).", [["rhinitis A", "DISEASE", 134, 144], ["foot-and-mouth disease", "DISEASE", 205, 227], ["Saffold virus", "ORGANISM", 25, 38], ["human", "ORGANISM", 62, 67], ["Cardiovirus", "CANCER", 68, 79], ["human", "ORGANISM", 82, 87], ["parechovirus", "GENE_OR_GENE_PRODUCT", 88, 100], ["Parechovirus genus", "ORGANISM", 102, 120], ["equine rhinitis A virus", "ORGANISM", 127, 150], ["foot-and-mouth disease virus", "ORGANISM", 205, 233], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 82, 87], ["equine rhinitis A virus", "SPECIES", 127, 150], ["foot-and-mouth disease virus", "SPECIES", 205, 233], ["Saffold virus", "SPECIES", 25, 38], ["human", "SPECIES", 62, 67], ["human parechovirus", "SPECIES", 82, 100], ["equine rhinitis A virus", "SPECIES", 127, 150], ["foot-and-mouth disease virus", "SPECIES", 205, 233], ["Saffold virus", "PROBLEM", 25, 38], ["human parechovirus (Parechovirus genus", "PROBLEM", 82, 120], ["equine rhinitis A virus", "PROBLEM", 127, 150], ["the Aphthovirus genus", "PROBLEM", 164, 185], ["mouth disease virus", "PROBLEM", 214, 233], ["equine rhinitis", "OBSERVATION", 127, 142], ["foot", "ANATOMY", 205, 209], ["mouth", "ANATOMY", 214, 219]]], ["Infectious viruses were produced upon transfection of all vRNAs, indicating efficient RNA replication in MEFs (data not shown).", [["MEFs", "ANATOMY", 105, 109], ["vRNAs", "GENE_OR_GENE_PRODUCT", 58, 63], ["MEFs", "CELL", 105, 109], ["vRNAs", "DNA", 58, 63], ["MEFs", "CELL_TYPE", 105, 109], ["Infectious viruses", "PROBLEM", 0, 18], ["all vRNAs", "TEST", 54, 63], ["efficient RNA replication in MEFs", "PROBLEM", 76, 109], ["RNA replication", "OBSERVATION", 86, 101]]], ["Replication of all viruses induced an MDA5- and MAVS-dependent, but RIG-I-independent, IFN-\u03b2 response (Figures 1B and 1C).", [["MDA5", "GENE_OR_GENE_PRODUCT", 38, 42], ["MAVS", "GENE_OR_GENE_PRODUCT", 48, 52], ["RIG-I", "GENE_OR_GENE_PRODUCT", 68, 73], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["MDA5", "PROTEIN", 38, 42], ["MAVS", "PROTEIN", 48, 52], ["IFN", "PROTEIN", 87, 90], ["\u03b2", "PROTEIN", 91, 92], ["all viruses", "PROBLEM", 15, 26], ["an MDA5", "TEST", 35, 42], ["IFN", "TEST", 87, 90], ["all viruses", "OBSERVATION", 15, 26]]], ["These data provide experimental evidence that a broad spectrum of picornaviruses is indeed recognized by MDA5.MDA5 Recognizes Viruses from Various Picornavirus Genera ::: ResultsTwo other cellular proteins, namely PKR and RNaseL, have also been implicated in recognition of some viruses (Kato et al., 2011).", [["cellular", "ANATOMY", 188, 196], ["picornaviruses", "ORGANISM", 66, 80], ["MDA5", "GENE_OR_GENE_PRODUCT", 105, 109], ["MDA5", "GENE_OR_GENE_PRODUCT", 110, 114], ["cellular", "CELL", 188, 196], ["PKR", "GENE_OR_GENE_PRODUCT", 214, 217], ["RNaseL", "GENE_OR_GENE_PRODUCT", 222, 228], ["MDA5", "PROTEIN", 105, 109], ["MDA5", "PROTEIN", 110, 114], ["cellular proteins", "PROTEIN", 188, 205], ["PKR", "PROTEIN", 214, 217], ["RNaseL", "PROTEIN", 222, 228], ["a broad spectrum of picornaviruses", "PROBLEM", 46, 80], ["other cellular proteins", "TEST", 182, 205], ["PKR", "TEST", 214, 217], ["some viruses", "PROBLEM", 274, 286], ["picornaviruses", "OBSERVATION", 66, 80]]], ["However, we found no difference in IFN-\u03b1/\u03b2 responses to mengo-Zn in cells deficient in RNaseL or PKR (Figure S1), arguing against a major role of these proteins in detecting picornavirus RNA (see Extended Results and Discussion).Enrichment of ssRNA and dsRNA Fractions from Picornavirus-Infected Cells ::: ResultsTo gain more insight into the identity of the RNA species detected by MDA5 in picornavirus-infected cells, we separately enriched for ssRNAs and dsRNAs by LiCl differential precipitation from mock- and CVB3-infected HeLa cells (Figure 2B).", [["cells", "ANATOMY", 68, 73], ["Cells", "ANATOMY", 296, 301], ["cells", "ANATOMY", 413, 418], ["HeLa cells", "ANATOMY", 529, 539], ["mengo-Zn", "CHEMICAL", 56, 64], ["LiCl", "CHEMICAL", 468, 472], ["mengo", "CHEMICAL", 56, 61], ["Zn", "CHEMICAL", 62, 64], ["LiCl", "CHEMICAL", 468, 472], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["\u03b2", "GENE_OR_GENE_PRODUCT", 41, 42], ["mengo-Zn", "SIMPLE_CHEMICAL", 56, 64], ["cells", "CELL", 68, 73], ["RNaseL", "GENE_OR_GENE_PRODUCT", 87, 93], ["PKR", "GENE_OR_GENE_PRODUCT", 97, 100], ["Figure S1", "GENE_OR_GENE_PRODUCT", 102, 111], ["Cells", "CELL", 296, 301], ["MDA5", "GENE_OR_GENE_PRODUCT", 383, 387], ["picornavirus", "ORGANISM", 391, 403], ["cells", "CELL", 413, 418], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 447, 453], ["LiCl", "SIMPLE_CHEMICAL", 468, 472], ["CVB3", "ORGANISM", 515, 519], ["HeLa cells", "CELL", 529, 539], ["Figure 2B", "CELL", 541, 550], ["IFN", "PROTEIN", 35, 38], ["\u03b1", "PROTEIN", 39, 40], ["\u03b2", "PROTEIN", 41, 42], ["RNaseL", "PROTEIN", 87, 93], ["PKR", "PROTEIN", 97, 100], ["Figure S1", "PROTEIN", 102, 111], ["picornavirus RNA", "RNA", 174, 190], ["RNA species", "RNA", 359, 370], ["MDA5", "PROTEIN", 383, 387], ["picornavirus-infected cells", "CELL_TYPE", 391, 418], ["ssRNAs", "PROTEIN", 447, 453], ["dsRNAs", "DNA", 458, 464], ["mock- and CVB3-infected HeLa cells", "CELL_LINE", 505, 539], ["CVB3", "SPECIES", 515, 519], ["IFN", "TEST", 35, 38], ["mengo", "TEST", 56, 61], ["Zn in cells deficient", "PROBLEM", 62, 83], ["PKR", "TEST", 97, 100], ["picornavirus RNA", "PROBLEM", 174, 190], ["ssRNA", "PROBLEM", 243, 248], ["dsRNA Fractions", "PROBLEM", 253, 268], ["Picornavirus", "PROBLEM", 274, 286], ["the RNA species", "PROBLEM", 355, 370], ["picornavirus", "PROBLEM", 391, 403], ["infected cells", "PROBLEM", 404, 418], ["ssRNAs", "PROBLEM", 447, 453], ["dsRNAs", "TREATMENT", 458, 464], ["mock", "TEST", 505, 509], ["CVB3", "TEST", 515, 519], ["infected HeLa cells", "PROBLEM", 520, 539], ["no", "UNCERTAINTY", 18, 20], ["ssRNA", "OBSERVATION", 243, 248], ["dsRNA Fractions", "OBSERVATION_MODIFIER", 253, 268], ["Infected Cells", "OBSERVATION", 287, 301], ["infected cells", "OBSERVATION", 404, 418], ["HeLa cells", "OBSERVATION", 529, 539]]], ["The ssRNA pool of infected cells contained one additional RNA species of the same electrophoretic mobility as purified CVB3 vRNA (Figure 2C), suggesting that it represents viral genomic ssRNA.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["CVB3", "ORGANISM", 119, 123], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 130, 139], ["infected cells", "CELL_TYPE", 18, 32], ["RNA species", "RNA", 58, 69], ["CVB3 vRNA", "RNA", 119, 128], ["viral genomic ssRNA", "DNA", 172, 191], ["infected cells", "PROBLEM", 18, 32], ["the same electrophoretic mobility", "PROBLEM", 73, 106], ["viral genomic ssRNA", "PROBLEM", 172, 191], ["ssRNA pool", "OBSERVATION", 4, 14], ["infected cells", "OBSERVATION", 18, 32], ["RNA species", "OBSERVATION", 58, 69], ["mobility", "OBSERVATION_MODIFIER", 98, 106], ["CVB3 vRNA", "OBSERVATION", 119, 128], ["suggesting that it represents", "UNCERTAINTY", 142, 171], ["viral genomic ssRNA", "OBSERVATION", 172, 191]]], ["Although partially ds, the viral RI is known to precipitate by 2M LiCl (Richards et al., 1984), the same condition used here to prepare ssRNA fractions.", [["LiCl", "CHEMICAL", 66, 70], ["LiCl", "CHEMICAL", 66, 70], ["2M LiCl", "SIMPLE_CHEMICAL", 63, 70], ["viral RI", "PROTEIN", 27, 35], ["partially ds", "PROBLEM", 9, 21]]], ["However, the amount of RI is most likely too low to be detected on gel.", [["RI", "GENE_OR_GENE_PRODUCT", 23, 25], ["RI", "PROTEIN", 23, 25], ["RI", "PROBLEM", 23, 25], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["RI", "OBSERVATION_MODIFIER", 23, 25], ["most likely", "UNCERTAINTY", 29, 40]]], ["The dsRNA pool of CVB3-infected cells contained an RNA species of approximately 7.5 kbp that was absent in the dsRNA pool of mock-infected cells (Figure 2B).", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 139, 144], ["CVB3", "ORGANISM", 18, 22], ["cells", "CELL", 32, 37], ["cells", "CELL", 139, 144], ["RNA species", "RNA", 51, 62], ["mock-infected cells", "CELL_TYPE", 125, 144], ["CVB3", "SPECIES", 18, 22], ["The dsRNA pool", "TEST", 0, 14], ["CVB3", "TEST", 18, 22], ["infected cells", "PROBLEM", 23, 37], ["an RNA species", "PROBLEM", 48, 62], ["infected cells", "PROBLEM", 130, 144], ["infected cells", "OBSERVATION", 23, 37], ["RNA species", "OBSERVATION", 51, 62], ["infected cells", "OBSERVATION", 130, 144]]], ["Both the viral ssRNA and dsRNA bands were absent in HeLa cells infected with CVB3 in the presence of GuHCl (Figure 2B), a well-known inhibitor of enterovirus (\u2212)RNA synthesis (Barton and Flanegan, 1997) (Figures 2D and S2), demonstrating that these RNAs were of viral origin.The Picornavirus 7.5 kbp RF Is a Potent MDA5 Ligand upon Transfection ::: ResultsThe dsRNA fraction from CVB3-infected cells (Figure 2B) was transfected into MEFs and IFN-\u03b2 mRNA levels were measured at 2 hr posttransfection (hr.p.t.), a time point preceding RNA replication (Figure S2), thereby excluding the possible role of other, newly produced viral RNA species.", [["HeLa cells", "ANATOMY", 52, 62], ["cells", "ANATOMY", 394, 399], ["MEFs", "ANATOMY", 433, 437], ["GuHCl", "CHEMICAL", 101, 106], ["GuHCl", "CHEMICAL", 101, 106], ["HeLa cells", "CELL", 52, 62], ["CVB3", "ORGANISM", 77, 81], ["GuHCl", "SIMPLE_CHEMICAL", 101, 106], ["enterovirus", "ORGANISM", 146, 157], ["MDA5", "GENE_OR_GENE_PRODUCT", 315, 319], ["CVB3", "ORGANISM", 380, 384], ["cells", "CELL", 394, 399], ["Figure 2B", "CELL", 401, 410], ["MEFs", "CELL", 433, 437], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 442, 447], ["HeLa cells", "CELL_LINE", 52, 62], ["Picornavirus 7.5 kbp RF", "DNA", 279, 302], ["Potent MDA5 Ligand", "PROTEIN", 308, 326], ["CVB3-infected cells", "CELL_LINE", 380, 399], ["IFN", "PROTEIN", 442, 445], ["viral RNA species", "RNA", 623, 640], ["CVB3", "SPECIES", 77, 81], ["CVB3", "SPECIES", 380, 384], ["the viral ssRNA and dsRNA bands", "TEST", 5, 36], ["HeLa cells", "PROBLEM", 52, 62], ["CVB3", "PROBLEM", 77, 81], ["enterovirus", "PROBLEM", 146, 157], ["RNA synthesis", "TEST", 161, 174], ["The Picornavirus", "TREATMENT", 275, 291], ["The dsRNA fraction", "TEST", 356, 374], ["CVB3", "TEST", 380, 384], ["infected cells", "PROBLEM", 385, 399], ["MEFs", "TEST", 433, 437], ["IFN", "TEST", 442, 445], ["mRNA levels", "TEST", 448, 459], ["newly produced viral RNA species", "PROBLEM", 608, 640], ["viral ssRNA", "OBSERVATION", 9, 20], ["dsRNA bands", "OBSERVATION", 25, 36], ["HeLa cells", "OBSERVATION_MODIFIER", 52, 62], ["viral origin", "OBSERVATION", 262, 274], ["infected cells", "OBSERVATION", 385, 399], ["viral RNA species", "OBSERVATION", 623, 640]]], ["The dsRNA fraction triggered a MDA5- and MAVS-dependent IFN-\u03b2 response (Figure 3A).", [["MDA5", "GENE_OR_GENE_PRODUCT", 31, 35], ["MAVS", "GENE_OR_GENE_PRODUCT", 41, 45], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 56, 61], ["MDA5", "PROTEIN", 31, 35], ["MAVS", "PROTEIN", 41, 45], ["IFN", "PROTEIN", 56, 59], ["\u03b2", "PROTEIN", 60, 61], ["The dsRNA fraction", "TEST", 0, 18], ["a MDA5", "TEST", 29, 35], ["MAVS", "TEST", 41, 45], ["dsRNA fraction", "OBSERVATION", 4, 18]]], ["We next set out to identify the IFN-stimulatory RNA species in this fraction.", [["IFN", "GENE_OR_GENE_PRODUCT", 32, 35], ["IFN-stimulatory RNA species", "RNA", 32, 59]]], ["In the dsRNA fractions, we observed two bands on gel; an infection-specific, 7.5 kbp species, and a larger fragment that was present in both mock- and CVB3-infected samples.", [["samples", "ANATOMY", 165, 172], ["infection", "DISEASE", 57, 66], ["CVB3", "ORGANISM", 151, 155], ["samples", "CANCER", 165, 172], ["CVB3", "SPECIES", 151, 155], ["two bands on gel", "PROBLEM", 36, 52], ["an infection", "PROBLEM", 54, 66], ["7.5 kbp species", "PROBLEM", 77, 92], ["a larger fragment", "PROBLEM", 98, 115], ["CVB3", "PROBLEM", 151, 155], ["infected samples", "PROBLEM", 156, 172], ["dsRNA fractions", "OBSERVATION", 7, 22], ["bands", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 57, 66], ["larger", "OBSERVATION_MODIFIER", 100, 106], ["fragment", "OBSERVATION", 107, 115], ["infected", "OBSERVATION", 156, 164]]], ["To determine the nature of the higher band, we treated the dsRNA fractions with nucleases specific for ssRNA (RNase A), dsRNA (RNase III), and DNA.", [["RNase A", "GENE_OR_GENE_PRODUCT", 110, 117], ["RNase III", "GENE_OR_GENE_PRODUCT", 127, 136], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["nucleases", "PROTEIN", 80, 89], ["ssRNA", "PROTEIN", 103, 108], ["RNase A", "PROTEIN", 110, 117], ["dsRNA", "PROTEIN", 120, 125], ["RNase III", "PROTEIN", 127, 136], ["the higher band", "PROBLEM", 27, 42], ["the dsRNA fractions", "TREATMENT", 55, 74], ["nucleases", "TREATMENT", 80, 89], ["ssRNA", "PROBLEM", 103, 108], ["dsRNA", "PROBLEM", 120, 125], ["DNA", "PROBLEM", 143, 146]]], ["The nonspecific larger band was completely digested upon DNase treatment, indicating that it was DNA (Figure 3B).", [["DNase", "CHEMICAL", 57, 62], ["DNase", "GENE_OR_GENE_PRODUCT", 57, 62], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNase", "PROTEIN", 57, 62], ["The nonspecific larger band", "PROBLEM", 0, 27], ["DNase treatment", "TREATMENT", 57, 72], ["DNA", "PROBLEM", 97, 100], ["nonspecific", "OBSERVATION_MODIFIER", 4, 15], ["larger", "OBSERVATION_MODIFIER", 16, 22], ["band", "OBSERVATION_MODIFIER", 23, 27], ["DNase treatment", "OBSERVATION_MODIFIER", 57, 72]]], ["The 7.5 kbp CVB3 RF was specifically digested by RNase III, confirming that this is a dsRNA molecule (Figure 3B).The Picornavirus 7.5 kbp RF Is a Potent MDA5 Ligand upon Transfection ::: ResultsNext, we examined the ability of purified CVB3 RF to activate MDA5.", [["CVB3", "ORGANISM", 12, 16], ["RNase III", "GENE_OR_GENE_PRODUCT", 49, 58], ["MDA5", "GENE_OR_GENE_PRODUCT", 153, 157], ["CVB3", "ORGANISM", 236, 240], ["MDA5", "GENE_OR_GENE_PRODUCT", 256, 260], ["7.5 kbp CVB3 RF", "DNA", 4, 19], ["RNase III", "PROTEIN", 49, 58], ["dsRNA molecule", "PROTEIN", 86, 100], ["Picornavirus 7.5 kbp RF", "DNA", 117, 140], ["Potent MDA5 Ligand", "PROTEIN", 146, 164], ["CVB3 RF", "PROTEIN", 236, 243], ["MDA5", "PROTEIN", 256, 260], ["CVB3", "SPECIES", 12, 16], ["CVB3", "SPECIES", 236, 240], ["The 7.5 kbp CVB3 RF", "TREATMENT", 0, 19], ["a dsRNA molecule", "PROBLEM", 84, 100], ["The Picornavirus", "TREATMENT", 113, 129]]], ["When gel-extracted and transfected into MEFs, the RF, but not the DNA molecule, induced high levels of IFN-\u03b2 transcription in an MDA5- and MAVS-specific manner (Figure 3C).", [["MEFs", "ANATOMY", 40, 44], ["MEFs", "CELL", 40, 44], ["RF", "GENE_OR_GENE_PRODUCT", 50, 52], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 103, 108], ["MDA5", "GENE_OR_GENE_PRODUCT", 129, 133], ["MAVS", "GENE_OR_GENE_PRODUCT", 139, 143], ["MEFs", "CELL_TYPE", 40, 44], ["RF", "PROTEIN", 50, 52], ["IFN", "PROTEIN", 103, 106], ["\u03b2", "PROTEIN", 107, 108], ["MDA5", "PROTEIN", 129, 133], ["MAVS", "PROTEIN", 139, 143], ["the DNA molecule", "PROBLEM", 62, 78], ["IFN", "TREATMENT", 103, 106], ["an MDA5", "TEST", 126, 133]]], ["Similar experiments were performed with nucleic acids extracted from cells infected with mengovirus.", [["cells", "ANATOMY", 69, 74], ["nucleic acids", "CHEMICAL", 40, 53], ["nucleic acids", "SIMPLE_CHEMICAL", 40, 53], ["cells", "CELL", 69, 74], ["nucleic acids", "TEST", 40, 53], ["mengovirus", "TREATMENT", 89, 99]]], ["The dsRNA fraction from mengovirus-infected cells appeared indistinguishable on gel from that from CVB3-infected cells (Figure 3D), and the gel-purified mengovirus RF also proved to be a potent MDA5 agonist (Figure 3E).", [["cells", "ANATOMY", 44, 49], ["cells", "ANATOMY", 113, 118], ["mengovirus", "GENE_OR_GENE_PRODUCT", 24, 34], ["cells", "CELL", 44, 49], ["CVB3", "ORGANISM", 99, 103], ["cells", "CELL", 113, 118], ["MDA5", "GENE_OR_GENE_PRODUCT", 194, 198], ["mengovirus-infected cells", "CELL_LINE", 24, 49], ["CVB3-infected cells", "CELL_LINE", 99, 118], ["mengovirus RF", "PROTEIN", 153, 166], ["MDA5", "PROTEIN", 194, 198], ["CVB3", "SPECIES", 99, 103], ["The dsRNA fraction", "TEST", 0, 18], ["mengovirus", "TEST", 24, 34], ["infected cells", "PROBLEM", 35, 49], ["CVB3", "PROBLEM", 99, 103], ["infected cells", "PROBLEM", 104, 118], ["the gel", "TREATMENT", 136, 143], ["purified mengovirus RF", "PROBLEM", 144, 166], ["a potent MDA5 agonist", "TREATMENT", 185, 206], ["dsRNA fraction", "OBSERVATION", 4, 18], ["infected cells", "OBSERVATION", 35, 49], ["infected cells", "OBSERVATION", 104, 118]]], ["These data show that the RF of prototype members of at least two genera of picornaviruses can specifically and potently induce an MDA5-dependent IFN-\u03b1/\u03b2 response.The Picornavirus 7.5 kbp RF Is a Potent MDA5 Ligand upon Transfection ::: ResultsTo investigate whether the RF can directly activate MDA5, we performed in vitro ATPase assays where recombinant MDA5 was incubated with gel-purified RF or the nonspecific DNA band in the presence of ATP.", [["ATP", "CHEMICAL", 442, 445], ["ATP", "CHEMICAL", 442, 445], ["picornaviruses", "ORGANISM", 75, 89], ["MDA5", "GENE_OR_GENE_PRODUCT", 130, 134], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 145, 150], ["\u03b2", "GENE_OR_GENE_PRODUCT", 151, 152], ["MDA5", "GENE_OR_GENE_PRODUCT", 202, 206], ["MDA5", "GENE_OR_GENE_PRODUCT", 295, 299], ["ATPase", "GENE_OR_GENE_PRODUCT", 323, 329], ["MDA5", "GENE_OR_GENE_PRODUCT", 355, 359], ["DNA", "CELLULAR_COMPONENT", 414, 417], ["ATP", "SIMPLE_CHEMICAL", 442, 445], ["RF", "PROTEIN", 25, 27], ["MDA5", "PROTEIN", 130, 134], ["IFN", "PROTEIN", 145, 148], ["\u03b1", "PROTEIN", 149, 150], ["\u03b2", "PROTEIN", 151, 152], ["Picornavirus 7.5 kbp RF", "DNA", 166, 189], ["Potent MDA5 Ligand", "PROTEIN", 195, 213], ["RF", "PROTEIN", 270, 272], ["MDA5", "PROTEIN", 295, 299], ["ATPase", "PROTEIN", 323, 329], ["MDA5", "PROTEIN", 355, 359], ["RF", "PROTEIN", 392, 394], ["These data", "TEST", 0, 10], ["picornaviruses", "PROBLEM", 75, 89], ["an MDA5", "TEST", 127, 134], ["The Picornavirus", "TREATMENT", 162, 178], ["vitro ATPase assays", "TEST", 317, 336], ["the nonspecific DNA band", "PROBLEM", 398, 422], ["ATP", "PROBLEM", 442, 445], ["picornaviruses", "OBSERVATION", 75, 89]]], ["ATP hydrolysis was followed at different time points by measuring free phosphate.", [["ATP", "CHEMICAL", 0, 3], ["phosphate", "CHEMICAL", 71, 80], ["ATP", "CHEMICAL", 0, 3], ["phosphate", "CHEMICAL", 71, 80], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["phosphate", "SIMPLE_CHEMICAL", 71, 80], ["ATP hydrolysis", "PROBLEM", 0, 14]]], ["CVB3 RF induced high levels of MDA5 ATPase activity\u2014hydrolyzing nearly 150 \u03bcM ATP in 60 min\u2014while the DNA band did not induce any ATP hydrolysis during this time period (Figure 3F).", [["ATP", "CHEMICAL", 78, 81], ["ATP", "CHEMICAL", 130, 133], ["ATP", "CHEMICAL", 78, 81], ["ATP", "CHEMICAL", 130, 133], ["CVB3", "ORGANISM", 0, 4], ["MDA5", "GENE_OR_GENE_PRODUCT", 31, 35], ["ATP", "SIMPLE_CHEMICAL", 78, 81], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["ATP", "SIMPLE_CHEMICAL", 130, 133], ["CVB3 RF", "PROTEIN", 0, 7], ["MDA5", "PROTEIN", 31, 35], ["ATPase", "PROTEIN", 36, 42], ["CVB3", "SPECIES", 0, 4], ["the DNA band", "PROBLEM", 98, 110], ["any ATP hydrolysis", "PROBLEM", 126, 144], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["These results are in line with our transfection data (Figures 3C and 3E) and confirm that RF can be directly recognized by MDA5 and potently induce its activation.Picornavirus ssRNAs Do Not Activate MDA5 ::: ResultsWe also tested the ssRNA fraction from infected cells (Figure 2B) for its IFN-\u03b2-stimulatory activity.", [["cells", "ANATOMY", 263, 268], ["RF", "GENE_OR_GENE_PRODUCT", 90, 92], ["MDA5", "GENE_OR_GENE_PRODUCT", 123, 127], ["MDA5", "GENE_OR_GENE_PRODUCT", 199, 203], ["cells", "CELL", 263, 268], ["Figure 2B", "CELL", 270, 279], ["IFN-\u03b2-", "GENE_OR_GENE_PRODUCT", 289, 295], ["RF", "PROTEIN", 90, 92], ["MDA5", "PROTEIN", 123, 127], ["MDA5", "PROTEIN", 199, 203], ["infected cells", "CELL_TYPE", 254, 268], ["IFN", "PROTEIN", 289, 292], ["our transfection data", "TEST", 31, 52], ["Picornavirus ssRNAs", "TREATMENT", 163, 182], ["infected cells", "PROBLEM", 254, 268], ["infected cells", "OBSERVATION", 254, 268]]], ["To our surprise, transfection of this fraction also led to an MDA5- and MAVS-dependent IFN-\u03b2 response (Figure 4A).", [["MDA5", "GENE_OR_GENE_PRODUCT", 62, 66], ["MAVS", "GENE_OR_GENE_PRODUCT", 72, 76], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["MDA5", "PROTEIN", 62, 66], ["MAVS", "PROTEIN", 72, 76], ["IFN", "PROTEIN", 87, 90], ["\u03b2", "PROTEIN", 91, 92], ["this fraction", "TEST", 33, 46], ["an MDA5", "TEST", 59, 66], ["MAVS", "TEST", 72, 76]]], ["However, subsequent nuclease digestion experiment revealed that the IFN-\u03b2-stimulatory activity is sensitive to RNase III (dsRNA-specific) treatment, but not RNase A (ssRNA-specific) (Figures 4B and 4C).", [["IFN-\u03b2-", "GENE_OR_GENE_PRODUCT", 68, 74], ["RNase III", "GENE_OR_GENE_PRODUCT", 111, 120], ["RNase A", "GENE_OR_GENE_PRODUCT", 157, 164], ["IFN", "PROTEIN", 68, 71], ["RNase III", "PROTEIN", 111, 120], ["RNase A", "PROTEIN", 157, 164], ["ssRNA", "PROTEIN", 166, 171], ["subsequent nuclease digestion experiment", "PROBLEM", 9, 49], ["the IFN", "TEST", 64, 71], ["RNase III (dsRNA", "TREATMENT", 111, 127], ["treatment", "TREATMENT", 138, 147], ["ssRNA", "TEST", 166, 171]]], ["Indeed, after removal of rRNAs\u2014the most abundant RNA species present in the ssRNA fractions\u2014we observed a RNA species on gel that is specifically present in infected cells and has the same electrophoretic mobility as the RF band found in the dsRNA fraction from infected cells (Figure S3A).", [["cells", "ANATOMY", 166, 171], ["cells", "ANATOMY", 271, 276], ["rRNAs", "CELLULAR_COMPONENT", 25, 30], ["cells", "CELL", 166, 171], ["cells", "CELL", 271, 276], ["rRNAs", "RNA", 25, 30], ["RNA species", "RNA", 49, 60], ["ssRNA fractions\u2014we", "RNA", 76, 94], ["RNA species", "RNA", 106, 117], ["infected cells", "CELL_TYPE", 157, 171], ["infected cells", "CELL_TYPE", 262, 276], ["removal", "TREATMENT", 14, 21], ["rRNAs", "TREATMENT", 25, 30], ["the most abundant RNA species", "PROBLEM", 31, 60], ["the ssRNA fractions\u2014we", "PROBLEM", 72, 94], ["a RNA species on gel", "PROBLEM", 104, 124], ["infected cells", "PROBLEM", 157, 171], ["the same electrophoretic mobility", "PROBLEM", 180, 213], ["the RF band", "PROBLEM", 217, 228], ["the dsRNA fraction", "PROBLEM", 238, 256], ["infected cells", "PROBLEM", 262, 276], ["most abundant", "OBSERVATION_MODIFIER", 35, 48], ["RNA species", "OBSERVATION", 49, 60], ["ssRNA fractions\u2014we", "OBSERVATION", 76, 94], ["RNA species", "OBSERVATION", 106, 117], ["infected cells", "OBSERVATION", 157, 171], ["dsRNA", "ANATOMY", 242, 247], ["infected cells", "OBSERVATION", 262, 276]]], ["These results suggest that residue amounts of RF are still present in our ssRNA fraction preparations, and the RF, but not viral ssRNAs, is responsible for the observed IFN-\u03b2 induction upon transfection of this fraction.", [["RF", "GENE_OR_GENE_PRODUCT", 46, 48], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 129, 135], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 169, 174], ["RF", "PROTEIN", 46, 48], ["RF", "PROTEIN", 111, 113], ["viral ssRNAs", "PROTEIN", 123, 135], ["IFN", "PROTEIN", 169, 172], ["\u03b2", "PROTEIN", 173, 174], ["residue amounts of RF", "PROBLEM", 27, 48], ["our ssRNA fraction preparations", "TREATMENT", 70, 101], ["the RF", "PROBLEM", 107, 113], ["viral ssRNAs", "PROBLEM", 123, 135], ["amounts", "OBSERVATION_MODIFIER", 35, 42], ["ssRNA fraction", "OBSERVATION", 74, 88], ["not", "UNCERTAINTY", 119, 122], ["viral ssRNAs", "OBSERVATION", 123, 135]]], ["In line with this conclusion, we found that VPg-containing vRNA (Figures 4D and 4E), VPg-unlinked viral mRNAs (Figure 4E), and in vitro transcribed ssRNAs of viral sequence (Figures S3B and S3C) all failed to induce any IFN-\u03b2 response when purified and transfected into cells.Picornavirus ssRNAs Do Not Activate MDA5 ::: ResultsThe viral RI was also reported to segregate in the ssRNA fraction according to the LiCl precipitation method (Richards et al., 1984).", [["cells", "ANATOMY", 270, 275], ["LiCl", "CHEMICAL", 411, 415], ["LiCl", "CHEMICAL", 411, 415], ["VPg", "GENE_OR_GENE_PRODUCT", 44, 47], ["4E", "GENE_OR_GENE_PRODUCT", 80, 82], ["Figure 4E", "GENE_OR_GENE_PRODUCT", 111, 120], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 148, 154], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 220, 225], ["cells", "CELL", 270, 275], ["MDA5", "GENE_OR_GENE_PRODUCT", 312, 316], ["LiCl", "SIMPLE_CHEMICAL", 411, 415], ["VPg", "PROTEIN", 44, 47], ["vRNA (Figures 4D and 4E), VPg-unlinked viral mRNAs", "RNA", 59, 109], ["viral sequence", "DNA", 158, 172], ["IFN", "PROTEIN", 220, 223], ["\u03b2", "PROTEIN", 224, 225], ["MDA5", "PROTEIN", 312, 316], ["viral RI", "PROTEIN", 332, 340], ["VPg", "TEST", 44, 47], ["vRNA", "PROBLEM", 59, 63], ["VPg", "TEST", 85, 88], ["viral sequence", "TEST", 158, 172], ["Figures S3B", "TEST", 174, 185], ["The viral RI", "PROBLEM", 328, 340], ["viral mRNAs", "OBSERVATION", 98, 109], ["viral RI", "OBSERVATION", 332, 340], ["ssRNA fraction", "OBSERVATION", 379, 393]]], ["To study the effect of RI on IFN-\u03b1/\u03b2 induction without complications from RF, we attempted to remove the remaining RF from CVB3 ssRNA fraction by repeating the 2M LiCl precipitation procedure.", [["LiCl", "CHEMICAL", 163, 167], ["LiCl", "CHEMICAL", 163, 167], ["RI", "SIMPLE_CHEMICAL", 23, 25], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 29, 34], ["\u03b2", "GENE_OR_GENE_PRODUCT", 35, 36], ["CVB3", "ORGANISM", 123, 127], ["LiCl", "SIMPLE_CHEMICAL", 163, 167], ["IFN", "PROTEIN", 29, 32], ["\u03b1", "PROTEIN", 33, 34], ["\u03b2", "PROTEIN", 35, 36], ["RF", "PROTEIN", 115, 117], ["CVB3", "SPECIES", 123, 127], ["IFN", "TREATMENT", 29, 32], ["complications", "PROBLEM", 55, 68], ["CVB3 ssRNA fraction", "TREATMENT", 123, 142], ["the 2M LiCl precipitation procedure", "TREATMENT", 156, 191]]], ["However, even after two additional rounds of precipitation, we did not observe significant loss of RF from the CVB3 ssRNA fraction, nor did we observe a reduced IFN-\u03b2 response upon transfection (data not shown).", [["CVB3", "ORGANISM", 111, 115], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 161, 166], ["RF", "PROTEIN", 99, 101], ["IFN", "PROTEIN", 161, 164], ["\u03b2", "PROTEIN", 165, 166], ["CVB3", "SPECIES", 111, 115], ["precipitation", "TREATMENT", 45, 58], ["significant loss of RF", "PROBLEM", 79, 101], ["a reduced IFN", "PROBLEM", 151, 164]]], ["Hence, we were unable to determine whether RI also exerts IFN-inducing activity.Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsOur results indicated that the picornavirus RF, and possibly also the RI, is a potent MDA5 activator when delivered into the cytoplasm by lipid-based transfection.", [["Cells", "ANATOMY", 159, 164], ["cytoplasm", "ANATOMY", 301, 310], ["RI", "GENE_OR_GENE_PRODUCT", 43, 45], ["IFN", "GENE_OR_GENE_PRODUCT", 58, 61], ["Viral", "ORGANISM", 93, 98], ["Not RI", "GENE_OR_GENE_PRODUCT", 107, 113], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 131, 136], ["Cells", "CELL", 159, 164], ["picornavirus", "ORGANISM", 207, 219], ["RI", "GENE_OR_GENE_PRODUCT", 246, 248], ["MDA5", "GENE_OR_GENE_PRODUCT", 262, 266], ["cytoplasm", "ORGANISM_SUBSTANCE", 301, 310], ["lipid", "SIMPLE_CHEMICAL", 314, 319], ["RI", "PROTEIN", 43, 45], ["IFN", "PROTEIN", 58, 61], ["Viral RF", "PROTEIN", 93, 101], ["IFN", "PROTEIN", 131, 134], ["-\u03b2", "PROTEIN", 134, 136], ["Infected Cells", "CELL_LINE", 150, 164], ["picornavirus RF", "PROTEIN", 207, 222], ["RI", "PROTEIN", 246, 248], ["MDA5", "PROTEIN", 262, 266], ["Viral RF", "PROBLEM", 93, 101], ["IFN-\u03b2 Induction", "TREATMENT", 131, 146], ["the picornavirus RF", "PROBLEM", 203, 222], ["a potent MDA5 activator", "TREATMENT", 253, 276], ["lipid-based transfection", "TREATMENT", 314, 338], ["Viral RF", "OBSERVATION", 93, 101], ["picornavirus RF", "OBSERVATION", 207, 222], ["transfection", "OBSERVATION", 326, 338]]], ["However, the amount of RF/RI and their accessibility to MDA5 may differ greatly from the situation in infected cells, where viral RNA is covered with replication enzymes and localized in virus-induced, membrane-associated replication organelles (reviewed in Belov and van Kuppeveld, 2012).", [["cells", "ANATOMY", 111, 116], ["membrane", "ANATOMY", 202, 210], ["organelles", "ANATOMY", 234, 244], ["MDA5", "GENE_OR_GENE_PRODUCT", 56, 60], ["cells", "CELL", 111, 116], ["membrane", "CELLULAR_COMPONENT", 202, 210], ["organelles", "CELLULAR_COMPONENT", 234, 244], ["RF", "PROTEIN", 23, 25], ["RI", "PROTEIN", 26, 28], ["MDA5", "PROTEIN", 56, 60], ["infected cells", "CELL_TYPE", 102, 116], ["viral RNA", "RNA", 124, 133], ["replication enzymes", "PROTEIN", 150, 169], ["RF/RI", "PROBLEM", 23, 28], ["infected cells", "PROBLEM", 102, 116], ["viral RNA", "PROBLEM", 124, 133], ["replication enzymes", "TEST", 150, 169], ["virus", "PROBLEM", 187, 192], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["infected cells", "OBSERVATION", 102, 116], ["viral RNA", "OBSERVATION", 124, 133]]], ["Therefore, we set out to dissect the IFN-stimulatory abilities of different viral RNAs produced in cells infected with mengo-Zn, which induces strong IFN-\u03b2 responses.Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsWe first generated a comprehensive profile of the kinetics of viral RNA replication as well as host IFN-\u03b2 response to mengo-Zn in HeLa cells by measuring viral RNA and IFN-\u03b2 mRNA levels by real-time quantitative PCR (qPCR) every hour up until 10 hr postinfection (hr.p.i.)", [["cells", "ANATOMY", 99, 104], ["Cells", "ANATOMY", 245, 250], ["HeLa cells", "ANATOMY", 392, 402], ["mengo-Zn", "CHEMICAL", 119, 127], ["mengo-Zn", "CHEMICAL", 380, 388], ["Zn", "CHEMICAL", 125, 127], ["mengo", "CHEMICAL", 380, 385], ["Zn", "CHEMICAL", 386, 388], ["IFN", "GENE_OR_GENE_PRODUCT", 37, 40], ["cells", "CELL", 99, 104], ["mengo-Zn", "SIMPLE_CHEMICAL", 119, 127], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["Viral", "ORGANISM", 179, 184], ["Not RI", "GENE_OR_GENE_PRODUCT", 193, 199], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 217, 222], ["Cells", "CELL", 245, 250], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 362, 367], ["mengo-Zn", "SIMPLE_CHEMICAL", 380, 388], ["HeLa cells", "CELL", 392, 402], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 430, 435], ["IFN", "PROTEIN", 37, 40], ["viral RNAs", "RNA", 76, 86], ["IFN", "PROTEIN", 150, 153], ["\u03b2", "PROTEIN", 154, 155], ["Viral RF", "PROTEIN", 179, 187], ["IFN", "PROTEIN", 217, 220], ["-\u03b2", "PROTEIN", 220, 222], ["Infected Cells", "CELL_LINE", 236, 250], ["IFN", "PROTEIN", 362, 365], ["\u03b2", "PROTEIN", 366, 367], ["HeLa cells", "CELL_LINE", 392, 402], ["viral RNA", "RNA", 416, 425], ["IFN-\u03b2 mRNA", "RNA", 430, 440], ["different viral RNAs", "PROBLEM", 66, 86], ["Viral RF", "PROBLEM", 179, 187], ["IFN-\u03b2 Induction", "TREATMENT", 217, 232], ["viral RNA replication", "TREATMENT", 324, 345], ["host IFN", "TEST", 357, 365], ["mengo", "TEST", 380, 385], ["Zn in HeLa cells", "TREATMENT", 386, 402], ["viral RNA", "TEST", 416, 425], ["IFN", "TEST", 430, 433], ["mRNA levels", "TEST", 436, 447], ["quantitative PCR", "TEST", 461, 477], ["viral RNAs", "OBSERVATION", 76, 86], ["Viral RF", "OBSERVATION", 179, 187]]], ["Viral RNA level remained at input levels in the first 3 hr of infection, then rapidly increased (i.e., active viral RNA replication) to reach a maximum at 6 hr.p.i., and stabilized at this level through 10 hr p.i.", [["infection", "DISEASE", 62, 71], ["Viral RNA", "RNA", 0, 9], ["Viral RNA level", "TEST", 0, 15], ["input levels", "TEST", 28, 40], ["infection", "PROBLEM", 62, 71], ["active viral RNA replication", "TREATMENT", 103, 131], ["RNA", "OBSERVATION", 6, 9], ["infection", "OBSERVATION", 62, 71]]], ["The host IFN-\u03b2 response showed a slight delay as IFN-\u03b2 mRNA levels in infected cells remained at background levels through the first 6 hr, then started to increase from 7 hr.p.i., and reached their maximum at 8\u20139 hr p.i.Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsTo study the separate contribution of viral ssRNA and dsRNA in inducing IFN-\u03b1/\u03b2 response during infection, we employed inhibitors of mengovirus replication, cycloheximide (CHX) and dipyridamole (DIP) (Figure 5B), which affect viral replication at different stages.", [["cells", "ANATOMY", 79, 84], ["Cells", "ANATOMY", 299, 304], ["infection", "DISEASE", 412, 421], ["cycloheximide", "CHEMICAL", 473, 486], ["CHX", "CHEMICAL", 488, 491], ["dipyridamole", "CHEMICAL", 497, 509], ["DIP", "CHEMICAL", 511, 514], ["cycloheximide", "CHEMICAL", 473, 486], ["CHX", "CHEMICAL", 488, 491], ["dipyridamole", "CHEMICAL", 497, 509], ["DIP", "CHEMICAL", 511, 514], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 49, 54], ["cells", "CELL", 79, 84], ["Viral", "ORGANISM", 233, 238], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 271, 276], ["Cells", "CELL", 299, 304], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 388, 393], ["\u03b2", "GENE_OR_GENE_PRODUCT", 394, 395], ["mengovirus", "SIMPLE_CHEMICAL", 449, 459], ["cycloheximide", "SIMPLE_CHEMICAL", 473, 486], ["CHX", "SIMPLE_CHEMICAL", 488, 491], ["dipyridamole", "SIMPLE_CHEMICAL", 497, 509], ["DIP", "SIMPLE_CHEMICAL", 511, 514], ["IFN", "PROTEIN", 9, 12], ["\u03b2", "PROTEIN", 13, 14], ["IFN-\u03b2 mRNA", "RNA", 49, 59], ["infected cells", "CELL_TYPE", 70, 84], ["Viral RF", "PROTEIN", 233, 241], ["IFN", "PROTEIN", 271, 274], ["-\u03b2", "PROTEIN", 274, 276], ["Infected Cells", "CELL_LINE", 290, 304], ["IFN", "PROTEIN", 388, 391], ["\u03b1", "PROTEIN", 392, 393], ["\u03b2", "PROTEIN", 394, 395], ["The host IFN", "TEST", 0, 12], ["a slight delay", "PROBLEM", 31, 45], ["IFN", "TEST", 49, 52], ["mRNA levels", "TEST", 55, 66], ["infected cells", "PROBLEM", 70, 84], ["Viral RF", "PROBLEM", 233, 241], ["IFN-\u03b2 Induction", "TREATMENT", 271, 286], ["viral ssRNA", "PROBLEM", 354, 365], ["dsRNA", "PROBLEM", 370, 375], ["infection", "PROBLEM", 412, 421], ["mengovirus replication", "TREATMENT", 449, 471], ["cycloheximide (CHX", "TREATMENT", 473, 491], ["dipyridamole (DIP) (Figure 5B", "TREATMENT", 497, 526], ["viral replication", "TREATMENT", 542, 559], ["slight", "OBSERVATION_MODIFIER", 33, 39], ["delay", "OBSERVATION_MODIFIER", 40, 45], ["infected cells", "OBSERVATION", 70, 84], ["Viral RF", "OBSERVATION", 233, 241], ["viral ssRNA", "OBSERVATION", 354, 365], ["viral replication", "OBSERVATION", 542, 559]]], ["CHX prevents protein synthesis and thereby RNA replication.", [["CHX", "CHEMICAL", 0, 3], ["CHX", "CHEMICAL", 0, 3], ["CHX", "SIMPLE_CHEMICAL", 0, 3], ["CHX", "TREATMENT", 0, 3], ["protein synthesis", "TREATMENT", 13, 30], ["RNA replication", "TREATMENT", 43, 58], ["protein synthesis", "OBSERVATION", 13, 30]]], ["DIP has little effect on (\u2212)RNA synthesis but strongly inhibits (+)RNA synthesis in cell-free extract (Fata-Hartley and Palmenberg, 2005).", [["cell", "ANATOMY", 84, 88], ["extract", "ANATOMY", 94, 101], ["DIP", "CHEMICAL", 0, 3], ["DIP", "SIMPLE_CHEMICAL", 0, 3], ["cell", "CELL", 84, 88], ["extract", "ORGANISM_SUBSTANCE", 94, 101], ["RNA synthesis", "PROBLEM", 28, 41], ["RNA synthesis", "TEST", 67, 80], ["little", "OBSERVATION_MODIFIER", 8, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21]]], ["Indeed, (\u2212)RNAs were detected in cells infected in the presence of DIP, but not CHX, using a strand-specific PCR (Figure 5C).", [["cells", "ANATOMY", 33, 38], ["CHX", "CHEMICAL", 80, 83], ["CHX", "CHEMICAL", 80, 83], ["cells", "CELL", 33, 38], ["DIP", "GENE_OR_GENE_PRODUCT", 67, 70], ["CHX", "SIMPLE_CHEMICAL", 80, 83], ["(\u2212)RNAs", "RNA", 8, 15], ["RNAs", "PROBLEM", 11, 15], ["DIP", "PROBLEM", 67, 70], ["CHX", "PROBLEM", 80, 83], ["a strand-specific PCR", "TEST", 91, 112]]], ["The finding that the signal obtained from DIP-treated cells was lower than that from no-drug-treated cells likely reflects a reduced amount of (\u2212)RNA as DIP only allows (\u2212)RNA synthesis from incoming genomic (+)RNA, whereas in the absence of DIP newly synthesized (+)RNAs can enter a new round of RNA replication, and therefore lead to the production of more RF.Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsTo determine the IFN-\u03b2 response to different viral RNA species formed in infected cells, we used DIP and CHX in a time-of-drug-addition experiment.", [["cells", "ANATOMY", 54, 59], ["cells", "ANATOMY", 101, 106], ["Cells", "ANATOMY", 441, 446], ["cells", "ANATOMY", 540, 545], ["DIP", "CHEMICAL", 42, 45], ["no-drug", "CHEMICAL", 85, 92], ["DIP", "CHEMICAL", 555, 558], ["CHX", "CHEMICAL", 563, 566], ["no-drug", "CHEMICAL", 85, 92], ["DIP", "CHEMICAL", 555, 558], ["CHX", "CHEMICAL", 563, 566], ["DIP", "SIMPLE_CHEMICAL", 42, 45], ["cells", "CELL", 54, 59], ["cells", "CELL", 101, 106], ["Viral", "ORGANISM", 375, 380], ["Not RI", "GENE_OR_GENE_PRODUCT", 389, 395], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 413, 418], ["Cells", "CELL", 441, 446], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 475, 480], ["cells", "CELL", 540, 545], ["DIP", "SIMPLE_CHEMICAL", 555, 558], ["CHX", "SIMPLE_CHEMICAL", 563, 566], ["DIP-treated cells", "CELL_LINE", 42, 59], ["no-drug-treated cells", "CELL_LINE", 85, 106], ["(\u2212)RNA", "RNA", 143, 149], ["incoming genomic (+)RNA", "RNA", 191, 214], ["RF", "PROTEIN", 359, 361], ["Viral RF", "PROTEIN", 375, 383], ["IFN", "PROTEIN", 413, 416], ["-\u03b2", "PROTEIN", 416, 418], ["Infected Cells", "CELL_LINE", 432, 446], ["IFN", "PROTEIN", 475, 478], ["\u03b2", "PROTEIN", 479, 480], ["viral RNA species", "RNA", 503, 520], ["infected cells", "CELL_TYPE", 531, 545], ["the signal", "TEST", 17, 27], ["DIP-treated cells", "PROBLEM", 42, 59], ["no-drug-treated cells", "TREATMENT", 85, 106], ["a reduced amount of (\u2212)RNA", "PROBLEM", 123, 149], ["RNA synthesis", "PROBLEM", 172, 185], ["incoming genomic (+)RNA", "PROBLEM", 191, 214], ["DIP newly synthesized (+)RNAs", "PROBLEM", 242, 271], ["RNA replication", "TREATMENT", 297, 312], ["Viral RF", "PROBLEM", 375, 383], ["IFN-\u03b2 Induction", "TREATMENT", 413, 428], ["the IFN", "TEST", 471, 478], ["different viral RNA species", "PROBLEM", 493, 520], ["infected cells", "PROBLEM", 531, 545], ["DIP and CHX", "TREATMENT", 555, 566], ["reduced", "OBSERVATION_MODIFIER", 125, 132], ["amount", "OBSERVATION_MODIFIER", 133, 139], ["RNA replication", "OBSERVATION", 297, 312], ["Viral RF", "OBSERVATION", 375, 383], ["viral RNA species", "OBSERVATION", 503, 520], ["infected cells", "OBSERVATION", 531, 545]]], ["HeLa cells were infected with mengo-Zn, and DIP or CHX was added to cells at the indicated times (Figure 5D).", [["HeLa cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 68, 73], ["mengo-Zn", "CHEMICAL", 30, 38], ["DIP", "CHEMICAL", 44, 47], ["CHX", "CHEMICAL", 51, 54], ["mengo", "CHEMICAL", 30, 35], ["Zn", "CHEMICAL", 36, 38], ["DIP", "CHEMICAL", 44, 47], ["CHX", "CHEMICAL", 51, 54], ["HeLa cells", "CELL", 0, 10], ["mengo-Zn", "SIMPLE_CHEMICAL", 30, 38], ["DIP", "SIMPLE_CHEMICAL", 44, 47], ["CHX", "SIMPLE_CHEMICAL", 51, 54], ["cells", "CELL", 68, 73], ["HeLa cells", "CELL_LINE", 0, 10], ["HeLa cells", "PROBLEM", 0, 10], ["mengo-Zn", "TREATMENT", 30, 38], ["DIP or CHX", "TREATMENT", 44, 54]]], ["Cells were incubated until 12 hr.p.i., harvested, and viral RNA and IFN-\u03b2 mRNA levels were determined by real-time qPCR.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 68, 73], ["viral RNA", "RNA", 54, 63], ["IFN-\u03b2 mRNA", "RNA", 68, 78], ["viral RNA", "TEST", 54, 63], ["IFN", "TEST", 68, 71], ["mRNA levels", "TEST", 74, 85], ["viral RNA", "OBSERVATION", 54, 63]]], ["As shown in Figure 5D, both DIP and CHX were effective in inhibiting viral RNA replication when added at early stages (0\u20132 hr.p.i.) of infection.", [["DIP", "CHEMICAL", 28, 31], ["CHX", "CHEMICAL", 36, 39], ["infection", "DISEASE", 135, 144], ["DIP", "CHEMICAL", 28, 31], ["CHX", "CHEMICAL", 36, 39], ["DIP", "SIMPLE_CHEMICAL", 28, 31], ["CHX", "SIMPLE_CHEMICAL", 36, 39], ["both DIP and CHX", "TREATMENT", 23, 39], ["viral RNA replication", "TREATMENT", 69, 90], ["infection", "PROBLEM", 135, 144], ["infection", "OBSERVATION", 135, 144]]], ["Later addition of the drugs resulted in partial, and eventually loss, of effect on RNA replication.Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsUnder conditions where CHX and DIP completely inhibited viral RNA replication (i.e., added at 0\u20132 hr.p.i., Figure 5D), no IFN-\u03b2 induction was detected in CHX-treated cells, whereas a 100-fold, MDA5-dependent (Figure S4) induction of IFN-\u03b2 mRNA level was observed in DIP-treated cells.", [["Cells", "ANATOMY", 178, 183], ["cells", "ANATOMY", 361, 366], ["cells", "ANATOMY", 473, 478], ["CHX", "CHEMICAL", 218, 221], ["DIP", "CHEMICAL", 226, 229], ["CHX", "CHEMICAL", 349, 352], ["DIP", "CHEMICAL", 461, 464], ["CHX", "CHEMICAL", 218, 221], ["DIP", "CHEMICAL", 226, 229], ["CHX", "CHEMICAL", 349, 352], ["Viral", "ORGANISM", 112, 117], ["Not RI", "GENE_OR_GENE_PRODUCT", 126, 132], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["Cells", "CELL", 178, 183], ["CHX", "SIMPLE_CHEMICAL", 218, 221], ["DIP", "SIMPLE_CHEMICAL", 226, 229], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 317, 322], ["CHX", "SIMPLE_CHEMICAL", 349, 352], ["cells", "CELL", 361, 366], ["MDA5", "GENE_OR_GENE_PRODUCT", 388, 392], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 428, 433], ["DIP", "SIMPLE_CHEMICAL", 461, 464], ["cells", "CELL", 473, 478], ["Viral RF", "PROTEIN", 112, 120], ["IFN", "PROTEIN", 150, 153], ["-\u03b2", "PROTEIN", 153, 155], ["Infected Cells", "CELL_LINE", 169, 183], ["IFN", "PROTEIN", 317, 320], ["CHX-treated cells", "CELL_LINE", 349, 366], ["MDA5", "PROTEIN", 388, 392], ["IFN-\u03b2 mRNA", "RNA", 428, 438], ["DIP-treated cells", "CELL_LINE", 461, 478], ["the drugs", "TREATMENT", 18, 27], ["RNA replication", "TREATMENT", 83, 98], ["Viral RF", "PROBLEM", 112, 120], ["IFN-\u03b2 Induction", "TREATMENT", 150, 165], ["CHX", "TREATMENT", 218, 221], ["DIP", "TREATMENT", 226, 229], ["viral RNA replication", "TREATMENT", 251, 272], ["IFN", "PROBLEM", 317, 320], ["IFN", "TEST", 428, 431], ["mRNA level", "TEST", 434, 444], ["Viral RF", "OBSERVATION", 112, 120]]], ["Additionally, when CHX or DIP was added at 3 hr.p.i., a maximal IFN-\u03b2 response was observed in DIP-treated cells, but virtually no IFN-\u03b2 was induced in the CHX-treated cells (Figure 5D).", [["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 168, 173], ["CHX", "CHEMICAL", 19, 22], ["DIP", "CHEMICAL", 26, 29], ["DIP", "CHEMICAL", 95, 98], ["CHX", "CHEMICAL", 156, 159], ["CHX", "CHEMICAL", 19, 22], ["DIP", "CHEMICAL", 26, 29], ["CHX", "CHEMICAL", 156, 159], ["CHX", "SIMPLE_CHEMICAL", 19, 22], ["DIP", "SIMPLE_CHEMICAL", 26, 29], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["DIP", "SIMPLE_CHEMICAL", 95, 98], ["cells", "CELL", 107, 112], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 131, 136], ["CHX", "SIMPLE_CHEMICAL", 156, 159], ["cells", "CELL", 168, 173], ["IFN", "PROTEIN", 64, 67], ["DIP-treated cells", "CELL_LINE", 95, 112], ["IFN-\u03b2", "PROTEIN", 131, 136], ["CHX-treated cells", "CELL_LINE", 156, 173], ["CHX", "TREATMENT", 19, 22], ["DIP", "TREATMENT", 26, 29], ["a maximal IFN", "TEST", 54, 67], ["DIP-treated cells", "PROBLEM", 95, 112], ["IFN", "PROBLEM", 131, 134]]], ["Analysis of viral RNA levels indicate that only a few new (+)RNAs had been made because addition of either CHX or DIP at this time point led to only a slight increase in viral RNA copy number at 12 hr.p.i.", [["CHX", "CHEMICAL", 107, 110], ["DIP", "CHEMICAL", 114, 117], ["CHX", "CHEMICAL", 107, 110], ["CHX", "SIMPLE_CHEMICAL", 107, 110], ["DIP", "SIMPLE_CHEMICAL", 114, 117], ["viral RNA", "RNA", 170, 179], ["Analysis of viral RNA levels", "TEST", 0, 28], ["a few new (+)RNAs", "PROBLEM", 48, 65], ["CHX", "TREATMENT", 107, 110], ["DIP", "TREATMENT", 114, 117], ["a slight increase", "PROBLEM", 149, 166], ["viral RNA", "OBSERVATION", 12, 21], ["few", "OBSERVATION_MODIFIER", 50, 53], ["new", "OBSERVATION_MODIFIER", 54, 57], ["slight", "OBSERVATION_MODIFIER", 151, 157], ["increase", "OBSERVATION_MODIFIER", 158, 166], ["viral RNA", "OBSERVATION", 170, 179]]], ["These newly synthesized (+)RNAs could serve as template to make additional RFs in the DIP-treated cells, but not in the CHX-treated cells, and result in the increase of IFN-\u03b2 induction observed at 3 hr p.i.", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 132, 137], ["CHX", "CHEMICAL", 120, 123], ["CHX", "CHEMICAL", 120, 123], ["DIP", "SIMPLE_CHEMICAL", 86, 89], ["cells", "CELL", 98, 103], ["CHX", "SIMPLE_CHEMICAL", 120, 123], ["cells", "CELL", 132, 137], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 169, 174], ["DIP-treated cells", "CELL_LINE", 86, 103], ["CHX-treated cells", "CELL_LINE", 120, 137], ["IFN", "PROTEIN", 169, 172], ["\u03b2", "PROTEIN", 173, 174], ["These newly synthesized (+)RNAs", "PROBLEM", 0, 31], ["additional RFs", "PROBLEM", 64, 78], ["the DIP-treated cells", "PROBLEM", 82, 103], ["IFN", "TREATMENT", 169, 172]]], ["It is theoretically possible that the observed differences in IFN-\u03b2 levels in CHX- and DIP-treated cells were due to nonspecific blockade or stimulation of the RLR signaling pathway by CHX or DIP, respectively.", [["cells", "ANATOMY", 99, 104], ["CHX", "CHEMICAL", 78, 81], ["DIP", "CHEMICAL", 87, 90], ["CHX", "CHEMICAL", 185, 188], ["CHX", "CHEMICAL", 78, 81], ["DIP", "CHEMICAL", 87, 90], ["CHX", "CHEMICAL", 185, 188], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 62, 67], ["CHX", "SIMPLE_CHEMICAL", 78, 81], ["DIP", "SIMPLE_CHEMICAL", 87, 90], ["cells", "CELL", 99, 104], ["RLR", "GENE_OR_GENE_PRODUCT", 160, 163], ["CHX", "SIMPLE_CHEMICAL", 185, 188], ["DIP", "SIMPLE_CHEMICAL", 192, 195], ["IFN", "PROTEIN", 62, 65], ["DIP-treated cells", "CELL_LINE", 87, 104], ["RLR", "PROTEIN", 160, 163], ["IFN", "TEST", 62, 65], ["CHX", "TEST", 78, 81], ["DIP-treated cells", "TREATMENT", 87, 104], ["nonspecific blockade", "TREATMENT", 117, 137], ["theoretically possible", "UNCERTAINTY", 6, 28]]], ["However, this is unlikely because these drugs had no such effects on poly(I:C)-induced IFN-\u03b2 responses (Figure S5).Formation of Viral RF, but Not RI, Is Required for IFN-\u03b2 Induction in Infected Cells ::: ResultsIn the experiment described above, the incoming vRNA alone (i.e., in the presence of CHX) induced no IFN-\u03b2 response.", [["Cells", "ANATOMY", 194, 199], ["poly(I:C", "CHEMICAL", 69, 77], ["CHX", "CHEMICAL", 296, 299], ["poly(I:C", "CHEMICAL", 69, 77], ["CHX", "CHEMICAL", 296, 299], ["poly(I:C", "SIMPLE_CHEMICAL", 69, 77], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["Viral", "ORGANISM", 128, 133], ["Not RI", "GENE_OR_GENE_PRODUCT", 142, 148], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 166, 171], ["Cells", "CELL", 194, 199], ["CHX", "SIMPLE_CHEMICAL", 296, 299], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 312, 317], ["IFN", "PROTEIN", 87, 90], ["\u03b2", "PROTEIN", 91, 92], ["Viral RF", "PROTEIN", 128, 136], ["IFN", "PROTEIN", 166, 169], ["-\u03b2", "PROTEIN", 169, 171], ["Infected Cells", "CELL_LINE", 185, 199], ["IFN", "PROTEIN", 312, 315], ["\u03b2", "PROTEIN", 316, 317], ["Viral RF", "PROBLEM", 128, 136], ["IFN-\u03b2 Induction", "TREATMENT", 166, 181], ["IFN", "PROBLEM", 312, 315], ["Viral RF", "OBSERVATION", 128, 136]]], ["To exclude that the amount of incoming vRNA at the used MOI was too low to induce a detectable IFN-\u03b2 mRNA upregulation, we increased the infection dose from MOI 10 to 1,000.", [["infection", "DISEASE", 137, 146], ["vRNA", "CELLULAR_COMPONENT", 39, 43], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 95, 100], ["IFN-\u03b2 mRNA", "RNA", 95, 105], ["incoming vRNA", "PROBLEM", 30, 43], ["the infection dose", "TREATMENT", 133, 151], ["amount", "OBSERVATION_MODIFIER", 20, 26], ["infection", "OBSERVATION", 137, 146]]], ["This resulted in increased levels of IFN-\u03b2 in no-drug- and DIP-treated samples, but in CHX-treated cells the IFN-\u03b2 level remained undetectable (Figure 5E).", [["samples", "ANATOMY", 71, 78], ["cells", "ANATOMY", 99, 104], ["DIP", "CHEMICAL", 59, 62], ["CHX", "CHEMICAL", 87, 90], ["DIP", "CHEMICAL", 59, 62], ["CHX", "CHEMICAL", 87, 90], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 37, 42], ["-drug", "SIMPLE_CHEMICAL", 48, 53], ["DIP", "SIMPLE_CHEMICAL", 59, 62], ["CHX", "SIMPLE_CHEMICAL", 87, 90], ["cells", "CELL", 99, 104], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["IFN-\u03b2", "PROTEIN", 37, 42], ["CHX-treated cells", "CELL_LINE", 87, 104], ["IFN", "PROTEIN", 109, 112], ["\u03b2", "PROTEIN", 113, 114], ["increased levels of IFN", "PROBLEM", 17, 40], ["-drug", "PROBLEM", 48, 53], ["DIP-treated samples", "PROBLEM", 59, 78], ["CHX", "TEST", 87, 90], ["the IFN", "TEST", 105, 112], ["\u03b2 level", "TEST", 113, 120], ["increased", "OBSERVATION_MODIFIER", 17, 26]]], ["This result clearly shows that the incoming vRNA, even when present at very high quantities, does not activate MDA5.", [["vRNA", "CELLULAR_COMPONENT", 44, 48], ["MDA5", "GENE_OR_GENE_PRODUCT", 111, 115], ["MDA5", "PROTEIN", 111, 115], ["the incoming vRNA", "PROBLEM", 31, 48], ["vRNA", "OBSERVATION", 44, 48]]], ["Taken together, our results demonstrate that (\u2212)RNA synthesis (i.e., formation of RF), but not (+)RNA synthesis (i.e., formation of RI), is required for achieving high levels of IFN-\u03b1/\u03b2 induction.Termini and Length Dependency of MDA5 Activation by\u00a0Long dsRNAs ::: ResultsWe next investigated whether the termini of picornavirus RF are important for MDA5 activation.", [["RI", "GENE_OR_GENE_PRODUCT", 132, 134], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 178, 183], ["\u03b2", "GENE_OR_GENE_PRODUCT", 184, 185], ["MDA5", "GENE_OR_GENE_PRODUCT", 229, 233], ["picornavirus", "ORGANISM", 315, 327], ["RF", "GENE_OR_GENE_PRODUCT", 328, 330], ["MDA5", "GENE_OR_GENE_PRODUCT", 349, 353], ["RF", "PROTEIN", 82, 84], ["RI", "PROTEIN", 132, 134], ["IFN", "PROTEIN", 178, 181], ["\u03b1", "PROTEIN", 182, 183], ["\u03b2", "PROTEIN", 184, 185], ["MDA5", "PROTEIN", 229, 233], ["Long dsRNAs", "DNA", 248, 259], ["picornavirus RF", "PROTEIN", 315, 330], ["MDA5", "PROTEIN", 349, 353], ["RNA synthesis", "PROBLEM", 48, 61], ["RF", "PROBLEM", 82, 84], ["RNA synthesis", "PROBLEM", 98, 111], ["IFN", "TREATMENT", 178, 181], ["picornavirus RF", "TREATMENT", 315, 330], ["MDA5 activation", "PROBLEM", 349, 364], ["Length", "OBSERVATION_MODIFIER", 208, 214], ["MDA5 Activation", "OBSERVATION", 229, 244], ["picornavirus", "OBSERVATION", 315, 327]]], ["The viral RF contains a VPg peptide at the 5\u2032 end of the (\u2212)RNA, but not at the 5\u2032 end of the (+)RNA, because of the activity of the unlinking enzyme.", [["viral RF", "PROTEIN", 4, 12], ["5\u2032 end", "RNA", 43, 49], ["(\u2212)RNA", "RNA", 57, 63], ["5\u2032 end", "RNA", 80, 86], ["(+)RNA", "RNA", 94, 100], ["unlinking enzyme", "PROTEIN", 133, 149], ["a VPg peptide", "TREATMENT", 22, 35], ["the (+)RNA", "PROBLEM", 90, 100], ["the unlinking enzyme", "TEST", 129, 149], ["viral RF", "OBSERVATION", 4, 12], ["VPg peptide", "OBSERVATION", 24, 35]]], ["Furthermore, the RF contains a large unpaired poly(A) tail at the 3\u2032 end of the (+)RNA (van Ooij et al., 2006).", [["poly", "CHEMICAL", 46, 50], ["poly(A)", "CHEMICAL", 46, 53], ["RF", "PROTEIN", 17, 19], ["poly(A) tail", "PROTEIN", 46, 58], ["large", "OBSERVATION_MODIFIER", 31, 36], ["unpaired", "OBSERVATION", 37, 45], ["poly", "OBSERVATION_MODIFIER", 46, 50], ["tail", "ANATOMY", 54, 58]]], ["To investigate whether these features are important for MDA5 activation, we produced CVB3 and mengovirus dsRNAs with 5\u2032ppp and perfectly paired termini by in vitro transcription (ivt dsRNA) and compared them with viral RF purified from infected cells for their ability to activate MDA5.", [["cells", "ANATOMY", 245, 250], ["MDA5", "GENE_OR_GENE_PRODUCT", 56, 60], ["CVB3", "ORGANISM", 85, 89], ["\u2032ppp", "GENE_OR_GENE_PRODUCT", 118, 122], ["cells", "CELL", 245, 250], ["MDA5", "GENE_OR_GENE_PRODUCT", 281, 285], ["MDA5", "PROTEIN", 56, 60], ["CVB3 and mengovirus dsRNAs", "DNA", 85, 111], ["5\u2032ppp", "DNA", 117, 122], ["viral RF", "PROTEIN", 213, 221], ["infected cells", "CELL_TYPE", 236, 250], ["MDA5", "PROTEIN", 281, 285], ["CVB3", "SPECIES", 85, 89], ["MDA5 activation", "PROBLEM", 56, 71], ["CVB3 and mengovirus dsRNAs", "TREATMENT", 85, 111], ["vitro transcription (ivt dsRNA", "TREATMENT", 158, 188], ["viral RF", "PROBLEM", 213, 221], ["infected cells", "PROBLEM", 236, 250], ["infected cells", "OBSERVATION", 236, 250]]], ["Strikingly, all dsRNAs triggered a similar IFN-\u03b2 response upon transfection into RIG-I\u2212/\u2212 MEFs (Figure 5F).", [["RIG-I\u2212/\u2212 MEFs", "ANATOMY", 81, 94], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 43, 48], ["RIG-I\u2212", "GENE_OR_GENE_PRODUCT", 81, 87], ["IFN", "PROTEIN", 43, 46], ["\u03b2", "PROTEIN", 47, 48], ["RIG-I\u2212/\u2212 MEFs", "CELL_LINE", 81, 94], ["all dsRNAs", "PROBLEM", 12, 22], ["RIG", "TEST", 81, 84], ["dsRNAs", "OBSERVATION", 16, 22]]], ["Additionally, CVB3 ivt dsRNA activated MDA5 to a similar extent as CVB3 RF in our in vitro ATPase assay (Figure 3F).", [["CVB3", "ORGANISM", 14, 18], ["MDA5", "GENE_OR_GENE_PRODUCT", 39, 43], ["CVB3", "ORGANISM", 67, 71], ["ATPase", "GENE_OR_GENE_PRODUCT", 91, 97], ["MDA5", "PROTEIN", 39, 43], ["CVB3 RF", "PROTEIN", 67, 74], ["ATPase", "PROTEIN", 91, 97], ["CVB3", "SPECIES", 14, 18], ["CVB3", "SPECIES", 67, 71], ["CVB3 ivt dsRNA", "TREATMENT", 14, 28], ["CVB3 RF", "PROBLEM", 67, 74]]], ["Thus, the recognition of long dsRNAs by MDA5 is likely independent of the termini of the RNA molecule.Termini and Length Dependency of MDA5 Activation by\u00a0Long dsRNAs ::: ResultsLastly, we investigated whether MDA5 activation by long dsRNAs is length dependent as proposed by Kato et al., who showed that only long polyIC molecules (>2 kb) are efficiently recognized by MDA5 (Kato et al., 2008).", [["MDA5", "GENE_OR_GENE_PRODUCT", 40, 44], ["MDA5", "GENE_OR_GENE_PRODUCT", 135, 139], ["MDA5", "GENE_OR_GENE_PRODUCT", 209, 213], ["MDA5", "GENE_OR_GENE_PRODUCT", 369, 373], ["long dsRNAs", "RNA", 25, 36], ["MDA5", "PROTEIN", 40, 44], ["RNA molecule", "PROTEIN", 89, 101], ["MDA5", "PROTEIN", 135, 139], ["Long dsRNAs", "DNA", 154, 165], ["MDA5", "PROTEIN", 209, 213], ["long dsRNAs", "DNA", 228, 239], ["polyIC molecules", "PROTEIN", 314, 330], ["MDA5", "PROTEIN", 369, 373], ["long dsRNAs", "PROBLEM", 25, 36], ["MDA5 activation", "PROBLEM", 209, 224], ["long dsRNAs", "PROBLEM", 228, 239], ["length dependent", "PROBLEM", 243, 259], ["long polyIC molecules", "PROBLEM", 309, 330], ["long dsRNAs", "OBSERVATION", 25, 36], ["RNA molecule", "OBSERVATION", 89, 101], ["Length", "OBSERVATION_MODIFIER", 114, 120], ["MDA5 Activation", "OBSERVATION", 135, 150]]], ["To this end we generated ivt dsRNAs of various lengths (0.1\u20137.4 kbp) and determined IFN-\u03b2 activation levels by real-time qPCR upon transfection of different amounts of these fragments.", [["fragments", "ANATOMY", 174, 183], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 84, 89], ["ivt dsRNAs", "DNA", 25, 35], ["IFN", "PROTEIN", 84, 87], ["\u03b2", "PROTEIN", 88, 89], ["ivt dsRNAs", "TREATMENT", 25, 35], ["IFN", "TEST", 84, 87], ["activation levels", "TEST", 90, 107], ["these fragments", "PROBLEM", 168, 183], ["fragments", "OBSERVATION", 174, 183]]], ["At relatively low quantities (10 ng), ivt dsRNAs shorter than 2.4 kbp induced only low levels of IFN-\u03b2 mRNA.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 97, 102], ["ivt dsRNAs", "RNA", 38, 48], ["IFN-\u03b2 mRNA", "RNA", 97, 107], ["ivt dsRNAs", "TEST", 38, 48], ["low levels of IFN-\u03b2 mRNA", "PROBLEM", 83, 107], ["low quantities", "OBSERVATION_MODIFIER", 14, 28], ["low levels", "OBSERVATION_MODIFIER", 83, 93]]], ["However, when larger amounts of dsRNA (100 ng) were transfected, smaller dsRNAs were also able to trigger an IFN-\u03b2 response (Figure 5G), indicating that there may not be a strict length cut-off value for MDA5 ligands.DiscussionSince the initial discovery of RLRs, significant progress has been made in identifying ligands for RIG-I, but the identity and molecular characteristics of viral MDA5 ligands remain largely unknown.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["MDA5", "GENE_OR_GENE_PRODUCT", 204, 208], ["RLRs", "GENE_OR_GENE_PRODUCT", 258, 262], ["RIG-I", "GENE_OR_GENE_PRODUCT", 326, 331], ["MDA5", "GENE_OR_GENE_PRODUCT", 389, 393], ["IFN", "PROTEIN", 109, 112], ["\u03b2", "PROTEIN", 113, 114], ["MDA5", "PROTEIN", 204, 208], ["RLRs", "PROTEIN", 258, 262], ["RIG-I", "PROTEIN", 326, 331], ["viral MDA5 ligands", "PROTEIN", 383, 401], ["dsRNA", "PROBLEM", 32, 37], ["smaller dsRNAs", "PROBLEM", 65, 79], ["an IFN", "TEST", 106, 112], ["MDA5 ligands", "PROBLEM", 204, 216], ["viral MDA5 ligands", "PROBLEM", 383, 401], ["larger", "OBSERVATION_MODIFIER", 14, 20], ["may not be", "UNCERTAINTY", 159, 169], ["viral MDA5 ligands", "OBSERVATION", 383, 401]]], ["Based on transfection experiments using poly(I:C), MDA5 is believed to recognize long dsRNAs.", [["poly(I:C", "CHEMICAL", 40, 48], ["poly(I:C", "GENE_OR_GENE_PRODUCT", 40, 48], ["MDA5", "GENE_OR_GENE_PRODUCT", 51, 55], ["MDA5", "PROTEIN", 51, 55], ["long dsRNAs", "DNA", 81, 92], ["MDA5", "TREATMENT", 51, 55], ["long dsRNAs", "PROBLEM", 81, 92]]], ["However, viral ssRNAs should not be excluded because base-paired regions in ssRNAs, as those in the picornavirus genomic RNA, could potentially be sufficient for MDA5 recognition.", [["ssRNAs", "GENE_OR_GENE_PRODUCT", 76, 82], ["MDA5", "GENE_OR_GENE_PRODUCT", 162, 166], ["viral ssRNAs", "DNA", 9, 21], ["paired regions", "DNA", 58, 72], ["ssRNAs", "DNA", 76, 82], ["picornavirus genomic RNA", "RNA", 100, 124], ["MDA5", "PROTEIN", 162, 166], ["viral ssRNAs", "PROBLEM", 9, 21], ["base-paired regions in ssRNAs", "PROBLEM", 53, 82], ["the picornavirus genomic RNA", "PROBLEM", 96, 124], ["viral ssRNAs", "OBSERVATION", 9, 21], ["should not be excluded", "UNCERTAINTY", 22, 44], ["picornavirus genomic RNA", "OBSERVATION", 100, 124]]], ["Furthermore, a virally encoded peptide, VPg, is covalently attached to the 5\u2032 terminus of picornavirus RNAs via a unique tyrosine-RNA bond, providing a potential \u201cnonself\u201d signature at the 5\u2032 end.", [["tyrosine", "CHEMICAL", 121, 129], ["tyrosine", "CHEMICAL", 121, 129], ["VPg", "GENE_OR_GENE_PRODUCT", 40, 43], ["picornavirus", "ORGANISM", 90, 102], ["VPg", "PROTEIN", 40, 43], ["5\u2032 terminus", "PROTEIN", 75, 86], ["picornavirus RNAs", "RNA", 90, 107], ["5\u2032 end", "DNA", 189, 195], ["a virally encoded peptide", "TREATMENT", 13, 38], ["VPg", "PROBLEM", 40, 43], ["picornavirus RNAs", "TREATMENT", 90, 107], ["a unique tyrosine-RNA bond", "TREATMENT", 112, 138], ["picornavirus RNAs", "OBSERVATION", 90, 107]]], ["Bearing this information in mind, we followed an unbiased approach to determine the IFN-stimulatory activities of different viral RNA species produced in picornavirus-infected cells.DiscussionThe viral dsRNA, RF, has been assumed to be the MDA5 ligand produced by picornaviruses based on the fact that all known activators of MDA5 are dsRNAs (mimics).", [["cells", "ANATOMY", 176, 181], ["picornavirus-infected", "DISEASE", 154, 175], ["IFN", "GENE_OR_GENE_PRODUCT", 84, 87], ["picornavirus", "ORGANISM", 154, 166], ["cells", "CELL", 176, 181], ["MDA5", "GENE_OR_GENE_PRODUCT", 240, 244], ["MDA5", "GENE_OR_GENE_PRODUCT", 326, 330], ["IFN", "PROTEIN", 84, 87], ["viral RNA species", "RNA", 124, 141], ["picornavirus-infected cells", "CELL_TYPE", 154, 181], ["RF", "PROTEIN", 209, 211], ["MDA5 ligand", "PROTEIN", 240, 251], ["MDA5", "PROTEIN", 326, 330], ["dsRNAs", "DNA", 335, 341], ["the IFN-stimulatory activities", "TREATMENT", 80, 110], ["different viral RNA species", "PROBLEM", 114, 141], ["picornavirus", "PROBLEM", 154, 166], ["infected cells", "PROBLEM", 167, 181], ["The viral dsRNA", "PROBLEM", 192, 207], ["picornaviruses", "PROBLEM", 264, 278], ["infected cells", "OBSERVATION", 167, 181], ["viral dsRNA", "OBSERVATION", 196, 207], ["picornaviruses", "OBSERVATION", 264, 278]]], ["Here, we provide experimental evidence that purified picornavirus RF can not only induce an MDA5-dependent IFN-\u03b1/\u03b2 response upon transfection, but also directly bind to, and activate, MDA5 in vitro.", [["picornavirus RF", "ORGANISM", 53, 68], ["MDA5", "GENE_OR_GENE_PRODUCT", 92, 96], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 107, 112], ["\u03b2", "GENE_OR_GENE_PRODUCT", 113, 114], ["MDA5", "GENE_OR_GENE_PRODUCT", 184, 188], ["picornavirus RF", "PROTEIN", 53, 68], ["MDA5", "PROTEIN", 92, 96], ["IFN", "PROTEIN", 107, 110], ["\u03b2", "PROTEIN", 113, 114], ["MDA5", "PROTEIN", 184, 188], ["purified picornavirus RF", "PROBLEM", 44, 68]]], ["Viral ssRNAs, on the other hand, proved poor MDA5 stimuli.", [["Viral", "ORGANISM", 0, 5], ["MDA5", "GENE_OR_GENE_PRODUCT", 45, 49], ["Viral ssRNAs", "PROTEIN", 0, 12], ["MDA5", "PROTEIN", 45, 49], ["Viral ssRNAs", "TEST", 0, 12], ["poor MDA5 stimuli", "PROBLEM", 40, 57], ["ssRNAs", "OBSERVATION", 6, 12], ["MDA5 stimuli", "OBSERVATION", 45, 57]]], ["Neither vRNA (VPg-containing) nor viral mRNA (VPg-lacking) induced an IFN-\u03b2 response when transfected into cells.", [["cells", "ANATOMY", 107, 112], ["vRNA", "GENE_OR_GENE_PRODUCT", 8, 12], ["VPg-containing)", "GENE_OR_GENE_PRODUCT", 14, 29], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["cells", "CELL", 107, 112], ["vRNA (VPg-containing) nor viral mRNA", "RNA", 8, 44], ["VPg", "PROTEIN", 46, 49], ["IFN", "PROTEIN", 70, 73], ["\u03b2", "PROTEIN", 74, 75], ["vRNA", "PROBLEM", 8, 12], ["VPg", "TEST", 14, 17], ["viral mRNA", "PROBLEM", 34, 44], ["VPg", "TEST", 46, 49], ["vRNA", "OBSERVATION", 8, 12]]], ["This is in line with the observation that the full-length EMCV RNA failed to activate MDA5 ATPase activity in vitro (Peisley et al., 2011).", [["EMCV", "ORGANISM", 58, 62], ["MDA5 ATPase", "GENE_OR_GENE_PRODUCT", 86, 97], ["EMCV RNA", "RNA", 58, 66], ["MDA5", "PROTEIN", 86, 90], ["ATPase", "PROTEIN", 91, 97], ["EMCV", "SPECIES", 58, 62], ["the full-length EMCV RNA", "TREATMENT", 42, 66]]], ["Although we could not test IFN-stimulatory activity of purified RI, this molecule does not seem to play a crucial role in inducing IFN-\u03b1/\u03b2 because treatment of the CVB3 ssRNA fraction with RNase A did not affect its ability to induce IFN-\u03b1/\u03b2.", [["RI", "GENE_OR_GENE_PRODUCT", 64, 66], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 131, 136], ["\u03b2", "GENE_OR_GENE_PRODUCT", 137, 138], ["CVB3", "ORGANISM", 164, 168], ["RNase A", "GENE_OR_GENE_PRODUCT", 189, 196], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 234, 239], ["IFN", "PROTEIN", 27, 30], ["purified RI", "PROTEIN", 55, 66], ["IFN", "PROTEIN", 131, 134], ["\u03b2", "PROTEIN", 137, 138], ["RNase A", "PROTEIN", 189, 196], ["IFN", "PROTEIN", 234, 237], ["CVB3", "SPECIES", 164, 168], ["treatment", "TREATMENT", 147, 156], ["the CVB3 ssRNA fraction", "TREATMENT", 160, 183]]], ["This observation also speaks against the hypothesis that other (viral) ssRNAs\u2014which might have been produced by the action of cellular RNases like RNaseL\u2014may be recognized by MDA5.DiscussionCollectively, our transfection experiments clearly identify the RF as an MDA5 agonist.", [["cellular", "ANATOMY", 126, 134], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 71, 77], ["cellular", "CELL", 126, 134], ["RNaseL", "GENE_OR_GENE_PRODUCT", 147, 153], ["MDA5", "GENE_OR_GENE_PRODUCT", 175, 179], ["MDA5", "GENE_OR_GENE_PRODUCT", 263, 267], ["ssRNAs", "PROTEIN", 71, 77], ["cellular RNases", "PROTEIN", 126, 141], ["RNaseL", "PROTEIN", 147, 153], ["MDA5", "PROTEIN", 175, 179], ["RF", "PROTEIN", 254, 256], ["MDA5", "PROTEIN", 263, 267], ["other (viral) ssRNAs", "PROBLEM", 57, 77], ["cellular RNases", "PROBLEM", 126, 141], ["an MDA5 agonist", "TREATMENT", 260, 275], ["cellular RNases", "OBSERVATION", 126, 141]]], ["Previously, Pichlmair and colleagues identified two virus-induced RNA species in their total RNA extract from EMCV-infected cells: one dsRNA of approximately 12 kbp and one high-molecular-weight RNA (HMW-RNA) that consisted of both ssRNAs and dsRNAs (Pichlmair et al., 2009).", [["cells", "ANATOMY", 124, 129], ["EMCV", "ORGANISM", 110, 114], ["cells", "CELL", 124, 129], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 232, 238], ["RNA species", "RNA", 66, 77], ["high-molecular-weight RNA", "RNA", 173, 198], ["HMW-RNA", "RNA", 200, 207], ["ssRNAs", "PROTEIN", 232, 238], ["dsRNAs", "DNA", 243, 249], ["EMCV", "SPECIES", 110, 114], ["two virus", "PROBLEM", 48, 57], ["RNA species", "PROBLEM", 66, 77], ["EMCV", "PROBLEM", 110, 114], ["infected cells", "PROBLEM", 115, 129], ["kbp", "TEST", 161, 164], ["RNA species", "OBSERVATION", 66, 77], ["infected cells", "OBSERVATION", 115, 129], ["one dsRNA", "OBSERVATION_MODIFIER", 131, 140], ["high", "OBSERVATION_MODIFIER", 173, 177], ["weight RNA", "OBSERVATION_MODIFIER", 188, 198], ["both", "ANATOMY_MODIFIER", 227, 231], ["ssRNAs", "ANATOMY", 232, 238], ["dsRNAs", "OBSERVATION", 243, 249]]], ["The HMW-RNA, but not the 12 kbp dsRNA, was found to be IFN-\u03b1/\u03b2 stimulatory upon transfection.", [["HMW", "GENE_OR_GENE_PRODUCT", 4, 7], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["\u03b2", "GENE_OR_GENE_PRODUCT", 61, 62], ["HMW-RNA", "RNA", 4, 11], ["IFN", "PROTEIN", 55, 58], ["\u03b1", "PROTEIN", 59, 60], ["\u03b2", "PROTEIN", 61, 62], ["the 12 kbp dsRNA", "PROBLEM", 21, 37], ["IFN", "TEST", 55, 58], ["RNA", "OBSERVATION", 8, 11]]], ["We never observed either of these RNAs in our total RNA extracts or the fractionated RNA preparations.", [["extracts", "ANATOMY", 56, 64], ["extracts", "ORGANISM_SUBSTANCE", 56, 64], ["RNAs", "RNA", 34, 38], ["the fractionated RNA preparations", "TREATMENT", 68, 101]]], ["The identity of the HMW-RNA and the IFN-stimulatory element(s) within their mixed RNA population remains unclear.DiscussionAlthough transfection may be a convenient method to study aspects of MDA5 ligand recognition, it may not faithfully recapitulate physiological conditions for several reasons.", [["HMW", "GENE_OR_GENE_PRODUCT", 20, 23], ["MDA5", "GENE_OR_GENE_PRODUCT", 192, 196], ["HMW-RNA", "RNA", 20, 27], ["IFN-stimulatory element", "DNA", 36, 59], ["MDA5", "PROTEIN", 192, 196], ["the HMW", "TEST", 16, 23], ["the IFN-stimulatory element", "TREATMENT", 32, 59], ["their mixed RNA population", "PROBLEM", 70, 96], ["MDA5 ligand recognition", "TEST", 192, 215], ["RNA", "ANATOMY", 24, 27], ["mixed", "OBSERVATION_MODIFIER", 76, 81], ["RNA population", "OBSERVATION", 82, 96]]], ["First, transfection delivers large amounts of viral RNA directly into the cytoplasm at once.", [["cytoplasm", "ANATOMY", 74, 83], ["cytoplasm", "ORGANISM_SUBSTANCE", 74, 83], ["viral RNA", "RNA", 46, 55], ["viral RNA", "TREATMENT", 46, 55], ["large", "OBSERVATION_MODIFIER", 29, 34], ["amounts", "OBSERVATION_MODIFIER", 35, 42], ["viral RNA", "OBSERVATION", 46, 55]]], ["This is different from the RNA release process during infectious entry as well as the gradual accumulation of viral RNAs during virus replication.", [["viral RNAs", "RNA", 110, 120], ["viral RNAs", "PROBLEM", 110, 120], ["virus replication", "TREATMENT", 128, 145], ["different", "OBSERVATION_MODIFIER", 8, 17], ["infectious", "OBSERVATION", 54, 64], ["gradual", "OBSERVATION_MODIFIER", 86, 93], ["accumulation", "OBSERVATION_MODIFIER", 94, 106], ["viral RNAs", "OBSERVATION", 110, 120]]], ["Second, purified, and therefore \u201cnaked,\u201d RNAs are transfected into cells whereas viral RNAs are heavily coated with viral and host factors during infection.", [["cells", "ANATOMY", 67, 72], ["infection", "DISEASE", 146, 155], ["cells", "CELL", 67, 72], ["\u201cnaked,\u201d RNAs", "RNA", 32, 45], ["viral RNAs", "RNA", 81, 91], ["viral and host factors", "PROTEIN", 116, 138], ["viral RNAs", "PROBLEM", 81, 91], ["viral and host factors during infection", "PROBLEM", 116, 155], ["viral RNAs", "OBSERVATION", 81, 91], ["infection", "OBSERVATION", 146, 155]]], ["Third, (+)RNA viruses induce the formation of membranous replication organelles, which may restrict access of MDA5 to replication intermediates such as RF and RI.", [["organelles", "ANATOMY", 69, 79], ["organelles", "CELLULAR_COMPONENT", 69, 79], ["MDA5", "GENE_OR_GENE_PRODUCT", 110, 114], ["MDA5", "PROTEIN", 110, 114], ["RF", "PROTEIN", 152, 154], ["RI", "PROTEIN", 159, 161], ["Third, (+)RNA viruses", "PROBLEM", 0, 21], ["membranous replication organelles", "PROBLEM", 46, 79], ["viruses", "OBSERVATION", 14, 21], ["membranous", "OBSERVATION_MODIFIER", 46, 56], ["replication organelles", "OBSERVATION", 57, 79]]], ["To gain insight into MDA5 activation in a more physiologically relevant situation, we studied MDA5 activation in infected cells.", [["cells", "ANATOMY", 122, 127], ["MDA5", "GENE_OR_GENE_PRODUCT", 21, 25], ["MDA5", "GENE_OR_GENE_PRODUCT", 94, 98], ["cells", "CELL", 122, 127], ["MDA5", "PROTEIN", 21, 25], ["MDA5", "PROTEIN", 94, 98], ["infected cells", "CELL_TYPE", 113, 127], ["infected cells", "PROBLEM", 113, 127], ["infected cells", "OBSERVATION", 113, 127]]], ["Our data show that the incoming genomic ssRNA alone cannot induce any detectable IFN-\u03b2 response even when large amounts were delivered by high MOI infection.", [["infection", "DISEASE", 147, 156], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 81, 86], ["IFN", "PROTEIN", 81, 84], ["\u03b2", "PROTEIN", 85, 86], ["Our data", "TEST", 0, 8], ["the incoming genomic ssRNA", "PROBLEM", 19, 45], ["high MOI infection", "PROBLEM", 138, 156], ["high MOI", "OBSERVATION_MODIFIER", 138, 146], ["infection", "OBSERVATION", 147, 156]]], ["When (\u2212)RNA synthesis (i.e., formation of RF) was permitted but (+)RNA synthesis (i.e., formation of RI) was inhibited, a significant upregulation of IFN-\u03b2 mRNA was observed.", [["RI", "GENE_OR_GENE_PRODUCT", 101, 103], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["RF", "PROTEIN", 42, 44], ["RI", "PROTEIN", 101, 103], ["IFN-\u03b2 mRNA", "RNA", 150, 160], ["RNA synthesis", "PROBLEM", 8, 21], ["RF", "PROBLEM", 42, 44], ["RNA synthesis", "PROBLEM", 67, 80], ["IFN", "TEST", 150, 153], ["mRNA", "PROBLEM", 156, 160], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["upregulation", "OBSERVATION_MODIFIER", 134, 146]]], ["These data further support the idea that picornavirus RF is the essential MDA5 agonist in the course of infection.", [["infection", "DISEASE", 104, 113], ["picornavirus", "ORGANISM", 41, 53], ["RF", "GENE_OR_GENE_PRODUCT", 54, 56], ["MDA5", "GENE_OR_GENE_PRODUCT", 74, 78], ["picornavirus RF", "PROTEIN", 41, 56], ["MDA5", "PROTEIN", 74, 78], ["picornavirus RF", "PROBLEM", 41, 56], ["infection", "PROBLEM", 104, 113], ["picornavirus", "OBSERVATION", 41, 53], ["MDA5 agonist", "OBSERVATION", 74, 86], ["infection", "OBSERVATION", 104, 113]]], ["Of note, a much higher IFN-\u03b2 response was observed when RNA replication was allowed to proceed fully (i.e., in the absence of inhibitor).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "PROTEIN", 23, 26], ["\u03b2", "PROTEIN", 27, 28], ["RNA replication", "TREATMENT", 56, 71]]], ["Although this finding may be interpreted as that RIs also activate MDA5, this increase can be attributed, at least partly, to the increased amount of RF produced from newly synthesized (+)RNAs that enter new rounds of RNA replication.DiscussionRecently, Z\u00fcst et al. suggested that MDA5 may also recognize RNA molecules with a \u201cnonself\u201d 5\u2032 termini, as a mutant coronavirus deficient in fully capping its mRNAs activated MDA5 in infected cells (Z\u00fcst et al., 2011).", [["cells", "ANATOMY", 436, 441], ["MDA5", "GENE_OR_GENE_PRODUCT", 67, 71], ["MDA5", "GENE_OR_GENE_PRODUCT", 281, 285], ["mutant coronavirus", "ORGANISM", 353, 371], ["MDA5", "GENE_OR_GENE_PRODUCT", 419, 423], ["cells", "CELL", 436, 441], ["MDA5", "PROTEIN", 67, 71], ["RF", "PROTEIN", 150, 152], ["newly synthesized (+)RNAs", "RNA", 167, 192], ["MDA5", "PROTEIN", 281, 285], ["RNA molecules", "PROTEIN", 305, 318], ["mRNAs", "RNA", 403, 408], ["MDA5", "PROTEIN", 419, 423], ["infected cells", "CELL_TYPE", 427, 441], ["newly synthesized (+)RNAs", "PROBLEM", 167, 192], ["RNA replication", "TREATMENT", 218, 233], ["a \u201cnonself\u201d 5\u2032 termini", "TREATMENT", 324, 346], ["a mutant coronavirus deficient", "PROBLEM", 351, 381], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["amount", "OBSERVATION_MODIFIER", 140, 146], ["RNA replication", "OBSERVATION", 218, 233]]], ["Because picornavirus RF harbors distinctive termini, we investigated whether this terminal composition of the RF is essential for MDA5 activation.", [["picornavirus RF", "ORGANISM", 8, 23], ["RF", "GENE_OR_GENE_PRODUCT", 110, 112], ["MDA5", "GENE_OR_GENE_PRODUCT", 130, 134], ["picornavirus RF", "PROTEIN", 8, 23], ["RF", "PROTEIN", 110, 112], ["MDA5", "PROTEIN", 130, 134], ["MDA5 activation", "PROBLEM", 130, 145], ["essential for", "UNCERTAINTY", 116, 129], ["MDA5 activation", "OBSERVATION", 130, 145]]], ["Changing the physiological terminal groups of RF into 5\u2032ppp and fully complemented 3\u2032 end did not change its ability to induce IFN-\u03b2 upregulation.", [["\u2032ppp", "GENE_OR_GENE_PRODUCT", 55, 59], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 127, 132], ["RF", "PROTEIN", 46, 48], ["5\u2032ppp and fully complemented 3\u2032 end", "DNA", 54, 89], ["IFN", "PROTEIN", 127, 130], ["\u03b2", "PROTEIN", 131, 132], ["IFN", "TREATMENT", 127, 130], ["terminal", "OBSERVATION_MODIFIER", 27, 35]]], ["Other features such as secondary structures are common requirements for ligand recognition; however, the picornavirus RF is not known to contain distinct higher structures.", [["picornavirus RF", "ORGANISM", 105, 120], ["picornavirus RF", "PROTEIN", 105, 120], ["secondary structures", "PROBLEM", 23, 43], ["ligand recognition", "TEST", 72, 90], ["the picornavirus RF", "PROBLEM", 101, 120], ["picornavirus", "OBSERVATION", 105, 117], ["distinct", "OBSERVATION_MODIFIER", 145, 153], ["higher", "OBSERVATION", 154, 160]]], ["Thus, it is likely that the long ds nature of the RF, and not its unique termini, renders this RNA a potent MDA5 activator.DiscussionWe also investigated the length dependency of MDA5 ligand recognition because it has been suggested that only dsRNAs longer than 2 kbp can induce MDA5 activation (Kato et al., 2008).", [["RF", "GENE_OR_GENE_PRODUCT", 50, 52], ["MDA5", "GENE_OR_GENE_PRODUCT", 108, 112], ["MDA5", "GENE_OR_GENE_PRODUCT", 179, 183], ["MDA5", "GENE_OR_GENE_PRODUCT", 279, 283], ["RF", "PROTEIN", 50, 52], ["MDA5", "PROTEIN", 108, 112], ["MDA5", "PROTEIN", 179, 183], ["dsRNAs", "DNA", 243, 249], ["MDA5", "PROTEIN", 279, 283], ["a potent MDA5 activator", "TREATMENT", 99, 122], ["MDA5 ligand recognition", "TREATMENT", 179, 202], ["is likely", "UNCERTAINTY", 9, 18]]], ["We tested dsRNAs of viral sequence in vitro that span a wide range of sizes (0.1\u20137.4 kbp), and found that although longer dsRNAs activate MDA5 more efficiently when provided at equal mass, short dsRNAs could also induce some levels of MDA5 activation when present in large quantities.", [["MDA5", "GENE_OR_GENE_PRODUCT", 138, 142], ["MDA5", "GENE_OR_GENE_PRODUCT", 235, 239], ["dsRNAs", "DNA", 10, 16], ["viral sequence", "DNA", 20, 34], ["dsRNAs", "DNA", 122, 128], ["MDA5", "PROTEIN", 138, 142], ["MDA5", "PROTEIN", 235, 239], ["viral sequence", "TEST", 20, 34], ["sizes", "TEST", 70, 75], ["longer dsRNAs activate MDA5", "PROBLEM", 115, 142], ["short dsRNAs", "PROBLEM", 189, 201], ["MDA5 activation", "PROBLEM", 235, 250], ["wide", "OBSERVATION_MODIFIER", 56, 60], ["sizes", "OBSERVATION_MODIFIER", 70, 75], ["mass", "OBSERVATION", 183, 187], ["MDA5 activation", "OBSERVATION", 235, 250]]], ["These data suggest that MDA5 may not require its substrate to be longer than a strict cut-off size.", [["MDA5", "GENE_OR_GENE_PRODUCT", 24, 28], ["MDA5", "PROTEIN", 24, 28], ["MDA5", "PROBLEM", 24, 28], ["off size", "OBSERVATION_MODIFIER", 90, 98]]], ["In line with this, others have demonstrated efficient activation of MDA5 ATPase activity by dsRNAs as short as 112 bp (Peisley et al., 2011).", [["MDA5 ATPase", "GENE_OR_GENE_PRODUCT", 68, 79], ["MDA5", "PROTEIN", 68, 72], ["ATPase", "PROTEIN", 73, 79], ["dsRNAs", "DNA", 92, 98], ["bp", "TEST", 115, 117]]], ["Authors of this paper also showed that MDA5 ATPase activity, which is triggered by ligand binding, induces disassembly of MDA5 from the RNA ligand, the rate of which is inversely related to the length of the bound RNA molecule (Peisley et al., 2011).", [["MDA5", "GENE_OR_GENE_PRODUCT", 39, 43], ["MDA5", "GENE_OR_GENE_PRODUCT", 122, 126], ["MDA5", "PROTEIN", 39, 43], ["ATPase", "PROTEIN", 44, 50], ["MDA5", "PROTEIN", 122, 126], ["RNA ligand", "PROTEIN", 136, 146], ["bound RNA molecule", "PROTEIN", 208, 226], ["MDA5 ATPase activity", "PROBLEM", 39, 59], ["MDA5", "OBSERVATION", 39, 43], ["ATPase activity", "OBSERVATION", 44, 59]]], ["This provides some molecular explanation why longer dsRNAs are more efficient in activating MDA5 than shorter ones.DiscussionWhile this paper was in preparation, another study reported that enterovirus dsRNAs, but not ssRNAs, can activate MDA5-dependent IFN-\u03b2 responses upon transfection (Triantafilou et al., 2012).", [["MDA5", "GENE_OR_GENE_PRODUCT", 92, 96], ["enterovirus", "ORGANISM", 190, 201], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 218, 224], ["MDA5", "GENE_OR_GENE_PRODUCT", 239, 243], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 254, 259], ["MDA5", "PROTEIN", 92, 96], ["enterovirus dsRNAs", "DNA", 190, 208], ["ssRNAs", "PROTEIN", 218, 224], ["MDA5", "PROTEIN", 239, 243], ["IFN", "PROTEIN", 254, 257], ["\u03b2", "PROTEIN", 258, 259], ["longer dsRNAs", "PROBLEM", 45, 58], ["another study", "TEST", 162, 175], ["enterovirus dsRNAs", "PROBLEM", 190, 208], ["MDA5", "TEST", 239, 243], ["enterovirus dsRNAs", "OBSERVATION", 190, 208]]], ["Also shown in this study is colocalization of MDA5 with dsRNA in enterovirus-infected cells.", [["cells", "ANATOMY", 86, 91], ["enterovirus-infected", "DISEASE", 65, 85], ["MDA5", "GENE_OR_GENE_PRODUCT", 46, 50], ["enterovirus", "ORGANISM", 65, 76], ["cells", "CELL", 86, 91], ["MDA5", "PROTEIN", 46, 50], ["enterovirus-infected cells", "CELL_TYPE", 65, 91], ["this study", "TEST", 14, 24], ["dsRNA", "PROBLEM", 56, 61], ["enterovirus", "PROBLEM", 65, 76], ["infected cells", "PROBLEM", 77, 91], ["dsRNA", "OBSERVATION", 56, 61], ["infected cells", "OBSERVATION", 77, 91]]], ["Although not providing evidence of direct binding or functional activation, these data nicely show that MDA5 and viral dsRNA can be found in physical vicinity, and therefore support our results that the RF can activate MDA5 in infected cells.DiscussionCollectively, our data suggest that the 7.5 kbp RF of picornaviruses is a highly potent MDA5 activator and is directly recognized by MDA5.", [["cells", "ANATOMY", 236, 241], ["MDA5", "GENE_OR_GENE_PRODUCT", 104, 108], ["MDA5", "GENE_OR_GENE_PRODUCT", 219, 223], ["cells", "CELL", 236, 241], ["MDA5", "GENE_OR_GENE_PRODUCT", 340, 344], ["MDA5", "GENE_OR_GENE_PRODUCT", 385, 389], ["MDA5", "PROTEIN", 104, 108], ["RF", "PROTEIN", 203, 205], ["MDA5", "PROTEIN", 219, 223], ["infected cells", "CELL_TYPE", 227, 241], ["MDA5", "PROTEIN", 340, 344], ["MDA5", "PROTEIN", 385, 389], ["direct binding", "PROBLEM", 35, 49], ["these data", "TEST", 76, 86], ["MDA5 and viral dsRNA", "PROBLEM", 104, 124], ["MDA5 in infected cells", "PROBLEM", 219, 241], ["the 7.5 kbp RF of picornaviruses", "PROBLEM", 288, 320], ["not providing evidence of", "UNCERTAINTY", 9, 34], ["infected cells", "OBSERVATION", 227, 241]]], ["Moreover, this study shows that manipulating specific steps of virus replication is a powerful approach to study recognition of specific viral RNA species by RLRs under physiological conditions.Discussion", [["RLRs", "GENE_OR_GENE_PRODUCT", 158, 162], ["viral RNA species", "RNA", 137, 154], ["RLRs", "PROTEIN", 158, 162], ["this study", "TEST", 10, 20], ["virus replication", "TREATMENT", 63, 80], ["study recognition", "TEST", 107, 124], ["specific viral RNA species", "PROBLEM", 128, 154], ["viral RNA species", "OBSERVATION", 137, 154]]]]}